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Abstract 
 
 
 
 
 
 
 
 
   Inflammatory Bowel Disease (IBD) can be classified into two main subtypes: 
Crohn’s Disease (CD) and Ulcerative Colitis (UC). The aim of this study is to 
identify the genetic contribution to the susceptibility to IBD. In the first part of 
the study, I focused on Crohn’s Disease, the subtype that shows the greatest 
heritability. Using both pooled and sub-phenotype data, followed by 
replication, the results reveal substantial genetic heterogeneity and the total 
number of confirmed CD susceptibility loci was increased from 71 published 
by others to 200. This was achieved by analyzing the data using a multi-
marker approach and high-resolution genetic maps in Linkage Disequilibrium 
Units. In the second part of the study, I focused on Ulcerative Colitis. The 
results show that although UC has a lower reported heritability, many loci 
were also found for Ulcerative Colitis. Some of these overlap with those found 
for Crohn’s Disease.  
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CHAPTER I. GENERAL INTRODUCTION 
 
 
I. INFLAMMATORY BOWEL DISEASE: THE 
STORY OF TWO DISEASES. 
 
 
 
   Inflammatory Bowel Disease (IBD) is an immunologically mediated 
relapsing inflammatory condition of unknown causes. IBD can be subdivided 
into two sub-types: Crohn’s Disease (CD) and Ulcerative Colitis (UC), as 
illustrated in Table 1. In the second half of the twentieth century, the incidence 
of IBD has been on the increase in the developed western world (Sartor, 
2006).  This suggests the presence of a strong environmental contribution to 
the aetiology of IBD. Therefore, why study the genetics of IBD? Evidence for a 
genetic contribution comes from increased concordance in Monozygotic twins 
(MZ) (~50% for CD and ~10% for UC) in comparison with Dizygotic twins 
(DZ). Although the MZ concordance is not 100% as would be expected for a 
Mendelian disease, there is a five-fold or greater increased risk of IBD in first-
degree relatives with either disease than in the general public (Xavier and 
Podolsky, 2007), which substantiates the fact that there is a significant genetic 
contribution towards the development of IBD. Thus, the findings on families  
(Ohmen et al., 1996) also point to the idea that some genes will be 
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phenotype-specific, while some overlap in susceptibility loci is to be expected 
between the two sub-types  (Giallourakis et al., 2003; Parkes et al., 2000). 
 
 
   Although both types of IBD involve chronic intestinal inflammation, they 
differ from each other in several genetic and phenotypic respects, including 
cytokine profiles and intestinal location of disease manifestation. CD primarily 
affects the ileal region of the intestine in a transmural (penetrating all layers) 
fashion. However, CD is also characterized by segmental inflammation 
(segments of the intestine affected) as well as extra-intestinal manifestation. 
Unlike CD, the inflammation in UC is uninterrupted and mostly confined to the 
mucosal layer of either the proximal or distal colon (large intestine, see Figure 
1). Table 1 summarizes the overlapping and distinct features between these 
two sub-types of IBD. 
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Table 1. Differences and similarities between CD and UC 
 
 Crohn’s Disease Ulcerative Colitis 
Prevalence 26-199 per 100 000 
(Loftus, 2004) 
37-246 per 100 000 
(Loftus, 2004) 
Disease 
manifestation 
Can affect the entire 
gastrointestinal tract, 
from mouth to anus 
 
Inflammation is chiefly 
located in the 
ileocaecal region. 
 
Intestinal inflammation 
has a discontinuous 
(segmental) pattern, 
where affected parts of 
the gut can be 
separated by healthy 
tissue. 
 
Can affect all layers of 
the gut (transmural 
inflammation) 
Inflammation is 
confined to the colon. 
 
 
Inflammation affects 
the proximal/distal end 
of the colon. 
 
Intestinal inflammation 
is continuous, first 
occurring in the rectum 
and then extends 
proximally. 
 
 
Mucosal inflammation 
only. 
 
Genetic 
Contribution* 
 
 
~50% 
 
~10% 
Environmental 
Factors 
Smoking, diet Diet, smoking and 
appendectomy are 
protective for UC 
(Budarf et al., 2009) 
 
* Estimated from Monozygotic/Dizygotic twin concordance rates. 
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    It is understood and widely accepted that the pathogenesis of IBD arises 
from the complex interplay between the innate and adaptive immunity of a 
susceptible individual, environmental triggers and the host microbiota (Xavier 
and Podolsky, 2007). This interplay increases the level of complexity in 
unraveling the pathogenesis of IBD since the contribution of environmental 
factors and that of the genetic inheritance of several susceptibility loci and the 
interaction of these is still unknown (See Figure 2).  
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Figure 1. The Human gut and structure of the small-intestinal epithelial 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. [A] Structure of the human intestine depicting the ileal region where 
the most common form of CD occurs [B](a) The five layers of the gut.i: 
mucosa (the inner-most layer), ii: the submucosa, iii-iv: underlying muscular 
layers, v:  serosa, lining the outer muscular layer. (b)Structure of the small 
intestinal epithelium containing cells important in the gut’s biochemical barrier, 
for example the Goblet cells(c) and the Paneth cells (d). ([A] Adapted from 
http://www.nlm.nih.gov/medlineplus/ency/imagepages/19221.htm[B] Adapted from Budarf et al, 2009). 
A 
B 
  
 15 
 
 
Figure 2. Interaction of the major IBD-contributory factors. 
Illustration of the major factors that influence and interact to contribute 
towards the development of IBD. The individual contribution of each of these 
components is still unclear, although the environmental component in the 
development of UC is much stronger than that of CD development. 
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II. AN OVERVIEW OF THE IMMUNE 
RESPONSE AND INFLAMMATORY 
BOWEL DISEASE 
 
 
 
 
   The anatomical and physiological properties of the intestinal tract play an 
important role in the mechanism of IBD. The gut is made up of five different 
layers, namely the mucosa, consisting of the inner-most layer, which lines the 
gut lumen, the submucosa, an inner and outer muscular layer and the serosa, 
which lines the outer muscular layer. (See Figure 1B(a). The epithelial cells of 
the mucosa are in close contact with the venous system (at their base), as 
well as being in direct contact with the gut contents at their apical surfaces.  
The mucosal epithelial layer contains several different cell types (See Figure 
1B(b,c,d). The mucus-secreting Goblet cells (See Figure 1B(c) are 
responsible for forming a protective layer on the luminal surface of the gut 
while the Paneth cells (See Figure 1B(d), located in the ileal crypts, drive the 
production of anti-microbial peptides (Wehkamp et al., 2007) and form the 
biochemical barrier of the gut. The correct function of this dual barrier 
represents a crucial first defence mechanism in the innate immune system 
(Budarf et al., 2009), which is the first response upon epithelial penetration of 
microbes. 
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   If the gut epithelial barrier is penetrated, White Blood Cells (WBCs) are 
immediately recruited to the epithelial surface where their phagocytic 
properties come into play.  The specialized receptors on WBCs, called Pattern 
Recognition Receptors (PRRs), are able to recognize the patterns of 
macromolecules present on the bacterial cell wall and hence initiate 
phagocytosis (cell-eating), which engulfs and destroys microbes. The 
recruitment of these cells initiates a cascade involving the production of the 
necessary cytokines and chemokines as well as triggering the killing of 
microbes, which will lead to the appropriate signals required to initiate the 
adaptive immune system (Budarf et al., 2009). 
 
 
  In the situation where the response from the innate immune system fails to 
contain the microbial invasion, the adaptive immune system is activated, 
mediated by the specialised B and T Lymphocytes.  
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III. THE GUT MICROBIOTA AND 
INFLAMMATORY BOWEL DISEASE  
 
 
 
 
 
 
 
 
   The involvement of bacteria in the pathogenesis of IBD is well established, 
both through lab based studies of the gut bacteria, which show abnormal 
bacterial flora (microbiota)  in IBD and  through association studies on IBD 
that identified susceptibility genes involved in bacterial recognition. However, 
the exact role of the microbiota in the pathogenesis of IBD is still unclear. In 
healthy conditions, the gut microbiota plays a commensal as well as beneficial 
role in the human gut. The microbiota assists the nutrition of the human host, 
via the production of short chain fatty acids and vitamins, such as vitamin K, 
vitamin B12 and folic acid, but also prevents the colonisation of the gut by 
harmful bacteria (Mai and Draganov, 2009). In contrast to this commensal 
role, the gut bacteria carry antigens such as lipopolysaccharide and 
peptidoglycans which can stimulate an immune response. There is a crucial 
fine balance between host immune tolerance and response and the gut 
microbiota. Dysbiosis, which is the imbalance of microbial communities inside 
the digestive tract, of the mucosal and faecal microbiota has been reported for 
both CD and UC (Cobrin and Abreu, 2005; Targan and Karp, 2005). A loss in 
microbial diversity is also commonly observed in IBD patients (Ott et al., 
2004).  
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   In the case of CD, dysbiosis of the faecal microbiota has also been reported 
in the unaffected family members of CD patients, when compared to healthy 
controls in the general population. Joossens et al  (Joossens et al., 2011) 
reported that this dysbiosis in the CD patients was mainly characterised by 
five predominant bacterial species. A decrease in the population levels of 
Bifidobacterium adolescentis, Dialister invisus, Clostidrium cluster XIVa 
(uncharacterised species), and Faecalibacterium prausnitzii and an increase 
in levels of Ruminococcus gnavus have been identified in CD patients 
(Joossens et al., 2011). F. prausnitzii are bacteria that produce butyrate, 
which have anti-inflammatory properties, and even lower numbers of F. 
prausnitzii are seen in patients who have had an ileocaecal resection 
(Joossens et al., 2011). R. gnavus do not produce butyrate but are known to 
degrade gastrointestinal mucin and exhibit high levels of β-glucuronidase  
(Beaud et al., 2005). This elevated enzymatic activity can lead to the 
production of compounds in the colon which are toxic and possibly lead to 
local inflammation (Joossens et al., 2011). This could suggest that increase in 
the levels of R. gnavus in certain regions of the colon and not others could at 
least in part explain the segmental nature of the inflammation, which is 
characteristic of CD. In the same study, the unaffected members of the CD 
families exhibited a decrease in the population levels of Collinsella 
aerofaciens, a member of the Escherichia coli-Shigella group and an increase 
in that of Ruminococcus torques. As R.gnavus, R. torques do not produce 
butyrate but have gastrointestinal mucin-degradation capacities. These 
findings suggest that there is a lack of butyrate-producing activity in CD 
patients, coupled with enhanced mucin-degradation capacity. 
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IV. GENETIC STUDIES 
 
  
 
   As previously shown in Table 1, CD has a disease prevalence of 
somewhere between 26 to 199 per 100,000 in populations of European 
ancestry (Loftus, 2004). Although it is a complex disease there is strong 
evidence for genetic susceptibility.  The estimated sibling recurrence risk ratio 
(λs) ranges from 15-35 (Schreiber et al., 2005), where λs is defined as the 
ratio of disease manifestation, given that one sibling is affected, compared 
with the disease prevalence in the population. However, it was reported 
earlier (Satsangi, 1994) that the highest λs of 35 was found in a study that 
only included patients with early onset CD (disease onset prior to the age of 
21) and the high values could also be attributable to inclusion of different 
ethnicities in the studies, in comparison with the general population, in 
particular Ashkenazi Jewish patients, (Ashkenazi Jewish communities are 
known to have a  high CD prevalence and a tendency towards familial CD). A 
UK-based study of homogeneous ethnicity and adult-onset disease put the λs 
estimate closer to 24.7 (Satsangi, 1994). Other studies have shown a high 
heritability of around 0.50, with the heritability being measured from the 
difference in correlation between monozygotic and dizygotic twins (Tysk et al., 
1988). Because of this high λs and high heritability for a polygenic disease, 
CD is one of the most widely studied multifactorial diseases. 
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   Early linkage studies, followed by Genome Wide Association Studies 
(GWAS), were crucial in identifying the first gene involved in IBD. Linkage 
analysis revealed several different linkage peaks across the genome 
(Cavanaugh, 2001; Parkes et al., 2000).  In particular there was an extensive 
linkage peak in Non Jewish CD families on Chromosome 16q, at the IBD1 
locus, where the gene NOD2 is located (Cavanaugh, 2001).  Subsequent 
analyses of this linkage region lead to the first breakthrough, with the 
discovery that three common NOD2 (previously known as CARD15) variants 
were associated with CD (Figure 3) (Hugot et al., 2001). The encoded protein, 
NOD2 is a Nucleotide-binding Oligomerisation Domain protein that has the 
ability to recognize, intracellularly, microbial cell-wall components, namely 
Muramyldipeptide (MDP), through its Leucine Rich Repeats (LRRs) (Figue 3). 
The three NOD2 mutations identified are located within or close to the LRRs, 
with the framshift mutation resulting in truncated version of the protein. No 
mutations within NOD2 that ablate the production of the entire protein have 
yet been identified (Eckmann and Karin, 2005). Functional evidence of the 
three identified NOD2 mutations, which are illustrated in Figure 3 and in Table 
2, will be further discussed in Chapter II. 
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Table 2. The CD-associated NOD2 mutations. 
 
rsID Change Type 
rs2066844  R702W Missense  
rs2066845 G908R Missense 
rs5743293 3020insC Frameshift 
 
 
 
 
 
 
 
 
 
Figure 3. Representation of the NOD2 gene and the relative positions of 
the three common CD-associated NOD2 mutations (rs2066844- R702W, 
rs2066845- G9608R and rs5743293- 3020insC). 
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   NOD2 is constitutively expressed in cells of the myeloid lineage including 
neutrophils and macrophages and its discovery thus provided the first genetic 
link between CD and an aberrant immune system (Budarf et al., 2009; 
Eckmann and Karin, 2005; Hugot et al., 2001). However, the strong evidence 
of linkage on Chromosome 16q could not be fully accounted for by NOD2 
alone since linkage on 16q is still observed in families that do not carry the 
common NOD2 mutations. This suggested that there were other, yet 
unreported, susceptibility genes in the 16q region.   
 
 
   UC is the more prevalent form of IBD, with a disease prevalence of around 
37-246 per 100,000 in populations of European ancestry (Loftus, 2004). The 
estimated siblings recurrence risk ratio λs is approximately 8.5 (Orholm et al., 
1991). UC has a lower genetic component than CD, with heritability estimated 
at about 10% (Thompson and Lees, 2011). Despite the complex nature of UC 
and the lower genetic contribution, early linkage studies still successfully 
identified linkage peaks for UC, notably on chromosomes 1, 4, 6, 12, 22 and 
X, some of which were shared with CD (Hampe et al., 1999; Parkes et al., 
2000). Unlike for the case of CD, no genes were pin-pointed and linkage was 
not observed for UC at the IBD1 locus (NOD2 region) on chromosome 16q 
(Ohmen et al., 1996). This  was one of the first indications for the existence of 
genetic differences between CD and UC, with NOD2 being a CD-specific 
factor with a large effect. 
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   Subsequent advances in genomics, including the creation of the 
International HapMap Project, followed by the advent of high-throughput 
Single Nucleotide Polymorphism (SNP) genotyping made possible large-scale 
GWASs, and it is data from these that will be used in my project. HapMap is a 
multi-national effort that aims to catalogue human genetic variation in order to 
help scientists identify susceptibility genes predisposing to disease as well as 
genes involved in individual responses to pharmacological drug metabolism 
and gene-environment interactions (Risch and Merikangas, 1996). 
 
 
   The term polymorphism is usually applied to variation which is present at a 
frequency of 1% or more in the general population. Although the data that will 
be discussed in this thesis will consist of genome-wide SNP data, there are 
other types of genetic variation present in the human genome. Genetic 
variation can be subdivided into small-scale sequence variation and large-
scale structural variation. The latter include Copy Number Variation (CNV), 
which involves the loss or gain of a copy of a sequence segment, which may 
include part or all of a gene, as well as Chromosomal Rearrangements such 
as translocations and inversions. Small-scale sequence variation includes 
Variable Number Tandem Repeats (VNTRs), such as Microsatellites, which 
consist of simple-sequence repeats in the genome. Microsatellites have been 
extensively used in Linkage studies as they exhibit substantial heterozygosity 
due to the fact that they are multi-allelic. Base insertions or deletions, also 
known as Indels, are also a common source of genetic small scale sequence 
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variation in addition to SNPs. While SNPs (due to allelic imbalance) can be 
used to detect CNVs genome-wide, CNVs are hard to analyze in genome-
wide studies.  The same applies to VNTRs, and microsatellites. Small indels 
are also not included in SNP arrays and all these types of variations may  be 
important particularly in regulatory regions of the human genome.  
 
i. Association Studies 
 
 
 
 
   Before the advent of GWAS, SNPs in candidate gene/regions, often but by 
no means always selected as the result of linkage studies, and most often 
with a strong hypothesis of putative function, were genotyped and tested for 
association with the underlying phenotype. Candidate gene association 
studies that were selected as a result of linkage studies would attempt to 
narrow down the very large linkage regions, generally spanning more than 
one megabase in length, in order to ultimately pin-point the causal variant. 
Indeed, this was the case for the breakthrough with NOD2 in relation to CD, 
where the linkage was followed up through fine-mapping by positional cloning 
and subsequent candidate gene analysis (Hugot et al., 2001). Linkage 
analysis comes with several advantages, particularly the ability to detect 
genetic variants of large effect with just a thousand genome-wide genetic 
markers from a few transmissions within the families studied. Linkage studies 
are also robust to confounding effects and information can be combined 
across families even in cases where there are different mutations presenting 
at the same locus. For these reasons, linkage analysis performs well for 
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highly penetrant, single–gene disorders but success has been more difficult 
when linkage analysis was employed for complex traits, which are polygenic 
conditions thought to be caused by a multitude of variants of low effect-size. 
Thus, association studies have become the preferred approach in identifying 
susceptibility loci for complex conditions (Risch and Merikangas, 1996). 
Although association studies are not robust to effects resulting from 
population structure,  association studies are not limited to families and it is 
thus easier to recruit a large number of patients and they provide better power 
for detecting common variants of low effect sizes. However the false-positive 
rate is higher in association studies than it is for linkage studies. 
 
 
   A GWAS consists of the hypothesis-free analysis of SNPs across the 
genome to investigate whether the genotype (genotypic test) or allele (allelic 
test) frequencies for each SNP is significantly different between cases (group 
affected by the trait) and ethnically matched controls (healthy group). A 
statistically significant difference provides evidence for association between a 
particular marker and the trait under study, which requires replication in an 
independent cohort. SNP genotyping platforms currently used in GWAS can 
accommodate around one million SNPs, beneficially increasing the SNP 
resolution across the genome but also giving rise to multiple testing issues 
due to the individual testing of each SNP. The consequent lack of power 
means that meta-analyses are now used to improve the number of genetic 
hits. A meta-analysis combines genotypic or allelic test statistics for the 
individual SNPs across all the independent GWASs in order to increase 
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power to detect association by having a much higher sample size. The 
significant results from a meta-analysis require validation and are followed up 
in an independent replication sample.  
 
 
   Despite their lack of power, the hypothesis-free nature of GWASs, coupled 
with the exponential improvement in high-throughput SNP analysis, has 
nowadays made GWAS the most favourable type of population-based 
disease-association mapping for complex diseases.  
 
 
 
ii. Linkage Disequilibrium 
 
   Linkage analysis relies on current recombination, and is thus low resolution 
due to the limited number of markers that can be informative to obtain linkage 
phase since there are only a few meiosis within the families studied whereas 
association relies on the presence and structure of Linkage Disequilibrium 
(LD), which reflects distant shared ancestry and therefore many 
recombination events,  both current and historic, providing a much higher 
resolution than linkage. LD is the non-random association of alleles at two 
closely-linked loci within a random-mating population. Recombination seems 
to be the major cause of LD breakdown, since LD patterns mirror 
recombination (Maniatis et al., 2002). However, natural selection, genetic drift, 
population subdivision and population bottlenecks are all factors that influence 
LD structure (Kong et al., 2010). Historically recent mutations are likely to be 
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in high LD with the surrounding SNPs, even in regions of recombination, but 
are likely to be rare unless selection or demographic processes have 
increased their frequency. 
 
 
   The extent of LD can be measured using several metrics although the most 
common include the covariance (D), the ratio of D to its maximum possible 
absolute value (D), association (ρ), correlation (r) and correlation coefficient 
(r2) (Tapper, 2007) (see Appendix I for formulae). Most of these metrics 
heavily rely on allele frequencies with the exception of D and ρ (Morton et al., 
2001; VanLiere and Rosenberg, 2008), which are less sensitive to variations 
in allele frequencies (Morton et al., 2001). r2 has more power for selecting 
tagging SNPs than D but is less good at signaling lack of recombination of 
low frequency alleles. It gives a value of 1 where the allele frequencies of the 
SNPs are the same and there is no recombination, but lower values where 
one of the two SNPs is rare.  r2 has been extensively used in GWA studies, 
for example in defining LD intervals in meta-analyses. 
 
 
   Each individual has two homologous chromosomes, one inherited from 
each parent. Therefore, since genotyping platforms are so far unable to 
assign SNP alleles to their respective homologues, the genotyped SNPs need 
to be phased. Phasing is the determination of which SNP allele belongs to the 
maternal or paternal homologue, which is in turn required in order to 
determine haplotype blocks. Haplotype blocks are genomic regions that 
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contain markers exhibiting strong LD with one another and thus tend to be 
inherited together from generation to generation. With the increasing 
technological advances and decreasing cost of SNP genotyping, haplotype 
inference and phasing using statistical approaches has become one of the 
major areas of statistical methodological expansions. Expectation 
Maximization (EM) is an algorithm that can be used or underlies many 
statistical approaches used for haplotype inference. EM utilizes an iterative 
approach in order to infer the haplotype phase, which maximizes the 
likelihood, or in other words best describes, the data observed. EM works well 
for a limited number of SNPs, generally ten, but haplotype phase accuracy 
declines with a greater number of SNPs and the process becomes 
computationally costly (Browning and Browning, 2011).  
 
  
   In such cases, Coalescent-based models, such as Approximate Coalescent 
models and Hidden Markov Models (HMM), provide more accurate haplotype 
phasing as haplotype frequencies are better modeled a priori  (Browning and 
Browning, 2011). The Approximate Coalescent Model assumes the ancestral 
convergence of alleles back in time, for which the parameters are sometimes 
estimated using a stochastic EM framework to explore all possible solutions or 
by Markov Chain Monte Carlo (MCMC) methods  (Browning and Browning, 
2011) . 
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   Although HapMap contains a reference panel of over three million SNPs, 
the current genotyping platforms used in GWASs only contain a subset of this 
reference panel. In fact, in some cases the SNPs only partially overlap 
between different genotyping arrays. Nevertheless, indirect association can 
still be observed if the typed SNP is in LD (high r2 value) with the putative 
causal agent.  The power to detect the untyped putative causal agent 
depends on the allele frequency, and its effect size, as well as the strength of 
LD with the genotyped SNP. Meta-analyses combine several different 
GWASs, often carried out using different SNP genotyping arrays, which 
despite some overlap, by design they contain different SNPs making the 
combination of test statistics for the same SNPs across the genome difficult 
among the different studies. Therefore, imputation has been suggested as a 
way to create a homogenous subset of SNPs to meta-analyse the different 
independent GWASs. Imputation is an inference method which takes 
advantage of association between the genotyped SNPs and untyped SNPs. 
Genotypes of untyped SNPs are inferred by reference to a panel of densely-
typed individuals (Guan and Stephens, 2008) (e.g. HapMap database, 1000 
Genomes Project). The imputed genotypes are obtained using a Bayesian 
approach that uses a predicted distribution that is based on haplotype 
inference from the observed genotypes (Sterne et al., 2009). Imputation has 
been used universally in GWASs, meta-analyses and other epidemiological 
studies and introduces small approximations in regions of conserved LD, but 
can potentially introduce significant bias and inaccuracies in regions of LD 
breakdown. Imputation algorithms are generally user-defined for each 
particular dataset in order to carefully model the distribution of each variable 
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with missing values. Even so, imputation remains an approximation 
technique. In fact, in a published cardiovascular risk prediction tool that was 
developed using imputation to handle missing data, it was initially reported 
that cardiovascular risk was unrelated to cholesterol (Sterne et al., 2009), 
(Hippisley-Cox et al., 2007). It was however subsequently clarified that when 
the analysis was carried out using only individuals without missing data, a 
clear association between cardiovascular risk and cholesterol was observed 
(Sterne et al., 2009), which highlights the limitations of using imputation for 
missing data. 
 
 
   In addition to these potential inaccuracies in the meta analyses, the lack of 
power in detecting genome-wide association could be due to the unrealistic 
assumption that one of the SNPs on the genotyping platform is either causal 
or in almost complete LD, as defined by r2, with the putative causal agent.  
This would not be the case for rare variants nor in regions of breakdown of 
LD.  In fact it is now widely accepted that the currently used standard methods 
of analysis are underpowered for detecting rare variants, which could be 
responsible for substantial allelic heterogeneity in complex diseases (Li and 
Leal, 2008). 
 
 
   Secondly, another reason for the lack of power comes from the stringent 
significance thresholds required as a result of multiple testing. Additionally, 
the P-value for each individual SNP across datasets does not need to reach 
  
 32 
nominal statistical significance across all the independent GWASs in order for 
the P-values in the datasets to be meta-analysed.  Another problem of the 
meta-analysis approach is that it inevitably leads to the pooling of several 
phenotypic subgroups, as well as different ages of onset (early-onset and 
adult-onset) as well as ethnicities in order to increase the sample size and 
hence power to detect association.  
 
 
iii. Crohn’s Disease and Ulcerative Colitis GWASs 
 
 
   The relatively large λs makes CD a good case for genetic studies. In fact, 
initial studies focused more on CD than UC. One of the first large-scale 
GWAS was conducted by The Wellcome Trust Case Control Consortium 
(WTCCC), which analysed ~14,000 cases of seven common diseases, 
including CD (WTCCC, 2007). The UK WTCCC Phase I CD GWAS analysis 
identified an initial 9 CD susceptibility loci using ~2,000 cases (WTCCC, 
2007). Several other GWASs investigated CD associations in different 
Caucasian populations, including Belgian (Libioulle et al., 2007), German 
(Hampe et al., 2007) and USA (McGovern et al., 2010), as well as different 
ethnicities, namely Jewish and Non-Jewish from North America (Rioux et al., 
2007). The largest CD association study to date consisted of a meta-analysis 
of six of the available independent GWAS datasets, one of which only 
consisted of early-onset CD patients (Imielinski et al., 2009), combining 6,333 
cases and 15,056 controls (Franke et al., 2010). This meta-analysis identified 
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and confirmed a total of 71 intervals (loci) for CD susceptibility. However, 
despite the large sample size, only NOD2 was detected on 16q, despite 
expectations of other loci on that chromosome. Additionally, in several cases, 
the LD intervals were quite large (over 1 Megabase) with several suggested 
genes within them. Despite the international efforts, the confirmed 71 CD loci 
found up until that time through the several GWASs and meta-analyses were 
reported to account for only 23.2% (Franke et al., 2010) of the genetic 
contribution, suggesting that there were many more loci to be found and that 
further research is required to fully understand the genetics of CD. 
 
 
    Following the WTCCC Phase I studies that encompassed CD, the WTCCC 
Phase II data generation extended the list of phenotypes under investigation, 
and now incorporated UC as one of the datasets. The WTCCC Phase II UC 
data consisted of a larger sample size than the WTCCC CD data, which is 
more convenient for detecting association in situations like UC, where the 
genetic contribution is lower than for other complex conditions like CD 
(Consortium et al., 2009).  Several other GWASs from a variety of geographic 
locations, including Germany, Belgium, Japan and Korea were carried out 
(Anderson et al., 2011; Asano et al., 2009; Consortium et al., 2009; Ellinghaus 
et al., 2013; Franke et al., 2008; Franke et al., 2010; Hampe et al., 1999; 
Haritunians et al., 2010; McGovern et al., 2010; Silverberg et al., 2009; Yang 
et al., 2013). 
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   More recently, with the aim of expanding the knowledge of the aetiology of 
IBD, a large-scale genome-wide meta-analysis was carried out, combining 
data from 15 GWASs of CD and/or UC together with Immunochip genotyping 
data, where the latter genotyping platform consisted of specific SNPs within or 
in regulatory regions of immune-related genes.  The sample size consisted of 
more than 75,000 cases and controls together, making this study the largest 
IBD meta-analysis to date (Jostins et al., 2012) and will be discussed in 
further detail in Chapter IV. This study identified and replicated 30 CD-
specific, 23 UC-specific and 110 UC and CD shared susceptibility loci, 
resulting in 163 confirmed general IBD susceptibility loci (Jostins et al., 2012). 
In the European population, the total number of confirmed UC loci now stands 
at 59, explaining, it is claimed, approximately 16% of the genetic contribution 
(Jostins et al., 2012).  
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V. ANOTHER APPROACH- LINKAGE 
DISEQUILIBRIUM UNIT MAPS 
 
 
 
 
   Another approach to association studies is to combine information from 
many adjacent markers, such as the multi-marker method developed by  
Maniatis et al  (Maniatis et al., 2007; Maniatis et al., 2005).  The power of this 
multi-marker method comes partly from the fact that it does not assume the 
putative causal agent to be in high LD, as measured by r2, with the genotyped 
SNP since SNPs within a genomic window are simultaneously analysed within 
a composite likelihood framework, and partly from the fact that this method 
incorporates the structure of LD in the human genome by modeling on genetic 
distances in LD Units (LDUs) in contrast to physical location in kb.  
 
   LDU maps represent the genetic distance of SNPs, as opposed to their 
physical distance. Conventional genetic maps in centi Morgans (cM) are 
based on recombinants from family data. Such maps can only capture the 
recently-occuring recombination events since there are only a few generations 
involved in family data. The main limitation of genetic maps in cM is their 
relative low resolution since only informative, in other words markers 
exhibiting heterozygosity in relevant members of the pedigree, can be used 
for such maps. Microstallite (STR) polymorphisms are ideal, but not frequent 
enough in the genome.  The later genetic map is based on approximately 
300,000 informative SNPs on Utah Residents samples with Northern and 
Western European ancestry from the Centre d’Étude du Polymorphisme 
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Humain (CEPH) collection, together with families from the deCODE project 
(Kong et al., 2010). On the other hand, LDU maps provide information from 
both current and historic recombination events based on the shared ancestry 
of unrelated individuals and they can be constructed from millions of markers.  
LDU maps are generally constructed from SNP data using an adaptation of 
the Malécot model of isolation by distance, which describes the decline of 
pairwise SNP association as a function of physical distance as shown in 
Figure 4, with cumulative distances in LDU (Maniatis et al., 2002).  
 
 
 
 
Figure 4. The Relationship between LD and physical distance 
Illustrates the best-fit line of various estimates of the observed pairwise SNP 
associations (ρ(obs). ε is the exponential decline in association ρ as a function 
of increasing physical distance between pairs of SNPs. The greater the 
exponential decline ε of pairwise SNP association, the faster the decay of LD 
(as shown at ε=0.008). 
  
 37 
 
   The methodology for constructing LDU maps is given by Maniatis et al 
(Maniatis et al., 2002) using the LDMAP software (Lau et al., 2007) and is an 
extension of earlier work (Morton et al., 2007). It is based on the Malécot 
model that describes the expected decline of association ρ(exp) between any 
pair of SNPs as: 
 �ሺࢋ�࢖ሻ = ሺ૚ − ࡸሻࡹࢋ−��࢏ࢊ࢏ + ࡸ 
 
where ρ(exp) is the expected association, M is the initial value of LD before 
decay begins, thus representing the intercept and L is the asymptote. M 
reflects the phylogenetic origin of haplotypes, where M=1 indicates a unique 
haplotype and hence a monophyletic origin, and M less than 1 suggests a 
polyphyletic origin, and thus the presence of more than one ancestral 
haplotype (Collins and Morton, 1998). L is the asymptote, which corrects for 
spurious associations at large distances. The exponential decline εi 
represents the decline of association as a function of physical distance (di) 
between a pair of SNPs, with di representing the distance in kb between a 
marker i and a neighbouring marker i+1. The product of εidi is analogous and 
more accurately known than the product of recombination θ and t time in 
generations and hence εidi  is a better metric for LD (Tapper, 2007). The 
observed pairwise SNP-by-SNP associations calculated using the parameter 
ρ(obs) are used to iteratively estimate, using Maximum Likelihood, the 
parameters M, ε and L. 
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   To do this, it is necessary first to assign phase, which is done using the Hill 
algorithm (Hill, 1974), which uses a maximum likelihood approach to infer 
phase for each pair of SNPs from the frequency of diploid genotypes.  The 3-
by-3 diplotype table can then be converted into a 2-by-2 table, from which the 
allele frequencies Q and R and the covariance D, are calculated. An example 
of the 2-by-2 haplotype table is illustrated in Table 3: 
 
 
 
Table 3. 2x2 count pf haplotype frequencies. 
 
 
 
SNP 
A 
 
SNP B  
1 2 
1 a = f11 b = f12 Q     (a+b) 
2 c = f21 d = f22 1-Q (c+d) 
 
R (a+c) 1-R (b+d) 
 
f is the frequency of the inferred haplotype and (1-Q ) and (1-R) are the allele 
frequencies.  
 
 
The covariance D can then be calculated as follows: 
 ࡰ = ࢌ૚૚ࢌ૛૛ −  ࢌ૚૛ࢌ૛૚ 
 
 
The observed association ρ(obs) can then be calculated as follows: 
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 �ሺ࢕࢈࢙ሻ=ሺࢇࢊ−࢈ࢉሻ ሺࢇ+࢈ሻሺ࢈+ࢊሻ⁄  
 
which is equivalent to: 
 �ሺ࢕࢈࢙ሻ= ࡰ ࡽሺ૚−ࡾሻ⁄  
 
 
 
where D is the covariance between the two markers, and Q and R are the 
allele frequencies calculated from the 2-by-2 haplotype table illustrated in 
Table 3. The difference between D and D is that for the latter, D is normalized 
by the theoretical maximum and minimum for the observed allele frequencies 
relative to the value of D,  as is shown in Appendix 1. 
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Figure 5. Expected Pairwise Association per SNP interval. 
This figure illustrates the first five SNPs of a chromosome, with the first SNP 
interval composed of pairwise SNP association between SNP1-SNP2, SNP1-
SNP3, SNP1-SNP4, SNP1-SNP5, which are used to estimate values of ε. 
 
 
   Figure 5 illustrates the first five SNPs on a chromosome, where the first 
SNP interval is composed of pairwise associations between SNP1-SNP2, 
SNP1-SNP3, SNP1-SNP4, SNP1-SNP5 …SNP1-SNPn. For each ith SNP 
interval, the Malécot model  
 �ሺࢋ�࢖ሻ = ሺ૚ − ࡸሻࡹࢋ−��࢏ࢊ࢏ + ࡸ 
 
is subsequently used to iteratively estimate, using a maximum likelihood 
approach, the values of M, ε and L, by using all the observed pairwise 
association for the SNPs covering that specific interval, and their 
corresponding distances di in kb, weighted by the information Kρ for each 
interval (Tapper, 2007). This information is now used to construct LDU maps 
where: 
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ࡸࡰ� =  �࢏ࢊ࢏ 
 
for every SNP interval. 
 
 
  These LDU maps can describe the underlying structure of LD (Maniatis et 
al., 2002) and are visualized by plotting marker locations in LDU against 
distances in kb, which demonstrate the non-linear relationship between 
physical distance and LD. These metric genetic maps are analogous to 
linkage maps in cM (Tapper et al., 2005). Blocks of conserved LD are areas of 
reduced haplotype diversity while steps represent LD breakdown most likely 
due to recombination as cross-over profiles agree with LDU patterns (Webb et 
al., 2008). Although patterns of LD are mainly a consequence of  
recombination (Jeffreys and Neumann, 2009), other factors, such as selection 
and genetic drift, as well as stochastic effects are important (Slatkin, 2008). 
HapMap Phase II data is used to obtain genetic distances in LDU since their 
estimation is based on a higher resolution as a result of a denser SNP 
coverage as opposed to HapMap III.    
 
 
   Subsequent to the construction of LDU maps, for each analytical window 
the same Malécot model is used to model the decline of affection-status-by-
SNP association as a function of genetic distance in order to estimate the 
location of the putative causal agent. This will be discussed in more detail in 
Chapter II. One of the major advantages of using composite likelihood over 
  
 42 
single-SNP testing is a greatly reduced number of tests and hence a less 
stringent multiple-testing correction. This method therefore addresses the 
current major problem of lack of power associated with single SNP testing and 
avoids the need for imputing as a result of analysing SNPs simultaneously in 
analytical windows. Other details are given in Maniatis et al (Maniatis et al., 
2007), which provides evidence of the power and resolution of this approach 
over single SNPs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 43 
VI. GENERAL AIMS OF STUDY 
 
 
 
 
   The overall aim of this study was to make progress on elucidating the 
complex genetics of IBD using the multi-marker LD mapping approach 
described in the previous section (Maniatis et al., 2007). The first step in this 
study was to re-analyse Chromosome 16q in relation to CD, on the publically 
available WTCCC CD data and the North American National Institute of 
Diabetes and Digestive and Kidney Diseases (NIDDK) IBD Genetics 
Consortium CD data (IBDGC) as a replication sample, with the aim of 
identifying novel susceptibility genes on Chromosome 16q, other than NOD2. 
The goal of this part was to shed light on the possibility of genetic 
heterogeneity underlying the region of significant linkage on 16q in patients 
who do not carry the common NOD2 mutations.  
 
 
   The second step was to apply the same multi-marker approach to the whole 
genome using the same data (WTCCC and NIDDK) for CD. The first aim was 
to identify whether the 71 previously reported CD loci based on the meta-
analysis of six GWASs, could be identified using only the WTCCC and NIDDK 
datasets.  The second was to see whether this method would identify novel 
susceptibility loci for CD, since the 71 loci did not appear to account for the 
total genetic contribution.  
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   Subsequently, the attention was shifted towards UC. The same method was 
applied to the WTCCC Phase II UC data and two NIDDK UC datasets as 
replication samples, in order to identify novel susceptibility loci for UC. 
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CHAPTER II. DISSECTING CHROMOSOME 
16: GENETIC AND PHENOTYPIC 
STRATIFICATION PROVIDES INSIGHT 
INTO CROHN’S DISEASE. 
 
 
 
 
 
I. INTRODUCTION 
 
 
 
   One of the major breakthroughs in CD genetics came in 2001 when three 
functional mutations within NOD2 were identified, as a culmination of the 
previous work using family and association studies. NOD2 encodes a protein 
that is responsible for recognizing pathogens through its Leucine Rich 
Repeats (LRRs) domain and hence this discovery provides a direct link to a 
genetically altered host immune system (Budarf et al., 2009; Hugot et al., 
2001).  
 
 
   It was however subsequently reported that there is a lack of direct 
relationship between the prevalence of these three mutations (rs2066844, 
rs2066845, rs5743293, see Table 2 and Figure 3 in Chapter I) in the general 
population and CD frequency (Hugot et al., 2007). Indeed, NOD2 mutations 
have not been found in all CD patients (Lesage et al., 2002), although this is 
not surprising in complex inheritance. It is also important to note that the 
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NOD2 mutations are also relatively frequent in healthy individuals in Central 
Europe, and the average frequency of these mutations in Caucasians is 4.3% 
for R702W (rs2066844), 1.2% for G908R (rs2066845) and 2.3% for the 
L1007fsinsC frameshift mutation (rs5743293) (Hugot et al., 2007). In addition, 
the linkage peak originally identified on chromosome 16 persisted even after 
the patients that were found to have the NOD2 mutations were removed from 
the data set, however in this case, the linkage peak shifted some 25cM 
downstream of the NOD2 gene (van Heel et al., 2003), suggesting the 
presence of other chromosome 16q susceptibility genes. Despite the shift in 
the linkage peak, no other signals on 16q have been found so far in published 
GWA studies. To add to the complexity, NOD2 mutations are associated with 
ileal CD but not with perianal or colonic disease (Ahmad et al., 2002), further 
suggesting the involvement of both genetic and phenotypic heterogeneity in 
relation to CD.   
 
 
   At the outset of this thesis work, the IBD Genetics Consortium had made 
significant progress in mapping genes involved in CD, and combined GWASs 
identified an initial 32 susceptibility loci (Barrett et al., 2008), which included 
NOD2 on chromosome 16q, followed by an additional 39 (Franke et al., 
2010), making a total of 71.  Several of these loci are implicated in other 
diseases involving inflammatory and immune dysregulation (thus, PTGER4 on 
Chromosome 5p, is common to CD, UC (Anderson et al., 2011) and multiple 
sclerosis).  However, this study reported that the 71 loci account for only 
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23.2% (Franke et al., 2010) of the genetic risk a problem of so-called “missing 
heritability”. 
 
 
  In this chapter I describe how the GWA database was revisited using the 
multi-marker LD mapping approach mentioned in the Introduction (Maniatis et 
al., 2007).  This first analysis focused on the previously identified IBD1 linkage 
region on Chromosome 16q (Cavanaugh, 2001), since the strong evidence for 
linkage in this region cannot be fully accounted for by NOD2 alone. Indeed, 
using this LDU multi-marker approach, several distinct association signals of 
high significance were identified on chromosome 16q alone. For this first step, 
I focused on three of these signals to study in detail. Each of the three signals 
was found in the WTCCC data and, quite independently, in the NIDDK 
dataset, which also contains information on Jewish ancestry as well as 
additional sub-phenotype data.  
 
 
The work in this chapter has already been published (Elding et al., 2011) and 
contributions made by others are mentioned in the subsequent text. 
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II. METHODS 
 
 
 
 
 
i. Subjects and Methods 
 
 
 
 
   2,009 cases of Crohn’s Disease and 3004 combined controls from the GWA 
scan of the UK WTCCC study (WTCCC, 2007) based on the Affymetrix 500K 
array, which contains approximately 500,000 SNPs, were analysed in this 
study. Half of the ~ 3,000 nationally-ascertained controls came from the 1958 
British Birth Cohort collection and the remainder from the UK Blood Services 
Collection of Common Controls (WTCCC, 2007).  
 
 
   For this study, the quality control filtering was conducted by Winston Lau 
and the procedure that was followed is described in detail in the Methods 
section of Chapter IV. After quality control, a total of 1698 cases and 2948 
combined controls were retained for analysis. The cases were confirmed 
patients of any subtype of CD using endoscopic, radiological procedures and 
histopathological criteria. The cases were not specifically enriched for early 
age of onset or family history and they were from a variety of IBD clinics. For 
the replication study, following quality control, 813 North American patients 
with CD and 947 controls made available by the NIDDK IBD Genetics 
Consortium (IBDGC) were analysed. The NIDDK IBDGC GWA scan was 
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based on the Illumina HumanHap300 array (Rioux et al., 2007), consisting of 
approximately 320,000 SNPs, and has a smaller sample size and SNP set 
that only partially overlaps with the WTCCC SNP array. The WTCCC reports 
fewer phenotypic data than the NIDDK study does, and the latter includes 
information on the involvement of other intestinal locations.  
 
 
ii. Genetic analysis 
 
 
 
 
   A high density LDU map for the whole of chromosome 16 had been 
previously constructed using the CEU (Utah residents with Northern and 
Western European ancestry) PHASE II data from the HapMap Project (Lau et 
al., 2007). See Chapter I for details about the construction of LDU maps. 
 
 
   The entire 16q was divided into non-overlapping windows based on the LDU 
map, with a minimum length of 10 LDU and a minimum number of 30 SNPs 
for each window (See Figure 6). 
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Figure 6. Partitioning the Chromosome. 
The chromosome arm is partitioned into non-overlapping 10 LDU windows 
and a minimum of 30 SNPs in each 10 LDU window.  
 
 
 
 
 
 This resulted in 98 windows for 16q for both GWA datasets. For each window 
the LDU mapping method previously published by Maniatis et al (Maniatis et 
al., 2007) was used, which will be described in detail in this section. This 
method returns a P-value and an estimate of the causal location (Ŝ) using 
genetic locations derived from a high–resolution linkage disequilibrium (LD) 
map (Maniatis et al., 2002). The association mapping approach that was 
applied for each window was based on the same Malécot model but ρ was 
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replaced with z, which reflects the association between the affection status 
and every SNP. 
 
 
Table 4. A 3x2 table of Affection Status-by-genotype, coverted into a 2x2 
table of Affection Status-by-SNP alleles. 
 
Affection Status Genotypes 
 AA Aa aa 
Affected     1 nAA nAa naa 
Unaffected 0 nAA nAa naa 
Affection Status Alleles 
 A a Total 
Affected     Count a= 2( nAA) +nAa b= 2( naa) + nAa f a+b 
Unaffected Count c= 2( nAA) +nAa d= 2( naa) + nAa 1-f  c+d 
Total           
Frequencies 
R 1-R 1 
                   Count a+c b+d n=a+b+c+d 
 
f is the frequency of the affected individuals and R is the allele frequency.  
 
 
 
The observed association z(obs) can then be calculated as follows (see Table 
4): 
 �ሺ࢕࢈࢙ሻ =  ሺࢇࢊ − ࢈ࢉሻ ሺࢇ + ࢈ሻሺ࢈ + ࢊሻ⁄  
 
Which is equivalent to: 
 �ሺ࢕࢈࢙ሻ =  ࡰ ࢌሺ૚ − ࡾሻ⁄  
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where D is the covariance between the Affection Status and the marker 
alleles and f is the frequency of affected individuals in the population and R is 
the allele frequency. 
 
    The objective of this method is to estimate Ŝ, which is the location of the 
causal variant on the HapMap LDU map. Therefore, the distance d in the 
model is replaced with |(Si-Ŝ)| where Si is the LDU location of the ith marker 
within the window and Ŝ is the location estimate.  
 �ሺࢋ�࢖ሻ = ሺ૚ − ࡸሻࡹࢋ−�|ࡿ࢏−ࡿ̂| + L 
 
   Each window was tested for association with CD by using composite 
likelihood (Λ) that combines information from all single-SNP tests within each 
window, and therefore avoids undue multiple testing correction. Λ is estimated 
as: 
 � =  ∑ ࢑࢏[�ሺ࢕࢈࢙ሻ࢏ −  �ሺࢋ�࢖ሻ࢏]૛ 
 
where is the observed association between the affection status and 
every ith SNP and is the expected association from the model, weighted 
for nominal information Ki.  
 
)( iobsz
)exp( iz
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   The significance of association for each window was obtained by calculating 
an F-statistic from the comparison between Λ from the null model, assuming 
no association, and Λ from the alternative, where the Ŝ is iteratively 
estimated. Since each window will contain a different number of SNPs, the P-
value takes into account the different degrees of freedom for each window. 
Therefore, for convenience, the F-statistic is converted to a χ2 with 1 degree 
of freedom (Maniatis et al., 2007).   
 
   A Bonferroni threshold was calculated in order to account for multiple 
testing, using the following formula: 
 
 ࡼ − ࢜ࢇ࢒࢛ࢋ ࢚ࢎ࢘ࢋ࢙ࢎ࢕࢒ࢊ =  �ࡺ࢛࢓࢈ࢋ࢘ ࢕ࢌ ࢚ࢋ࢙࢚࢙ 
 
 
where α is the commonly accepted probability of a 5% false positive rate. The 
Bonferroni P-value threshold used was 5x10-4. This P-value threshold 
corresponds to the 98 analytical windows on chromosome 16q that were 
tested for this analysis. 
 
   The 95% confidence interval (CI) for the estimated location Ŝ was obtained 
as: 
 ࡿ̂  ± ࢚ሺࡿࡱሻ 
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where t is the tabulated value of Student's t-test and SE is the Standard Error 
of the parameter Ŝ. The predicted estimates of Ŝ and 95% CIs are obtained 
by fitting the LDU genetic distances since this approach increases the power 
of association (Maniatis et al., 2007). For convenience, these estimates are 
converted back to kb (NCBI build 37) by linear interpolation of the two flanking 
SNPs in HapMap. Therefore the 95% CIs measured in kb cannot be 
symmetrical because of the ‘block-step’ structure of the human genome. 
When Ŝ is in an LD block (horizontal line) then all markers within that block 
have the same LDU location. In such cases, the midpoint of that block was 
taken as an estimate of Ŝ in kb.  
 
 
  The significance around the Ŝ region was additionally analysed by 
calculating a curvature that reflects the likelihood surface. This curvature is 
based on χ21 estimates at fine resolution. Each χ 21 is estimated in the same 
way as above but the model that estimates Ŝ is compared against a model, 
whereby Ŝ is fixed incrementally. These χ 21 values are converted to Z 
estimates using the following formula:  
 
ࢆ =  �૚૛−૛࢒࢔૚૙ 
 
   Therefore, these logs of the likelihood odds ratios (LOD) provide a measure 
of confidence. All Z estimates are plotted against the kb map in order to 
visualise the locations in the map that deviate from the maximum likelihood 
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estimation (Ŝ), as shown in Figure 7B and Figure 7C. The smaller the Z 
estimate, the greater the  maximum likelihood. 
 
 
iii. Genetic and Phenotypic stratification 
 
 
 
   In order to stratify the data with respect to carrier status for the most 
common NOD2 mutations, in the absence of actual data on those mutations, 
linked SNPs were used.  rs2076756 was used in the WTCCC dataset (G 
being the minor allele with a frequency of 0.24, in the controls, and 0.32 in the 
cases) and rs5743289 for the NIDDK dataset (T being the minor allele 
frequency of 0.17 in controls and 0.24 in cases). These SNPs, which are 
approximately a 100bp apart, are in a region of conserved LD that contains 
the three NOD2 mutations (see LDU map in Fig 6A; and as previously 
reported for rs2076756).  
 
 
   The WTCCC dataset contains patients of any subtype of CD but with no 
sub-classification available in the database. The NIDDK database on the 
other hand, contains additional information on disease, in particular that of 
possible extra-ileal intestinal involvement and also classifies the patients and 
controls according to ancestry (Jewish/Non-Jewish).  Since there was prior 
expectation of genetic differentiation across these categories we exploited this 
  
 56 
extra information to stratify the analyses of the CDH3, CDH1 and IRF8 
regions. 
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III. RESULTS 
 
 
 
 
 
 
   Initially, using the WTCCC data for chromosome 16q, three major signals 
were identified, in the regions of NOD2/CYLD, CDH3/CDH1 and IRF8 (Tables 
4, 6 and 7). The NIDDK GWAS data was then used to replicate this study.   
 
 
 
I. NOD2 and CYLD region 
 
 
 
   Table 5 and Figure 7A show the significance and estimated locations (Ŝ) for 
the genomic region that harbours NOD2 and CYLD for both datasets. Two 
separate signals of association mapped to different locations in this region. 
Analysis of a  window that included marker information from NOD2 but not 
CYLD yielded a highly significant association with CD for the WTCCC dataset, 
which was replicated using the NIDDK dataset. The estimated (Ŝ) location 
was identical for both datasets (50,749.2 kb, 95% CI for WTCCC: 50,707-
50,766 kb and 95% CI for NIDDK: 50,708-50,839 kb), which is within an LDU 
block that spans 16 kb. The block includes exons 4 and 8, which harbour two 
of the most frequent functional mutations (rs2066844- R702W and 
rs2066845- G908R, respectively) within the NOD2 gene. The third most 
frequent mutation (rs5743293- L1007fsinsC) is on a neighbouring LD block 
with a very slightly different LDU location (see LDU block, Figure 7A).  
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   The analysis of the WTCCC data for the adjacent window containing CYLD 
yielded an estimated location 11 kb (Ŝ: 50,847.3 kb, 95% CI: 50,839-50,851 
kb) downstream of the gene (Figure 7A) and approximately 98 kb downstream 
of the NOD2 signal. This signal was replicated with the NIDDK data with an 
estimated location 234 base pairs downstream from the WTCCC Ŝ (Ŝ: 
50,846.5 kb, 95% CI: 50,846-50,847 kb). For the CYLD window, the 95% CI 
was smaller than that obtained for the NOD2 window because there is less LD 
in the region. 
 
 
   Analysis of a window that included marker information from both NOD2 and 
CYLD (NOD2&CYLD window, see Table 5) yielded an estimated location Ŝ 
between NOD2 and CYLD for the WTCCC data, and the likelihood surface 
incorporated both genes (Figure 7A, 7B and 7C). The analysis of the same 
NOD2&CYLD window using the NIDDK data produced a very similar 
likelihood surface that incorporated both NOD2 and CYLD although the 
estimated location pointed within NOD2, very close to the three NOD2 
mutations, as for the window that contained marker information for NOD2 
alone (Figure 7A, 7B and 7C). 
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Table 5. Association statistics and estimated location of the causal 
variation for three different windows covering NOD2 alone (50,731-
50,767 kb), CYLD alone (50,776-50,836 kb) and NOD2 and CYLD 
combined in relation to the locations one the human genome sequence. 
 
Data 
 
Window+ Cases χ21† P-value Estimate
d 
Location 
(kb) 
95% Confidence 
Interval CI (kb) 
WTCCC NOD2&CYLD 1698 79.7 410-19 50,802.5 50,701-50,846 
NIDDK NOD2&CYLD 813 31.9 210-08 50,749.2 50,708-50,839 
       
WTCCC NOD2 1698 62.6 310-15 50,749.2 50,707-50,766 
NIDDK NOD2    813 37.1 
 110-9 50,749.2 50,708-50,839 
       
WTCCC CYLD 1698 54.4 210-13 50,847.3 50,839-50,851 
NIDDK CYLD    813 12.5 410-4 50,846.5 50,846-50,847 
+Window with marker information covering NOD2 or the adjacent window 
covering CYLD.†A window χ2 using composite likelihood. 
 
 
 
   Figure 7A shows the estimates of Ŝ for the two different NOD2/CYLD 
windows and datasets. For both datasets, the CYLD window was significantly 
associated with CD (210-13 and 410-4 for WTCCC and NIDDK respectively, 
Table 5).  
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Figure 7. LDU mapping of the associations detected in the NOD2, CYLD and combined windows.  
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Gold font relates to analysis results for the combined NOD2&CYLD window. Maroon font illustrates results for the NOD2 
window alone whereas green font represents results for the CYLD window alone. [A] Analysis of all patients with SNP 
data grouped in two separate windows covering either NOD2 (NOD2 window) or CYLD (CYLD window), and analysis of all 
patients with SNP data grouped in a window combining marker information for both NOD2 and CYLD (NOD2&CYLD 
window). The vertical lines are the estimated locations (Ŝ) for the NOD2 window, the CYLD window and the NOD2&CYLD window. 
The grey dashed line shows the LDU map constructed from the HapMap CEU data. [B] stratified data enriched for carriers of 
the most frequent NOD2 mutations. rs2066844, rs2066845 and rs5743293 are the three major NOD2 mutations. The dark blue 
line represents the likelihood surface for the NIDDK NOD2&CYLD window analysis of the unstratified data. The gold line represents 
the likelihood surface for the WTCCC NOD2&CYLD window analysis of the unstratified data. The magenta line represents the 
likelihood surface of the NOD2&CYLD window analysis of the NIDDK patients who carry the NOD2 mutations. The light blue line 
represents the likelihood surface of the NOD2&CYLD window analysis of the WTCCC patients who carry the NOD2 mutations. [C] 
stratified data enriched for non-carriers for the most frequent NOD2 mutations. The dark blue line represents the likelihood 
surface for the NIDDK NOD2&CYLD window analysis of the unstratified data. The gold line represents the likelihood surface for the 
WTCCC NOD2&CYLD window analysis of the unstratified data. The magenta line represents the likelihood surface of the 
NOD2&CYLD window analysis of the NIDDK patients who do not carry the NOD2 mutations. The light blue line represents the 
likelihood surface of the NOD2&CYLD window analysis of the WTCCC patients who do not carry the NOD2 mutations. 
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II. Genetic Heterogeneity within the NOD2 and CYLD region 
 
 
 
 
   These results showed that the NOD2 region is more complex than previously 
thought. The two different Ŝ locations within the NOD2/CYLD region are an 
indication of the existence of different risk alleles in different patients. The three 
frequent causal NOD2 mutations (Hampe et al., 2001; Hugot et al., 2001; Hugot 
et al., 2007) were not included in the genotyping platforms for both WTCCC and 
NIDDK and hence the carriers of the mutations could not be identified. However, 
the data included known SNPs that are in strong LD with these mutations (i.e.: 
form part of the background haplotype on which the functionally significant 
mutations arose). The relationship between these two genes was therefore 
further investigated by analysing a window that included marker information from 
both NOD2 and CYLD, but stratifying the data according to specific SNPs. The 
stratification separated, as far as possible, (in the absence of data on the 
causative NOD2 mutations), patients without the main functional NOD2 mutations 
from those with greatest likelihood of carrying them. 
 
The group that includes all the carriers of the disease-associated allele 
[heterozygous and homozygous for the minor allele, i.e. carriers with AG/GG or 
CT/TT genotypes for the rs2076756 (WTCCC) and rs5743289 (NIDDK) SNPs 
respectively] unsurprisingly yielded much higher significance levels than before, 
even though the number of patients was much smaller than that of the full dataset 
(Table 6). This confirms the notion that these two groups of patients included the 
majority of cases with the functional NOD2 mutations. In addition, the Ŝ was 
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within NOD2 despite analysing both genes in the same window (NOD2&CYLD 
window, Table 6, Figure 7B). The position of Ŝ (50,749.2 kb) was exactly the 
same as for the NOD2 window in Figure 7A using the unstratified data. 
 
 
   The analysis of the non-carrier cases for the WTCCC (AA for rs2076756) and 
NIDDK (CC rs5743289), produced essentially identical results to each other, 
both, pointing towards a location approximately 11 kb downstream of CYLD 
(Table 6, Figure 7C). This genetic stratification reveals heterogeneity among 
patients with CD and suggests that a second locus in the vicinity of CYLD plays a 
larger role in patients who do not carry NOD2 mutations. 
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Table 6. Association statistics and estiamted location of the causal 
variation for a window covering NOD2 (50,50,731-50,767 kb) and CYLD 
(50,776-50,836 kb) in relation to the locations on the human genome 
sequence. 
 
 
*Data stratified based on the AA, AG, GG genotypes for the rs2076756 SNP from 
the WTCCC data (50,756.9 kb) and CC, CT, TT genotypes for the rs5743289 
SNP from the NIDDK data (50,756.8 kb). +Window with marker information from 
both genes.†A window χ2 using composite likelihood. 
 
 
 
 
III. CDH3/CDH1 and IRF8  
 
 
 
   Table 7 shows the significance and estimated locations for the CDH3/CDH1 
and IRF8 windows. The original analysis of the WTCCC data had shown that 
both windows were significantly associated with CD (110-8 and 610-9, 
respectively).  Neither of these signals were however initially replicated with the 
NIDDK GWA scan of the full data-set but showed significant association when 
the windows were analysed based on a subset of the data, using phenotypic 
Data 
 
Window+ Cases χ21† P-value Estimated 
Location (kb) 
Signal 
WTCCC  
  
 
  
AA* NOD2 &CYLD   805   46.0 110-11 50,846.3 CYLD 
AG* NOD2 &CYLD   665 124.6 610-29 50,749.2 NOD2 
GG* NOD2 &CYLD   199   82.8 910-20 50,749.2 NOD2 
 
 
    
 
NIDDK  
    
 
CC* NOD2 &CYLD 482   13.5 210-4 50,846.3 CYLD 
CT* NOD2 &CYLD 266   60.5 710-15 50,749.2 NOD2 
TT* NOD2 &CYLD   60 103.3 310-24 50,749.2 NOD2 
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information provided by the NIDDK IBDGC. This subset included patients with 
ileal CD who had involvement of at least one extra-ileal intestinal location, i.e. 
jejunal, colorectal or perianal. The signal near CDH3/CDH1 was replicated using 
this subset of the NIDDK data despite the much smaller number of cases (Table 
7). For both GWA scans, the estimated location Ŝ for the former window was 
between CDH3 and CDH1, within an LDU block that spans 65 kb (Figure 8). The 
causal locus could be anywhere within that block, which encompasses the 3' 
region of CDH3 through to CDH1 intron 2 (Figure 8), but it also includes a 
functional promoter SNP rs16260 (Li et al., 2000) (Figure 8) previously 
associated with Irritable Bowel Syndrome (IBS).  
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Figure 8. Localisation within the CDH3/CDH1 region. 
The LD map of the region is illustrated by the black line, which is obtained by plotting HapMap LDUs (Y axis) against kb (X axis). 
The red vertical arrow is the estimated location Ŝ for both data sets but because of the very long LD block, the causal location(s) 
could reside anywhere in this block. The rs16260 is a functional SNP within this block, which is located 365 nucleotides upstream of 
the transcription start site for CDH1. NIDDK Ileal+ data: ileal CD with involvement of at least one extra-ileal intestinal location. The 
blue horizontal dashed line shows the 95% Confidence Interval for the WTCCC CD dataset. The purple horizontal dashed line 
represents the 95% Confidence Interval for the NIDDK Combined Ileal+ data. The orange triangles represent the SNPs on the 
Affymetrix 500K genotyping array used in the WTCCC CD study. The blue diamonds represent the SNPs on the Affymetrix 500K 
genotyping array used in the WTCCC study. The orange triangles represent the SNPs on the Illumina HumanHap 300v.1 
genotyping array used in the NIDDK study.  
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For the IRF8 window, the WTCCC data yielded an Ŝ location 29 kb downstream 
of the gene, within a small block that is flanked by LD breakdown (Figure 9). The 
analysis of the NIDDK data for patients with any extra-ileal intestinal involvement 
showed a signal, which is 1.7 kb telomeric to IRF8 within a region of LD 
breakdown (Figure 9).  
 
 
 
Table 7. Association statistics and estimated location of the causal 
variation for two different windows covering CDH3 (68,678-68,733 kb), 
CDH1 (68,711-68,869 kb) and IRF8 (85,933-85,956 kb) in relation to the 
locations on the human genome sequence. 
 
Data 
 
Window Case
s 
χ21† P-value Estimated 
Location (kb) 
95% Confidence 
Interval CI (kb) 
WTCCC CDH3/CDH1 1698   32.6 110-8 68,746.1 68,682 – 68,836 
NIDDK* CDH3/CDH1    
315 
     6.2 
 110-2 68,746.1 68,684 – 68,836 
 
WTCCC IRF8 1698   34.7 410-9 85,982.3 85,982 – 85,984 
NIDDK* 
Jewish§ 
 
IRF8 
 
38 
 
  20.9 
 
510-6 
 
85,958.2 
 
85,949 – 85,961 
Non-
Jewish§ 
IRF8 277     5.3 210-2 85,958.2 85,935 – 85,961 
 
*Ileal CD with involvement of at least one other extra-ileal intestinal location. §432 
Jewish and 515 non-Jewish controls were used for these analyses.†A window χ2 
using composite likelihood. Note that the 95% CI for IRF8 for the UK and North 
American data are non-overlapping suggesting heterogeneity of location of the 
causative change, i.e.: allelic heterogeneity. 
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Figure 9. Localisation within the IRF8 region. 
The LD map of the region is illustrated by the black line, which is obtained by plotting HapMap LDUs (Y axis) against kb (X axis). 
The red vertical arrow is the estimated location Ŝ for both data sets NIDDK Ileal+ data: ileal CD with involvement of at least one 
extra-ileal intestinal location. Two SNPs have been identified for UC and MS in GWA meta-analyses.The short light blue horizontal 
dashed line shows the 95% Confidence Interval for the WTCCC CD dataset. The purple horizontal dashed line represents the 95% 
Confidence Interval for the NIDDK Jewish Ileal+ data. The green horizontal dashed line represents the 95% Confidence Interval for 
the NIDDK Non Jewish Ileal+ data. The 95% CIs are non-symmetrical due to the block-step structure of the human genome. The 
blue diamonds represent the SNPs on the Affymetrix 500K genotyping array used in the WTCCC study. The blue diamonds 
represent the SNPs on the Affymetrix 500K genotyping array used in the WTCCC study. The orange triangles represent the SNPs 
on the Illumina HumanHap 300v.1 genotyping array used in the NIDDK study.  
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   These two NIDDK datasets yielded essentially identical Ŝ locations. The 95% 
CI for both the Jewish and non-Jewish data included part of the IRF8 gene with 
an estimated location 24 kb upstream of the WTCCC signal (Table 7, Figure 9), 
further suggesting allelic heterogeneity.  
 
 In this analysis 98 windows were tested.  Statistical significance observed in the 
WTCCC data passed the Bonferroni threshold calculated based on these 98 tests 
(See Methods Section of this chapter). These signals were replicated using the 
NIDDK data with its smaller sample size and SNP coverage.  
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IV. DISCUSSION 
 
 
 
 
 
 
   Here, using the multi-marker genetic mapping approach on the available 
WTCCC, three novel significant signals of association with CD were found on 
chromosome 16q alone, all of which were replicated using the NIDDK GWAS 
data supporting the presence of genetic heterogeneity on chromosome 16q. 
 
 
   Evidence is presented for the first time that there is an independent 
involvement of a locus in the vicinity of NOD2, near the neighbouring gene CYLD, 
The pattern of association shows clear evidence of an independent signal but 
does not formally show that the CYLD gene is involved.  A distant enhancer 
affecting NOD2 expression could be implicated but other evidence suggests that 
CYLD itself may be important. 
 
 
   First, in support of this notion, genome-wide cDNA microarray analysis 
demonstrates that CYLD gene expression is down-regulated in CD (Costello et 
al., 2005).  NOD2 interacts with Nuclear Factor- кB (NF-кB) signalling in a 
complex way, which includes involvement of ubiquitinylation (Abbott et al., 2004). 
Functional studies have so far provided conflicting evidence on the effect that the 
three NOD2 mutations have with respect to inflammation and bacterial 
recognition (Eckmann and Karin, 2005). On the one hand, it was reported that 
upon bacterial LPS stimulation, the three mutant NOD2 alleles result in the 
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ablation of the NOD2 Peptidoglycan-sensing activities and the failure to activate 
NF-кB (Bonen et al., 2003).  On the other hand,  a mouse-model of the frameshift 
3020insC mutation showed increased levels of the cytokine IL-1β, which is a pro-
inflammatory cytokine, after stimulation with MDP (Maeda et al., 2005). It is of 
interest that CYLD is a deubiquitinating (removal of ubiquitin) enzyme which has 
been shown to regulate cell proliferation, cell survival and inflammatory 
responses (Brummelkamp et al., 2003) and is also involved in NF-кB signalling. 
Dysregulation of NF-кB signalling leads to a defective immune system causing an 
immunodeficient or autoimmune phenotype depending on whether NF-кB 
function is impaired or persistent (Courtois and Gilmore, 2006).   
 
 
   CYLD is important in immune homoeostasis since it prevents the spontaneous 
activation of NF-кB in peripheral T and B lymphocytes. The peripheral T-cells 
from CYLD-deficient mice have increased sensitivity and a heightened response 
to T-Cell Receptor (TCR) stimulation, which leads to spontaneous inflammation in 
the colon (Reiley et al., 2007), and colitis-associated tumorigenesis (Zhang et al., 
2006). Inflammation is the major underlying phenotype of CD and some Crohn’s 
Disease patients develop colon cancer at a later stage in life. In this study a 
causal locus downstream of CYLD was mapped, which lies 2kb upstream of a 
putative gene regulatory element (Pennacchio et al., 2006) and approximately 
7kb upstream of a Leprosy susceptibility GWAS SNP (Zhang et al., 2011).  The 
element is located in an LD block spanning 8.3kb (Figure 7A, B).  This regulatory 
element could potentially be an enhancer for CYLD, especially since CYLD 
expression has been found to be downregulated in CD. However, the estimated 
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location of the putative causal agent in this possible regulatory region could also 
be pointing to a mutation in  which acts as a distant element in relation to NOD2. 
  
 
   The lower significance in the NIDDK data, as compared to the WTCCC result, 
is probably not only due to the difference in sample size but also because the 
phenotypic classifications were different in the two studies.  The WTCCC 
included any subtype of CD and not just the ileal form of the condition. The 95% 
Confidence Interval (CI) for the CYLD window is very narrow for both datasets 
because the Ŝ is within a region of LD breakdown caused by a recombination hot 
spot.  
 
 
   Unfortunately, the data analysed in this study did not contain the actual NOD2 
mutations and the results are therefore based on data stratified according to a 
SNP, which is in complete LD with the three common NOD2 mutations. 
Subsequent to publishing the Chromosome 16q study (Elding et al., 2011), a 
meta-analysis on Leprosy (Zhang et al., 2011) identified a susceptibility GWAS 
SNP closely located to the CYLD signals identified in this Chapter using the LDU 
multi-marker mapping approach. This is of interest since both CD and Leprosy 
display common immunologic characteristics, which include a Th1-cell response 
with granuloma formation (Zhang et al., 2009). It is also suggested that some CD 
cases might have a common mycobacterial cause as seen in Leprosy (Schurr 
and Gros, 2009).  Additionally, the ENCODE  (ENCyclopaedia Of DNA Elements) 
Consortium subsequently published a comprehensive list of all the DNA 
functional elements in the human genome, including Transcription Factor Binding 
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sites and their respective Transcription Factors as well as DNAse I 
Hypersensitive site, which are sites that are commonly found in transcriptionally 
active genes. It was interesting to find that the estimated location of the putative 
causal agent and the 95 % CI for the CYLD signal that was identified in this 
Chapter contained several transcription factor binding sites. Indeed the estimated 
location of the putative causal agent mapped precisely upstream of a binding site 
for the transcription factor CEBPB, in a DNase I Hypersensitive Site. The gene 
that codes for this transcription factor is essential in the regulation of genes that 
are implicated in inflammatory and immune responses (Boi et al., 2012; Mayer et 
al., 2013). The IBDase FP7 European consortium performed an independent 
conditional analysis where they stratified patients based on the actual NOD2 
mutations and subsequently identified the involvement of CYLD independently 
from that of NOD2 in patients that do not carry the common NOD2 mutations (I. 
Cleynen, 2011), which to an extent re-enforces the findings presented here. 
Indeed, CYLD is known to be modulated by some bacteria and viruses and as 
introduced in Chapter I of this thesis, the gut microbiota are known to play a 
significant role in IBD aetiology.  
 
 
  The second and third region were identified using the phenotypically stratified 
data that contained patients with ileal as well as extra-ileal involvement 
demonstrating that considering phenotypic heterogeneity is clearly important.  
The second region covers the genes CDH3 and CDH1 encoding cadherin 
proteins that participate in cell recognition, signalling, morphogenesis and tumour 
progression. CDH1 encodes an epithelial cadherin (E-Cadherin) expressed in the 
intestine with essential functions in intestinal homeostasis (Schneider et al., 
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2010). The loss of E-cadherin expression leads to apoptosis and shedding of 
cells and to disruption of the maturation of Paneth and Goblet cells, important in 
the innate immune system and microbial defence (Schneider et al., 2010).  E-
cadherin helps to maintain the intestinal epithelial defence system, and reduced 
CDH1 expression is a feature of CD and UC patients with an inflamed intestinal 
epithelium (Gassler et al., 2001). A genome-wide linkage analysis on CD 
reported evidence of linkage on 16q, some 25cM downstream of NOD2, in 
families that did not carry the NOD2 mutations (van Heel et al., 2003). Notably, 
CDH3 and CDH1 are at that linkage peak, approximately 25Mb downstream of 
NOD2.      
 
      
   However, GWA studies and meta-analyses on CD did not detect these genes 
despite the large number of samples and imputation based on the latest HapMap 
samples. A GWA study on Ulcerative Colitis on the other hand, did report CDH1 
as a new susceptibility locus (Barrett et al., 2009), with the most significant SNP 
for UC 180kb upstream of the gene, which will be further discussed in Chapter IV. 
Although CDH1 has not been reported for CD by others to date, this analysis 
demonstrates that the most likely location of the causal variant is within an 
interval that is flanked by CDH3 and CDH1. This interval is an LD block that 
includes a functional promoter variant (rs16260; Figure 8) (Li et al., 2000) that is 
also associated with IBS (Villani et al., 2010), a chronic inflammatory condition 
involving recurrent abdominal discomfort. CDH1 was also detected in a GWA 
meta-analysis for colorectal cancer and the reported SNPs fall within our 
confidence interval (Houlston et al., 2008). CDH3, which encodes Placental-
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Cadherin (P-cadherin), is also implicated in colorectal carcinomas (Milicic et al., 
2008). 
 
 
   The third region became statistically significant after separating the data further 
into Jewish and non-Jewish patients and this effect shows the importance of 
considering heterogeneity of ancestry. The third region covers the IRF8 gene, 
which encodes the transcription factor also known as Interferon Consensus 
Sequence-Binding Protein, which plays a negative regulatory role in cells of the 
immune system.  Using a subset of the NIDDK data (Jewish patients with ileal 
CD plus additional extra-ileal involvement) yielded an estimated causal location 
24 kb away from the estimate obtained using the WTCCC data. The difference in 
localisation may reflect allelic heterogeneity.  
 
 
   The significant association in the IRF8 region on chromosome 16q was 
originally identified in a meta-analysis on Multiple Sclerosis (MS) (De Jager et al., 
2009), which was shortly followed by a meta-analysis that identified an 
association between the region harbouring IRF8 and UC (Anderson et al., 2011), 
the other sub-type of IBD. However, the latest association studies on CD failed to 
reveal any CD-specific associations on Chromosome 16q other than NOD2. 
Thus, the analysis presented here, together with other GWASs, confirm the 
continually emerging evidence for the presence of shared loci among different 
immune and inflammatory-mediated complex diseases. IRF8 has been 
additionally implicated in Systemic Lupus Erythematosus (SLE) (Lessard et al., 
2012) as well as MS (De Jager et al., 2009), UC (Anderson et al., 2011) and CD 
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(Elding et al., 2011) (Figure 9). This greatly suggests the implication of shared 
pathways between these diseases, and hence calls in the need for pathway 
analysis in complex diseases. IRF8 expression is crucial in bone metabolism, 
with IRF8-deficient mice displaying extensive osteoporosis, one of the extra-
intestinal manifestations associated with CD (Zhao et al., 2009). 
 
 
   This analysis provided a novel insight into the genetic and phenotypic 
heterogeneity of CD and demonstrates that the approach taken in this part of the 
project may be a promising way forward to study other frequent and complex 
diseases. Following the results that were obtained from this hypothesis-driven 
part of this project, the next step was to perform a hypothesis-free GWAS, using 
the LDU multi-marker mapping approach to the WTCCC and NIDDK CD 
datasets, which will be explored in the next chapter. 
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CHAPTER III. NOVEL GENE REGIONS 
IDENTIFIED FOR CROHN’S DISEASE. 
 
 
 
 
 
I. INTRODUCTION 
 
 
 
   The analysis of chromosome 16q using only two GWASs described in Chapter 
II was very encouraging and illustrated how this LDU multi-marker approach can 
provide additional study power and highlighted the importance of genetic 
heterogeneity (i.e. the involvement of different risk genes in different patients) as 
well as that of phenotypic heterogeneity. This paved the way to studying the 
whole genome. 
 
 
   The purpose of the next part of the project was thus to analyse the whole 
genome using the same approach, and exploiting the positive experience of the 
use of phenotypic sub-classification, in order to see whether it was possible to 
find additional susceptibility disease genes (see the Methods section of Chapter II 
for further details). The work described in this chapter has been published (Elding 
et al., 2013). 
 
 
 
 
  
 82 
II. METHODS 
 
 
 
 
i. Genetic Analysis 
 
 
 
   As in the previous chapter, a total of 1,698 cases of CD and 2,948 ethnically 
matched controls were analysed from the UK WTCCC GWAS data (WTCCC, 
2007) and the GWAS replication data consisted of 813 North American CD 
patients and 947 ethnically matched controls from the NIDDK IBDGC. Data 
quality control was carried out by Winston Lau as described in the previous 
Chapter. 
 
 
   Each chromosome arm was divided into non-overlapping analytical windows for 
both the WTCCC and the entire NIDDK GWA data-sets, as described in the 
Methods section of Chapter II. For each window along the whole genome, a 
composite-likelihood (Λ) test was used, in which all the SNPs within a window 
were tested simultaneously (see previous chapter for more details about the 
methodology used). The method returned a P-value together with an estimated 
location (Ŝ) of the putative causal agent and the LDU estimation of Ŝ for each 
window is converted back to kb (NCBI build 37) by using linear interpolation of 
the two flanking SNPs in HapMap. In cases where Ŝ mapped to the end of a 
window, the window was extended in that direction to capture SNPs on the far 
side to improve the accuracy of location.  
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ii. Phenotypic Stratification 
 
 
 
 
   The previous analysis (See Chapter II) showed that stratifying the analysis 
according to the occurrence of extra-ileal intestinal involvement as opposed to 
ileal inflammation alone (a subdivision of which appears to be linked with genetic 
stratification) increased the power of detecting association of the 16q windows. 
Since the NIDDK GWAS data contains a detailed description of the location of 
patients’ intestinal inflammation, the NIDDK data was stratified according to this 
information. For all the analytical windows that showed nominal statistical 
evidence of association using the WTCCC data, we analysed the same windows 
using the entire NIDDK data and also using a subset of the NIDDK data 
containing CD cases that reported extra-ileal in addition to ileal inflammation.  
Unlike the controls, the vast majority of cases in this subdivision were non-
Jewish. We therefore analysed only non-Jewish patients with extra-ileal 
inflammation and non-Jewish controls. This subdivision reduced the sample size 
from 813 to 277 CD cases and from 947 to 515 controls. Preliminary analyses 
showed that fewer signals were obtained by doing this, as might be expected 
because of the reduced power, but our aim was to reduce as far as possible false 
positives obtained as a result of ethnic stratification. 
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iii. Previously reported and novel significant gene-regions 
 
   The first part of this analysis was to look for signals within the previously 
published intervals from the recent meta-analysis (Franke et al., 2010) and 
present P-values for the relevant data sets (See Table 8).  For the novel 
discovery analysis a Meta-analysis P-value is presented for each analytical 
window that shows a) evidence of nominal statistical significance for both data 
samples and b) the Ŝ estimate for both samples are within 150 kb of one another. 
These criteria were used in order to reduce the possibility of detecting more than 
one signal, as a result of heterogeneity, and thus facilitate the meta-analysis of 
shared locations.  
 
 
iv. Meta-analysis of shared locations 
 
 
 
   The significant P-values obtained from the independent datasets were 
combined using Fisher’s combined probability test. For k independent tests, 
where each independent test of the null hypothesis results in a P-value, the P-
values for each independent test can be combined as follows: 
 
�૛ =  −૛ ∑ ࢒࢔ ሺࡼሻ࢑࢏=૚  
 
where the χ2 has 2k degrees of freedom. 
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   In order to account for multiple testing, we used a Bonferroni P-value threshold 
of 1x10-5, which corresponds to the total number of analytical windows and the 
additional analyses performed for the NIDDK data using the extra-ileal subgroup. 
In order to capture replications of slightly lower significance but with more 
precisely agreeing Ŝ values, a second threshold was used in which the Ŝ for both 
datasets had to lie within 80 kb of each other to be considered a replication and 
with a Meta P-value within the range of 1x10-3 and 1x10-5.  
 
 
v. Significant gene-regions and Gene Ontology 
 
 
 
   For each of the replicated windows, the closest gene within a maximum 
distance of approximately 300 kb of the estimated location Ŝ for each sample 
was retrieved and then listed in the tables (See Tables 8 and 9). In the case 
where the closest gene was more than ~300kb away, the estimated location Ŝ is 
listed as being ‘intergenic’.  Using BioMart, the Gene Ontology (GO) annotations 
attributed to each gene were retrieved and the results are shown in Appendix II. 
 
 
 
 
 
 
 
 
  
 86 
 
III. RESULTS 
 
 
 
 
 
iv. Identifying the previously reported CD intervals 
 
 
 
 
   The first goal was to determine whether the LDU mapping method could detect 
the 71 loci previously identified from the most recent large meta-analysis of six 
independent datasets.  Our aim was to consider the reported intervals rather than 
focusing on the specific genes flagged in the Consortium study.  Table 8 presents 
the statistical evidence and location estimates, for signals within these 71 
intervals (Franke et al., 2010). Since the majority of these intervals 
(approximately 80%) were more than 150 kb in length (defined around the most 
significant SNP using LD information), it was difficult to meta-analyse the results 
obtained using the multi-marker mapping procedure used in this analysis, since 
there was a risk of combining independent signals. The P-values obtained from 
WTCCC and NIDDK are therefore presented separately. Using the multi-marker 
mapping approach, a total 66 out of the 71 intervals (loci) were identified in one 
or both of these data sets using an uncorrected significance threshold of P<0.05. 
Only five intervals showed no evidence of association for either WTCCC or 
NIDDK using the LDU method. The majority of these 66 signals (88%) were 
identified with the larger WTCCC data with the remaining 8 intervals (12%) 
showing nominal evidence of association for the smaller NIDDK data set alone. 
Interestingly, these eight (12%) include regions (e.g. 10q22, 16p11 and 19q13) 
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that have previously been implicated for paediatric IBD patients (Imielinski et al., 
2009). This is consistent with the fact that the NIDDK dataset probably includes a 
larger number of patients with early onset CD (~37%) than WTCCC, where this 
information is not recorded. It is worth noting that one of the 6 contributory data 
sets to the most recent meta-analysis also included entirely paediatric IBD 
patients (Franke et al., 2010). The first published results by the WTCCC 
(WTCCC, 2007) reported 9 loci but Table 7 shows 28 signals for WTCCC alone 
that passed the genome-wide significance threshold of 1x10-5. 
 
 
v. Genetic Heterogeneity within the previously reported CD 
intervals 
 
 
 
   Unlike the recent meta-analysis, where a particular gene or genes within these 
intervals was identified through a series of in silico analyses, the genes closest to 
the location estimates are presented here (Table 8). In several cases these agree 
with the previously identified genes (e.g. STAT3, IL23R), but in other cases there 
are differences. For several regions two different estimates of localisation (Ŝ) 
were obtained for WTCCC and NIDDK, both within the same interval. 
Heterogeneity in some regions is expected but location estimates can help 
identify this. For example for the interleukin-rich interval (2q12.1), the WTCCC 
dataset yielded an estimate within IL18RAP but for NIDDK the Ŝ is within IL1RL1. 
Both genes have been previously suggested as candidates within the 2q12.1 
interval (Franke et al., 2010) but an independent fine mapping study has shown 
strong association to the IL18RAP rs917997 SNP for both CD and UC 
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(Zhernakova et al., 2008), which is approximately 10 kb away from WTCCC Ŝ 
(Figure 10). A recent study (Rivas et al., 2011) using deep sequencing identified 
a rare coding variant (V527L) of possible functional significance within IL18RAP, 
which is only 8 kb away from the WTCCC location, though it is probable that 
other functional variants are also involved.  As far as the second gene is 
concerned, the importance of IL1RL1 to inflammatory processes has also been 
documented (Akhabir and Sandford, 2010) for a variety of human pathologies 
including celiac disease (Amundsen et al., 2010). The LDU map clearly shows 
that there are several recombination hot spots between IL18RAP and IL1RL1 
(Figure 10) making it likely that these two signals are independent and that there 
is genetic heterogeneity within these previously identified intervals. This is similar 
to that previously noted in the case of NOD2 and CYLD, in the previous 
chromosome 16q study (Elding et al., 2011), as described in Chapter II.  
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Figure 10. Localisation within the IL1RL1/IL18RAP region. 
The LD map of the region is shown by plotting HapMap LDUs (Y axis) against kb 
(X axis). The red vertical arrows are the estimated locations Ŝ for the WTCCC 
and NIDDK datasets. The WTCCC Ŝ is within an intron and between a microRNA 
(miR4772) and coding rare variant for CD (p.V527L ).  The red diamonds 
represent the SNPs in this region on the WTCCC Affymetrix 500K genotyping 
array whereas the blue diamonds represent the SNPs in this region on the 
NIDDK Illumina HumanHap 300 genotyping array 
 
 
 
 
vi. 134 novel gene-regions identified 
 
   In addition to the 66 localization estimates obtained, 134 novel signals were 
identified. Table 7 shows the list of 78 of the 134 novel signals that passed the 
genome-wide significance threshold of 1x10-5. Here the distance between the Ŝ 
locations of each signal does not exceed 150 kb, so the meta-analysis P-value is 
provided (as outlined in methods). Approximately 78% of the WTCCC signals 
were replicated using the complete NIDDK data set. However, in a third of these, 
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the association was significant in the complete but also in the smaller subset of 
the data. In this third, the smaller NIDDK extra-ileal subset showed higher 
significance despite the substantial decrease in the number of cases and 
controls.  Furthermore 22% of the WTCCC signals were only replicated using this 
subset of the NIDDK data. 
 
 
 
 
 
 
Figure 11. Localisation within the ERBB4 region. 
LD map of the region is shown by plotting HapMap Regional LDUs (Y axis) 
against kb (X axis). The red vertical arrows are the estimated locations Ŝ for the 
WTCCC and NIDDK datasets. The red diamonds represent the SNPs found in 
this region on the WTCCC Affymetrix 500K genotyping array whereas the blue 
diamonds represent the SNPs found in this region on the NIDDK Illumina 
HumanHap 300 genotyping array. 
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   For the majority (74%) of the 78 signals, the location estimates from both 
datasets point to the same gene, with approximately half of the signals being 
intragenic and half intergenic locations (gene with asterisk implies that at least 
one of the signals is within the gene (Table 9 and 10). In all cases, including the 
~50% that reside outside of genes, the closest gene is considered as a 
candidate. It should however be noted that in some cases long range cis-
elements may be involved, which regulate genes far outside the 150 kb distance, 
with other genes intervening, or regulatory elements may exist within an intron of 
an adjacent gene (Jones and Swallow, 2011). Indeed, cis-acting gene expression 
Quantitative Trait Loci (eQTL) have been implicated in both Mendelian and 
complex disorders. eQTLs are loci in the genome that control mRNA expression 
levels. There have been several efforts in correlating GWAS disease-risk loci with 
eQTL genes in an attempt to further explain the missing heritability that is very 
common to complex conditions, including CD. In fact, some GWAS CD 
susceptibility SNPs have been shown to be associatd with variable expression 
levels of PTGER4, CARD9, ERAP2, TNFSF11 in Epstein-Barr Virus (EBV) 
transformed Lympholastoid Cell Lines (LCLs) (Libioulle et al., 2007; Montgomery 
and Dermitzakis, 2011). 
  
 
   Several of the novel genes have been reported to be involved in inflammatory/ 
immune dysregulation conditions (e.g. DOCK8, ITGA9). In other cases the genes 
have been previously implicated in colonic inflammation or colonic cell 
morphology based on functional studies. By way of illustration, Figure 11 
presents an example of the estimated locations (Ŝ) for the genomic region that 
harbours ERBB4 (2q34 window). For both datasets, this window was significantly 
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associated with CD with a Meta P-value of 310-6 (Table 9).  Figure 11 shows the 
LDU map starting from the 3' region and spanning half way down the gene, which 
stretches across more than 1 Megabase. The map shows numerous short LD 
blocks across the region. However, despite the large LD breakdown in the area, 
both estimates of Ŝ are close to each other and within the same intron. 
 
 
   Table 10 shows the list of 56 of the 134 novel signals that showed association 
with CD where the P-values (1x10-3 – 1x10-5range) based upon meta-analyses 
were below the Bonferroni threshold but estimates of localization in the two data 
sets were not more than 80 kb apart from each other.   Most of the signals (96%) 
in Table 10, give estimates of Ŝ for the same gene. 
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IV. DISCUSSION  
 
 
 
 
 
 
 
   Using the LD approach 66 of the 71 previously reported loci from meta-analysis 
were confirmed and 134 novel gene regions that are associated with Crohn’s 
Disease have been identified, providing evidence for 200 gene regions that 
include CD susceptibility loci. More precise location estimates are provided for 
the 66 previously published intervals, as well as locations for the 134 new 
signals. The very large numbers of genes listed in Table 9 and 10 support the 
idea that CD is truly polygenic and complex in nature and that much of this 
complexity is genetic in origin. Many genes show functions that are compatible 
with involvement in immune/inflammatory processes as well as integrity of the 
intestinal epithelium and differentiation.  
 
 
   In the CD analysis described in this chapter, many of the replicated signals 
were identified only, or more strongly, using a subset of the NIDDK data, which 
contained patients with ileal CD who had involvement of at least one extra-ileal 
intestinal location.  Despite the substantial decrease in sample size, analysis of 
this sub-phenotype using this method yielded much higher power than the 
analysis of the full data. This indicates that phenotypic heterogeneity is clearly 
important and that accurate as well as detailed phenotype information is crucial in 
genetic studies, especially when assessing a trait showing clinical variation.  
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   Rather than mapping to LD intervals around the most significant SNP, this 
method provides estimated locations of the putative causal agents. These 
location estimates are of great importance since they do not only pinpoint precise 
locations but also provide the possibility of detecting possible heterogeneity, as 
shown with the example of NOD2/CYLD on chromosome 16q described in the 
previous Chapter and with the example of IL1RL1/IL18RAP on chromosome 2q 
identified here .  
 
 
   Several of the genes that were identified in this part of the analysis had been 
previously implicated in IBD through functional studies. An example is ERBB4 
(which encodes Receptor protein-tyrosine kinase erbB-4) on 2q34 (See Table 9). 
ERBB4 is expressed at high levels in the inflamed colonic mucosa of CD patients 
(Frey et al., 2009).  Using adult mouse colon, it was also shown that ERBB4 is an 
important regulator in the epithelial response to inflammation and injury (Frey et 
al., 2009). ERBB4 expression has been linked to a number of cellular processes 
such as cell survival, proliferation and tumorigenesis in different tissues (Erlich et 
al., 2001; Starr et al., 2006). A recent study suggested that this elevated ERBB4 
expression could lead to colitis-associated development of colorectal tumours 
(Frey et al., 2010). ERRB4 has also been implicated, together with E-cadherin 
(encoded by CDH1 on 16q22.1, previously identified as a risk gene for CD and 
ulcerative colitis), in the suppression of anoikis (Kang et al., 2007) (programmed 
cell death as a result of cell detachment from the extracellular matrix), suggesting 
that there may be interaction between these two genes. Despite the fact that 
ERBB4 is a very large gene (>1 Mb), the estimated locations of the putative 
causal agent for both datasets (WTCCC and NIDDK) are very close and within 
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the same intron, making it an excellent target for follow-up fine mapping studies 
and re-sequencing.  
 
 
   Several of the genes listed in Table 10, which presents 56 gene regions with 
lower confidence of association, but with very close location estimates between 
the two datasets, are also very interesting. For example, the window harbouring 
the BTLA gene gave location estimates that are just 2 kb apart. A study using a 
mouse model of colitis has shown functional evidence of BTLA involvement in 
colitis (Steinberg et al., 2008).  Box 1 illustrates a functional overview of some 
genes of interest that were identified in this part of the project. The molecular and 
functional attributes of all the genes identified in this chapter are illustrated in 
Appendix II. 
 
 
   The LDU multi-marker mapping approach successfully identified many 
additional novel CD susceptibility loci by re-analysing publically available GWAS 
data. The next step would be to shift the focus towards UC and identify whether, 
using the LDU multi-marker mapping approach, more loci could be detected for 
this-subtype, which is known to have a lower genetic contribution than UC. 
 
 
 
 
 
Box 1: Functional overview of some genes of interest identified. 
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ERBB4: (v-erb-a erythroblastic leukemia viral oncogene homologue 4). This 
gene is a member of the Tyrosine protein kinase family and the Epidermal 
Growth Factor receptor subfamily. ErbB4 is a TNF-inducible receptor and has 
been found to regulate repair in response to injury and inflammation. Activation 
of E-Cadherin (encoded by CDH1- See Table 3) which suppresses anoikis (a type 
of apoptosis involving detachment from the extracellular matrix) activates 
ErbB4 receptor tyrosine kinase and subsequent activation of PI3 Kinase 
pathway leading to cell proliferation. 
 
 
BTLA: (B and T Lymphocyte Associated). BTLA is a member of the 
immunoglobulin superfamily containing a single Ig domain. It is also a receptor 
that relays inhibitory signals to suppress the immune response. BTLA 
engagement is required to prevent colitis acceleration in a mouse model.  The 
expression of TNFSF14 and BTLA on both adaptive and innate cells strongly 
indicates that this ligand-receptor system could play several roles in immunity 
and inflammation. Mutations in this gene have been associated with an increased 
risk of Rheumatoid Arthritis. 
 
ITGA9: (integrin alpha 9). This gene encodes an alpha integrin. Integrin are 
heterodimeric integral membrane glycoproteins composed of an alpha chain and 
beta chain that mediate cell-cell and cell-matrix adhesions. ITGA9 is normally 
active in colonic epithelia. Alpha-9 deficient bone marrow cells in mice show a 
marked decrease in STAT3 phosphorylation (See Table 1 on chromosome 17q) 
after G-CSF stimulation in granulopoeisis. 
 
DOCK8: (dictator of cytokinesis 8).  This gene encodes a member of the 
DOCK180 family of Guanine Nucleotide Exchange Factors. Mutations in this gene 
result in the autosomal recessive hyperimmunoglobulin E (hyper-IgE) syndrome 
characterized by immunodeficiency, lack of connective tissue and recurrent 
infections among other symptoms. DOCK8 is most highly expressed in B and T 
lymphocytes and mutations in DOCK8 diminish clonal expansion of both CD4 and 
CD8 T cells after engagement of TCR and co-stimulatory molecules.  It was found 
that patients with large homozygous deletions in DOCK8 had IBD or suggestive 
IBD. DOCK8 is also required to form a normal T-cell immune-synapse with 
antigen-presenting Dendritic Cells (DCs). 
 
BRD7: (bromodomain containing 7). The product of this gene has been identified 
as a component of one form of SWI/SNF chromatin remodeling complex which 
also interacts with p53. BRD7 depletion delays replicative senescence and 
extends cellular life-span.  
 
TEC: (Tec protein tyrosine kinase). Tec is part of the Tec family non-receptor 
protein tyrosine kinases. Tec kinase is an central component of T-cell signaling 
and has a distinct role in T cell activation. This gene plays a role in Calcium 
influx, apoptosis, gene expression, actin re-organisation as well as cell-adhesion 
and migration and is found to be activated by bacterial Lipopolysaccharide 
(LPS). 
 
USP1: (ubiquitin-specific peptidase 1). This gene encodes a member of the 
ubiquiting specific processing (UBP) family of proteases that is a 
deubiquitinating (DUB) enzyme. PCNA (a central component of the ubiquitin-
based molecular switch dictating error-free versus error-prone DNA repair) 
polyubiquitination is negatively regulated by USP1 in the absence of DNA 
damage. 
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Table 8. Whole-genome association statistics and closest gene to the 
estimated location Ŝ of the causal variant for the previously reported 71 LD 
intervals. 
 
Chr 
 
Reported 
Interval (Mb) WTCCC Ŝ 
WTCCC P-
value NIDDK Ŝ 
NIDDK P-
value 
Gene (WTCCC/ 
NIDDK If different) 
       
1p31.3 67.36 - 67.77 67,684.8 2.1x10-11 67,707.3 3.0x10-10 IL23R* 
1p13.2 113.95 - 114.62 114,560.3 1.4x10-03 114,108.3 5.0x10-03 OLFML3/MAGI3* 
1p36.23 7.74 - 7.97 - - 7,801.1 2.2x10-05 CAMTA1* 
1q23.3 160.69 - 162.47 160,887.0 2.6x10-03 160,837.3 5.8x10-03 ITLN2/CD244 
1q25.1 172.66 - 172.95 172,891.9 3.6x10-13 - - TNFSF18 
1q32.1 200.85 - 201.06 200,877.3 3.0x10-14 200,957.2 1.5x10-02 C1orf106*/KIF21B* 
1q22 154.97 - 156.13 - - - - - 
1q31.3 197.32 - 197.95 197,786.1 1.2x10-04 - - DENND1B 
1q32.1 206.80 - 207.03 - - - - - 
2p23.3 25.45 - 25.60 25,389.2 3.5x10-02 - - POMC* 
2p23.3 27.39 - 27.86 27,697.4 5.4x10-04 27,619.3 2.3x10-11 IFT172*/PPM1G* 
2p21 43.45 - 43.95 43,840.8 2.0x10-05 43,581.0 1.1x10-02 THADA* 
2p15 60.92 - 61.89 61,395.5 1.9x10-05 - - C2orf74 
2q37.1 234.15 - 234.57 234,144.8 5.6x10-25 234,171.9 2.2x10-09 ATG16L1* 
2q12.1 102.80 - 103.30 103,059.8 1.8x10-08 102,951.7 1.7x10-05 IL18RAP*/IL1RL1* 
2q33.1 198.14 - 198.96 198,957.7 1.6x10-02 198,205.8 1.1x10-03 PLCL1*/ANKRD44 
2q37.1 231.05 - 231.23 231,109.3 2.8x10-05 - - SP140* 
3p21.31 48.18 - 51.75 49,743.9 1.7x10-31 48,818.0 3.3x10-19 RNF123*/PRKAR2A* 
3p24.3 18.60 - 18.88 18,707.0 5.3x10-03 18,629.1 2.6x10-05 SATB1 
5p13.1 39.84 - 40.96 40,447.1 6.0x10-51 40,288.0 2.7x10-07 PTGER4 
5q31.1 129.38 - 132.02 131,748.2 2.7x10-22 131,631.4 8.9x10-07 C5orf56*/SLC22A4* 
5q33.1 150.03 - 150.40 150,230.7 3.6x10-09 - - IRGM 
5q33.3 158.50 - 158.95 158,825.7 5.6x10-06 158,826.0 3.5x10-02 IL12B 
5q13.2 72.45 - 72.58 72,465.4 5.8x10-03 - - TMEM174 
5q15 96.08 - 96.42 96,372.2 1.3x10-08 - - LNPEP 
5q31.3 141.41 - 141.64 141,480.3 1.3x10-02 - - NDFIP1 
5q35.2 173.22 - 173.54 - - 173,417.9 6.7x10-03 C5orf47* 
6p22.3 20.49 - 21.14 20,559.3 4.3x10-03 20,433.1 2.8x10-03 CDKAL1*/E2F3* 
6p21.32 31.38 - 32.87 32,720.6 1.2x10-27 32,193.4 1.6x10-07 HLA-DQB2 
6p25.2 3.41 - 3.47 3,417.6 1.5x10-07 - - SLC22A23* 
6q21 106.39 - 106.56 - - 106,421.7 4.0x10-02 PRDM1 
6q27 167.34 - 167.55 167,441.4 3.3x10-09 167,355.9 8.5x10-03 FGFR1OP*/RNASET2* 
6q15 90.80 - 91.08 - - - - - 
6q25.3 159.34 - 159.54 159,539.7 1.2x10-03 - - FNDC1 
7p12.2 50.25 - 50.33 50,255.3 9.4x10-04 - - C7orf72 
8q24.13 126.47 - 126.58 126,544.1 4.5x10-05 - - TRIB1 
8q24.21 129.49 - 129.60 129,567.2 1.3x10-04 129,570.7 2.9x10-03 intergenic 
9p24.1 4.94 - 5.30 5,274.6 1.4x10-04 5,270.3 5.4x10-03 RLN2 
9q32 117.43 - 117.70 117,555.6 3.9x10-04 - - TNFSF15 
9q34.3 139.13 - 139.42 139,280.8 2.3x10-05 139,299.7 2.6x10-03 SNAPC4*/SDCCAG3* 
10p11.21 35.18 - 35.90 35,554.8 3.4x10-29 - - CCNY* 
10p15.1 6.03 - 6.17 6,189.9 3.6x10-03 6,165.5 1.2x10-08 PFKFB3*/RBM17 
10q21.2 64.30 - 64.76 64,448.3 1.2x10-18 - - ZNF365 
10q24.2 101.27 - 101.34 101,324.7 1.2x10-32 101,274.6 2.3x10-02 NKX2-3 
10q21.1 59.83 - 60.14 59,892.8 9.3x10-09 59,893.1 1.6x10-02 IPMK 
10q22.3 81.00 - 81.10 - - 81,019.8 1.5x10-02 ZMIZ1* 
11q13.5 76.02 - 76.36 76,304.4 4.4x10-10 - - C11orf30 
11q12.2 61.52 - 61.68 61,680.2 3.4x10-02 - - RAB3IL1* 
11q13.1 63.82 - 64.29 64,027.0 5.8x10-03 64,137.4 3.2x10-02 PLCB3*/RPS6KA4* 
12q12 40.13 - 41.02 40,598.3 3.0x10-02 40,368.0 1.7x10-03 LRRK2/SLC2A13* 
13q14.11 44.23 - 44.64 44,491.1 6.6x10-12 44,607.7 3.0x10-02 LACC1/LINC00284 
13q14.11 42.82 - 43.10 43,022.6 1.3x10-07 - - TNFSF11 
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Table 8 
Cont.       
 
Chr 
Reported 
Interval (Mb) WTCCC Ŝ 
WTCCC P-
value NIDDK Ŝ 
NIDDK P-
value 
Gene (WTCCC/ 
NIDDK If different) 
       
14q24.1 69.16 - 69.32 69,199.5 4.1x10-02 - - ZFP36L1 
14q31.3 88.21 - 88.64 88,364.3 6.2x10-05 88,216.2 5.1x10-03 GALC 
15q22.33 67.41 - 67.48 67,410.8 1.5x10-02 - - SMAD3* 
16p11.2 28.29 - 29.03 - - 28,940.3 4.5x10-02 CD19 
16q12.1 50.46 - 50.85 50,803.2 2.6x10-15 50,803.2 1.1x10-09 NOD2* 
  50,846.3 1.6x10-13 50,846.5 4.1x10-04 CYLD 
17q12 37.37 - 38.26 37,985.9 1.1x10-03 37,888.9 4.2x10-05 IKZF3*/MIEN1 
17q21.2 40.32 - 41.00 40,501.5 2.0x10-18 - - STAT3* 
17q12 32.49 - 32.68 - - 32,634.2 4.1x10-02 CCL8 
18p11.21 12.74 - 12.93 12,875.2 2.9x10-12 - - PTPN2* 
19p13.3 1.09 - 1.18 1,127.7 2.0x10-02 - - SBNO2* 
19p13.2 10.40 - 10.64 10,560.9 1.3x10-02 - - PDE4A* 
19q13.11 33.73 - 33.78 - - - - - 
19q13.33 49.09 - 49.28 - - 49,212.0 3.6x10-04 FUT2 
20q13.33 62.18 - 62.48 62,327.9 2.3x10-04 - - RTEL1-TNFRSF6B* 
21q12.1 16.70 - 16.85 16,841.4 4.4x10-07 - - USP25 
21q22.3 45.59 - 45.70 45,609.1 5.5x10-06 - - ICOSLG 
21q11.21 21.81 - 22.06 - - - - - 
22q12.2 29.90 - 30.67 30,228.8 8.0x10-07 - - ASCC2* 
22q13.1 39.67 - 39.81 - - 39,686.8 1.1x10-02 RPL3 
 
Bold denotes that the signal is replicated using the data taken only from the Non-
Jewish ‘Ileal’ patients who also had extra-ileal inflammation; *at least one of the 
estimated locations Ŝ is located within the identified gene. 
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Table 9. Whole-genome assocation statistics and the closest gene to the 
estimated location Ŝ of the causal variant for the convincingly confirmed 78 
gene-regions. 
 
Chr WTCCC Ŝ NIDDK Ŝ 
Gene (WTCCC/NIDDK if 
different) Meta-P-value 
   
 
 
1p31.3 61,982.8 61,938.8 NFIA§ 1.4x10-07 
1p31.3 64,095.1 64,005.9 PGM1*/EFCAB7*§ 1.1x10-08 
1q21.3 151,788.8 151,837.4 RORC*/THEM4 1.2x10-09 
1q42.2 233,765.3 233,835.4 KCNK1*§ 5.3x10-08 
1q43 236,709.1 236,684.6 LGALS8* 2.8x10-07 
1q43 236,862.0 236,805.4 ACTN2*/HEATR1 1.3x10-10 
2p25.2 6,394.6 6,425.5 LOC400940 5.1x10-09 
2p24.2 16,442.2 16,452.4 FAM49A 5.6x10-06 
2p23.3 25,247.9 25,138.3 DNAJC27-AS1*/ADCY3* 8.7x10-18 
2p13.1 74,616.6 74,659.7 DCTN1*/RTKN*§ 4.9x10-22 
2q14.1 117,951.4 117,821.6 intergenic 3.3x10-06 
2q24.3 168,944.1 168,810.8 STK39* 3.3x10-07 
2q32.1 185,889.2 185,791.4 ZNF804A* 7.4x10-09 
2q34 212,427.1 212,442.8 ERBB4* 3.1x10-06 
3p22.3 36,213.9 36,097.7 STAC/ARPP21 2.6x10-09 
3p22.2 37,598.6 37,602.5 ITGA9* 6.2x10-09 
3q11.2 96,376.9 96,304.5 EPHA6§ 6.6x10-09 
3q12.1 99,338.2 99,330.9 COL8A1 1.2x10-07 
4p12-11 48,197.8 48,342.9 TEC*/SLAIN2 3.4x10-15 
4q12 54,551.5 54,668.6 LNX1/RPL21P44§ 2.7x10-06 
4q12 55,260.5 55,241.3 PDGFRA§ 2.9x10-09 
4q25 110,193.1 110,128.2 COL25A1*§ 6.8x10-06 
4q35.1 186,241.5 186,267.1 SNX25* 5.2x10-08 
5q22.2 112,590.6 112,572.4 MCC*§ 8.5x10-06 
5q23.2 126,822.9 126,898.0 MEGF10/PRRC1§ 5.5x10-10 
6p22.3 24,443.8 24,457.3 GPLD1* 4.0x10-07 
6p22.1 29,605.2 29,575.4 GABBR1* 5.5x10-06 
6q12 65,246.8 65,244.5 EYS* 1.6x10-07 
6q25.3 159,670.8 159,794.4 FNDC1* 1.5x10-08 
6q27 166,505.9 166,501.1 T§ 7.0x10-07 
7p21.1 20,044.2 19,975.1 MACC1/TMEM196 1.9x10-07 
7p15.3 24,175.9 24,271.9 NPY§ 3.9x10-07 
7p14.1 41,898.3 41,939.6 INHBA-AS1/GLI3 2.1x10-06 
7q21.11 80,401.5 80,470.9 SEMA3C* 4.8x10-06 
7q31.31 120,409.2 120,337.3 TSPAN12/KCND2* 8.7x10-06 
7q31.33 125,266.9 125,219.7 Intergenic§ 3.7x10-10 
7q32.3 131,467.2 131,394.6 PODXL§ 7.8x10-07 
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Table 9 
continued 
Chr 
 
 
 
WTCCC Ŝ 
 
 
 
NIDDK Ŝ 
 
 
 
Gene (WTCCC/NIDDK if 
different) 
 
 
 
Meta-P-value 
8p22 17,632.9 17,635.3 MTUS1* 5.5x10-07 
8q12.1 57,504.1 57,507.6 LOC100507632 5.2x10-06 
8q21.13 80,385.0 80,277.0 STMN2§ 1.3x10-12 
8q21.13 83,670.2 83,786.5 intergenic 1.9x10-08 
8q22.3 104,465.6 104,363.8 DCAF13/FZD6§ 4.4x10-06 
8q23.3 114,908.3 114,815.4 intergenic§ 4.9x10-11 
9p24.3 396.8 468.1 DOCK8*§ 2.6x10-07 
10p12.1 25,571.8 25,686.6 GPR158*§ 1.5x10-09 
10q21.1 61,019.5 61,135.2 FAM13C* 2.2x10-06 
10q21.2 63,604.2 63,553.3 ARID5B/C10orf107 7.3x10-09 
10q22.2 75,697.5 75,698.5 PLAU§ 2.6x10-13 
10q22.3 79,392.4 79,247.9 KCNMA1* 2.5x10-06 
10q25.1 111,613.9 111,622.3 XPNPEP1 1.8x10-06 
10q25.3 115,370.8 115,381.2 NRAP* 1.0x10-05 
11p15.4 5,785.5 5,836.4 OR52N4/OR52N2§ 3.3x10-10 
11p14.1 27,827.8 27,790.8 BDNF 8.2x10-07 
11q12.1 56,626.0 56,625.0 OR9G4 1.0x10-05 
11q24.2 126,774.5 126,749.9 KIRREL3* 1.1x10-06 
12p11.22 28,744.2 28,741.7 CCDC91§ 1.1x10-06 
12q12 44,676.8 44,823.7 TMEM117*§ 2.4x10-06 
12q22 92,998.8 93,090.8 C12orf74§ 7.6x10-09 
12q23.1 101,350.2 101,350.1 ANO4* 9.3x10-06 
13q14.3 52,081.3 52,078.0 MIR4703 8.9x10-08 
14q21.1 39,671.6 39,601.9 PNN/GEMIN2*§ 6.4x10-07 
14q31.1 80,015.5 80,139.6 NRXN3*§ 7.6x10-07 
15q13.3 31,839.1 31,737.8 OTUD7A* 1.0x10-08 
15q14 34,414.0 34,291.8 PGBD4/CHRM5* 8.9x10-06 
16p13.3 7,262.9 7,200.6 RBFOX1§ 1.0x10-05 
16p13.3 7,272.8 7,391.8 RBFOX1* 3.6x10-06 
16q12.1 50,417.0 50,417.2 BRD7 2.0x10-08 
16q22.1 67,464.1 67,422.7 HSD11B2§ 7.5x10-08 
16q24.1 85,982.3 85,958.0 IRF8 1.5x10-08 
17q25.1 73,344.9 73,411.5 GRB2*/MIR3678 4.3x10-14 
18q11.2 19,677.2 19,620.4 GATA6 2.6x10-07 
18q12.3 40,517.4 40,666.0 RIT2*§ 6.0x10-18 
18q21.1 44,940.9 44,800.7 IER3IP1§ 7.8x10-06 
20p12.3 7,901.0 7,878.5 HAO1*§ 1.4x10-07 
20q12 37,960.3 38,106.0 LOC339568 3.9x10-06 
20q13.12 44,741.5 44,672.0 CD40/SLC12A5*§ 7.7x10-08 
22q12.3 37,325.9 37,349.3 CSF2RB*/LOC1005006241 2.6x10-08 
Xq28 147,228.4 147,114.7 FMR1NB 4.4x10-07 
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Bold denotes that the signal is replicated using the data taken only from the Non-
Jewish ‘Ileal’ patients who also had extra-ileal inflammation; *at least one of the 
estimated locations Ŝ is located within the identified gene;§the signal is significant 
in the Pooled NIDDK data as well as the stratified Non Jewish Ileal and extra-ileal 
dataset. 
 
 
 
 
 
 
 
Table 10. Whole-genome association statistics and the closest gene to the 
estimated location Ŝ of the causal variant for the confirmed 56 gene-
regions (P-value 10-3-10-5). 
 
Chr  WTCCC Ŝ NIDDK Ŝ 
Gene (WTCCC/NIDDK if 
different) Meta-P-value 
   
 
 
1p34.1 45,764.3 45,764.4 LOC400752 3.6x10-04 
1p32.2 58,535.6 58,575.4 DAB1* 2.7x10-04 
1p31.3 68,056.4 68,072.2 GADD45A 2.9x10-05 
1p31.1 83,125.7 83054.7 intergenic 1.4x10-04 
1q31.3 194,273.4 194,332.3 intergenic§ 2.2x10-04 
1q32.1 204,129.7 204,143.0 REN* 3.4x10-04 
1q42.12 225,508.2 225,554.8 DNAH14* 3.0x10-05 
1q42.12 226,248.8 226,249.4 H3F3A§ 9.1x10-04 
2p14 67,869.6 67,871.1 ETAA1§ 2.1x10-05 
2q11.2 102,625.1 102,625.1 IL1R2* 4.9x10-04 
2q31.1 170,038.8 170,037.2 LRP2* 8.4x10-04 
2q36.3 226,258.2 226,258.4 NYAP2 1.2x10-05 
3p14.3 55,192.0 55,115.1 CACNA2D3 5.7x10-05 
3p12.3 77,377.2 77,377.3 ROBO2* 8.2x10-04 
3q13.2 112,181.4 112,184.1 BTLA* 2.9x10-05 
3q24 148,459.5 148,419.7 AGTR1* 2.1x10-04 
4p15.33 13,075.6 13,050.3 HSP90AB2§ 1.5x10-04 
4q13.2 67,799.9 67,792.9 intergenic 8.2x10-04 
4q27 121,797.6 121872.1 PRDM5* 2.1x10-05 
5p14.3 23,042.2 23,002.6 CDH12 3.9x10-05 
5q21.1 100,970.9 100,970.8 intergenic 6.0x10-04 
5q33.3 156,594.7 156,627.7 FAM71B/ITK*§ 8.2x10-05 
6p22.3 21,462.0 21,467.8 SOX4 5.6x10-04 
6q21 107,433.4 107,473.5 BEND3* 3.6x10-05 
6q21 113,971.2 113,977.4 MARCKS 7.1x10-05 
6q22.31 125,214.4 125,215.3 STL§ 3.0x10-04 
6q23.3 137,546.9 137,565.2 IFNGR1 3.5x10-04 
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Table 10 
continued 
Chr  
 
WTCCC Ŝ 
 
NIDDK Ŝ 
 
Gene (WTCCC/NIDDK if 
different) 
 
Meta-P-value 
6q25.3 156,152.9 156,190.7 intergenic 1.9x10-04 
6q25.3 158,344.5 158,365.2 SNX9*§ 3.1x10-04 
7p21.1 20,286.7 20,301.2 MACC1 5.5x10-05 
7p14.3 34,739.3 34,757.7 NPSR1* 3.2x10-04 
7q31.32 122,995.2 122,993.0 IQUB§ 1.6x10-04 
7q34 142,653.2 142,650.9 KEL* 1.1x10-04 
8q24.22 134,050.4 134,063.7 SLA* 1.5x10-04 
9q21.13 74,603.0 74678.4 C9orf85/C9orf57 7.7x10-4 
9q21.2 80,206.6 80,206.7 GNA14*§ 2.7x10-04 
9q33.1 121,364.8 121,365.0 intergenic 5.1x10-04 
10q23.31 90,787.7 90,787.7 FAS§ 2.7x10-04 
11p15.5 1,539.0 1,539.0 MOB2* 2.1x10-04 
11p15.3 12,387.3 12,331.6 MICALCL* 5.1x10-05 
12q14.3 67,645.2 67,640.5 CAND1 6.9x10-04 
12q21.32 89,154.8 89,148.0 KITLG§ 5.7x10-05 
12q24.32 126,746.8 126,753.9 LOC100128554§ 9.9x10-04 
13q12.13 27,389.5 27,391.1 GPR12 1.3x10-04 
13q13.3 36,090.9 36,159.4 NBEA* 2.7x10-04 
13q31.3 90,018.8 90,018.6 intergenic 7.5x10-04 
13q31.3 90,206.6 90,176.3 intergenic 6.9x10-04 
14q31.1 82,444.3 82,452.3 intergenic§ 5.4x10-05 
15q21.2 50,193.4 50,171.3 ATP8B4* 8.8x10-04 
16q21 61,777.3 61,777.1 CDH8* 1.4x10-05 
16q23.1 76,295.6 76,275.6 CNTNAP4 9.1x10-04 
16q23.1 78,458.5 78,410.4 WWOX*§ 6.6x10-04 
20p21.1 15,802.7 15,876.4 MACROD2* 7.1x10-04 
21q22.2 41,532.5 41,513.2 DSCAM* 7.3x10-04 
22q12.3 35,540.3 35,540.4 ISX§ 2.8x10-04 
Xq23 115,981.3 115,966.6 intergenic 7.3x10-05 
 
Bold denotes that the signal is replicated using the data taken only from the Non-
Jewish ‘Ileal’ patients who also had extra-ileal inflammation; *at least one of the 
estimated locations Ŝ is located within the identified gene; §the signal is significant 
in the Pooled NIDDK data as well as the stratified Non Jewish Ileal and extra-ileal 
dataset. 
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CHAPTER IV. NOVEL GENE REGIONS 
IDENTIFIED FOR ULCERATIVE COLITIS. 
 
 
 
 
 
 
I. INTRODUCTION 
 
 
 
 
 
   Following the success in identifying novel genes for Crohn’s disease using the 
LDU mapping approach, the attention was shifted towards Ulcerative Colitis. The 
progress in identifying genetic risk factors for UC has been slower than that for 
CD. This is mainly attributable to the fact that much of the attention for 
association studies was initially given to CD because it has a higher genetic 
contribution than UC.  
 
 
   However, early linkage analyses had been successful in identifying UC-specific 
linkage peaks, as well as highlighting the similarities between CD and UC. 
Interestingly, Giallourakis et al identified an IBD risk haplotype at the IBD5 locus, 
which harbours a cytokine cluster, as a general IBD susceptibility factor, with an 
added epistatic effect between the IBD5 risk haplotype and the NOD2 mutations 
in the case of UC despite the fact that NOD2 is not a risk factor for UC 
(Giallourakis et al., 2003). Additionally, the shared IBD2 locus on chromosome 12 
shows much stronger linkage for UC than for CD (Parkes et al., 2000). 
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  The initial UC association analyses involved testing hits that were previously 
identified and confirmed for CD in UC datasets. Subsequently, genome-wide 
analysis of larger UC cohorts were carried out, where novel UC loci were 
identified, owing to the much larger sample sizes and hence higher power than 
could be envisaged just a few years before. These novel genes provide 
invaluable insight into the pathogenesis of UC.  For instance, CDH1, ECM and 
LAMB1 are all implicated in the correct functioning of the gut’s mucosal barrier, 
which is at the forefront of IBD pathogenesis. In this context it is noteworthy that 
CDH1, encoding the E-Cadherin protein, was identified for the first time in this 
project as a susceptibility gene for CD, as is described in Chapter II of this thesis. 
In fact, CDH1 is an interesting finding since it provides a direct link between UC 
and colorectal cancer, which is known to be more prevalent among UC cases. 
The promoter region of CDH1 has been shown to be hypermethylated in colon 
cancer, which is an epigenetic mark commonly associated with gene silencing 
and thus, in this scenario, reduced expression of CDH1. This reduced expression 
could provide a tumour cell sufficient selective advantage for outgrowth (Wheeler 
et al., 2001). It has additionally been reported that a loss of E-Cadherin function 
displays preferential right-sided tumorigenesis as opposed to left-sided 
pathogenesis (Porter et al., 2002). Upon investigation of this left-side protection, it 
has been functionally shown that P-Cadherin, encoded by CDH3 (See Chapter 
II), is expressed very early in colorectal dysplasia (Hardy et al., 2002) and an 
increase in P-Cadherin, which can substitute for many E-Cadherin functionalities, 
compensates for the down-regulation effect of E-Cadherin, namely decreased 
cell-adhesion and facilitation of cell migration (Porter et al., 2002).  
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   Independently of CDH1, the risk of colorectal cancer in UC patients increases 
with disease duration as well as extent of disease, severity of inflammation and 
early onset of UC. This increased risk of colorectal cancer in UC patients could 
also in part be explained by the fact that premature telomere shortening, which is 
often associated with cancer, is observed in the colonic cells of UC patients 
(Risques et al., 2008).  
 
 
   The largest UC-specific GWAS carried out to date consisted of  a meta-analysis 
of six GWASes containing approximately 6,687 cases and 19,718 controls as a 
discovery panel and 9,628 cases combined with 12,917 controls as a replication 
dataset. This study successfully increased the number of UC loci from 29 to 47. 
Subsequently, an IBD meta-analysis identified 12 new additional UC-specific loci. 
However, the total disease variance explained by these loci remains at 7.5%. The 
problem of missing heritability thus applies to UC as well.  
 
 
    
 
   Since the LDU mapping approach demonstrated a higher power to detect 
association and discover more susceptibility loci for CD, as described in Chapters 
II and III, the aim of the analysis that will be described in this chapter was to re-
analyse the WTCCC Phase 2 UC dataset, followed by replication, in an attempt 
to unearth novel susceptibility loci for UC. 
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II. METHODS 
 
 
i. Subjects 
 
 
 
   The UK WTCCC Phase II Ulcerative Colitis case-control dataset used in this 
part of the project consisted of 2,869 Ulcerative Colitis cases, and 5,986 
nationally-ascertained controls prior to quality control. 2,988 control samples 
came from the National Blood Services (NBS) Collection of common controls and 
2,998 control samples came from the 1958 British Birth Cohort (BC). The 
diagnosis of Ulcerative Colitis cases was done using standard endoscopic, 
radiologic and histopathological criteria and the samples were recruited from ten 
centres within the United Kingdom (Cambridge. Oxford, London, Newcastle, 
Sheffield, Edinburgh, Dundee, Manchester, Torbay and Exeter) (Consortium et 
al., 2009). The cases and the controls were genotyped on the high-resolution 
Affymetrix 6.0 array, containing approximately 1 million SNPs.  
 
 
   In order to replicate the findings, two replication datasets were used. Prior to 
quality control filtering, the first replication dataset consisted of 538 control 
samples, which came from a Parkinson’s Disease GWA study and 487 Ulcerative 
Colitis cases came from a subset of the NIDDK International IBD Genetics 
Consortium UC data. All the NIDDK UC cases were reported to have the disease 
extending beyond the rectum (Silverberg et al., 2009). Both the cases and the 
controls for this replication dataset were genotyped on the Illumina 550v.3 
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genotyping platform consisting of approximately 550,000 SNPs. The  samples for 
this case-control dataset were of white European, non-Hispanic ancestry 
(Silverberg et al., 2009). 
 
 
   The second replication dataset consisted of the other subset of the NIDDK UC 
cases containing 540 UC cases genotyped on the Illumina HumanHap 300v.2 
genotyping platform. The ethnically-matched controls used were 515 Non-Jewish 
controls, which are a subset of the NIDDK CD GWAS described in Chapter II and 
III, genotyped on the Illumina HumanHap 300v.1 platform. Both the Illumina 
HumanHap 300v.1 and 300v.2 contain approximately of 320,000 SNPs.  Different 
sets of control data were used since the NIDDK UC data did not have matching 
controls and therefore, ethnically-matched control data (PD GWAS Controls and 
NIDDK Non-Jewish CD GWAS Controls) genotyped on similar platforms were 
used in order to facilitate the merging of genotype data between the cases and 
controls. Table 11 summarises the data sets used in this part of the project, 
including the number of samples used after quality control, where the latter will be 
discussed in detail in the following section. 
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Table 11. Summary of datasets used for the UC GWAS. 
 
Cases Controls Sample Size Genotyping 
Platform 
WTCCC2  
UC  
WTCCC2 
NBS and 
1958BC 
Controls:  
                 
2,705 
(1958BC) 
2,674 (NBS)  
Affymetrix 6.0 
(~ 1 million SNPs) 
Cases:      2,361 
 
Total    7,740 
NIDDK  
UC IBDO§ 
UC GRU§ 
Parkinson’s 
Disease 
GWAS 
Controls 
Controls:   534              Illumina 
HumanHap550v.3 
(~ 550,000 SNPs) 
Cases:      126 (UC 
IBDO) 
359 (UC GRU) 
 
Total 1,019 
NIDDK UC 
GRU§ 
NIDDK CD 
Non-
Jewish 
Controls 
Controls: 503 UC Cases: 
Illumina 
HumanHap300v.2 
CD Controls: 
Illumina 
HumanHap300v.1 
(~ 320,000 SNPs) 
Cases: 534 
Total 1,037 
 
§ IBDO samples are patients that gave consent for their DNA to be used for IBD 
Research Only whereas GRU samples gave consent for their DNA to be used for 
General Research Use. 
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ii. Quality Control- WTCCC 2 UC Case-Control Dataset 
 
 
   The WTCCC provided quality control exclusion lists for both the SNP data as 
well as the sample data for each of the UC, NBS and 1958BC data-sets. Before 
carrying out any quality control analyses myself, the data were filtered according 
to these lists. The SNP exclusion list contained 5 exclusion criteria for each SNP, 
namely Minor Allele Frequency (MAF), information, Hardy Weinberg Equilibrium 
(HWE) test, missingness and plate effect. If a SNP failed to pass any one of 
these criteria, it was advised that the SNP should be excluded from the data. The 
exclusion thresholds that the WTCCC used for each of these criteria will be 
explained in more detail below. 
 
 
   For this WTCCC SNP exclusion list, the MAF threshold used for each SNP was 
1%. Therefore, any SNP where the MAF falls below 1% was included in the 
exclusion list. The information criterion is a measure of statistical information 
about allele frequency in the genotype data, ranging from 0 to 1 and reflects the 
level of certainty regarding the called genotype, where 0 denotes complete 
uncertainty and 1 complete certainty. In order for SNPs to be retained in the data, 
the information had to be higher that 0.975. The HWE test is a measure of 
deviation from HWE in the general population. This test is generally carried out in 
controls since true association in cases can distort HWE tests. Since in most 
cases deviation from HWE generally reflects poor genotyping, or copy number 
variation for which the analysis would be confusing, HWE testing is routinely 
done for quality control prior to association studies. The P-value threshold used 
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by the WTCCC for the HWE test for each SNP was 1x10-20 and therefore, any 
SNPs with a lower P-value was incorporated in the exclusion list. The 
missingness relates to the proportion of genotypes, which fail to reach the 
maximum call probability threshold of 0.90. If this missingness proportion is 
higher than 0.02, the SNP is marked for exclusion. The plate criterion is 
introduced because cases and controls were plated on different plates and 
consists of a P-value of a n-degree of freedom test of plate association. If the P-
value is lower than 1x10-05, the SNP is marked for exclusion.  
 
  The WTCCC sample exclusion list considered six criteria for quality control, 
namely SNP missingness across a sample, relatedness of samples, ancestry, 
gender, channel and identity. If a sample failed to pass any one of these criteria, 
it was suggested that the sample should be excluded from the data.   
 
 
   The missingness criterion can be subdivided into two sub-criteria. Firstly, the 
individuals were compared on the basis of a fraction of successfully called SNPs 
that were heterozygous, and then on the proportion of SNPs where the maximum 
call probability did not meet the 0.90 threshold. If any individuals were outlying in 
either sub-criteria, they were listed in the exclusion list. The individuals in the data 
were tested for relatedness by the WTCCC by running a Hidden Markov Model 
(HMM), which identifies the proportion Identity-by-Descent (IBD) between pairs of 
individuals.  In this analysis, if two individuals were more than 5% identical by 
descent, the individual with the lowest genotype call rate was marked for 
exclusion from the data. For the ancestry analysis, the individuals were projected 
onto the first two principal components of a Principal Components Analysis (PCA) 
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of HapMap individuals. If any individuals were shown to differ from the remaining 
individuals in the dataset in terms of ancestry, they were flagged for exclusion in 
the WTCCC exclusion list provided.  The WTCCC inferred the gender from the 
intensities of the A-allele probes on the X chromosome, which were normalized 
against the intensities of the autosomal SNPs. If certain individuals showed 
discrepancies between the gender supplied and the inferred gender, or if the 
gender could not be inferred from the intensities, these individuals were listed in 
the exclusion list. The channel criterion consisted of excluding individuals where 
the mean of their A and B allele intensities from 10,000 SNPs on chromosome 22 
was outlying when compared to the sample at large.  The identity analysis that 
the WTCCC carried out checked the genotype concordance of approximately 30 
SNPs that were previously genotyped using the Sequenom at the Wellcome 
Trust Sanger Institute (WTSI) and the genotypes obtained for the Affymetrix 6.0 
platform for these SNPs for each individual. If the concordance between the two 
platforms was lower than 90%, the individual was marked for exclusion from the 
data.  
 
 
   After filtering the data for these SNP and individual exclusion criteria, the 
routine and widely-applied GWAS quality control outlined in the next section was 
carried out. Appendix III and IV illustrate flowcharts outlining the steps carried out 
for the data manipulation of the WTCCC2 and NIDDK Data. 
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a. Principal Components Analysis 
 
 
 
   After removing SNPs and individuals that were indicated in the sample 
exclusion lists provided by the WTCCC, Principal Components Analysis (PCA)  
was carried out to detect possible outliers in the dataset. In order to perform the 
PCA, any SNPs with a Minor Allele Frequency (MAF) smaller than 0.05, missing 
rate of more than 5% and an LD r2 threshold larger than 0.2 were removed. The 
LD pruning was done in order to avoid a heavy influence from clusters of SNPs in 
LD with each other for both the PCA and Relatedness analysis described below. 
The PCA was carried out in the publically available software R using the 
packages gdsfmt and SNPRelate (Zheng et al., 2012). The first step was to 
calculate the genetic covariance matrix from the genotype data, as well as the 
correlation coefficients between the sample loadings and the SNP genotypes, 
followed by the calculation of SNP eigenvectors (Zheng et al., 2012). The PCA 
results, as illustrated in Figure 12, showed that there were two outliers, one in 
each of the 1958BC and NBS datasets. Despite previous filtering for identity by 
descent outliers using the WTCCC exclusion lists, subsequent analysis of these 
two individuals showed that they were almost certainly the same individual or 
identical twins, since visual inspection of the data showed that the SNP 
genotypes were the same for both individuals, with the only difference in the 
genotypes due to missingness. This could be due to the fact that separate 
WTCCC exclusion lists were provided for the two control groups (1958BC and 
NBS) thus suggesting that QC was carried out on the two data separately, which 
would have missed identifying these two related individuals. Therefore, the 
sample that had most missing genotypes was removed from the data before 
further proceeding with the quality control analysis. 
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Figure 12. Principal Components Analysis of WTCCC Phase II Case-Control 
Dataset. 
The Y-axis represents the first Principal Component and the X-axis represents 
the second Principal Component. The blue triangles represent the sample 
loadings for the WTCCC UC Cases, the black diamonds the sample loadings for 
the WTCCC 1958BC Controls and the red squares the sample loadings for the 
WTCCC NBS controls. The samples circled in red are the outliers identified in 
this analysis and the outlier with most missingness was removed from the data. 
 
 
 
 
 
 
 
 
   The PCA procedure was repeated using the WTCCC2 UC Case-Control Data 
merged with the HapMap 3 dataset. This was done in order to see how the 
WTCCC2 UC Case-Control dataset clusters with respect to the populations in 
HapMap 3 (See Figure 13). Since the two datasets came from different studies, 
the strand orientation was not the same for all SNPs. To overcome this problem, 
the data were merged in PLINK, which flags any SNPs found to be in opposite 
strand orientation between both datasets, followed by flipping the strand for the 
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SNPs in question in the WTCCC2 UC Case-Control data to match that in 
HapMap3. Additionally, since the Affymetrix 6.0 genotyping platform contained 
palindromic SNPs (A/T or G/C SNPs), these needed to be removed from the data 
for the quality control analysis only, prior to merging with the HapMap 3 data as 
the strand orientation of these SNPs between two different datasets cannot be 
determined.  
 
 
   As expected, the data cluster with the European population CEU, which 
consists of Utah residents with Northern and Western European ancestry from 
the CEPH (Centre d’Étude du Polymorphisme Humain) collection and with the 
Tuscan population from Italy, (TSI). 
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Figure 13. Principal Components Analysis of merged HapMap3 and WTCCC2 UC Case-Control Datasets. 
The Y-axis represents the first Principal Component and the X-axis represents the second Principal Component. The data points on 
the plot illustrate the sample loadings. The WTCCC Case-Control data cluster with the CEU and TSI, as expected. 
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b. Relatedness Analysis- Identity-by-Descent and Identity-
by-State Analysis 
 
 
 
 
  The relatedness analysis was equally carried out in R using the packages 
gdsfmt and SNPRelate. 
 
 
   The Identity-by-Descent (IBD) analysis using the PLINK Method of Moments 
(MoM) was carried out in order to identify whether any individuals in the UC case-
control data set were related after the initial individual filtering. As expected, since 
the related individuals had already been removed, the results of this analysis 
showed no significant relatedness between the individuals, as shown in Figure 
14. 
 
 
   The Identity-by-State (IBS) analysis was done by creating a n × n matrix 
containing genome-wide average IBS pairwise identities, followed by a 
Multidimensional Scaling (MDS) analysis, which allowed the visualisation of 
similarities and differences in the individuals under study. The IBS and MDS 
analyses were carried out on the HapMap3 dataset merged with the WTCCC2 
UC Case-Control data, as was done for the PCA described in the previous 
section. The results of the MDS analysis, as illustrated in Figure 15, demonstrate 
that no outliers were detected and also that allele sharing was, as expected, 
highest between the WTCCC UC Case-Control dataset, the CEU and TSI since 
all three are European populations. 
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Figure 14. Identity-by-Descent Analysis of the merged WTCCC2 UC Case-
Control Dataset based on pairwise kinship coefficients. 
The Y-axis represents the k1 pairwise IBD coefficients, which are probabilities of 
sharing one IBD. The X-axis represents the k0 pairwise IBD coefficients, which is 
the probability of sharing zero IBD. The red dashed line represents the expected 
IBD. The black circles represent the samples in the WTCCC UC Case-Control 
data. The results show that there is no relatedness among the samples in the 
WTCCC Case-Control data. 
 
 
 
 
c. SNP filtering and individual missingness 
 
 
  In order to minimize false positive associations due to artifacts in the data the 
quality control was made more stringent. SNPs with a MAF lower than 0.03, HWE 
test P-value lower than 1.57x10-3 and a missing rate greater than 20% were 
further excluded from the data. The final sample count is listed in Table 11. 
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Figure 15. Multidimensional Scaling Analysis, basd on IBS distances of the merged HapMap3 and WTCCC2 UC Case-
Control dataset. 
The Y-axis represents the second vector of the MDS and the X-axis the first vector. The data points on the plot represent the 
HapMap3 and WTCCC Case-Control samples. No outliers were detected in this analysis. 
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iii. Quality Control Analysis- NIDDK UC datasets 
 
 
 
 
   For the additional two Ulcerative Colitis Datasets, the same quality control 
procedure outlined in section II.ii.a-c of this Chapter was carried out. However, 
prior to combining the UC Cases with the Controls, the PCA was carried out on 
the separate datasets, since no prior exclusion lists were given for the separate 
data unlike for the WTCCC2 UC described before. The NIDDK UC IBDO Cases 
(See Table 11) showed no outliers (See Figure 16) but GRU Cases genotyped on 
the Illumina HumanHap550v.3 (See Table 11) showed 1 major outlier, as shown 
circled in Figure 17. This was expected, as in the NIDDK data release notes it 
was noted that after the original analysis of this data it was subsequently 
identified that one of the samples was Trinidadian. Similarly, the Parkinson’s 
Disease Control data also showed four outliers (See Figure 18).  
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Figure 16. Principal Components Analysis of NIDDK IBDO UC Cases 
genotyped on the Illumina HumanHap 550v.3 platform. 
The Y-axis represents the first Principal Component and the X-axis represents 
the second Principal Component. The red circles represent the sample loadings 
for the NIDDK IBDO UC Cases. No outliers were detected in this analysis. The 
NIDDK IBDO UC Cases are patients who gave consent for their DNA to be used 
for IBD research only. 
 
 
 
 
 
   After removing the outliers from both datasets, the Parkinson’s Disease GWAS 
controls were merged with the NIDDK UC IBDO and GRU cases genotyped on 
the Illumina HumanHap550v3. Again, since the two datasets came from different 
studies, there were differences in strand orientation for certain SNPs, despite 
being genotyped on the same platform. Therefore, in order to merge the two 
datasets, the same procedure in PLINK was followed as described earlier. 
However, in this case, the Illumina HumanHap550v.3 did not contain any 
palindromic SNPs. After the Cases and Controls were successfully merged, the 
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Case-Control dataset was then merged with the HapMap 3 data, after flipping the 
strand orientation to match that of HapMap 3, and the PCA was carried out 
(Figure 19).  
 
 
 
 
Figure 17. Principal Components Analysis of NIDDK GRU UC Cases 
genotyped on the Illumina HumanHap 550v.3 platform. 
The Y-axis represents the first Principal Component and the X-axis represents 
the second Principal Component. The black diamonds represent the sample 
loadings for the NIDDK GRU UC Cases. The samples circled in red represents 
the outlier identified in this analysis, which was removed from the data. The 
NIDDK GRU UC Cases are patients who gave consent for their DNA to be used 
for general research use. 
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Figure 18. Principal Components Analysis of Parkinson's Disease GWAS 
Control data genotyped on the Illumina HumanHap 550v.3 platform. 
The Y-axis represents the first Principal Component and the X-axis represents 
the second Principal Component. The blue triangles represent the sample 
loadings for the PD GWAS Controls. The samples circled in red are the outliers 
identified in this analysis, which were removed from the data. 
 
 
 
 
 
 
 
 
  Despite the previous filtering, additional outliers could still be detected when the 
NIDDK IBDO and GRU UC Cases genotyped on the Illumina HumanHap 550v.3 
were merged with the PD GWAS Control data and with the HapMap3 data 
(Figure 19). Two outliers were found in the NIDDK UC GRU cases and one in the 
Parkinson’s Disease GWAS controls. These three outliers were also detected in 
the IBS-based MDS analysis (Figure 20) but no outliers were visible in the IBD 
analysis (Figure 21). 
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Figure 19. Principal Compoenents Analysis of NIDDK IBDO and GRU UC Cases merged with Parkinson's Disease GWAS 
Controls genotyped on the Illumina HumanHap 550v.3 and HapMap3 data. 
The Y-axis represents the first Principal Component and the X-axis represents the second Principal Component. The data points on 
the plot represent the sample loadings for the HapMap3, PD GWAS Controls and NIDDK UC data. The samples circled in red are 
the outliers identified in this analysis, which were removed from the data. 
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V1 
V2 
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Figure 20. Multidimensional Scaling Analysis based on IBS distances of NIDDK IBDO and GRU UC Cases merged with 
Parkinson's Disease GWAS Controls genotyped on the Illumina HumanHap 550v.3 platform and HapMap3 data. 
The Y-axis represents the second vector of the MDS and the X-axis the first vector. The data points on the plot represent the 
HapMap3, the PD GWAS controls and NIDDK UC Data. The samples circled in red represent the outliers identified in this analysis, 
which are the same as those illustrated in Figure 19. The samples were removed from the data. 
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Figure 21. IBD analysis of the merged Parkinson's Disease GWAS Controls 
and NIDDK IBDO and GRU UC Cases genotyped on the Illumina HumanHap 
500v.3 platform based on pairwise kinship coefficients. 
The Y-axis represents the k1 pairwise IBD coefficients, which are probabilities of 
sharing one IBD. The X-axis represents the k0 pairwise IBD coefficients, which is 
the probability of sharing zero IBD. The red dashed line represents the expected 
IBD. The black circles represent the samples in the PD GWAS controls and 
NIDDK IBDO and GRU UC Cases. The results show that there is no relatedness 
among the samples analysed. 
 
 
 
   The final step in the quality control filtering of this case-control dataset, SNPs 
with a MAF higher than 0.03, HWE test P-value lower than 1.57x10-3 and a 
missing rate greater than 20%. The final SNP and individual count is listed in 
Table 11. 
 
 
   The same quality control procedure was carried out for the remaining NIDDK 
GRU UC Cases, which were genotyped on the Illumina HumanHap300v.2 
platfrom and the NIDDK Non-Jewish CD Controls dataset, genotyped on the 
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Illumina HumanHap300v.1 (See Table 11). Although both datasets were 
genotyped on the Illumina HumanHap300, they were genotyped on different 
versions of the platform and therefore they did not contain the same set of SNPs.  
Therefore, prior to merging the NIDDK UC GRU Cases and the NIDDK Non-
Jewish CD Controls, the SNPs that were not present on both platforms were 
removed. Subsequently, merging of the dataset was carried out in PLINK, as 
described earlier, after the necessary strand orientation flipping was done. After 
the successful merging of the cases with the controls, the quality controls 
analysis described in II.ii.a-c was carried out.  
 
 
 
 
Figure 22. Principal Components Analysis of merged NIDDK Non-Jewish 
CD Controls genotyped on the Illumina HumanHap 300v.1 and NIDDK GRU 
UC Cases genotyped on the Illumina HumanHap 300v.2 platform. 
The Y-axis represents the first Principal Component and the X-axis represents 
the second Principal Component. The red squares represent the sample loadings 
for the NIDDK GRU UC Cases and the black diamonds represent the sample 
loadings for the NIDDK Non Jewish CD Controls. The samples circled in red are 
the outliers identified in this analysis, which were removed from the data. 
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   The PCA revealed six outliers in the data, all of which came from the NIDDK 
Non-Jewish Control data, as shown circled in red in Figure 22. After these six 
outliers were removed from the data and the data were merged with the 
HapMap3 data, five outliers in the NIDDK GRU UC cases and four outliers in the 
NIDDK Non Jewish CD Controls were detected in a PCA analysis (Figure 23), as 
well as in the MDS analyses based on IBS distances (Figure 24). These 
individuals were removed from the data prior to proceeding with the quality 
control analysis. 
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Figure 23. Principal Components Anlaysis of merged NIDDK Non-Jewish CD Controls (Illumina HumanHap 300v.1), NIDDK 
GRU UC Cases (Illumina HumanHap 300v.2) and HapMap3 data. 
The Y-axis represents the first Principal Component and the X-axis represents the second Principal Component. The data points on 
the plot represent the sample loadings for the HapMap3, NIDDK Non Jewish CD Controls and NIDDK GRU UC Cases. The 
samples circled in red are the outliers identified in this analysis, which were removed from the data. 
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Figure 24. Multidimensional Scaling Analysis of merged NIDDK Non-Jewish CD Controls, NIDDK GRU UC Cases and 
HapMap3 data, basd on IBS Distances. 
The Y-axis represents the second vector of the MDS and the X-axis the first vector. The data points on the plot represent the 
HapMap3, the NIDDK Non Jewish CD Controls and NIDDK GRU UC Data. The samples circled in red represent the outliers 
identified in this analysis, which are the same as those illustrated in Figure 19. The samples were removed from the data. 
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The subsequent IBD analysis also revealed two pairs of related individuals 
(Figure 25). The first pair consisted of two Non-Jewish CD controls whereas the 
second pair consisted of a Non-Jewish CD control and a GRU UC Case.  One 
member of the first pair was removed and the NIDDK Non Jewish CD control was 
removed from the second pair. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25. IBD analysis of the merged NIDDK Non-Jewish CD Controls and 
NIDDK GRU UC Cases based on pairwise kinship coefficients. 
The Y-axis represents the k1 pairwise IBD coefficients, which are probabilities of 
sharing one IBD. The X-axis represents the k0 pairwise IBD coefficients, which is 
the probability of sharing zero IBD. The red dashed line represents the expected 
IBD. The black circles represent the samples in the NIDDK Non Jewish CD 
Controls and NIDDK GRU UC Cases. The results show that there are two pairs 
of related individuals in the merged data. A member from each pair was removed 
from the merged data. 
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iv. Genetic Analysis 
 
 
   The LDU mapping approach described in the Methods section of Chapter II 
was applied to the WTCCC2 Ulcerative Case-Control dataset,  the merged 
NIDDK IBDO and GRU UC Cases and PD GWAS controls genotyped on the 
Illumina HumanHap550v.3 platform, and finally the merged NIDDK Non-Jewish 
CD controls and NIDDK GRU UC Cases genotyped on the Illumina 
HumanHap300v.1 and Illumina HumanHap300v.2 platforms respectively. 
 
 
   Each chromosome was divided into approximately 10 LDU non-overlapping 
windows for each dataset. Approximately the same LDU locations for the 
boundaries used for the Crohn’s Disease analyses described in Chapters II and 
III were used for the UC datasets. This was done in order to facilitate the 
comparison of significant gene regions between the two subtypes IBD subtypes, 
which was to be our next aim.  All the SNPs within a window were simultaneously 
tested within a composite likelihood (Λ) framework. The P-value was obtained, 
together with the estimated location Ŝ of the putative causal agent in LDU. The 
latter was then converted into kb by linear interpolation of the two flanking SNPs 
in HapMap. 
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v. Replications and meta-analysis of shared locations 
 
  
  The meta-analysis of the P-values was carried out if the analytical windows 
showed nominal statistical significance for at least 2 datasets and the estimated 
locations Ŝ for these nominally significant windows were within 80 kb of one 
another, which is a more stringent distance threshold for replication than was 
used for the CD GWAS described Chapter III since the UC data contain a greater 
SNP density. 
 
 
  The meta-analysis of the significant P-values obtained from the independent 
datasets was done using Fisher’s combined probability test (see Methods section 
of Chapter III). The P-value for each test was combined as follows in order to 
produce a meta-analysis χ2 with 2k degrees of freedom for k number of tests: 
 �૛ =  −૛ ∑ ࢒࢔ ሺࡼሻ࢑࢏=૚  
 
 
 
    
   A Bonferroni threshold was calculated as follows in order to account for multiple 
testing (see Methods section of Chapter II): 
 ࡼ − ࢜ࢇ࢒࢛ࢋ ࢚ࢎ࢘ࢋ࢙ࢎ࢕࢒ࢊ =  �ࡺ࢛࢓࢈ࢋ࢘ ࢕ࢌ ࢚ࢋ࢙࢚࢙ 
 
where α is the commonly accepted probability of 5% false positive rate. The 
Bonferroni P-value threshold used was 1 x 10-5. This P-value threshold 
  
 139 
corresponds to the total number of genome-wide analytical windows  that were 
carried out for this analysis. 
 
 
vi. Significant gene-regions identified 
 
 
 
   As described in Chapter III, the gene closest to the estimated location Ŝ was 
retrieved from a list of genome-wide RefSeq genes for each of the replicated 
analytical windows. If the distance between the gene retrieved  and the estimated 
location Ŝ was larger than 300 kb, the estimated location Ŝ is listed as being 
“intergenic”. Using BioMart, the Gene Ontology (GO) annotations attributed to 
each gene were retrieved and the results are shown in Appendix V. 
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III. RESULTS 
 
 
 
 
 
i. Identifying the previously reported UC intervals. 
 
 
 
 
   As for the GWAS described in Chapter III of this thesis, the first step was to 
identify whether the LDU mapping method could detect the 59 previously 
reported loci. 47 of these 59 loci had been identified in a meta-analysis that 
consisted of six independent GWAS data and approximately 1.4 million 
autosomal markers. The remaining 12 loci were identified in the latest IBD meta-
analysis, which consisted of fifteen GWAS data on CD and/or UC, as well as 
Immunochip data for approximately 75,000 cases and controls. In order for a 
previous locus to be considered as replicated using the LDU mapping method, 
the estimated location Ŝ or the 95% CI had to lie within, or overlap in the case of 
the 95% CI, the reported LD interval. This approach was taken since the genes 
represented in both published studies are the result of in-silico analyses that 
aimed to identify positional candidate genes of interest, rather than the certain 
causal location with direct evidence from functional studies. Out of the 59 
previously identified loci, 53 were also found in at least one dataset within this 
study using an uncorrected significance threshold of P-value lower than 0.05. Six 
intervals showed no evidence of association with any of the three independent 
data sets. The statistical evidence and location estimates for the 53 loci are 
illustrated in Table 12. Most of the signals were identified in the larger WTCCC 
UC data set (49 out of 53 signals) and 65% of these (32 of the 49 signals) 
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survived the genome-wide significance Bonferroni threshold of 1x10-05.  40% of 
the signals (21 out of 53) replicated in two datasets and 8% (4) replicated in all 
three datasets, with an estimated location Ŝ within 80 kb between all three 
datasets. Three of the 53 signals were replicated in the NIDDK IBDO + GRU 
dataset genotyped on the Illumina HumanHap 550v.3 (referred to as NIDDK 550 
in Table 12) alone. In most cases, the previously reported intervals were quite 
large in size and the estimated locations Ŝ in the replication data sets were not 
within 80 kb of the other signal(s).  In those cases it was thus not possible to 
meta-analyse the P-values for the individual datasets and the individual P-values 
for the datasets are shown in Table 12. Indeed, differences in estimated locations 
Ŝ larger than 80 kb could suggest the presence of more than one signal. This 
could be the case for the signal on Chromosome 11q (Table 12), shown in Figure 
26. The previously reported interval spanned half a megabase in size and the 
LDU mapping approach further refined this interval with the identification of two 
signals using the WTCCC UC data within this interval and one using the NIDDK 
UC 550 data. The estimated locations for both datasets are located immediately 
upstream or within MAML2 and in a region of LD breakdown (Figure 26). 
Considering the LD breakdown in the region, the dense SNP coverage in both 
datasets, and that none of the 95% CI overlap between the different datasets, it is 
unlikely that these signals represent one location and could be an indication for 
the presence of allelic heterogeneity. In such a case, meta-analysing P-values 
would imply the presence of only one signal and thus mask the presence of 
heterogeneity. 
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  For 49% of the 53 loci identified (26 out of 53), the estimated location Ŝ is within 
a gene. The Consortium had reported positional candidate genes for 33 loci out 
of the 59 identified loci and 62% (16 out of 33 loci) of the genes illustrated in 
Table 12 match the genes reported by the Consortium for these intervals. 
 
Since the reported LD intervals are quite large, in the instances where replication 
points to more than one gene it is difficult to determine whether this could be 
attributable to genuine genetic heterogeneity or simply an artifact of SNP 
resolution between the datasets. In Table 12 it can be seen that although some 
signals were identified using more than one dataset, the estimated location Ŝ for 
the datasets points to the same gene. 19 of the intervals shown in Table 12 have 
also been found to be shared with CD (Anderson et al., 2011) (see Table 12). 
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Table 12. Whole-genome association statistics and closest gene to the estimated location Ŝ of the causal variant for the 
previously reported UC loci. 
 
Chr 
Reported LD 
Interval (Mb) 
WTCCC Ŝ 
(kb) 
WTCCC 
P-value 
NIDDK 
550 Ŝ (kb) 
NIDDK 
550 P-
value 
NIDDK 
300 Ŝ (kb) 
NIDDK 
300 P-
value 
WTCCC UC-
NIDDK 550 
Ŝ difference 
(kb) 
WTCCC UC-
NIDDK 300 
Ŝ difference 
(kb) 
NIDDK 550- 
NIDDK 300 
Ŝ difference 
(kb) 
Meta P-
value Gene 
1p 2.40-2.81 2,473.7 2.1x10-05 - - 2,469.2 2.3x10-02 - 4.5 - 7.5x10-06 HES5/LOC115110 
1p 7.91-8.21 - - 8,270.0 1.8x10-02 7,921.9 5.6x10-03 - - 348.1 - UTS2/SLC45A1 
1p 20.06-20.31 20,213.3 7.3x10-11 20,169.9 7.6x10-06 20,141.4 1.7x10-03 43.5 72.0 28.5 8.3x10-16 OTUD3*/RNF186* 
1p 22.67-22.74 22,695.0 2.3x10-02 - - - - - - - - ZBTB40 
1p 67.53-67.77 67,769.1 1.2x10-04 - - 67,741.5 3.5x10-05 - 27.6 - 8.4x10-08 IL23R*§ 
1q 161.27-161.64 161,409.4 1.4x10-03 - - 161,479.8 6.9x10-03 - 70.4 - 1.2x10-04 FCGR2A* 
1q 200.79-201.06 201,015.5 2.5x10-19 201,041.9 4.7x10-03 201,012.1 6.5x10-04 26.3 3.5 29.8 1.2x10-21 CACNA1S*§ 
1q 206.78-207.04 206,932.3 2.9x10-05 - - 206,939.9 2.1x10-03 - 7.6 - 1.1x10-06 IL10§ 
2p 60.91-62.02 61,186.8 1.3x10-09 - - 61,181.8 7.0x10-03 - 5.0 - 2.3x10-10 PUS10*§ 
2q 102.29-102.76 102,170.4 5.1x10-05 - - 102,733.0 3.7x10-03 - 562.7 - - IL1R1/RFX8§ 
2q 199.27-200.10 199,497.6 4.9x10-17 - - - - - - - - PLCL1 
2q 218.87-219.26 219,001.3 7.0x10-06 218,928.7 4.7x10-04 218,972.1 1.5x10-08 72.7 29.3 43.4 3.7x10-14 CXCR2*/RUFY4* 
2q 241.55-241.67 241,563.4 1.8x10-06 - - - - - - - - GPR35* 
3p 48.16-51.79 49,894.9 3.4x10-53 48,687.8 4.1x10-09 - - 1,207.1 - - - CELSR3*/CAMKV§ 
3p 52.80-53.30 52,833.5 3.2x10-13 53,252.5 2.2x10-02 - - 419.1 - - - ITIH3*/TKT 
4q 103.26-103.76 103,419.3 2.2x10-12 - - 104,361.3 5.5x10-08 - 942.5 - - NFKB1/TACR3 
4q 122.98-123.56 123,025.1 6.5x10-09 - - - - - - - - KIAA1109 
5p 0.43-0.75 562.8 9.2x10-09 578.8 2.0x10-03 - - 15.9 - - 4.8x10-10 SLC9A3/CEP72 
5p 10.67-10.85 - - 10,710.8 3.0x10-06 - - - - - - DAP* 
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Chr 
Reported LD 
Interval (Mb) 
WTCCC Ŝ 
(kb) 
WTCCC 
P-value 
NIDDK 
550 Ŝ (kb) 
NIDDK 
550 P-
value 
NIDDK 
300 Ŝ (kb) 
NIDDK 
300 P-
value 
WTCCC UC-
NIDDK 550 
Ŝ difference 
(kb) 
WTCCC UC-
NIDDK 300 
Ŝ difference 
(kb) 
NIDDK 550- 
NIDDK 300 
Ŝ difference 
(kb) 
Meta P-
value Gene 
5p 35.79-36.03 35,811.4 2.5x10-12 - - - - - - - - SPEF2* 
5p 40.28-40.81 - - 40,617.6 3.3x10-13 - - - - - - PTGER4 
5q 134.38-134.50 134,463.1 7.2x10-05 - - - - - - - - C5orf66* 
5q 158.53-158.93 158,825.8 1.1x10-02 - - - - - - - - IL12B 
6p 31.38-32.90 32,804.8 2.9x10-12 32,739.0 3.0x10-14 - - 65.8 - - 5.0x10-24 TAP2*/HLA-DQB2 
6q 137.84-138.13 137,978.5 4.0x10-08 - - - - - - - - OLIG3 
7p 2.73-2.93 2,759.0 3.0x10-07 - - - - - - - - AMZ1 
7p 26.97-27.47 27,412.2 6.4x10-08 - - - - - - - - EVX1 
7q 107.41-107.60 107,459.0 6.1x10-10 - - - - - - - - SLC26A3 
 
- 107,476.9 9.9x10-27 - - 107,603.9 2.1x10-02 - 127.0 - - LAMB1*/SLC26A3 
7q 128.54-128.77 129,310.2 2.5x10-05 - - - - - - - - KCP 
9p 4.94-5.29 5,012.4 4.8x10-27 - - 4,911.4 1.1x10-02 - 101.0 - - RCL1/JAK2* 
9q 117.44-117.70 117,559.8 2.2x10-13 - - - - - - - - TNFSF15* 
9q 139.13-139.43 139,262.0 8.7x10-13 - - - - - - - - CARD9* 
10p 35.18-35.90 35,554.4 8.8x10-05 - - - - - - - - CCNY* 
10q 101.26-101.34 101,754.7 3.2x10-16 101,342.5 3.1x10-02 - - 72.6 - - - NKX2-3/SLC25A28 
11q 76.04-76.34 76,303.3 3.5x10-07 - - - - - - - - C11orf30 
11q 95.77-96.27 95,762.1 3.1x10-02 95,703.9 1.0x10-02 - - 58.2 - - 2.9x10-03 MAML2* 
 
- 96,008.6 4.2x10-08 - - - - - - - - MAML2* 
11q 114.25-114.57 114,331.5 4.3x10-07 - - 114,239.1 9.3x10-03 - 92.4 - - C11orf71/REXO2 
12q 68.43-68.63 68,478.2 6.7x10-11 68,493.0 1.4x10-04 68,416.4 1.1x10-02 14.8 61.8 76.5 7.2x10-14 IFNG 
13q 27.49-27.56 27,543.0 3.3x10-17 27,564.7 4.0x10-03 - - 21.6 - - 6.0x10-18 USP12 
13q 41.00-41.05 41,025.9 1.4x10-03 - - 41,014.0 2.7x10-03 - 11.9 - 4.9x10-05 LINC00598* 
15q 41.29-41.81 41,799.3 7.0x10-15 - - - - - - - - LTK* 
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Chr 
Reported LD 
Interval (Mb) 
WTCCC Ŝ 
(kb) 
WTCCC 
P-value 
NIDDK 
550 Ŝ (kb) 
NIDDK 
550 P-
value 
NIDDK 
300 Ŝ (kb) 
NIDDK 
300 P-
value 
WTCCC UC-
NIDDK 550 
Ŝ difference 
(kb) 
WTCCC UC-
NIDDK 300 
Ŝ difference 
(kb) 
NIDDK 550- 
NIDDK 300 
Ŝ difference 
(kb) 
Meta P-
value Gene 
16q 68.42-68.84 68,592.0 8.9x10-13 - - - - - - - - ZFP90 
16q 85.97-86.02 85,996.3 1.5x10-04 - - - - - - - - IRF8 
17q 37.37-38.26 37,756.0 1.0x10-19 38,257.1 1.3x10-02 - - 501.1 - - - NR1D1/NEUROD2 
17q 70.39-70.89 70,697.0 1.1x10-02 - - - - - - - - SLC39A11* 
19q 46.87-47.37 33,806.8 - 46,837.5 5.2x10-03 - - - - - - HIF3A* 
20q 33.55-34.05 43,065.0 2.5x10-09 - - - - - - - - MMP24 
20q 43.06-43.27 - 4.6x10-09 - - - - - - - - HNF4A 
20q 62.19-62.51 62,326.9 5.9x10-04 - - - - - - - - RTEL1* 
21q 16.70-16.85 16,818.4 4.9x10-07 16,802.9 5.6x10-05 - - 15.5 - - 6.9x10-10 USP25 
21q 40.42-40.49 40,474.0 3.6x10-03 - - - - - - - - PSMG1 
21q 45.59-45.70 45,608.8 2.2x10-04 - - - - - - - - ICOSLG 
22q 50.31-50.49 50,351.1 3.4x10-02 - - - - - - - - PIM3 
 
* denotes that at least one of the estimated locations Ŝ is located within the identified gene. The intervals highlighted in blue 
correspond to the loci previously identified in the IBD meta-analysis that also used the Immunochip genotyping array (Jostins et al., 
2012). The intervals  highlighted in grey correspond to loci that have been found to be shared with CD (Anderson et al., 2011). § The 
Meta P-value is only provided in instances where the Ŝ difference is less than 80 kb between datasets. 
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Figure 26. Localisation within the MAML2 region. 
The Y-axis represents genomic LDU distances and the X-axis represents physical distances in kilobases. The solid black line 
represents the LDU map of the region constructed from the HapMap CEU data. The red vertical arrow is the estimated location Ŝ of 
the causal variants. The blue diamonds show the SNPs found in this regions on the WTCCC UC Affymetrix 6.0 array. The light 
green horizontal dashed lines represent the 95% CIs of the estimated locations Ŝ. The orange triangles are the SNPs on the 
NIDDK UC Illumina HumanHap 550v.3 array in this region. 
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i. 138 novel gene-regions identified 
 
 
The second step was to determine whether the LDU mapping method would be 
able to detect novel signals using the three UC case-controls datasets.  For this a 
meta-analysis approach was used in which the maximum distance between the 
estimated Ŝ  locations was set at 80kb.  138 novel gene-regions that passed the 
Bonferroni genome-wide significance threshold of 1x10-05 were identified. Since 
the distance between the estimated locations Ŝ was less than 80 kb, the meta-
analysis P-value is provided for these replications.  10 of these 138 gene-regions 
replicate with all three datasets, with a meta P-value surviving the Bonferroni 
genome-wide significance threshold. One of these ten replications, the ERAP1 
gene-region, is illustrated in Figure 27. For this region, the estimated Ŝ locations 
for the WTCCC UC and NIDDK UC Illumina HumanHap 550v.3 datasets lie 
within intron 17 of the ERAP1 gene whereas, although still very close, the 
estimated Ŝ location of the NIDDK UC Illumina HumanHap 300v.1 & v.2 dataset 
lies downstream of the gene. The estimated locations Ŝ and their 95% CI are 
illustrated in Figure 27.  
 
   The remaining 128 novel gene-regions were replicated in two out of three 
datasets, with a meta P-value surviving the Bonferroni genome-wide significance 
threshold. 
 
    Out of these 138 gene regions, 12 signals were intergenic locations, where the 
closest gene was further than 300kb from the estimated locations Ŝ. Of the
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remaining 126 gene-regions, 57% of the signals were intragenic locations, with 
the estimated location Ŝ being within a gene for at least one of the datasets. 
Additionally, in 75% of the 126 gene-regions, the estimated locations Ŝ for the 
datasets point to the same gene. 
 
 
 
 
Table 13. Whole-genome association statistics and closest gene to the 
estimated location Ŝ of the causal variant for the 10 novel gene-regions that 
replicate in all three datasets with estimated locations Ŝ within 80 kb of 
each other. 
 
Chr WTCCC UC NIDDK   
IBDO + GRU 
Illumina 
550v.3 
NIDDK 
GRU UC 
Illumina  
300 
Meta  
 P-value 
Gene 
1q 171,661.9 171,697.8 171,620.2 8.3x10-09 VAMP4*/MYOC* 
3q 109,508.6 109,515.6 109,521.4 2.0x10-11 intergenic 
4p 30,242.7 30,306.9 30,277.9 9.3x10-07 intergenic 
4q 101,853.1 101,798.3 101,799.1 1.0x10-15 PPP3CA 
5q 96,109.8 96,108.9 96,134.9 8.9x10-07 ERAP1* 
6p 33,051.2 32,998.7 33,051.2 2.0x10-10 HLA-DPB1*/HLA-DOA 
7q 144,299.5 144,249.7 144,297.3 3.3x10-07 TPK1* 
10p 14,105.9 14,066.5 14,108.0 6.7x10-09 FRMD4A* 
12p 28,679.5 28,595.9 28,309.1 7.3x10-27 CCDC91* 
20q 31,663.2 31,722.5 31,682.8 2.1x10-09 BPIFB3/BPIFB4* 
 
 
* denotes that at least one of the estimated locations Ŝ is located within the 
identified gene. Genes in bold are genes that have been identified in Chapter III 
for CD. The gene region highlighted in grey is included in this table even though 
the  estimated locations are further than 80 kb from one another because all the 
estimated locations for this gene-region are genetically very close as measure in 
LDU, due to its occurrence within a long region of very high LD). 
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Figure 27. Localisation within the ERAP1 region. 
The Y-axis represents genomic LDU locations whereas the X-axis represents genomic physical locations in kilobases. The solid 
black line represents the LDU map of the region constructed from the HapMap CEU data. The red vertical arrows are the estimated 
locations Ŝ of the causal variants. The dark green lines highlight the exons of the ERAP1 gene. The dark blue bashed line 
reporesentes the 95% CI for the WTCCC UC estimated location Ŝ.  The light blue dashed line represents the 95% CI for the NIDDK 
UC Illumina HumanHap 550v.3 estimated location Ŝ. The grey dashed line represents the 95% CI of the NIDDK UC Illumina 
HumanHap 300v.1&v.2 estimated location Ŝ. The light blue diamonds show the SNPs found in this regions on the WTCCC UC 
Affymetrix 6.0 array, the dark blue circles represent those on the NIDDK UC Illumina HumanHap 550v.3 array and the red triangles 
represent the SNPs in this regions that are common to both the NIDDK Illumina HumanHap 300v.1 and Illumina HumanHap 300v.2 
arrays. 
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Table 14. Whole-genome association statistics and closest gene to the 
estimated location Ŝ of the causal variant for the 128 novel gene-regions 
that replicate with two datasets with an estimated location Ŝ within 80 kb 
between datasets. a) Whole-genome association statistics and closest gene 
to the estiamted location Ŝ of the causal variant for the 108 novel gene-
regions that replicate with two datasets with an estimated location Ŝ within 
80 kb for WTCCC UC and NIDDK UC 550 or WTCCC UC and NIDDK UC 300 
datasets. b) Whole-genome association statistics and closest gene to the 
estiamted location Ŝ of the causal variant for the 20 novel gene-regions that 
replicate with two datasets with an estimated location Ŝ within 80 kb for 
NIDDK UC 550 and NIDDK UC 300 datasets. 
 
 
 
 
Table 14 a) 
 
Chr UC Replication  
(Signal 1/Signal 2) 
Signal 1 Signal 2 Meta P-
value 
Gene 
1p WTCCC/NIDDK 300 26,531.4 26,528.4 3.4x10-10 CATSPER4* 
1p WTCCC/NIDDK 550 79,063.7 78,988.3 3.3x10-12 IFI44L/PTGFR* 
1p WTCCC/NIDDK 550 92,316.2 92,316.9 1.0x10-08 TGFBR3* 
1p WTCCC/NIDDK 300 101,501.7 101,500.7 4.0x10-11 DPH5 
1q WTCCC/NIDDK 300 151,907.1 151,985.6 8.3x10-17 THEM4/NBPF18P 
1q WTCCC/NIDDK 300 173,304.4 173,370.2 4.6x10-07 LOC100506023* 
1q WTCCC/NIDDK 550 232,574.7 232,566.9 7.6x10-07 SIPA1L2* 
1q WTCCC/NIDDK 550 236,586.9 236,539.8 1.0x10-05 EDARADD* 
2p WTCCC/NIDDK 550 3,006.2 2,935.2 3.2x10-06 TSSC1 
2p WTCCC/NIDDK 550 15,189.0 15,112.8 3.3x10-07 NBAS 
2p WTCCC/NIDDK 550 44,039.9 44,002.0 7.3x10-08 ABCG5*/DYNC2LI1* 
2p WTCCC/NIDDK 300 49,056.4 49,085.9 7.2x10-08 STON1-GTF2A1L 
2p WTCCC/NIDDK 300 80,620.5 80,665.6 7.7x10-08 CTNNA2* 
2p WTCCC/NIDDK 300 81,633.5 81,665.4 2.3x10-08 intergenic 
2q WTCCC/NIDDK 550 100,805.3 100,871.1 1.1x10-10 LOC150577 
2q WTCCC/NIDDK 300 103,125.4 103,159.7 5.7x10-26 SLC9A4* 
2q WTCCC/NIDDK 550 160,866.9 160,889.9 1.9x10-07 PLA2R1* 
2q WTCCC/NIDDK 550 168,748.0 168,738.6 7.5x10-06 B3GALT1 
2q WTCCC/NIDDK 550 169,969.0 170,001.5 4.7x10-06 LRP2* 
2q WTCCC/NIDDK 550 226,257.7 226,231.6 8.8x10-08 NYAP2 
2q WTCCC/NIDDK 550 237,052.2 237,064.0 3.3x10-06 AGAP1/GBX2 
3p WTCCC/NIDDK 550 29,707.3 29,707.6 1.1x10-09 RBMS3* 
3p WTCCC/NIDDK 300 30,626.6 30,680.0 2.7x10-07 TGFBR2* 
3p WTCCC/NIDDK 550 60,514.8 60,478.9 3.8x10-06 FHIT* 
3p WTCCC/NIDDK 300 61,299.4 61,267.2 9.0x10-08 FHIT 
3q WTCCC/NIDDK 550 156,277.0 156,274.8 9.7x10-06 SSR3 
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Chr UC Replication  
(Signal 1/Signal 2) 
Signal 1 Signal 2 Meta P-
value 
Gene 
3q WTCCC/NIDDK 550 197,297.5 197,240.1 1.1x10-07 BDH1* 
4p WTCCC/NIDDK 550 36,825.2 36,753.0 2.7x10-06 intergenic 
4q WTCCC/NIDDK 300 84,227.2 84,162.2 6.1x10-07 HPSE*/COQ2 
4q WTCCC/NIDDK 550 124,451.7 124,448.6 2.7x10-08 LOC285419/SPRY1 
4q WTCCC/NIDDK 300 163,012.0 163,030.3 1.4x10-06 FSTL5* 
5p WTCCC/NIDDK 550 2,740.1 2,774.8 5.0x10-06 IRX2/C5orf38 
5p WTCCC/NIDDK 550 3,176.2 3,114.8 8.5x10-07 LINC01019 
5p WTCCC/NIDDK 300 9,782.2 9,824.2 1.5x10-08 LOC285692* 
5p WTCCC/NIDDK 550 15,752.0 15,789.8 1.6x10-07 FBXL7* 
5p WTCCC/NIDDK 550 28,770.4 28,718.5 2.6x10-07 LSP1P3 
5p WTCCC/NIDDK 550 39,115.8 39,195.1 8.4x10-09 FYB* 
5q WTCCC/NIDDK 550 115,387.3 115,419.8 5.6x10-08 ARL14EPL*/COMMD10 
5q WTCCC/NIDDK 550 132,476.0 132,529.7 8.3x10-07 HSPA4/FSTL4 
5q WTCCC/NIDDK 300 139,269.1 139,264.8 4.3x10-06 NRG2* 
5q WTCCC/NIDDK 550 143,483.6 143,484.5 9.9x10-07 YIPF5 
5q WTCCC/NIDDK 550 179,756.8 179,816.5 6.4x10-06 GFPT2* 
6p WTCCC/NIDDK 550 12,353.2 12,297.1 5.1x10-08 EDN1* 
6p WTCCC/NIDDK 300 12,951.2 13,029.5 4.3x10-06 PHACTR1* 
6q WTCCC/NIDDK 550 70,361.8 70,362.8 2.3x10-11 LMBRD1 
6q WTCCC/NIDDK 550 86,817.3 86,798.5 4.6x10-23 MIR548AD 
6q WTCCC/NIDDK 550 103,900.6 103,905.8 5.2x10-09 HACE1 
6q WTCCC/NIDDK 550 119,030.3 119,029.7 2.8x10-15 CEP85L* 
7p WTCCC/NIDDK 300 16,695.7 16,710.5 5.9x10-07 BZW2* 
7p WTCCC/NIDDK 300 41,923.9 41,941.0 1.4x10-10 GLI3 
7q WTCCC/NIDDK 550 67,238.6 67,292.7 6.7x10-07 intergenic 
7q WTCCC/NIDDK 300 80,060.8 80,056.9 3.7x10-06 GNAT3 
7q WTCCC/NIDDK 550 102,791.0 102,791.4 4.4x10-10 NAPEPLD 
7q WTCCC/NIDDK 550 108,774.1 108,747.1 3.7x10-10 C7orf66 
7q WTCCC/NIDDK 300 146,952.3 146,936.0 3.3x10-10 CNTNAP2* 
7q WTCCC/NIDDK 550 147,981.9 147,927.4 1.8x10-06 MIR548T* 
8p WTCCC/NIDDK 550 6,758.4 6,789.3 2.0x10-08 DEFB1/DEFA4 
8p WTCCC/NIDDK 550 24,858.2 24,844.8 1.0x10-08 NEFL 
8q WTCCC/NIDDK 550 56,505.8 56,523.5 1.9x10-09 XKR4 
8q WTCCC/NIDDK 300 60,327.6 60,254.8 8.1x10-06 TOX 
9p WTCCC/NIDDK 550 1,317.7 1,237.9 2.4x10-07 DMRT2 
9p WTCCC/NIDDK 300 14,404.6 14,446.0 6.2x10-06 NFIB 
9p WTCCC/NIDDK 550 30,225.6 30,292.2 1.1x10-08 LOC401497 
9q WTCCC/NIDDK 300 81,509.0 81,572.2 1.5x10-06 intergenic 
9q WTCCC/NIDDK 300 90,393.1 90,420.4 1.7x10-08 CTSL3P* 
9q WTCCC/NIDDK 300 103,473.9 103,545.4 3.0x10-08 MURC 
  
 154 
Chr UC Replication  
(Signal 1/Signal 2) 
Signal 1 Signal 2 Meta P-
value 
Gene 
9q WTCCC/NIDDK 550 115,736.2 115,723.4 2.6x10-06 ZNF883 
9q WTCCC/NIDDK 550 120,967.8 121,009.7 1.2x10-07 intergenic 
10p WTCCC/NIDDK 300 36,971.1 36,941.3 1.2x10-08 ANKRD30A 
10q WTCCC/NIDDK 550 63,552.9 63,553.5 1.7x10-08 C10orf107 
10q WTCCC/NIDDK 550 90,739.8 90,787.4 6.0x10-07 ACTA2*/FAS 
10q WTCCC/NIDDK 550 102,848.6 102,880.7 7.5x10-06 TLX1NB* 
10q WTCCC/NIDDK 550 104,232.3 104,210.8 3.3x10-14 TMEM180*/C10orf95* 
10q WTCCC/NIDDK 550 121,292.5 121,287.8 2.6x10-06 RGS10* 
11p WTCCC/NIDDK 300 13,317.5 13,353.6 6.7x10-10 ARNTL* 
11p WTCCC/NIDDK 300 15,470.0 15,402.1 8.8x10-09 INSC 
11p WTCCC/NIDDK 550 17,426.6 17,426.3 8.1x10-13 ABCC8* 
11p WTCCC/NIDDK 550 20,160.1 20,124.2 7.7x10-08 NAV2* 
11p WTCCC/NIDDK 300 42,635.2 42,657.9 3.7x10-07 intergenic 
11q WTCCC/NIDDK 550 77,904.5 77,918.6 3.4x10-21 USP35* 
11q WTCCC/NIDDK 550 102,575.7 102,575.7 1.3x10-12 MMP27* 
11q WTCCC/NIDDK 550 117,040.9 116,994.7 3.9x10-09 PAFAH1B2* 
12p WTCCC/NIDDK 550 32,931.7 32,998.7 2.6x10-07 PKP2/PKP2* 
12q WTCCC/NIDDK 300 73,009.6 72,984.5 2.5x10-07 TRHDE* 
12q WTCCC/NIDDK 550 108,637.3 108,693.5 2.6x10-07 WSCD2*/CMKLR1* 
12q WTCCC/NIDDK 550 126,545.5 126,511.6 7.6x10-07 LINC00939 
13q WTCCC/NIDDK 550 40,510.3 40,546.3 2.2x10-12 COG6 
13q WTCCC/NIDDK 300 71,015.4 71,012.4 1.5x10-07 ATXN8OS 
14q WTCCC/NIDDK 300 27,211.4 27,271.3 3.4x10-18 NOVA1/MIR4307 
14q WTCCC/NIDDK 550 40,736.6 40,766.6 6.1x10-10 intergenic 
14q WTCCC/NIDDK 550 56,435.8 56,498.9 3.2x10-06 PELI2 
14q WTCCC/NIDDK 550 62,955.4 62,954.2 5.6x10-09 KCNH5 
14q WTCCC/NIDDK 550 85,994.1 86,053.4 9.4x10-07 FLRT2* 
14q WTCCC/NIDDK 550 96,023.1 96,032.9 1.4x10-06 GLRX5 
15q WTCCC/NIDDK 300 47,995.0 47,981.0 1.0x10-06 SEMA6D* 
15q WTCCC/NIDDK 550 61,432.1 61,378.3 2.0x10-07 RORA* 
15q WTCCC/NIDDK 550 63,050.8 63,098.4 2.1x10-09 TLN2* 
15q WTCCC/NIDDK 550 63,819.8 63,758.9 2.0x10-10 USP3* 
16p WTCCC/NIDDK 550 20,025.2 20,036.1 6.8x10-08 GPR139 
17q WTCCC/NIDDK 550 70,080.6 70,145.4 2.7x10-09 FLJ37644*/SOX9 
18q WTCCC/NIDDK 300 30,889.1 30,891.0 9.9x10-11 CCDC178* 
18q WTCCC/NIDDK 550 39,026.9 39,010.8 8.8x10-06 KC6 
18q WTCCC/NIDDK 550 46,156.0 46,112.6 8.4x10-08 CTIF* 
18q WTCCC/NIDDK 300 67,510.4 67,442.5 5.3x10-06 DOK6* 
20p WTCCC/NIDDK 550 14,314.2 14,352.4 1.2x10-17 FLRT3*/MACROD2* 
20q WTCCC/NIDDK 550 45,577.9 45,571.8 1.9x10-08 EYA2* 
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Chr UC Replication  
(Signal 1/Signal 2) 
Signal 1 Signal 2 Meta P-
value 
Gene 
21q WTCCC/NIDDK 550 26,833.1 26,770.9 3.5x10-17 LINC00158* 
22q WTCCC/NIDDK 550 34,860.0 34,784.2 9.7x10-07 intergenic 
 
 
 
 
 
 
Table 14 b) 
 
Chr UC Replication  
(Signal 1/Signal 2) 
Signal 1 Signal 2 Meta P-
value 
Gene 
1q NIDDK 550/NIDDK 300 177,964.6 178,030.4 8.7x10-06 LOC730102 
1q NIDDK 550/NIDDK 300 226,845.3 226,846.9 5.6x10-06 ITPKB-IT1* 
2p NIDDK 550/NIDDK 300 29,978.8 29,979.3 2.6x10-07 ALK* 
2q NIDDK 550/NIDDK 300 134,975.7 135,031.4 4.1x10-10 MGAT5* 
2q NIDDK 550/NIDDK 300 137,187.7 137,187.0 8.0x10-27 CXCR4 
2q NIDDK 550/NIDDK 300 181,752.0 181,676.6 1.2x10-07 UBE2E3 
3q NIDDK 550/NIDDK 300 114,511.3 114,511.1 1.5x10-07 ZBTB20* 
4p NIDDK 550/NIDDK 300 38,734.2 38,707.6 1.6x10-19 KLF3 
4q NIDDK 550/NIDDK 300 148,723.6 148,722.9 3.6x10-07 ARHGAP10* 
5p NIDDK 550/NIDDK 300 30,570.2 30,547.0 3.3x10-07 intergenic 
5q NIDDK 550/NIDDK 300 170,170.2 170,212.3 3.5x10-06 KCNIP1/GABRP* 
5q NIDDK 550/NIDDK 300 176,784.7 176,827.1 2.2x10-07 RGS14/PFN3* 
10q NIDDK 550/NIDDK 300 52,198.4 52,261.6 1.4x10-08 SGMS1* 
12p NIDDK 550/NIDDK 300 1,495.7 1,509.9 1.3x10-06 ERC1* 
12q NIDDK 550/NIDDK 300 119,858.9 119,858.9 3.8x10-06 CCDC60* 
15q NIDDK 550/NIDDK 300 72,677.4 72,710.7 3.4x10-12 HEXA-AS1/TMEM202 
16q NIDDK 550/NIDDK 300 82,279.3 82,278.8 4.6x10-08 MPHOSPH6 
18q NIDDK 550/NIDDK 300 41,809.4 41,810.7 4.8x10-08 intergenic 
18q NIDDK 550/NIDDK 300 59,990.6 60,005.0 2.8x10-09 TNFRSF11A* 
20q NIDDK 550/NIDDK 300 54,350.0 54,421.0 8.3x10-06 CBLN4 
 
* denotes that at least one of the estimated locations Ŝ is located within the 
identified gene. Genes in bold are genes that have been identified in Chapter III 
for CD. 
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   From the 128 novel gene-regions illustrated in Table 14 a) and b), 68% of the 
signals have an estimated location Ŝ less than 50 kb apart in the two datasets 
and 40% had an estimated location Ŝ within less than 25 kb of each other. An 
example is shown in Figure 28, which illustrates the MMP27 gene-region. The 
estimated locations Ŝ  for the WTCCC UC data and the NIDDK UC Illumina 
HumanHap 500v.3 data are identical for this region and are located in a small 
block of LD. Additionally, 7 of the 138 novel gene-regions were also identified in 
the CD analysis carried out in Chapter III, as shown in bold in Table 13 and 13. 
The molecular and functional attributes of all the genes identified in this chapter 
are shown in Appendix V. 
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Figure 28. Localisation within the MMP27 gene-region. 
The Y-axis represents genomic LDU locations whereas the X-axis represents genomic physical locations in kilobases. The solid 
black line represents the LDU map of the region constructed from the HapMap CEU data. The red vertical arrow is the estimated 
location Ŝ of the putative causal agents. The dark green lines highlight the exons of the MMP27 gene. The light blue triangles show 
the SNPs found in this region on the NIDDK UC Illumina HumanHap 550v.3 array and the dark blue diamonds are the SNPs on the 
WTCCC UC Affymetrix 6.0 array in this region. 
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IV. DISCUSSION 
 
 
 
 
 
 
 In this Chapter, the LDU multi-marker mapping approach successfully identified, 
with the additional provision of location estimates rather than LD intervals, 53 out 
of 59 previously reported UC loci. There could be several reasons for the failure 
in replicating the six remaining previously identified intervals. One reason could 
be the discrepancy in SNP resolution between the study carried out here and the 
meta-analysis that originally identified these intervals, since imputation was used 
in the meta-anaysis, which greatly increased the SNP resolution. Additionally, the 
original meta-analysis contained six GWAS datasets and therefore there is 
missing SNP data in the study carried out in this chapter, which solely made use 
of the WTCCC and NIDDK UC data. However, imputation was not carried out for 
the UC GWAS described in this chapter.  Additionally, their efforts to combine 
data for the purpose of power may have increased heterogeneity within the 
dataset. Unlike in the case of the NIDDK CD dataset, there is lack of information 
on the UC phenotype. Based on the results form Chapters II and III, we can only 
predict that this increase in heterogeneity may translate to missing information. 
 
 
In addition, 138 novel gene-regions were identified, with a closer replication of 
location estimates between the UC datasets. For the previously identified 
intervals, most of the signals were identified using the WTCCC UC data alone 
using this method and thus were not meta-analysed. The previously reported 
intervals together with the novel loci identified in this project increases the 
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number of UC loci found to date to 197, which is quite a substantial number 
considering that although polygenic, UC has been judged to have a lower genetic 
contribution than CD. It could be argued that even if some of these signals are 
false positives, many of the putative causal agents involved in UC are thus likely 
to be of low effect size. However, in the presence of disease heterogeneity, some 
of the signals could have a larger effect size in fewer people. 
 
 
  Previous genetic and animal studies have provided evidence for the 
involvement of a defective epithelial barrier in the gut (Consortium et al., 2009; 
Gitter et al., 2001; Schmitz et al., 1999). In the current study, several genes 
involved in cell motility, cell-cell junction and cell adhesion were identified. 
Examples of such genes are CTNNA2, TLN2, FLRT2, FLRT3 and PKP2. Box 2 
provides functional information on selected genes from Tables 13 and 14 a) and 
b). The molecular and functional Gene Ontology terms attributed to all the novel 
genes that were identified in this Chapter are given in Appendix V. 
 
 
 It is also interesting that some of the genes identified here are involved in 
peptidase activity, such as ERAP1, USP3, USP35 and TRHDE. ERAP1 
(Endoplasmic Reticulum AminoPeptidase 1), illustrated in Figure 27, is a zinc 
metallopeptidase known to be implicated in the processing of antigenic peptides 
prior to presentation on the Major Histocompatibility Complex (MHC) Class I 
molecules (Agrawal and Brown, 2014). It is also involved in the regulation of the 
adaptive immune response and the inhibition of ERAP1 has been found to 
increase the presentation of cell surface antigens as well as that of cytotoxic T-
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cell responses (Zervoudi et al., 2013). ERAP1 has also been previously identified 
as a general IBD susceptibility locus in the latest IBD meta-analysis, with the 
reported SNP located approximately 100 kb downstream of the estimated 
locations presented here (Jostins et al., 2012).  
 
    
   Some of the genes that encode proteins with peptidase activity also form part of 
the proteinaceous Extra-Cellular Matrix (ECM), for example MMP27 and NAV2.  
For instance, MMP27 is a very interesting candidate that has been found for the 
first time here, with identical estimated Ŝ locations between the WTCCC UC and 
NIDDK Illumina HumanHap 500v.3 data, located in intron 17 of the MMP27 gene. 
MMP27 is part of the Matrix MetalloProteinase (MMP) family (Figure 28).  
 
   MMPs are involved in the degradation of components of the ECM, such as 
collagen, which is an important process that contributes to processes such as cell 
survival, cell growth, as well as cell migration and cell invasion (Noel et al., 2012). 
MMPs are secreted as inactive proteins, which then become activated after 
cleavage by extracellular proteinases. Proteinases like MMPs disrupt the 
physiological barriers in order to facilitate the migration of cells and the release of 
chemotactic and growth factors from the ECM.  Dyresgulation of MMPs 
contributes to cancer, as well as ulcer formation, which is central to the 
phenotype of UC (Nagase et al., 2006). Dysregulation of MMPs has also been 
identified in coronary pathology, such as Myocardial Infarction (MI) and Coronary 
Artery Disease (CAD), where both conditions exhibit inflammatory features. 
However, although the chicken MMP27 protein has been found to digest gelatin 
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and casein and causes autolysis of the MMP27 enzyme, little information is 
available on the mammalian MMP27 enzyme (Nagase et al., 2006). 
 
   Another interesting candidate identified in this part of the project is the Ubiquitin 
Specific Protease USP3, which is a hydrolase enzyme that deubiquitinates 
monoubiquitinated target proteins. Two of its target proteins are H2A and H2B, 
which are proteins involved in DNA-Damage Repair (DDR) check-point of the 
mitotic cycle. Thus, USP3 is essential for the proper progression through S phase 
and subsequent mitotic entry (Nicassio et al., 2007). As mentioned in the 
introduction of this chapter, studies have shown that improper cell-cycling is 
exhibited in UC patients. Indeed, it was found that the cell-cycle of colonic cells in 
UC patients progresses faster than that of colonic cells in healthy controls, which 
suggests a role for a dysregulated cell-cycle in UC and possibly why the 
progression to colorectal cancer is frequent among UC patients.  USP3 has also 
been found to be associated with both CD and UC in an association study that 
targeted genes encoding proteases that also identified CYLD, as discussed in 
Chapter II (Cleynen et al., 2014). 
 
 
   Other genes involved in the cell cycle have been identified in the UC meta-
analysis described here, namely MPHOSPH6, which is a protein phosphorylated 
in the M-Phase of the cell cycle, and PPP3CA, a Serine/Threonine protein 
phosphatase, thus similar to cyclin-dependent kinases (cdks) and RGS14, which 
has also been found to be required for phagocytosis (Lim et al., 2013).  
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   In summary, using the LDU mapping approach, many novel signals have been 
identified, within or close to genes that are functionally relevant to the UC 
phenotype, as well as that of colorectal cancer. However, it is important to note 
that the genes presented here are the genes which are closest to the location 
estimate obtained and therefore are not necessarily causal since long-acting cis 
elements may be involved. Also, promoters and enhancers located within one 
gene but regulate a more distant gene are also known to exist and this cannot be 
identified with the LDU mapping approach or other association testing methods. 
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Box 2: Functional overview of some genes of interest identified in Chapter 
IV [Tables 13 and 14 a) and b)]. 
 
 
 
 
 
 
 
TRHDE: (Thyrotropin-Releasing Hormone-Degrading Enzyme). TRHDE is 
an extracellular peptidase, a member of the peptidase M1 family that 
specifically cleaves and inactivates the neuropeptide thyrotropin-releasing 
hormone.  This gene was also identified in a GWA study of Rheumatoid 
Arthritis and in a study on Grave’s Disease where both diseases display a huge 
involvement of a dysregulated immune system. 
 
 
CTNNA2: (Catenin, alpha-2). CTNNA2 is also known as Cadherin-associated 
protein as a result of the physical interaction between CTNNA2 and Cadherins. 
Catenins anchor Cadherins to the cell’s cytoskeleton. Together with CDH1, 
which encodes E-Cadherin (See Chapter II), CTNNA2 was found to be a 
mutator driver gene involved in gastric cancer (Wang et al., 2014). 
 
 
ERAP1: (Endoplasmic Reticulum Amino-Peptidase 1). Like TRHDE, ERAP1 
is a member of the M1 family of zinc metalloproteinases. ERAP1 is involved 
in the processing of immune-related receptor ligands, such as HLA-B27 
ligands, via peptide trimming. Upon LPS stimulation, it has been demonstrated 
that the secretion of ERAP1 is mediated by Toll-Like Receptors (TLRs) 
through intermediate cytokines such as IFN-β and TNF-α that ultimately 
results in the activation of processes that mediate inflammation. ERAP1 was 
also found to be associated with Ankylosing Spondylitis, Psoriatic Arthritis 
and Bechet’s Disease, which are all conditions with an inflammatory 
aetiology. 
 
 
PKP2: (Plakophilin 2). PKP2 is a protein located in the desmosomes, which 
are cellular structures that link cells together, as well as in the cell nucleus. 
PKP2 is essential in bridging the cytoplasmic end of Cadherin proteins, such 
as E-Cadherin, with cytoskeletal intermediate filaments. PKP2 may be 
involved in the re-organisation of actin leading to the assembly of 
desmosomes. 
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CHAPTER V. GENERAL DISCUSSION AND 
FUTURE WORK. 
 
 
 
 
 
i. The story so far. 
 
 
 
   Disease-gene mapping using linkage analyses has a long history, but 
association mapping was still emerging when techniques that allow high-
throughput SNP genotyping were being developed. The success of GWAS as a 
method of gene-mapping has been surrounded by skepticism from much of the 
scientific community since although many loci have been identified, a substantial 
number of cases and controls (75,000 cases and controls combined in the latest 
IBD meta-analysis) were needed to achieve these results and the genetic 
contribution that these loci explain remains low. Another factor that contributed to 
this skepticism is the fact that the genes that have been identified in GWAS have 
been done so by in silico analyses of LD intervals. Indeed, in the case of large LD 
intervals or LD-intervals which are gene-rich, many candidate genes have been 
reported and thus it is not known which are the actual putative causal agents 
within these intervals. 
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a. Genetic and phenotypic heterogenetiy.   
 
 
 In this project it was firstly shown that with detailed phenotypic information, one 
can detect a greater proportion of the genes involved, as well as phenotypic and 
genetic heterogeneity, even with the use of smaller data sets, and thus sample 
sizes.  By scanning the genome using a method based on composite likelihood 
that takes directly into account the underlying LD structure in the genome, more 
information than previously reported was extracted from these publically available 
GWAS datasets without recourse to enormous meta-analyses. In addition, the 
estimated locations of the putative causal agents that this LDU mapping method 
provides is essential in narrowing down the locations of the potential putative 
causal agents. The location estimates provide a starting point for targeted 
functional analyses and sequencing. Another major advantage of location 
estimates of the putative causal agents is the ability to more easily identify the 
possible presence of genetic heterogeneity, which is known to be involved in the 
aetiology of many complex diseases (Silverman and Palmer, 2000). Previous 
studies by our group and others have already reported the increased power of 
using composite likelihood, rather than single-SNP testing and modelling on LDU 
distances as opposed to physical locations in kb (Andrew et al., 2008; Maniatis et 
al., 2007; Politopoulos et al., 2011). The work presented in this thesis, part of 
which is published,  illustrates this further by extending to genome-wide data 
(Elding et al., 2011, 2013).   
 
 
  
 167 
   In Chapters III and IV a large number of signals associated with CD and UC 
were identified, which mainly identify single genes with confirmation in 
independent cohorts, making it likely that most are real.  In some cases they may 
have a large effect and in some cases only a small effect on the risk of CD or UC. 
Since the location of the causal variant is based on an estimation within a 95% 
confidence interval, the actual causal variant or variants that are in direct LD are 
still to be found and it is thus not possible to measure the effect size or indeed the 
direction of effect of the causal variant. Critically, as also demonstrated in the 
second chapter, it is likely that different risk genes are involved to a greater or 
lesser extent in different patients. The genomic locations that are provided in this 
project are estimates of the positions of the variants of functional significance 
assuming a mono-phylogenetic origin and thus no substantial allelic 
heterogeneity. Previous studies demonstrated the greater power of using LDU as 
compared to physical maps for detecting association and refining location using 
the same multi-marker methodology (Andrew et al., 2008; Gibson et al., 2008; 
Politopoulos et al., 2011). The close distance between the location estimates for 
many of the signals in the two different cohorts analysed in Chapter III and IV 
suggests that these allelic variants will often be the same, but in some cases 
there are clear indications of independent allelic variants, perhaps controlling the 
expression of the same gene (in cis). Genetic heterogeneity can also be 
attributed to unlinked loci.  
 
 
   It has been previously found that the reported NOD2 mutations determine ileal 
disease only and that disease heterogeneity may be genetically determined, 
coupled with the fact that ileal disease is generally associated with an early age 
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of diagnosis (Ahmad et al., 2002).  This therefore demonstrates the importance of 
considering phenotypic subgroups of CD and hence collecting more accurate 
phenotypic description of patient data for GWAS, especially since it is well 
established that response to treatment in CD patients is somewhat dependent on 
the disease location rather than disease behaviour (Weiss et al., 2010). The 95% 
CIs of the estimated locations Ŝ can help in pin-pointing such cases where 
independent allelic variants are likely to play a role. An example is the case of 
IRF8 described in Chapter II (Figure 9) where although the SNP coverage in the 
region is quite similar between the two datasets, the estimated locations have 
non-overlapping 95% CIs. Although this could be attributable to the only partially-
overlapping genotyping arrays used in both studies, it could also be an indication 
of the involvement of independent allelic variants at that locus. In either case this 
method offers greater precision for future in-depth analysis using bioinformatics 
and re-sequencing.  
 
 
   One major problem is that phenotypic heterogeneity is currently under-studied, 
especially in large-scale genetic studies. For instance, the prevalence of CD 
among Ashkenazi Jews is higher than that for non Jewish Europeans, but 
surprisingly, in 1996 it was shown that no linkage is observed on chromosome 
16q in Ashkenazi Jewish families  (Ohmen et al., 1996). Also, as discussed in 
Chapter I, no linkage was ever observed on chromosome 16q in UC families 
(Ohmen et al., 1996), which was one of the first lines of evidence for the 
presence of genetic heterogeneity between the two sub-types of IBD. 
Additionally, although there is a substantial overlap in susceptibility loci between 
early-onset and adult-onset, there is also a degree of heterogeneity. For instance, 
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the signal on Chromsome 16p (Table 8 and 15) was found to be associated in 
early-onset CD patients (Imielinski et al., 2009). Indeed, in this thesis work, the 
signal on Chromosome 16p was identified using the NIDDK CD dataset only 
(Table 8 and 15), which contains patients with early-onset CD, but not in 
WTCCC.  Despite this knowledge, disease phenotype is not well recorded in the 
publically available data-bases and heterogeneity for neither CD or UC has been 
studied in detail to date. The focus has been toward large meta-analyses 
combining different sub-types and age of onset. 
 
 
   The main reason for the limited study of heterogeneity is because the main 
concern has been to  increase the sample size and hence power to detect 
association.  The extent to which the meta-analysis approach results in a gain in 
power is variable since combination of groups of patients who have been 
ascertained by different criteria and from different geographic locations will mean 
that variants that only apply to a specific sub-group will go unseen.  Here I show 
that stratifying the data based on subtypes of CD proves to be more beneficial in 
dissecting the underlying genetic heterogeneity involved in CD, in contrast to 
increasing the sample size, at least with the method reported here.  It will be 
important in the future to reconsider the collection of clinical data and attempt to 
record more complete information. 
 
 
   The previous linkage peaks significant for IBD  (Cavanaugh, 2001; Cavanaugh 
et al., 1998; Hampe et al., 1999; Hampe et al., 1999; Hugot et al., 1996; Ohmen 
et al., 1996; Parkes et al., 2000; Satsangi et al., 1996) have all been identified in 
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GWAS, with the exception of IBD4 in relation to CD and IBD6 on Chromosome 
19p13 in relation to UC, as shown in Table 15. In the linkage study that identified 
IBD6, it was reported that there was substantial heterogeneity in relation to CD 
with respect to significance of linkage and the carrier status of the NOD2 
mutations in CD patients. The same study did not find significant linkage at the 
IBD4 locus (van Heel et al., 2003). Indeed, the IBD6 locus was only identified 
after the patients with the NOD2 mutations were removed from the data, 
suggesting the presence of genetic heterogeneity. Since the same study detected 
evidence for the presence of epistatic interactions between the IBD5 and the 
IBD6 loci, the authors hypothesized that the Canadian study that detected linkage 
at the IBD6 locus could be explained by the fact that their study showed a 
stronger IBD5 linkage signal than the one reported by van Heel et al. and could 
thus facilitate the detection of linkage at the IBD6 locus in the Canadian families. 
The IBD8 UC linkage peak is identified in a GWAS for the first time in the work 
described in Chapter IV of this thesis. 
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Table 15. Follow up of significant IBD linkage peaks in GWAS. 
 
   CD UC 
Locus Chr Linkage 
Significance 
Confirmed  from 
previous Meta-
Analyses  
Newly reported in 
this thesis 
 
Confirmed  from 
previous Meta-
Analyses  
Newly reported in 
this thesis 
 
IBD1 16q12 CD NOD2 CYLD  - - 
IBD2 12p13.2-q24.1 CD and UC LRRK2/SLC2A13 ANO4 
 C12orf74  
TMEM117 
CCDC91  
CAND1  
KITLG 
IFNG CCDC91 
PKP2  
TRHDE 
WSCD2/CMKLR1 
IBD3 6p21.3 CD and UC HLA-DQB2 - TAP2/HLA-DQB-2 HLA-DPB1/HLA-
DOA 
IBD4 14q11-q12 CD Not identified in 
GWAS 
- Not identified in GWAS NOVA1/MIR4307 
IBD5 5q31 CD C5orf56/SLC22A4 - C5orf66 HSPA4/FSTL4  
NRG2  
YIPF5 
IBD6 19p13 CD and UC SBNO2  
PDE4A 
- Not identified in GWAS - 
IBD7 1p36 CD and UC CAMTA1 - OTUD3/RNF186  
ZBTB40 
CATSPER4 
IBD8 16p CD and UC CD19 RBFOX1 Not identified in GWAS GPR139 
 
Genes separated by “/” represent one signal from the same window but estimated locations Ŝ of the causal variant for the discovery 
and replication dataset(s) point to different genes. Red font implies that although linkage has been observed, no signal has been 
detected in previous GWAS or in this thesis work. Blue font represents significant linkage peaks that have not been detected by 
previous GWAS but association in the linkage region has been identified in this thesis work. The significance and estimated 
locations Ŝ for these signals are illustrated in Tables 8, 9 and 10 for CD and in Tables 12, 13 and 14 for UC. 
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   It is also of interest to consider our GWAS results described in Chapters III and 
IV in relation to previous candidate gene studies. Like single-SNP analysis, the 
LDU mapping approach still failed to replicate some genes that had been 
reported to be associated from single gene studies. For instance IL16, TLR4 and 
MUC3A  (Franchimont et al., 2004; Glas et al., 2003; Kyo et al., 2001; Ouburg et 
al., 2005) are among the examples of genes that were good functional 
candidates in early candidate gene studies but were never identified in GWA 
studies.  In the case of IL16, functional analysis revealed the involvement of a 
polymorphism located in promoter region of IL16 in CD patients only (Glas et al., 
2003) and an amino acid substitution (Asp299Gly) polymorphism in the TLR4 
gene was reported to be involved in both CD and UC (Franchimont et al., 2004). 
Apart from possible ethnic or disease sub-group differences, the failure to 
replicate these loci could be simply due to the fact that these loci might have 
been false-positives in the previous studies. Another reason for failing to replicate 
true susceptibility loci in functionally implicated genes could be the low SNP 
coverage or problems with these regions affecting the current genotyping 
platforms. In the case of MUC3, the Genome Browser sequence is still incorrectly 
annotated and fails to detect that it is a duplicated gene (Gum et al., 2003; Kyo et 
al., 2001; Pratt et al., 2000), suggesting that the LDU map is also inaccurate, 
since an error in the physical map will be reflected in the genetic map.  
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b. Interactions and Epistatic effects. 
 
 
 
   Aside from the impact of accurate phenotypic description and that of 
heterogeneity, another complication in identifying susceptibility loci for IBD, or 
complex diseases in general, arises from the presence of interactions or epistasis 
between loci. Indeed, this could be another reason behind the failure in 
replicating findings from functional candidate gene studies in association studies 
and meta-analyses. DMBT1, a scavenger  and antibacterial pattern recognition 
receptor, was never identified in GWASes and is an example of such interaction. 
A candidate gene study had identified an association between a deletion variant 
of the DMBT1 allele and and increased risk for CD (Renner et al., 2007). More 
recently functional and epistatic analyses have shown evidence of interaction. 
DMBT1 is a target gene of the IL-22 cytokine, which is in turn modulated by CD-
risk variants in IL23R, an established IBD susceptibility locus (Zervoudi et al., 
2013). The risk variants in IL23R have also been shown to modulate the 
expression of DMBT1 in the intestines of CD patients (Zervoudi et al., 2013).  
 
 
   Another example comes from NOD2.  As mentioned in the introduction of 
Chapter IV,  it had already been established that NOD2 is a CD-specific risk 
factor but although linkage and association analyses failed to identify NOD2 in 
relation to UC, it was still shown that there is a possible epistatic interaction 
between the cytokine cluster-containing IBD5 locus and the NOD2 mutations and 
that these two loci could interact in a synergistic way to contribute towards the 
onset of UC (Giallourakis et al., 2003). In fact, the same study also reported that 
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much of the significance of the IBD5 association signal arose from UC patients 
that carried the NOD2 mutations (Giallourakis et al., 2003).  
 
 
   In addition to epistatic effects, gene-environment interactions are of great 
importance in complex conditions and can have a considerable impact on the 
development of the phenotype. In fact, an individual can inherit the predisposing 
factors to a particular disease but never develop the disease itself unless 
exposed to an environmental factor. Therefore, the analogy that “genetics loads 
the gun but the environment pulls the trigger” perfectly captures the complex 
interplay between host genetics, including gene-gene-interactions, and disease 
onset (Olden, 2006; Ramos and Olden, 2008). After all, autoimmune or immune 
deficiency diseases like IBD involve the host’s response to an environmental 
stimulus. Thus, in a genetically susceptible host, this gene-environment 
interaction can lead to the onset of disease. Indeed, the term gene-environment 
interaction can be defined as the environment’s impact on the direction and 
degree of a genetic variant’s effect on phenotype (Ramos and Olden, 2008). In 
the case of IBD, it is well established that diet and the gut microbiota composition 
of an individual are major environmental factors that play a role in the onset of 
IBD. In addition, smoking is an environmental factor which shows different 
directions of effect with respect to CD and UC, with smoking apparently being 
‘protective’ for UC. Gene-environment interaction studies have so far been 
hampered by the fact that studies in experimental models they have to be done in 
model animals or cell lines and are usually limited to one environmental 
component, which may not be sufficient to show what occurs in vivo.  
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   Further epidemiological and genetic association studies that contain data on 
environmental factors are needed.  These will provide information that will 
eventually help in elucidating the mechanisms and pathways involved in disease 
onset as well as in providing the opportunity for possible intervention prior to 
disease onset, where predisposing genetic factors are known to be involved. 
 
 
 
ii. Considerations for future work involving the LDU 
mapping approach 
 
 
   Although the LDU mapping method used in this project shows several 
advantages over other types of association methods, there are limitations that 
need to be considered. As for the case with other association testing methods, 
this method is not immune to false-positive results.  A Bonferroni threshold was 
used throughout this project in an attempt to account for false-positives arising 
purely by chance due to multiple testing. Bonferroni correction is known to be a 
very conservative method to account for multiple testing, which makes it a difficult 
case to find a fine balance between eliminating false-positives and reducing 
false-negatives as a result of multiple testing corrections in association studies. 
However, false-positives could also arise due to the presence of population sub-
structure in the datasets. For all the datasets that were analysed in this project, 
the data were projected on the first two Principal Components of HapMap3 data 
in order to detect any genome-wide population sub-structure within the GWAS 
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data. This method for detecting structure is routinely done in association studies 
and is thought to work well on a genome-wide level. Indeed, in the quality control 
analyses of previously published GWAS, as well as in the quality control that was 
carried out in this thesis work population outliers that were known to exist within 
the data were successfully identified. However, what if the data exhibits hidden 
sub-structure, such as locus-specific effects which reflect very subtle differences 
in recent ancestry? 
 
 
    In recently admixed populations, such as in African Americans, two or more 
populations would have been mixing for a short amount of time thus leading to a 
new population  (Glas et al., 2003). The ancestry of this new population can be 
accounted for by the different proportions from the original populations. Unlike in 
non-admixed populations, where the whole genome is representative of the 
population under study, in these recently admixed populations the genome is 
subdivided, due to recombination, into short sections of differing ancestry, which 
makes it difficult to identify the ancestral genetic information of such individuals 
(Glas et al., 2003). Although the scenario of such admixture is highly unlikely to 
apply to the datatsets used in this thesis work,  independent work carried out on 
UK samples as part of the People of the British Isles (PoBI) project identified the 
presence of population structure within the UK when surnames were taken into 
account and the data were modeled using a simple point admixture approach 
based on maximum likelihood (Winney et al., 2012). This fine population structure 
within the UK was never detected when traditional methods, such as PCA or Fst, 
were carried out. However subtle  stratification due to difference in the  
representation of geographic regions in the UK is masked in the PCA since there 
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are only short segments of the genome that differ, in other words there is the 
presence of locus specific differences in ancestry. One of the factors that 
contributes to these regions of local ancestry is natural selection. Indeed, IBD is 
an immune-mediated disease and natural selection has played a significant role 
in shaping host immune defence by acting on immune-related genes (Barreiro 
and Quintana-Murci, 2010). Natural selection on immune related genes, whether 
negative, positive or balancing selection, reflects past infectious epidemics and 
thus past population demographics. The effect of this selection on host immunity 
could hence partly contribute to the differences in prevalence of certain diseases 
in different populations (McEvoy et al., 2009). Locus specific ancestry differences 
could thus be one of the causes of spurious association with any association 
testing methods used in complex disease genetics.  
  
 
   Another issue to be considered when using the LDU mapping method is the 
selection of the difference in distance between the estimated locations Ŝ between 
datasets in order for a location to be considered a replication. In fact, for the main 
CD meta-analysis carried out in Chapter III the difference in distance between the 
estimated locations Ŝ, for the locations where the meta P-value survived the 
Bonferroni threshold, was set to lie within 150 kb between the WTCCC CD and 
NIDDK CD datasets, but the majority fell within 80kb. Since the UC SNP data had 
a much higher SNP resolution (1 million SNPs) I used the more stringent 
estimated location Ŝ difference threshold of 80 kb. However, making the decision 
about this difference threshold is rather arbitrary.  Another approach would be to 
use a LDU cut-off for distance difference thresholds or to take into account the 
95% Confidence Intervals of the estimated locations Ŝ.  Clearly, the difference in 
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SNP content and resolution in the different datasets that are meta-analysed may 
affect the estimations of Ŝ. A computational approach to resolving this dilemma 
would be complicated.   
 
   This highlights the problem of the heterogeneity introduced into the datasets by 
the difference in SNP coverage on the platforms used at different times by the 
various investigators.  A solution that investigators have used to overcome this 
problem has been to impute genotypes in order to homogenise the set of SNPs 
that are being tested in the different datasets.  Imputation could also potentially 
be used in conjunction with the LDU mapping approach, in order to meta-analyse 
the same set of SNPs across datasets. However, the advantage of the LDU 
mapping approach is that comparisons can be made across data sets even with 
very different SNP coverage.   
 
   A high-resolution, homogeneous subset of SNPs across datasets, together with 
better refined phenotypes should reduce the complications that heterogeneity 
brings to disease-gene mapping. 
 
 
iii. Future work- Inflammatory Bowel Disease meta-analysis 
and beyond. 
    
 
   The work that was carried out during the course of this thesis focused on CD 
and UC specific analyses. The next step would be to conduct an analysis 
specifically for IBD. There are two possible approaches that could be taken in 
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order to carry out this work. The first method would involve the meta-analysis of 
the location estimates that are close to each other from the nominally significant 
windows in the CD and UC datasets independently and subsequently meta-
analysing the P-values and applying a Bonferroni correction for multiple testing. 
Taking this approach will involve the careful consideration about what difference 
in distance between the estimated locations obtained by the CD and UC datasets 
should be used, especially in the light of the considerations that have been 
discussed above, since genetic heterogeneity involving the same genetic region 
will become more likely when considering CD and UC together.  
 
 
   The second approach would be to combine the genotype data for both 
diseases, for example combining the WTCCC CD with WTCCC UC as one data 
set and combining the NIDDK CD together with the NIDDK UC datasets as a 
replication data set. The major problem with this approach is that all the CD and 
UC datasets are genotyped on different genotyping platforms. Therefore the 
direct concatenation of datasets will not be possible, and SNPs that are not 
common to the genotyping platforms of the data being concatenated will be lost, 
thus leading to a loss in SNP resolution.  However, these SNPs could perhaps be 
imputed, without having a huge impact on the LDU mapping approach since 
much of the power of this approach comes from the LDU maps, which are 
obtained using the HapMap data. This approach would also overcome the issue 
that the NIDDK CD Controls would need to be used twice if the UC and CD 
datasets were to be analysed separately, since the NIDDK CD Controls were 
used in Chapters II, III and IV. Indeed, both approaches could be carried out and 
the results can be compared, although in my opinion, the second approach would 
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be best as it would require less decision-making about distance threshold for 
estimated locations that could affect the final results and it also provides the 
opportunity to increase the sample size for each CD-UC dataset, which will lead 
to an increase in power to detect association pertaining to IBD, given that in this 
case only loci that are in common between the disease categories are of interest. 
Thus, the second approach seems to provide a better balance between Type I 
(False Positives) and Type II errors (False Negatives).  
 
 
   In the meantime, it is worthwhile to look at the genes that have been identified 
in both disease sub-types independently, in the work described in Chapters III 
and IV. Table 16 illustrates the genes that are common to both CD and UC and 
were found independently in Chapter III (Tables 8 and 9) and Chapter IV (Table 
14). 
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Table 16. Genes common to both CD and UC identified in this thesis work. 
 
Chr LD Interval (Mb)§ 
WTCCC CD 
Ŝ 
NIDDK CD 
Ŝ 
WTCCC 
UC Ŝ 
NIDDK 
UC 550 Ŝ 
NIDDK  UC 
300 Ŝ 
Overlap in 95% CI of significant estimated locations 
Ŝ Gene 
1p 67.53-67.77 67,864.8 67,707.3 67,769.1 - 67,741.5 WTCCC CD/NIDDK CD/NIDDK UC 300 IL23R* 
2q - 170,038.8 170,037.2 169,969.0 170,001.5 - None LRP2* 
2q - 226,258.2 226,258.4 226,257.7 226,231.6 - WTCCC CD/NIDDK CD/WTCCC UC NYAP2 
5p 40.28-40.81 40,447.1 40,288.0 - 40,617.6 - WTCCC CD/NIDDK UC 550 PTGER4 
5q 158.53-158.93 158,825.7 158,826.0 158,825.8 - - All IL12B 
7p - 41,898.3 41,939.6 41,923.9 - 41,941.0 All GLI3 
9q 117.44-117.70 117,555.6 - 117,559.8 - - All TNFSF15* 
10p 35.18-35.90 35,554.8 - 35,554.4 - - All CCNY* 
10q - 63,604.2 63.553.3 63,552.9 63,553.5 - NIDDK CD/WTCCC UC/ NIDDK UC 550 C10orf107 
10q - 90,787.7 90,787.7 90,739.8 90,787.4 - WTCCC CD/NIDDK CD/NIDDK UC 550 FAS 
10q 101.26-101.34 101,324.7 101,274.6 101,754.7 101,342.5 - None NKX2-3 
11q 76.04-76.34 76,304.4 - 76,303.3 - - All C11orf30 
12p - 28,744.32 28,741.7 28,6769.5 28,595.9 28,309.1 NIDDK CD/WTCCC UC/NIDDK UC 300 CCDC91* 
16q - 85,982.3 85,958.0 85,996.3 - - WTCCC CD/WTCCC UC IRF8* 
20p - 15,802.7 15,876.4 14,314.2 14,352.4 - None MACROD2* 
20q 62.19-62.51 62,327.9 - 62,326.9 - - All RTEL1* 
21q 16.70-16.85 16,841.4 - 16,818.4 16,802.9 - All USP25 
21q 45.59-45.70 45,609.1 - 45,608.8 - - All ICOSLG 
 
* denotes that at least one of the estimated locations Ŝ is located within the identified gene. § LD interval if the signal was reported 
in the published meta-analysis previous to this thesis work. – means no significant signal detected within the datasets. Signals 
highlighted in green represent the signals that have been identified in this thesis work. 
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   In the CD analysis, approximately half of the signals that were identified in this 
thesis work, highlighted in dark green in Table 16, were replicated using the 
smaller NIDDK CD dataset containing Ileal patients that exhibited extra-ileal 
manifestations and half using the NIDDK Pooled dataset (Table 9 and Table 
10). In 5 of the 7 shared genes shown in Table 16, the difference in location 
estimates between both the CD datasets and the UC datasets is less than 70kb, 
but not for  the remaining two signals.  In the case of CCDC91, shown in Figure 
29, the difference in location estimates was larger than 400 kb but genetically, 
the location estimates lie close to one another, being within approximately one 
LDU of each other. CCDC91 is an interesting finding since although not much in 
known about this gene, Ph.D. thesis work carried out by Tao Jiong at the 
National University of Singapore that focused on looking at genomic copy 
number alterations identified a deletion of the CCDC91 gene region in a gastric 
cancer cell line (Jiong, 2011). In addition, independent studies have identified 
this region as a CNV region, where both amplification and deletion of the 
CCDC91 gene and the surrounding region have been detected in cancer cell 
lines (Bignell et al., 2010; Johnson et al., 2010; Shih Ie et al., 2011). In the case 
of MACROD2, the location estimates between CD and UC were approximately 
1,500 kb apart, but the location estimates for all the CD and UC datasets lie 
within the MACROD2 gene. MACROD2 is also located at a site of genomic 
instability, with recurrent microdeletions being reported within the MACROD2 
gene locus, both in the general population and in patients of colorectal 
carcinomas (Linnebacher et al., 2013). The genomic instability of these two 
regions,  and possibly that of other regions along the genome, could explain the 
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difficulty in obtaining close location estimates between different datasets, since 
this instability is also very likely to be reflected in the LDU map of the region. 
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Figure 29. Localisation within the CCDC91 gene-region. 
The Y-axis represents genomic LDU locations whereas the X-axis represents genomic physical locations in kilobases. The solid 
black line represents the LDU map of the region constructed from the HapMap CEU data. The red vertical arrows are the estimated 
locations Ŝ of the putative causal agents for the UC data. The blue vertical dashed arrows are the estimated locations Ŝ of the 
putative causal agents for the CD data. 
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    Other future work would also be to combine the results from GWAS with 
intestinal expression data.  
 
 
   The co-localisation of eQTL loci with some of the estimated locations outside 
exonic regions obtained in this project would help to narrow the region housing 
the likely causal variants involved in regulation. This co-localisation could also  be 
done in conjunction with ChIP-Seq (ChIP-Sequencing) analysis, and other 
functional annotations from the ENCODE project, which can be used to point to 
DNA-protein binding sites, especially for the identified regions that do not harbour 
any genes and could thus represent non-coding regulatory SNPs. This co-
localisation approach is illustrated in Figure 30. Technological advances in Next-
Generation Sequencing paved the way to RNA-Seq (RNA-Sequencing), or 
“Whole-Transcriptome Shotgun Sequencing”, which is one way of carrying out 
expression analysis. One application of  RNA-Seq is to explore the RNA levels 
from a genome at a given time. This tissue-specific expression information, 
together with the results from previous meta-analyses and the estimated 
locations identified in this thesis work could be consolidated in order to pinpoint 
the genes involved in CD and UC.  
 
 
   Considering that complex diseases, such as IBD, result from the contribution of 
both environmental and genetic factors, investigating the impact of the 
interactions between environmental factors and regulatory SNPs will also be a 
crucial element in dissecting the environmental triggers that contribute to the 
onset of IBD as well as in identifying the mechansims and pathways that lead to 
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the disease phenotype.  In fact, interactions between the environment and 
regulatory SNPs affecting Allele-Specific Expression (ASE) has already been 
demonstrated in a study that looked at monozygotic twins (Buil et al., 2014).  
 
 
 
 
 
 
 
Figure 30. A co-localisation approach for future studies of possible 
regulatory regions.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Genetic variation in regulation does not necessarily involve the closest gene. 
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Another approach will be the investigation of gene-gene interactions, which as 
discussed in this Chapter, are known to contribute to the onset of IBD. For 
example the approach of stratifying the data by NOD2 could be used to explore 
the effect on unlinked associations, perhaps by examining loci flagged in the 
literature or perhaps genome-wide. 
 
 
 
   From the studies carried out on the gut microbiota in relation to IBD 
pathogenesis no causal bacterial agent has been identified so far and it is still 
unclear whether the dysbiosis observed is the result of, or indeed precedes, the  
onset of IBD, leading to the chicken and the egg dilemma- which of the two 
comes first? The improvements in techniques for microbial community profiling, 
such as the advent of Next-Generation Sequencing, opened the doors to high-
throughput analyses of genomes of entire communities, in other words 
Metagenomic analyses, including previously unculturable organisms. The aim of 
metagenomics analyses is to determine the role that the microbes play in human 
health as well as in the onset of diseases. Indeed, the Human Microbiome Project 
(HMP) was conceived, which started in 2007 with the aim of developing the 
necessary tools and datasets in order to study the role that microbes play in 
relation to human health and disease. The project is currently in its second and 
final phase generating datasets that integrate the biological properties from both 
microbiome and host from studies related to micobiome-associated diseases and 
is expected to end in 2015. Such datasets could be exploited in order to unravel 
the  host-microbiota interactions that take place in the pathogenesis of IBD and 
elucidate whether microbiota dysregulation takes place prior to or after the onset 
of IBD. The data generated from such studies could be used as phenotypes in 
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GWA studies in order to identify possible association between a particular 
microbiota species and disease outcome. Another approach would be to assess 
the clustering of the microbiota composition of CD or UC patients according the 
specific sub-phenotypes (e.g.: ileal only disease for CD and proximal versus 
distal colonic inflammation in UC). Depending on the findings, this would also 
provide the opportunity for therapeutic development and possibly prevention of 
dysbiosis in genetically susceptible hosts. 
 
 
 
   From previous association studies, as well as from the work presented in this 
thesis, it can be concluded that with increasing bioinformatics and statistical 
advances, association studies are identifying many loci at a much faster pace 
than can be functionally tested, not only for IBD, but for complex diseases 
globally. It is only very recently that functional techniques such as RNA-Seq are 
scaling up to genome-wide level. Combining the ever increasing statistical tools 
together with the emerging functional techniques, including the human 
microbiome data, could thus open the door to unraveling the mechanisms behind 
IBD and ultimately target the relevant pathways in the specific CD and UC 
subgroups for sub-phenotype stratified treatment. 
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Appendix I- Different LD metrics 
 
 
 
 
 
 
Formula for Covariance D: 
 
 
 
where f is the frequency of the inferred haplotype. 
 
 
 
Formula for D’: 
 
When D is negative,  
 
 
 
When D is positive,  
 
 
 
 
Formula for association ρ: 
 
 
 
 
 
where D is the covariance and Q and R are the allele frequencies. 
 
 
 
 
 
Formula for correlation r: 
 
 
 
 
where D is the covariance and Q and R are the allele frequencies. 
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Formula for correlation coefficient r2: 
 
 
 
 
 
where D is the covariance and Q and R are the allele frequencies. 
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Appendix II- BioMart Analysis from the Crohn’s Disease 
GWAS described in Chapter III. 
 
 
Ensembl Gene ID GO Term 
Accession 
GO Term Name Gene 
Symbol 
ENSG00000077522 GO:0042981 regulation of apoptotic process ACTN2 
ENSG00000077522 GO:0007155 cell adhesion ACTN2 
ENSG00000077522 GO:0006936 muscle contraction ACTN2 
ENSG00000077522 GO:0007268 synaptic transmission ACTN2 
ENSG00000077522 GO:0048041 focal adhesion assembly ACTN2 
ENSG00000077522 GO:0030168 platelet activation ACTN2 
ENSG00000077522 GO:0051289 protein homotetramerization ACTN2 
ENSG00000077522 GO:0007596 blood coagulation ACTN2 
ENSG00000077522 GO:0002576 platelet degranulation ACTN2 
ENSG00000077522 GO:0030035 microspike assembly ACTN2 
ENSG00000077522 GO:0030049 muscle filament sliding ACTN2 
ENSG00000077522 GO:0005737 cytoplasm ACTN2 
ENSG00000077522 GO:0005576 extracellular region ACTN2 
ENSG00000077522 GO:0005829 cytosol ACTN2 
ENSG00000077522 GO:0005856 cytoskeleton ACTN2 
ENSG00000077522 GO:0030018 Z disc ACTN2 
ENSG00000077522 GO:0043197 dendritic spine ACTN2 
ENSG00000077522 GO:0030175 filopodium ACTN2 
ENSG00000077522 GO:0005925 focal adhesion ACTN2 
ENSG00000077522 GO:0031143 pseudopodium ACTN2 
ENSG00000077522 GO:0030017 sarcomere ACTN2 
ENSG00000077522 GO:0005884 actin filament ACTN2 
ENSG00000077522 GO:0030864 cortical actin cytoskeleton ACTN2 
ENSG00000077522 GO:0031093 platelet alpha granule lumen ACTN2 
ENSG00000077522 GO:0005515 protein binding ACTN2 
ENSG00000077522 GO:0005509 calcium ion binding ACTN2 
ENSG00000077522 GO:0005178 integrin binding ACTN2 
ENSG00000077522 GO:0046983 protein dimerization activity ACTN2 
ENSG00000077522 GO:0051015 actin filament binding ACTN2 
ENSG00000077522 GO:0042802 identical protein binding ACTN2 
ENSG00000077522 GO:0030375 thyroid hormone receptor coactivator activity ACTN2 
ENSG00000077522 GO:0044325 ion channel binding ACTN2 
ENSG00000077522 GO:0008307 structural constituent of muscle ACTN2 
ENSG00000077522 GO:0031432 titin binding ACTN2 
ENSG00000077522 GO:0070080 titin Z domain binding ACTN2 
ENSG00000077522 GO:0051370 ZASP binding ACTN2 
ENSG00000077522 GO:0051374 FATZ 1 binding ACTN2 
ENSG00000077522 GO:0030374 ligand-dependent nuclear receptor 
transcription coactivator activity 
ACTN2 
ENSG00000077522 GO:0003779 actin binding ACTN2 
ENSG00000138031 GO:0055085 transmembrane transport ADCY3 
ENSG00000138031 GO:0007165 signal transduction ADCY3 
ENSG00000138031 GO:0044281 small molecule metabolic process ADCY3 
ENSG00000138031 GO:0035556 intracellular signal transduction ADCY3 
ENSG00000138031 GO:0007143 female meiosis ADCY3 
ENSG00000138031 GO:0050896 response to stimulus ADCY3 
ENSG00000138031 GO:0007189 activation of adenylate cyclase activity by G-
protein signaling pathway 
ADCY3 
ENSG00000138031 GO:0006833 water transport ADCY3 
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ENSG00000138031 GO:0007268 synaptic transmission ADCY3 
ENSG00000138031 GO:0006184 GTP catabolic process ADCY3 
ENSG00000138031 GO:0009190 cyclic nucleotide biosynthetic process ADCY3 
ENSG00000138031 GO:0007608 sensory perception of smell ADCY3 
ENSG00000138031 GO:0007193 inhibition of adenylate cyclase activity by G-
protein signaling pathway 
ADCY3 
ENSG00000138031 GO:0007173 epidermal growth factor receptor signaling 
pathway 
ADCY3 
ENSG00000138031 GO:0071377 cellular response to glucagon stimulus ADCY3 
ENSG00000138031 GO:0007202 activation of phospholipase C activity ADCY3 
ENSG00000138031 GO:0008543 fibroblast growth factor receptor signaling 
pathway 
ADCY3 
ENSG00000138031 GO:0048011 nerve growth factor receptor signaling 
pathway 
ADCY3 
ENSG00000138031 GO:0006112 energy reserve metabolic process ADCY3 
ENSG00000138031 GO:0006171 cAMP biosynthetic process ADCY3 
ENSG00000138031 GO:0034199 activation of protein kinase A activity ADCY3 
ENSG00000138031 GO:0005634 nucleus ADCY3 
ENSG00000138031 GO:0005737 cytoplasm ADCY3 
ENSG00000138031 GO:0005886 plasma membrane ADCY3 
ENSG00000138031 GO:0005624 membrane fraction ADCY3 
ENSG00000138031 GO:0005887 integral to plasma membrane ADCY3 
ENSG00000138031 GO:0045121 membrane raft ADCY3 
ENSG00000138031 GO:0000166 nucleotide binding ADCY3 
ENSG00000138031 GO:0005524 ATP binding ADCY3 
ENSG00000138031 GO:0046872 metal ion binding ADCY3 
ENSG00000138031 GO:0005516 calmodulin binding ADCY3 
ENSG00000138031 GO:0003924 GTPase activity ADCY3 
ENSG00000138031 GO:0016849 phosphorus-oxygen lyase activity ADCY3 
ENSG00000138031 GO:0004016 adenylate cyclase activity ADCY3 
ENSG00000138031 GO:0008294 calcium- and calmodulin-responsive 
adenylate cyclase activity 
ADCY3 
ENSG00000138031 GO:0005515 protein binding ADCY3 
ENSG00000144891 GO:0050729 positive regulation of inflammatory response AGTR1 
ENSG00000144891 GO:0051482 elevation of cytosolic calcium ion 
concentration involved in G-protein signaling 
coupled to IP3 second messenger 
AGTR1 
ENSG00000144891 GO:0007186 G-protein coupled receptor signaling 
pathway 
AGTR1 
ENSG00000144891 GO:0001558 regulation of cell growth AGTR1 
ENSG00000144891 GO:0007204 elevation of cytosolic calcium ion 
concentration 
AGTR1 
ENSG00000144891 GO:0019722 calcium-mediated signaling AGTR1 
ENSG00000144891 GO:0042127 regulation of cell proliferation AGTR1 
ENSG00000144891 GO:0007266 Rho protein signal transduction AGTR1 
ENSG00000144891 GO:2000379 positive regulation of reactive oxygen 
species metabolic process 
AGTR1 
ENSG00000144891 GO:0007200 activation of phospholipase C activity by G-
protein coupled receptor protein signaling 
pathway coupled to IP3 second messenger 
AGTR1 
ENSG00000144891 GO:0001822 kidney development AGTR1 
ENSG00000144891 GO:0060326 cell chemotaxis AGTR1 
ENSG00000144891 GO:0010744 positive regulation of macrophage derived 
foam cell differentiation 
AGTR1 
ENSG00000144891 GO:0032270 positive regulation of cellular protein 
metabolic process 
AGTR1 
ENSG00000144891 GO:0019229 regulation of vasoconstriction AGTR1 
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ENSG00000144891 GO:0050727 regulation of inflammatory response AGTR1 
ENSG00000144891 GO:0002034 regulation of blood vessel size by renin-
angiotensin 
AGTR1 
ENSG00000144891 GO:0010873 positive regulation of cholesterol 
esterification 
AGTR1 
ENSG00000144891 GO:0034374 low-density lipoprotein particle remodeling AGTR1 
ENSG00000144891 GO:0002018 renin-angiotensin regulation of aldosterone 
production 
AGTR1 
ENSG00000144891 GO:0033864 positive regulation of NAD(P)H oxidase 
activity 
AGTR1 
ENSG00000144891 GO:0035813 regulation of renal sodium excretion AGTR1 
ENSG00000144891 GO:0003081 regulation of systemic arterial blood pressure 
by renin-angiotensin 
AGTR1 
ENSG00000144891 GO:0042312 regulation of vasodilation AGTR1 
ENSG00000144891 GO:0032430 positive regulation of phospholipase A2 
activity 
AGTR1 
ENSG00000144891 GO:0016021 integral to membrane AGTR1 
ENSG00000144891 GO:0005886 plasma membrane AGTR1 
ENSG00000144891 GO:0005887 integral to plasma membrane AGTR1 
ENSG00000144891 GO:0004872 receptor activity AGTR1 
ENSG00000144891 GO:0005515 protein binding AGTR1 
ENSG00000144891 GO:0046982 protein heterodimerization activity AGTR1 
ENSG00000144891 GO:0004871 signal transducer activity AGTR1 
ENSG00000144891 GO:0004930 G-protein coupled receptor activity AGTR1 
ENSG00000144891 GO:0010698 acetyltransferase activator activity AGTR1 
ENSG00000144891 GO:0004945 angiotensin type II receptor activity AGTR1 
ENSG00000144891 GO:0031711 bradykinin receptor binding AGTR1 
ENSG00000144891 GO:0001596 angiotensin type I receptor activity AGTR1 
ENSG00000151572 GO:0006811 ion transport ANO4 
ENSG00000151572 GO:0016020 membrane ANO4 
ENSG00000151572 GO:0016021 integral to membrane ANO4 
ENSG00000151572 GO:0034707 chloride channel complex ANO4 
ENSG00000151572 GO:0005216 ion channel activity ANO4 
ENSG00000151572 GO:0005254 chloride channel activity ANO4 
ENSG00000262139 GO:0006811 ion transport ANO4 
ENSG00000262139 GO:0016020 membrane ANO4 
ENSG00000262139 GO:0016021 integral to membrane ANO4 
ENSG00000262139 GO:0034707 chloride channel complex ANO4 
ENSG00000262139 GO:0005216 ion channel activity ANO4 
ENSG00000262139 GO:0005254 chloride channel activity ANO4 
ENSG00000150347 GO:0060612 adipose tissue development ARID5B 
ENSG00000150347 GO:0035264 multicellular organism growth ARID5B 
ENSG00000150347 GO:0045892 negative regulation of transcription, DNA-
dependent 
ARID5B 
ENSG00000150347 GO:0009791 post-embryonic development ARID5B 
ENSG00000150347 GO:0008584 male gonad development ARID5B 
ENSG00000150347 GO:0008585 female gonad development ARID5B 
ENSG00000150347 GO:0006807 nitrogen compound metabolic process ARID5B 
ENSG00000150347 GO:0048705 skeletal system morphogenesis ARID5B 
ENSG00000150347 GO:0010761 fibroblast migration ARID5B 
ENSG00000150347 GO:0001889 liver development ARID5B 
ENSG00000150347 GO:0048008 platelet-derived growth factor receptor 
signaling pathway 
ARID5B 
ENSG00000150347 GO:0045444 fat cell differentiation ARID5B 
ENSG00000150347 GO:0030325 adrenal gland development ARID5B 
ENSG00000150347 GO:0048468 cell development ARID5B 
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ENSG00000150347 GO:0001822 kidney development ARID5B 
ENSG00000150347 GO:0060021 palate development ARID5B 
ENSG00000150347 GO:0060325 face morphogenesis ARID5B 
ENSG00000150347 GO:0048644 muscle organ morphogenesis ARID5B 
ENSG00000150347 GO:0051091 positive regulation of sequence-specific DNA 
binding transcription factor activity 
ARID5B 
ENSG00000150347 GO:0060613 fat pad development ARID5B 
ENSG00000150347 GO:0005634 nucleus ARID5B 
ENSG00000150347 GO:0005622 intracellular ARID5B 
ENSG00000150347 GO:0003677 DNA binding ARID5B 
ENSG00000150347 GO:0005515 protein binding ARID5B 
ENSG00000150347 GO:0044212 transcription regulatory region DNA binding ARID5B 
ENSG00000150347 GO:0003713 transcription coactivator activity ARID5B 
ENSG00000172995 GO:0034605 cellular response to heat ARPP21 
ENSG00000172995 GO:0003676 nucleic acid binding ARPP21 
ENSG00000172995 GO:0008150 biological_process ARPP21 
ENSG00000172995 GO:0005575 cellular_component ARPP21 
ENSG00000172995 GO:0005737 cytoplasm ARPP21 
ENSG00000172995 GO:0003674 molecular_function ARPP21 
ENSG00000172995 GO:0005516 calmodulin binding ARPP21 
ENSG00000104043 GO:0006812 cation transport ATP8B4 
ENSG00000104043 GO:0015914 phospholipid transport ATP8B4 
ENSG00000104043 GO:0016020 membrane ATP8B4 
ENSG00000104043 GO:0016021 integral to membrane ATP8B4 
ENSG00000104043 GO:0000166 nucleotide binding ATP8B4 
ENSG00000104043 GO:0005524 ATP binding ATP8B4 
ENSG00000104043 GO:0016787 hydrolase activity ATP8B4 
ENSG00000104043 GO:0046872 metal ion binding ATP8B4 
ENSG00000104043 GO:0000287 magnesium ion binding ATP8B4 
ENSG00000104043 GO:0016820 hydrolase activity, acting on acid anhydrides, 
catalyzing transmembrane movement of 
substances 
ATP8B4 
ENSG00000104043 GO:0015662 ATPase activity, coupled to transmembrane 
movement of ions, phosphorylative 
mechanism 
ATP8B4 
ENSG00000104043 GO:0004012 phospholipid-translocating ATPase activity ATP8B4 
ENSG00000176697 GO:0007411 axon guidance BDNF 
ENSG00000176697 GO:0007399 nervous system development BDNF 
ENSG00000176697 GO:0045666 positive regulation of neuron differentiation BDNF 
ENSG00000176697 GO:0048839 inner ear development BDNF 
ENSG00000176697 GO:0007631 feeding behavior BDNF 
ENSG00000176697 GO:0042493 response to drug BDNF 
ENSG00000176697 GO:0007412 axon target recognition BDNF 
ENSG00000176697 GO:0014047 glutamate secretion BDNF 
ENSG00000176697 GO:0048167 regulation of synaptic plasticity BDNF 
ENSG00000176697 GO:0001657 ureteric bud development BDNF 
ENSG00000176697 GO:0016358 dendrite development BDNF 
ENSG00000176697 GO:0043524 negative regulation of neuron apoptosis BDNF 
ENSG00000176697 GO:0006916 anti-apoptosis BDNF 
ENSG00000176697 GO:0007611 learning or memory BDNF 
ENSG00000176697 GO:0021675 nerve development BDNF 
ENSG00000176697 GO:0019222 regulation of metabolic process BDNF 
ENSG00000176697 GO:0007406 negative regulation of neuroblast proliferation BDNF 
ENSG00000176697 GO:0042596 fear response BDNF 
ENSG00000176697 GO:0046668 regulation of retinal cell programmed cell 
death 
BDNF 
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ENSG00000176697 GO:0008038 neuron recognition BDNF 
ENSG00000176697 GO:0005576 extracellular region BDNF 
ENSG00000176697 GO:0016023 cytoplasmic membrane-bounded vesicle BDNF 
ENSG00000176697 GO:0005102 receptor binding BDNF 
ENSG00000176697 GO:0008083 growth factor activity BDNF 
ENSG00000176697 GO:0043523 regulation of neuron apoptosis BDNF 
ENSG00000176697 GO:0007610 behavior BDNF 
ENSG00000176697 GO:0005515 protein binding BDNF 
ENSG00000178409 
 
BEND3 
ENSG00000166164 GO:0007049 cell cycle BRD7 
ENSG00000166164 GO:0016055 Wnt receptor signaling pathway BRD7 
ENSG00000166164 GO:0006357 regulation of transcription from RNA 
polymerase II promoter 
BRD7 
ENSG00000166164 GO:0008285 negative regulation of cell proliferation BRD7 
ENSG00000166164 GO:0045893 positive regulation of transcription, DNA-
dependent 
BRD7 
ENSG00000166164 GO:2000134 negative regulation of G1/S transition of 
mitotic cell cycle 
BRD7 
ENSG00000166164 GO:0045892 negative regulation of transcription, DNA-
dependent 
BRD7 
ENSG00000166164 GO:0035066 positive regulation of histone acetylation BRD7 
ENSG00000166164 GO:0005634 nucleus BRD7 
ENSG00000166164 GO:0005737 cytoplasm BRD7 
ENSG00000166164 GO:0005515 protein binding BRD7 
ENSG00000166164 GO:0003714 transcription corepressor activity BRD7 
ENSG00000166164 GO:0042393 histone binding BRD7 
ENSG00000166164 GO:0008134 transcription factor binding BRD7 
ENSG00000166164 GO:0044212 transcription regulatory region DNA binding BRD7 
ENSG00000166164 GO:0002039 p53 binding BRD7 
ENSG00000166164 GO:0003713 transcription coactivator activity BRD7 
ENSG00000166164 GO:0070577 histone acetyl-lysine binding BRD7 
ENSG00000186265 GO:0030889 negative regulation of B cell proliferation BTLA 
ENSG00000186265 GO:0046642 negative regulation of alpha-beta T cell 
proliferation 
BTLA 
ENSG00000186265 GO:0031295 T cell costimulation BTLA 
ENSG00000186265 GO:0002768 immune response-regulating cell surface 
receptor signaling pathway 
BTLA 
ENSG00000186265 GO:0042130 negative regulation of T cell proliferation BTLA 
ENSG00000186265 GO:0007166 cell surface receptor signaling pathway BTLA 
ENSG00000186265 GO:0005886 plasma membrane BTLA 
ENSG00000186265 GO:0005887 integral to plasma membrane BTLA 
ENSG00000186265 GO:0009897 external side of plasma membrane BTLA 
ENSG00000186265 GO:0004872 receptor activity BTLA 
ENSG00000186265 GO:0005515 protein binding BTLA 
ENSG00000183346 
 
C10orf107 
ENSG00000214215 
 
C12orf74 
ENSG00000204669 GO:0016020 membrane C9orf57 
ENSG00000204669 GO:0016021 integral to membrane C9orf57 
ENSG00000155621 
 
C9orf85 
ENSG00000157445 GO:0006811 ion transport CACNA2D3 
ENSG00000157445 GO:0006816 calcium ion transport CACNA2D3 
ENSG00000157445 GO:0051925 regulation of calcium ion transport via 
voltage-gated calcium channel activity 
CACNA2D3 
ENSG00000157445 GO:0016020 membrane CACNA2D3 
ENSG00000157445 GO:0016021 integral to membrane CACNA2D3 
ENSG00000157445 GO:0005515 protein binding CACNA2D3 
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ENSG00000157445 GO:0046872 metal ion binding CACNA2D3 
ENSG00000157445 GO:0005245 voltage-gated calcium channel activity CACNA2D3 
ENSG00000157445 GO:0005244 voltage-gated ion channel activity CACNA2D3 
ENSG00000157445 GO:0005262 calcium channel activity CACNA2D3 
ENSG00000111530 GO:0016567 protein ubiquitination CAND1 
ENSG00000111530 GO:0030154 cell differentiation CAND1 
ENSG00000111530 GO:0006355 regulation of transcription, DNA-dependent CAND1 
ENSG00000111530 GO:0043086 negative regulation of catalytic activity CAND1 
ENSG00000111530 GO:0045899 positive regulation of RNA polymerase II 
transcriptional preinitiation complex 
assembly 
CAND1 
ENSG00000111530 GO:0005634 nucleus CAND1 
ENSG00000111530 GO:0000151 ubiquitin ligase complex CAND1 
ENSG00000111530 GO:0005488 binding CAND1 
ENSG00000111530 GO:0005515 protein binding CAND1 
ENSG00000111530 GO:0017025 TBP-class protein binding CAND1 
ENSG00000123106 GO:0005634 nucleus CCDC91 
ENSG00000123106 GO:0005794 Golgi apparatus CCDC91 
ENSG00000123106 GO:0042802 identical protein binding CCDC91 
ENSG00000123106 GO:0015031 protein transport CCDC91 
ENSG00000123106 GO:0016020 membrane CCDC91 
ENSG00000101017 GO:0050776 regulation of immune response CD40 
ENSG00000101017 GO:0007165 signal transduction CD40 
ENSG00000101017 GO:0006954 inflammatory response CD40 
ENSG00000101017 GO:0045944 positive regulation of transcription from RNA 
polymerase II promoter 
CD40 
ENSG00000101017 GO:0043123 positive regulation of I-kappaB kinase/NF-
kappaB cascade 
CD40 
ENSG00000101017 GO:0006874 cellular calcium ion homeostasis CD40 
ENSG00000101017 GO:0006461 protein complex assembly CD40 
ENSG00000101017 GO:0043406 positive regulation of MAP kinase activity CD40 
ENSG00000101017 GO:0030168 platelet activation CD40 
ENSG00000101017 GO:0051023 regulation of immunoglobulin secretion CD40 
ENSG00000101017 GO:0051092 positive regulation of NF-kappaB 
transcription factor activity 
CD40 
ENSG00000101017 GO:0001934 positive regulation of protein phosphorylation CD40 
ENSG00000101017 GO:0051607 defense response to virus CD40 
ENSG00000101017 GO:0030890 positive regulation of B cell proliferation CD40 
ENSG00000101017 GO:0042100 B cell proliferation CD40 
ENSG00000101017 GO:0071260 cellular response to mechanical stimulus CD40 
ENSG00000101017 GO:0032735 positive regulation of interleukin-12 
production 
CD40 
ENSG00000101017 GO:0002768 immune response-regulating cell surface 
receptor signaling pathway 
CD40 
ENSG00000101017 GO:0048304 positive regulation of isotype switching to IgG 
isotypes 
CD40 
ENSG00000101017 GO:0032855 positive regulation of Rac GTPase activity CD40 
ENSG00000101017 GO:0090037 positive regulation of protein kinase C 
signaling cascade 
CD40 
ENSG00000101017 GO:0042511 positive regulation of tyrosine 
phosphorylation of Stat1 protein 
CD40 
ENSG00000101017 GO:0043089 positive regulation of Cdc42 GTPase activity CD40 
ENSG00000101017 GO:2000353 positive regulation of endothelial cell 
apoptosis 
CD40 
ENSG00000101017 GO:0042113 B cell activation CD40 
ENSG00000101017 GO:0005886 plasma membrane CD40 
ENSG00000101017 GO:0005576 extracellular region CD40 
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ENSG00000101017 GO:0043231 intracellular membrane-bounded organelle CD40 
ENSG00000101017 GO:0005887 integral to plasma membrane CD40 
ENSG00000101017 GO:0009897 external side of plasma membrane CD40 
ENSG00000101017 GO:0035631 CD40 receptor complex CD40 
ENSG00000101017 GO:0004872 receptor activity CD40 
ENSG00000101017 GO:0005488 binding CD40 
ENSG00000101017 GO:0005515 protein binding CD40 
ENSG00000101017 GO:0004871 signal transducer activity CD40 
ENSG00000101017 GO:0019899 enzyme binding CD40 
ENSG00000154162 GO:0007156 homophilic cell adhesion CDH12 
ENSG00000154162 GO:0016337 cell-cell adhesion CDH12 
ENSG00000154162 GO:0034332 adherens junction organization CDH12 
ENSG00000154162 GO:0034329 cell junction assembly CDH12 
ENSG00000154162 GO:0045216 cell-cell junction organization CDH12 
ENSG00000154162 GO:0016020 membrane CDH12 
ENSG00000154162 GO:0016021 integral to membrane CDH12 
ENSG00000154162 GO:0005886 plasma membrane CDH12 
ENSG00000154162 GO:0005509 calcium ion binding CDH12 
ENSG00000154162 GO:0007155 cell adhesion CDH12 
ENSG00000150394 GO:0007155 cell adhesion CDH8 
ENSG00000150394 GO:0007156 homophilic cell adhesion CDH8 
ENSG00000150394 GO:0034332 adherens junction organization CDH8 
ENSG00000150394 GO:0034329 cell junction assembly CDH8 
ENSG00000150394 GO:0045216 cell-cell junction organization CDH8 
ENSG00000150394 GO:0016020 membrane CDH8 
ENSG00000150394 GO:0016021 integral to membrane CDH8 
ENSG00000150394 GO:0005886 plasma membrane CDH8 
ENSG00000150394 GO:0005509 calcium ion binding CDH8 
ENSG00000184984 GO:0008283 cell proliferation CHRM5 
ENSG00000184984 GO:0007186 G-protein coupled receptor signaling 
pathway 
CHRM5 
ENSG00000184984 GO:0007213 G-protein coupled acetylcholine receptor 
signaling pathway 
CHRM5 
ENSG00000184984 GO:0019226 transmission of nerve impulse CHRM5 
ENSG00000184984 GO:0007197 inhibition of adenylate cyclase activity by G-
protein coupled acetylcholine receptor 
signaling pathway 
CHRM5 
ENSG00000184984 GO:0015872 dopamine transport CHRM5 
ENSG00000184984 GO:0060304 regulation of phosphatidylinositol 
dephosphorylation 
CHRM5 
ENSG00000184984 GO:0016021 integral to membrane CHRM5 
ENSG00000184984 GO:0005886 plasma membrane CHRM5 
ENSG00000184984 GO:0030054 cell junction CHRM5 
ENSG00000184984 GO:0045202 synapse CHRM5 
ENSG00000184984 GO:0045211 postsynaptic membrane CHRM5 
ENSG00000184984 GO:0005887 integral to plasma membrane CHRM5 
ENSG00000184984 GO:0004872 receptor activity CHRM5 
ENSG00000184984 GO:0004871 signal transducer activity CHRM5 
ENSG00000184984 GO:0004930 G-protein coupled receptor activity CHRM5 
ENSG00000184984 GO:0004435 phosphatidylinositol phospholipase C activity CHRM5 
ENSG00000184984 GO:0016907 G-protein coupled acetylcholine receptor 
activity 
CHRM5 
ENSG00000152910 GO:0007165 signal transduction CNTNAP4 
ENSG00000152910 GO:0007155 cell adhesion CNTNAP4 
ENSG00000152910 GO:0030425 dendrite CNTNAP4 
ENSG00000152910 GO:0005515 protein binding CNTNAP4 
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ENSG00000152910 GO:0005102 receptor binding CNTNAP4 
ENSG00000152910 GO:0016020 membrane CNTNAP4 
ENSG00000152910 GO:0016021 integral to membrane CNTNAP4 
ENSG00000188517 GO:0016020 membrane COL25A1 
ENSG00000188517 GO:0016021 integral to membrane COL25A1 
ENSG00000188517 GO:0005615 extracellular space COL25A1 
ENSG00000188517 GO:0005581 collagen COL25A1 
ENSG00000188517 GO:0001540 beta-amyloid binding COL25A1 
ENSG00000188517 GO:0008201 heparin binding COL25A1 
ENSG00000144810 GO:0007155 cell adhesion COL8A1 
ENSG00000144810 GO:0001525 angiogenesis COL8A1 
ENSG00000144810 GO:0050673 epithelial cell proliferation COL8A1 
ENSG00000144810 GO:0010811 positive regulation of cell-substrate adhesion COL8A1 
ENSG00000144810 GO:0048593 camera-type eye morphogenesis COL8A1 
ENSG00000144810 GO:0005576 extracellular region COL8A1 
ENSG00000144810 GO:0005581 collagen COL8A1 
ENSG00000144810 GO:0005604 basement membrane COL8A1 
ENSG00000144810 GO:0031012 extracellular matrix COL8A1 
ENSG00000144810 GO:0005591 collagen type VIII COL8A1 
ENSG00000100368 GO:0007165 signal transduction CSF2RB 
ENSG00000100368 GO:0019221 cytokine-mediated signaling pathway CSF2RB 
ENSG00000100368 GO:0007585 respiratory gaseous exchange CSF2RB 
ENSG00000100368 GO:0036016 cellular response to interleukin-3 CSF2RB 
ENSG00000100368 GO:0038043 interleukin-5-mediated signaling pathway CSF2RB 
ENSG00000100368 GO:0016021 integral to membrane CSF2RB 
ENSG00000100368 GO:0005886 plasma membrane CSF2RB 
ENSG00000100368 GO:0005887 integral to plasma membrane CSF2RB 
ENSG00000100368 GO:0030526 granulocyte macrophage colony-stimulating 
factor receptor complex 
CSF2RB 
ENSG00000100368 GO:0004872 receptor activity CSF2RB 
ENSG00000100368 GO:0005515 protein binding CSF2RB 
ENSG00000100368 GO:0004896 cytokine receptor activity CSF2RB 
ENSG00000100368 GO:0004912 interleukin-3 receptor activity CSF2RB 
ENSG00000100368 GO:0004914 interleukin-5 receptor activity CSF2RB 
ENSG00000100368 GO:0016020 membrane CSF2RB 
ENSG00000173406 GO:0021942 radial glia guided migration of Purkinje cell DAB1 
ENSG00000173406 GO:0021813 cell-cell adhesion involved in neuronal-glial 
interactions involved in cerebral cortex radial 
glia guided migration 
DAB1 
ENSG00000173406 GO:0021799 cerebral cortex radially oriented cell 
migration 
DAB1 
ENSG00000173406 GO:0021589 cerebellum structural organization DAB1 
ENSG00000173406 GO:0021795 cerebral cortex cell migration DAB1 
ENSG00000173406 GO:0046426 negative regulation of JAK-STAT cascade DAB1 
ENSG00000173406 GO:0048712 negative regulation of astrocyte 
differentiation 
DAB1 
ENSG00000173406 GO:0007162 negative regulation of cell adhesion DAB1 
ENSG00000173406 GO:0016358 dendrite development DAB1 
ENSG00000173406 GO:0045666 positive regulation of neuron differentiation DAB1 
ENSG00000173406 GO:0021517 ventral spinal cord development DAB1 
ENSG00000173406 GO:0050771 negative regulation of axonogenesis DAB1 
ENSG00000173406 GO:0051645 Golgi localization DAB1 
ENSG00000173406 GO:0045860 positive regulation of protein kinase activity DAB1 
ENSG00000173406 GO:0001764 neuron migration DAB1 
ENSG00000173406 GO:0007628 adult walking behavior DAB1 
ENSG00000173406 GO:0007264 small GTPase mediated signal transduction DAB1 
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ENSG00000173406 GO:0048471 perinuclear region of cytoplasm DAB1 
ENSG00000173406 GO:0005515 protein binding DAB1 
ENSG00000173406 GO:0007275 multicellular organismal development DAB1 
ENSG00000173406 GO:0030154 cell differentiation DAB1 
ENSG00000173406 GO:0007399 nervous system development DAB1 
ENSG00000164934 GO:0016567 protein ubiquitination DCAF13 
ENSG00000164934 GO:0006364 rRNA processing DCAF13 
ENSG00000164934 GO:0005634 nucleus DCAF13 
ENSG00000164934 GO:0005730 nucleolus DCAF13 
ENSG00000164934 GO:0030529 ribonucleoprotein complex DCAF13 
ENSG00000164934 GO:0080008 CUL4 RING ubiquitin ligase complex DCAF13 
ENSG00000164934 GO:0005515 protein binding DCAF13 
ENSG00000204843 GO:0007399 nervous system development DCTN1 
ENSG00000204843 GO:0007067 mitosis DCTN1 
ENSG00000204843 GO:0000278 mitotic cell cycle DCTN1 
ENSG00000204843 GO:0006810 transport DCTN1 
ENSG00000204843 GO:0000086 G2/M transition of mitotic cell cycle DCTN1 
ENSG00000204843 GO:0008219 cell death DCTN1 
ENSG00000204843 GO:0030968 endoplasmic reticulum unfolded protein 
response 
DCTN1 
ENSG00000204843 GO:0006987 activation of signaling protein activity 
involved in unfolded protein response 
DCTN1 
ENSG00000204843 GO:0005737 cytoplasm DCTN1 
ENSG00000204843 GO:0005829 cytosol DCTN1 
ENSG00000204843 GO:0005856 cytoskeleton DCTN1 
ENSG00000204843 GO:0005813 centrosome DCTN1 
ENSG00000204843 GO:0005874 microtubule DCTN1 
ENSG00000204843 GO:0000776 kinetochore DCTN1 
ENSG00000204843 GO:0031252 cell leading edge DCTN1 
ENSG00000204843 GO:0000922 spindle pole DCTN1 
ENSG00000204843 GO:0005868 cytoplasmic dynein complex DCTN1 
ENSG00000204843 GO:0005515 protein binding DCTN1 
ENSG00000204843 GO:0003774 motor activity DCTN1 
ENSG00000185842 GO:0007018 microtubule-based movement DNAH14 
ENSG00000185842 GO:0005737 cytoplasm DNAH14 
ENSG00000185842 GO:0005856 cytoskeleton DNAH14 
ENSG00000185842 GO:0030286 dynein complex DNAH14 
ENSG00000185842 GO:0005874 microtubule DNAH14 
ENSG00000185842 GO:0005929 cilium DNAH14 
ENSG00000185842 GO:0035085 cilium axoneme DNAH14 
ENSG00000185842 GO:0000166 nucleotide binding DNAH14 
ENSG00000185842 GO:0005524 ATP binding DNAH14 
ENSG00000185842 GO:0003777 microtubule motor activity DNAH14 
ENSG00000185842 GO:0017111 nucleoside-triphosphatase activity DNAH14 
ENSG00000107099 GO:0007596 blood coagulation DOCK8 
ENSG00000107099 GO:0005829 cytosol DOCK8 
ENSG00000107099 GO:0005488 binding DOCK8 
ENSG00000107099 GO:0005525 GTP binding DOCK8 
ENSG00000107099 GO:0005085 guanyl-nucleotide exchange factor activity DOCK8 
ENSG00000107099 GO:0051020 GTPase binding DOCK8 
ENSG00000171587 GO:0007399 nervous system development DSCAM 
ENSG00000171587 GO:0007626 locomotory behavior DSCAM 
ENSG00000171587 GO:0007155 cell adhesion DSCAM 
ENSG00000171587 GO:0048813 dendrite morphogenesis DSCAM 
ENSG00000171587 GO:0007162 negative regulation of cell adhesion DSCAM 
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ENSG00000171587 GO:0042327 positive regulation of phosphorylation DSCAM 
ENSG00000171587 GO:0060060 post-embryonic retina morphogenesis in 
camera-type eye 
DSCAM 
ENSG00000171587 GO:0048842 positive regulation of axon extension 
involved in axon guidance 
DSCAM 
ENSG00000171587 GO:0070593 dendrite self-avoidance DSCAM 
ENSG00000171587 GO:0005886 plasma membrane DSCAM 
ENSG00000171587 GO:0005576 extracellular region DSCAM 
ENSG00000171587 GO:0030424 axon DSCAM 
ENSG00000171587 GO:0005624 membrane fraction DSCAM 
ENSG00000171587 GO:0005887 integral to plasma membrane DSCAM 
ENSG00000171587 GO:0030426 growth cone DSCAM 
ENSG00000171587 GO:0005515 protein binding DSCAM 
ENSG00000203965 GO:0005509 calcium ion binding EFCAB7 
ENSG00000080224 GO:0006468 protein phosphorylation EPHA6 
ENSG00000080224 GO:0016020 membrane EPHA6 
ENSG00000080224 GO:0016021 integral to membrane EPHA6 
ENSG00000080224 GO:0005515 protein binding EPHA6 
ENSG00000080224 GO:0005524 ATP binding EPHA6 
ENSG00000080224 GO:0005003 ephrin receptor activity EPHA6 
ENSG00000080224 GO:0008150 biological_process EPHA6 
ENSG00000080224 GO:0005575 cellular_component EPHA6 
ENSG00000080224 GO:0005887 integral to plasma membrane EPHA6 
ENSG00000080224 GO:0004872 receptor activity EPHA6 
ENSG00000080224 GO:0000166 nucleotide binding EPHA6 
ENSG00000080224 GO:0003674 molecular_function EPHA6 
ENSG00000080224 GO:0004672 protein kinase activity EPHA6 
ENSG00000080224 GO:0004713 protein tyrosine kinase activity EPHA6 
ENSG00000080224 GO:0016772 transferase activity, transferring phosphorus-
containing groups 
EPHA6 
ENSG00000178568 GO:0008283 cell proliferation ERBB4 
ENSG00000178568 GO:0007275 multicellular organismal development ERBB4 
ENSG00000178568 GO:0006915 apoptotic process ERBB4 
ENSG00000178568 GO:0007399 nervous system development ERBB4 
ENSG00000178568 GO:0008285 negative regulation of cell proliferation ERBB4 
ENSG00000178568 GO:0021537 telencephalon development ERBB4 
ENSG00000178568 GO:0045893 positive regulation of transcription, DNA-
dependent 
ERBB4 
ENSG00000178568 GO:0050679 positive regulation of epithelial cell 
proliferation 
ERBB4 
ENSG00000178568 GO:0008284 positive regulation of cell proliferation ERBB4 
ENSG00000178568 GO:0007165 signal transduction ERBB4 
ENSG00000178568 GO:0043066 negative regulation of apoptotic process ERBB4 
ENSG00000178568 GO:0045165 cell fate commitment ERBB4 
ENSG00000178568 GO:0007507 heart development ERBB4 
ENSG00000178568 GO:0018108 peptidyl-tyrosine phosphorylation ERBB4 
ENSG00000178568 GO:0060749 mammary gland alveolus development ERBB4 
ENSG00000178568 GO:0006468 protein phosphorylation ERBB4 
ENSG00000178568 GO:0007169 transmembrane receptor protein tyrosine 
kinase signaling pathway 
ERBB4 
ENSG00000178568 GO:0060045 positive regulation of cardiac muscle cell 
proliferation 
ERBB4 
ENSG00000178568 GO:0042493 response to drug ERBB4 
ENSG00000178568 GO:0030334 regulation of cell migration ERBB4 
ENSG00000178568 GO:0001755 neural crest cell migration ERBB4 
ENSG00000178568 GO:0032570 response to progesterone stimulus ERBB4 
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ENSG00000178568 GO:0070374 positive regulation of ERK1 and ERK2 
cascade 
ERBB4 
ENSG00000178568 GO:0009880 embryonic pattern specification ERBB4 
ENSG00000178568 GO:0030335 positive regulation of cell migration ERBB4 
ENSG00000178568 GO:0046326 positive regulation of glucose import ERBB4 
ENSG00000178568 GO:0042542 response to hydrogen peroxide ERBB4 
ENSG00000178568 GO:0045768 positive regulation of anti-apoptosis ERBB4 
ENSG00000178568 GO:0060644 mammary gland epithelial cell differentiation ERBB4 
ENSG00000178568 GO:0046777 protein autophosphorylation ERBB4 
ENSG00000178568 GO:0001934 positive regulation of protein phosphorylation ERBB4 
ENSG00000178568 GO:0007595 lactation ERBB4 
ENSG00000178568 GO:0016477 cell migration ERBB4 
ENSG00000178568 GO:0060074 synapse maturation ERBB4 
ENSG00000178568 GO:0032230 positive regulation of synaptic transmission, 
GABAergic 
ERBB4 
ENSG00000178568 GO:0043129 surfactant homeostasis ERBB4 
ENSG00000178568 GO:0043552 positive regulation of phosphatidylinositol 3-
kinase activity 
ERBB4 
ENSG00000178568 GO:0021551 central nervous system morphogenesis ERBB4 
ENSG00000178568 GO:0021889 olfactory bulb interneuron differentiation ERBB4 
ENSG00000178568 GO:0042523 positive regulation of tyrosine 
phosphorylation of Stat5 protein 
ERBB4 
ENSG00000178568 GO:0061026 cardiac muscle tissue regeneration ERBB4 
ENSG00000178568 GO:2000366 positive regulation of STAT protein import 
into nucleus 
ERBB4 
ENSG00000178568 GO:0030879 mammary gland development ERBB4 
ENSG00000178568 GO:0016020 membrane ERBB4 
ENSG00000178568 GO:0016021 integral to membrane ERBB4 
ENSG00000178568 GO:0005634 nucleus ERBB4 
ENSG00000178568 GO:0005737 cytoplasm ERBB4 
ENSG00000178568 GO:0005886 plasma membrane ERBB4 
ENSG00000178568 GO:0005576 extracellular region ERBB4 
ENSG00000178568 GO:0005739 mitochondrion ERBB4 
ENSG00000178568 GO:0005829 cytosol ERBB4 
ENSG00000178568 GO:0005759 mitochondrial matrix ERBB4 
ENSG00000178568 GO:0016323 basolateral plasma membrane ERBB4 
ENSG00000178568 GO:0005654 nucleoplasm ERBB4 
ENSG00000178568 GO:0014069 postsynaptic density ERBB4 
ENSG00000178568 GO:0005901 caveola ERBB4 
ENSG00000178568 GO:0045121 membrane raft ERBB4 
ENSG00000178568 GO:0004872 receptor activity ERBB4 
ENSG00000178568 GO:0000166 nucleotide binding ERBB4 
ENSG00000178568 GO:0042803 protein homodimerization activity ERBB4 
ENSG00000178568 GO:0005515 protein binding ERBB4 
ENSG00000178568 GO:0005524 ATP binding ERBB4 
ENSG00000178568 GO:0005154 epidermal growth factor receptor binding ERBB4 
ENSG00000178568 GO:0004672 protein kinase activity ERBB4 
ENSG00000178568 GO:0004714 transmembrane receptor protein tyrosine 
kinase activity 
ERBB4 
ENSG00000178568 GO:0004713 protein tyrosine kinase activity ERBB4 
ENSG00000178568 GO:0044212 transcription regulatory region DNA binding ERBB4 
ENSG00000178568 GO:0004716 receptor signaling protein tyrosine kinase 
activity 
ERBB4 
ENSG00000143971 GO:0005634 nucleus ETAA1 
ENSG00000143971 GO:0005737 cytoplasm ETAA1 
ENSG00000188107 GO:0005515 protein binding EYS 
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ENSG00000188107 GO:0005509 calcium ion binding EYS 
ENSG00000188107 GO:0007601 visual perception EYS 
ENSG00000188107 GO:0050896 response to stimulus EYS 
ENSG00000188107 GO:0005576 extracellular region EYS 
ENSG00000148541 
 
FAM13C 
ENSG00000197872 GO:0005622 intracellular FAM49A 
ENSG00000170613 GO:0005634 nucleus FAM71B 
ENSG00000170613 GO:0005737 cytoplasm FAM71B 
ENSG00000026103 GO:0006915 apoptotic process FAS 
ENSG00000026103 GO:0007165 signal transduction FAS 
ENSG00000026103 GO:0042981 regulation of apoptotic process FAS 
ENSG00000026103 GO:0007283 spermatogenesis FAS 
ENSG00000026103 GO:0048536 spleen development FAS 
ENSG00000026103 GO:0006917 induction of apoptosis FAS 
ENSG00000026103 GO:0006955 immune response FAS 
ENSG00000026103 GO:0010467 gene expression FAS 
ENSG00000026103 GO:0032496 response to lipopolysaccharide FAS 
ENSG00000026103 GO:0043627 response to estrogen stimulus FAS 
ENSG00000026103 GO:0042493 response to drug FAS 
ENSG00000026103 GO:0043065 positive regulation of apoptotic process FAS 
ENSG00000026103 GO:0042698 ovulation cycle FAS 
ENSG00000026103 GO:0007568 aging FAS 
ENSG00000026103 GO:0009636 response to toxin FAS 
ENSG00000026103 GO:0034097 response to cytokine stimulus FAS 
ENSG00000026103 GO:0006461 protein complex assembly FAS 
ENSG00000026103 GO:0001666 response to hypoxia FAS 
ENSG00000026103 GO:0042127 regulation of cell proliferation FAS 
ENSG00000026103 GO:0008625 induction of apoptosis via death domain 
receptors 
FAS 
ENSG00000026103 GO:0010940 positive regulation of necrotic cell death FAS 
ENSG00000026103 GO:0006916 anti-apoptosis FAS 
ENSG00000026103 GO:0051384 response to glucocorticoid stimulus FAS 
ENSG00000026103 GO:0010035 response to inorganic substance FAS 
ENSG00000026103 GO:0045060 negative thymic T cell selection FAS 
ENSG00000026103 GO:0051402 neuron apoptosis FAS 
ENSG00000026103 GO:0019724 B cell mediated immunity FAS 
ENSG00000026103 GO:0043434 response to peptide hormone stimulus FAS 
ENSG00000026103 GO:0006919 activation of cysteine-type endopeptidase 
activity involved in apoptotic process 
FAS 
ENSG00000026103 GO:0003014 renal system process FAS 
ENSG00000026103 GO:0071285 cellular response to lithium ion FAS 
ENSG00000026103 GO:0008633 activation of pro-apoptotic gene products FAS 
ENSG00000026103 GO:0071260 cellular response to mechanical stimulus FAS 
ENSG00000026103 GO:0008624 induction of apoptosis by extracellular 
signals 
FAS 
ENSG00000026103 GO:0070848 response to growth factor stimulus FAS 
ENSG00000026103 GO:0032464 positive regulation of protein 
homooligomerization 
FAS 
ENSG00000026103 GO:0006924 activation-induced cell death of T cells FAS 
ENSG00000026103 GO:0006927 transformed cell apoptosis FAS 
ENSG00000026103 GO:0006925 inflammatory cell apoptosis FAS 
ENSG00000026103 GO:0045637 regulation of myeloid cell differentiation FAS 
ENSG00000026103 GO:0050869 negative regulation of B cell activation FAS 
ENSG00000026103 GO:0002377 immunoglobulin production FAS 
ENSG00000026103 GO:0031104 dendrite regeneration FAS 
ENSG00000026103 GO:0045619 regulation of lymphocyte differentiation FAS 
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ENSG00000026103 GO:0071455 cellular response to hyperoxia FAS 
ENSG00000026103 GO:0033209 tumor necrosis factor-mediated signaling 
pathway 
FAS 
ENSG00000026103 GO:0043066 negative regulation of apoptotic process FAS 
ENSG00000026103 GO:0043029 T cell homeostasis FAS 
ENSG00000026103 GO:0051260 protein homooligomerization FAS 
ENSG00000026103 GO:0016021 integral to membrane FAS 
ENSG00000026103 GO:0005634 nucleus FAS 
ENSG00000026103 GO:0005737 cytoplasm FAS 
ENSG00000026103 GO:0005886 plasma membrane FAS 
ENSG00000026103 GO:0005576 extracellular region FAS 
ENSG00000026103 GO:0005829 cytosol FAS 
ENSG00000026103 GO:0048471 perinuclear region of cytoplasm FAS 
ENSG00000026103 GO:0005625 soluble fraction FAS 
ENSG00000026103 GO:0045121 membrane raft FAS 
ENSG00000026103 GO:0009897 external side of plasma membrane FAS 
ENSG00000026103 GO:0031265 CD95 death-inducing signaling complex FAS 
ENSG00000026103 GO:0031264 death-inducing signaling complex FAS 
ENSG00000026103 GO:0009986 cell surface FAS 
ENSG00000026103 GO:0004872 receptor activity FAS 
ENSG00000026103 GO:0005488 binding FAS 
ENSG00000026103 GO:0005515 protein binding FAS 
ENSG00000026103 GO:0019900 kinase binding FAS 
ENSG00000026103 GO:0004871 signal transducer activity FAS 
ENSG00000026103 GO:0004888 transmembrane signaling receptor activity FAS 
ENSG00000026103 GO:0042802 identical protein binding FAS 
ENSG00000026103 GO:0005031 tumor necrosis factor-activated receptor 
activity 
FAS 
ENSG00000176988 GO:0016020 membrane FMR1NB 
ENSG00000176988 GO:0016021 integral to membrane FMR1NB 
ENSG00000164694 GO:0071456 cellular response to hypoxia FNDC1 
ENSG00000164694 GO:0001934 positive regulation of protein phosphorylation FNDC1 
ENSG00000164694 GO:0051223 regulation of protein transport FNDC1 
ENSG00000164694 GO:0010666 positive regulation of cardiac muscle cell 
apoptosis 
FNDC1 
ENSG00000164694 GO:0005737 cytoplasm FNDC1 
ENSG00000164694 GO:0005886 plasma membrane FNDC1 
ENSG00000164694 GO:0005576 extracellular region FNDC1 
ENSG00000164694 GO:0031966 mitochondrial membrane FNDC1 
ENSG00000164694 GO:0005911 cell-cell junction FNDC1 
ENSG00000164694 GO:0005515 protein binding FNDC1 
ENSG00000164930 GO:0007275 multicellular organismal development FZD6 
ENSG00000164930 GO:0016055 Wnt receptor signaling pathway FZD6 
ENSG00000164930 GO:0001736 establishment of planar polarity FZD6 
ENSG00000164930 GO:0007409 axonogenesis FZD6 
ENSG00000164930 GO:0042472 inner ear morphogenesis FZD6 
ENSG00000164930 GO:0001525 angiogenesis FZD6 
ENSG00000164930 GO:0043433 negative regulation of sequence-specific 
DNA binding transcription factor activity 
FZD6 
ENSG00000164930 GO:0001843 neural tube closure FZD6 
ENSG00000164930 GO:0090090 negative regulation of canonical Wnt 
receptor signaling pathway 
FZD6 
ENSG00000164930 GO:0007166 cell surface receptor signaling pathway FZD6 
ENSG00000164930 GO:0030168 platelet activation FZD6 
ENSG00000164930 GO:0001942 hair follicle development FZD6 
ENSG00000164930 GO:0035567 non-canonical Wnt receptor signaling FZD6 
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pathway 
ENSG00000164930 GO:0033278 cell proliferation in midbrain FZD6 
ENSG00000164930 GO:0060071 Wnt receptor signaling pathway, planar cell 
polarity pathway 
FZD6 
ENSG00000164930 GO:0008406 gonad development FZD6 
ENSG00000164930 GO:0007199 G-protein signaling, coupled to cGMP 
nucleotide second messenger 
FZD6 
ENSG00000164930 GO:0030901 midbrain development FZD6 
ENSG00000164930 GO:0016020 membrane FZD6 
ENSG00000164930 GO:0016021 integral to membrane FZD6 
ENSG00000164930 GO:0005737 cytoplasm FZD6 
ENSG00000164930 GO:0005886 plasma membrane FZD6 
ENSG00000164930 GO:0005887 integral to plasma membrane FZD6 
ENSG00000164930 GO:0045177 apical part of cell FZD6 
ENSG00000164930 GO:0016327 apicolateral plasma membrane FZD6 
ENSG00000164930 GO:0032589 neuron projection membrane FZD6 
ENSG00000164930 GO:0004872 receptor activity FZD6 
ENSG00000164930 GO:0005515 protein binding FZD6 
ENSG00000164930 GO:0004871 signal transducer activity FZD6 
ENSG00000164930 GO:0004930 G-protein coupled receptor activity FZD6 
ENSG00000164930 GO:0004888 transmembrane signaling receptor activity FZD6 
ENSG00000164930 GO:0017147 Wnt-protein binding FZD6 
ENSG00000164930 GO:0042813 Wnt-activated receptor activity FZD6 
ENSG00000164930 GO:0030165 PDZ domain binding FZD6 
ENSG00000237051 GO:0008285 negative regulation of cell proliferation GABBR1 
ENSG00000237051 GO:0007186 G-protein coupled receptor signaling 
pathway 
GABBR1 
ENSG00000237051 GO:0001649 osteoblast differentiation GABBR1 
ENSG00000237051 GO:0007194 negative regulation of adenylate cyclase 
activity 
GABBR1 
ENSG00000237051 GO:0014048 regulation of glutamate secretion GABBR1 
ENSG00000237051 GO:0014053 negative regulation of gamma-aminobutyric 
acid secretion 
GABBR1 
ENSG00000237051 GO:0030817 regulation of cAMP biosynthetic process GABBR1 
ENSG00000237051 GO:0032811 negative regulation of epinephrine secretion GABBR1 
ENSG00000237051 GO:0033602 negative regulation of dopamine secretion GABBR1 
ENSG00000237051 GO:0035094 response to nicotine GABBR1 
ENSG00000237051 GO:0045471 response to ethanol GABBR1 
ENSG00000237051 GO:0050805 negative regulation of synaptic transmission GABBR1 
ENSG00000237051 GO:0060124 positive regulation of growth hormone 
secretion 
GABBR1 
ENSG00000237051 GO:0016020 membrane GABBR1 
ENSG00000237051 GO:0016021 integral to membrane GABBR1 
ENSG00000237051 GO:0005737 cytoplasm GABBR1 
ENSG00000237051 GO:0005789 endoplasmic reticulum membrane GABBR1 
ENSG00000237051 GO:0043025 neuronal cell body GABBR1 
ENSG00000237051 GO:0019717 synaptosome GABBR1 
ENSG00000237051 GO:0008021 synaptic vesicle GABBR1 
ENSG00000237051 GO:0031966 mitochondrial membrane GABBR1 
ENSG00000237051 GO:0043197 dendritic spine GABBR1 
ENSG00000237051 GO:0005625 soluble fraction GABBR1 
ENSG00000237051 GO:0005792 microsome GABBR1 
ENSG00000237051 GO:0030673 axolemma GABBR1 
ENSG00000237051 GO:0043198 dendritic shaft GABBR1 
ENSG00000237051 GO:0045121 membrane raft GABBR1 
ENSG00000237051 GO:0004872 receptor activity GABBR1 
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ENSG00000237051 GO:0004871 signal transducer activity GABBR1 
ENSG00000237051 GO:0004930 G-protein coupled receptor activity GABBR1 
ENSG00000237051 GO:0004965 G-protein coupled GABA receptor activity GABBR1 
ENSG00000237051 GO:0008134 transcription factor binding GABBR1 
ENSG00000204681 GO:0008285 negative regulation of cell proliferation GABBR1 
ENSG00000204681 GO:0007186 G-protein coupled receptor signaling 
pathway 
GABBR1 
ENSG00000204681 GO:0001649 osteoblast differentiation GABBR1 
ENSG00000204681 GO:0007194 negative regulation of adenylate cyclase 
activity 
GABBR1 
ENSG00000204681 GO:0014048 regulation of glutamate secretion GABBR1 
ENSG00000204681 GO:0014053 negative regulation of gamma-aminobutyric 
acid secretion 
GABBR1 
ENSG00000204681 GO:0030817 regulation of cAMP biosynthetic process GABBR1 
ENSG00000204681 GO:0032811 negative regulation of epinephrine secretion GABBR1 
ENSG00000204681 GO:0033602 negative regulation of dopamine secretion GABBR1 
ENSG00000204681 GO:0035094 response to nicotine GABBR1 
ENSG00000204681 GO:0045471 response to ethanol GABBR1 
ENSG00000204681 GO:0050805 negative regulation of synaptic transmission GABBR1 
ENSG00000204681 GO:0060124 positive regulation of growth hormone 
secretion 
GABBR1 
ENSG00000204681 GO:0016020 membrane GABBR1 
ENSG00000204681 GO:0016021 integral to membrane GABBR1 
ENSG00000204681 GO:0005737 cytoplasm GABBR1 
ENSG00000204681 GO:0005789 endoplasmic reticulum membrane GABBR1 
ENSG00000204681 GO:0043025 neuronal cell body GABBR1 
ENSG00000204681 GO:0019717 synaptosome GABBR1 
ENSG00000204681 GO:0008021 synaptic vesicle GABBR1 
ENSG00000204681 GO:0031966 mitochondrial membrane GABBR1 
ENSG00000204681 GO:0043197 dendritic spine GABBR1 
ENSG00000204681 GO:0005625 soluble fraction GABBR1 
ENSG00000204681 GO:0005792 microsome GABBR1 
ENSG00000204681 GO:0030673 axolemma GABBR1 
ENSG00000204681 GO:0043198 dendritic shaft GABBR1 
ENSG00000204681 GO:0045121 membrane raft GABBR1 
ENSG00000204681 GO:0004872 receptor activity GABBR1 
ENSG00000204681 GO:0004871 signal transducer activity GABBR1 
ENSG00000204681 GO:0004930 G-protein coupled receptor activity GABBR1 
ENSG00000204681 GO:0004965 G-protein coupled GABA receptor activity GABBR1 
ENSG00000204681 GO:0008134 transcription factor binding GABBR1 
ENSG00000204681 GO:0007268 synaptic transmission GABBR1 
ENSG00000204681 GO:0007214 gamma-aminobutyric acid signaling pathway GABBR1 
ENSG00000204681 GO:0005886 plasma membrane GABBR1 
ENSG00000204681 GO:0005576 extracellular region GABBR1 
ENSG00000204681 GO:0030054 cell junction GABBR1 
ENSG00000204681 GO:0045202 synapse GABBR1 
ENSG00000204681 GO:0045211 postsynaptic membrane GABBR1 
ENSG00000204681 GO:0005887 integral to plasma membrane GABBR1 
ENSG00000204681 GO:0005515 protein binding GABBR1 
ENSG00000232569 GO:0008285 negative regulation of cell proliferation GABBR1 
ENSG00000232569 GO:0007186 G-protein coupled receptor signaling 
pathway 
GABBR1 
ENSG00000232569 GO:0001649 osteoblast differentiation GABBR1 
ENSG00000232569 GO:0007194 negative regulation of adenylate cyclase 
activity 
GABBR1 
ENSG00000232569 GO:0014048 regulation of glutamate secretion GABBR1 
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ENSG00000232569 GO:0014053 negative regulation of gamma-aminobutyric 
acid secretion 
GABBR1 
ENSG00000232569 GO:0030817 regulation of cAMP biosynthetic process GABBR1 
ENSG00000232569 GO:0032811 negative regulation of epinephrine secretion GABBR1 
ENSG00000232569 GO:0033602 negative regulation of dopamine secretion GABBR1 
ENSG00000232569 GO:0035094 response to nicotine GABBR1 
ENSG00000232569 GO:0045471 response to ethanol GABBR1 
ENSG00000232569 GO:0050805 negative regulation of synaptic transmission GABBR1 
ENSG00000232569 GO:0060124 positive regulation of growth hormone 
secretion 
GABBR1 
ENSG00000232569 GO:0016020 membrane GABBR1 
ENSG00000232569 GO:0016021 integral to membrane GABBR1 
ENSG00000232569 GO:0005737 cytoplasm GABBR1 
ENSG00000232569 GO:0005789 endoplasmic reticulum membrane GABBR1 
ENSG00000232569 GO:0043025 neuronal cell body GABBR1 
ENSG00000232569 GO:0019717 synaptosome GABBR1 
ENSG00000232569 GO:0008021 synaptic vesicle GABBR1 
ENSG00000232569 GO:0031966 mitochondrial membrane GABBR1 
ENSG00000232569 GO:0043197 dendritic spine GABBR1 
ENSG00000232569 GO:0005625 soluble fraction GABBR1 
ENSG00000232569 GO:0005792 microsome GABBR1 
ENSG00000232569 GO:0030673 axolemma GABBR1 
ENSG00000232569 GO:0043198 dendritic shaft GABBR1 
ENSG00000232569 GO:0045121 membrane raft GABBR1 
ENSG00000232569 GO:0004872 receptor activity GABBR1 
ENSG00000232569 GO:0004871 signal transducer activity GABBR1 
ENSG00000232569 GO:0004930 G-protein coupled receptor activity GABBR1 
ENSG00000232569 GO:0004965 G-protein coupled GABA receptor activity GABBR1 
ENSG00000232569 GO:0008134 transcription factor binding GABBR1 
ENSG00000232569 GO:0007268 synaptic transmission GABBR1 
ENSG00000232569 GO:0007214 gamma-aminobutyric acid signaling pathway GABBR1 
ENSG00000232569 GO:0005886 plasma membrane GABBR1 
ENSG00000232569 GO:0005576 extracellular region GABBR1 
ENSG00000232569 GO:0030054 cell junction GABBR1 
ENSG00000232569 GO:0045202 synapse GABBR1 
ENSG00000232569 GO:0045211 postsynaptic membrane GABBR1 
ENSG00000232569 GO:0005887 integral to plasma membrane GABBR1 
ENSG00000232569 GO:0005515 protein binding GABBR1 
ENSG00000206511 GO:0008285 negative regulation of cell proliferation GABBR1 
ENSG00000206511 GO:0007186 G-protein coupled receptor signaling 
pathway 
GABBR1 
ENSG00000206511 GO:0001649 osteoblast differentiation GABBR1 
ENSG00000206511 GO:0007194 negative regulation of adenylate cyclase 
activity 
GABBR1 
ENSG00000206511 GO:0014048 regulation of glutamate secretion GABBR1 
ENSG00000206511 GO:0014053 negative regulation of gamma-aminobutyric 
acid secretion 
GABBR1 
ENSG00000206511 GO:0030817 regulation of cAMP biosynthetic process GABBR1 
ENSG00000206511 GO:0032811 negative regulation of epinephrine secretion GABBR1 
ENSG00000206511 GO:0033602 negative regulation of dopamine secretion GABBR1 
ENSG00000206511 GO:0035094 response to nicotine GABBR1 
ENSG00000206511 GO:0045471 response to ethanol GABBR1 
ENSG00000206511 GO:0050805 negative regulation of synaptic transmission GABBR1 
ENSG00000206511 GO:0060124 positive regulation of growth hormone 
secretion 
GABBR1 
ENSG00000206511 GO:0016020 membrane GABBR1 
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ENSG00000206511 GO:0016021 integral to membrane GABBR1 
ENSG00000206511 GO:0005737 cytoplasm GABBR1 
ENSG00000206511 GO:0005789 endoplasmic reticulum membrane GABBR1 
ENSG00000206511 GO:0043025 neuronal cell body GABBR1 
ENSG00000206511 GO:0019717 synaptosome GABBR1 
ENSG00000206511 GO:0008021 synaptic vesicle GABBR1 
ENSG00000206511 GO:0031966 mitochondrial membrane GABBR1 
ENSG00000206511 GO:0043197 dendritic spine GABBR1 
ENSG00000206511 GO:0005625 soluble fraction GABBR1 
ENSG00000206511 GO:0005792 microsome GABBR1 
ENSG00000206511 GO:0030673 axolemma GABBR1 
ENSG00000206511 GO:0043198 dendritic shaft GABBR1 
ENSG00000206511 GO:0045121 membrane raft GABBR1 
ENSG00000206511 GO:0004872 receptor activity GABBR1 
ENSG00000206511 GO:0004871 signal transducer activity GABBR1 
ENSG00000206511 GO:0004930 G-protein coupled receptor activity GABBR1 
ENSG00000206511 GO:0004965 G-protein coupled GABA receptor activity GABBR1 
ENSG00000206511 GO:0008134 transcription factor binding GABBR1 
ENSG00000206511 GO:0007268 synaptic transmission GABBR1 
ENSG00000206511 GO:0007214 gamma-aminobutyric acid signaling pathway GABBR1 
ENSG00000206511 GO:0005886 plasma membrane GABBR1 
ENSG00000206511 GO:0005576 extracellular region GABBR1 
ENSG00000206511 GO:0030054 cell junction GABBR1 
ENSG00000206511 GO:0045202 synapse GABBR1 
ENSG00000206511 GO:0045211 postsynaptic membrane GABBR1 
ENSG00000206511 GO:0005887 integral to plasma membrane GABBR1 
ENSG00000206511 GO:0005515 protein binding GABBR1 
ENSG00000232632 GO:0008285 negative regulation of cell proliferation GABBR1 
ENSG00000232632 GO:0007186 G-protein coupled receptor signaling 
pathway 
GABBR1 
ENSG00000232632 GO:0001649 osteoblast differentiation GABBR1 
ENSG00000232632 GO:0007194 negative regulation of adenylate cyclase 
activity 
GABBR1 
ENSG00000232632 GO:0014048 regulation of glutamate secretion GABBR1 
ENSG00000232632 GO:0014053 negative regulation of gamma-aminobutyric 
acid secretion 
GABBR1 
ENSG00000232632 GO:0030817 regulation of cAMP biosynthetic process GABBR1 
ENSG00000232632 GO:0032811 negative regulation of epinephrine secretion GABBR1 
ENSG00000232632 GO:0033602 negative regulation of dopamine secretion GABBR1 
ENSG00000232632 GO:0035094 response to nicotine GABBR1 
ENSG00000232632 GO:0045471 response to ethanol GABBR1 
ENSG00000232632 GO:0050805 negative regulation of synaptic transmission GABBR1 
ENSG00000232632 GO:0060124 positive regulation of growth hormone 
secretion 
GABBR1 
ENSG00000232632 GO:0016020 membrane GABBR1 
ENSG00000232632 GO:0016021 integral to membrane GABBR1 
ENSG00000232632 GO:0005737 cytoplasm GABBR1 
ENSG00000232632 GO:0005789 endoplasmic reticulum membrane GABBR1 
ENSG00000232632 GO:0043025 neuronal cell body GABBR1 
ENSG00000232632 GO:0019717 synaptosome GABBR1 
ENSG00000232632 GO:0008021 synaptic vesicle GABBR1 
ENSG00000232632 GO:0031966 mitochondrial membrane GABBR1 
ENSG00000232632 GO:0043197 dendritic spine GABBR1 
ENSG00000232632 GO:0005625 soluble fraction GABBR1 
ENSG00000232632 GO:0005792 microsome GABBR1 
ENSG00000232632 GO:0030673 axolemma GABBR1 
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ENSG00000232632 GO:0043198 dendritic shaft GABBR1 
ENSG00000232632 GO:0045121 membrane raft GABBR1 
ENSG00000232632 GO:0004872 receptor activity GABBR1 
ENSG00000232632 GO:0004871 signal transducer activity GABBR1 
ENSG00000232632 GO:0004930 G-protein coupled receptor activity GABBR1 
ENSG00000232632 GO:0004965 G-protein coupled GABA receptor activity GABBR1 
ENSG00000232632 GO:0008134 transcription factor binding GABBR1 
ENSG00000232632 GO:0007268 synaptic transmission GABBR1 
ENSG00000232632 GO:0007214 gamma-aminobutyric acid signaling pathway GABBR1 
ENSG00000232632 GO:0005886 plasma membrane GABBR1 
ENSG00000232632 GO:0005576 extracellular region GABBR1 
ENSG00000232632 GO:0030054 cell junction GABBR1 
ENSG00000232632 GO:0045202 synapse GABBR1 
ENSG00000232632 GO:0045211 postsynaptic membrane GABBR1 
ENSG00000232632 GO:0005887 integral to plasma membrane GABBR1 
ENSG00000232632 GO:0005515 protein binding GABBR1 
ENSG00000206466 GO:0008285 negative regulation of cell proliferation GABBR1 
ENSG00000206466 GO:0007186 G-protein coupled receptor signaling 
pathway 
GABBR1 
ENSG00000206466 GO:0001649 osteoblast differentiation GABBR1 
ENSG00000206466 GO:0007194 negative regulation of adenylate cyclase 
activity 
GABBR1 
ENSG00000206466 GO:0014048 regulation of glutamate secretion GABBR1 
ENSG00000206466 GO:0014053 negative regulation of gamma-aminobutyric 
acid secretion 
GABBR1 
ENSG00000206466 GO:0030817 regulation of cAMP biosynthetic process GABBR1 
ENSG00000206466 GO:0032811 negative regulation of epinephrine secretion GABBR1 
ENSG00000206466 GO:0033602 negative regulation of dopamine secretion GABBR1 
ENSG00000206466 GO:0035094 response to nicotine GABBR1 
ENSG00000206466 GO:0045471 response to ethanol GABBR1 
ENSG00000206466 GO:0050805 negative regulation of synaptic transmission GABBR1 
ENSG00000206466 GO:0060124 positive regulation of growth hormone 
secretion 
GABBR1 
ENSG00000206466 GO:0016020 membrane GABBR1 
ENSG00000206466 GO:0016021 integral to membrane GABBR1 
ENSG00000206466 GO:0005737 cytoplasm GABBR1 
ENSG00000206466 GO:0005789 endoplasmic reticulum membrane GABBR1 
ENSG00000206466 GO:0043025 neuronal cell body GABBR1 
ENSG00000206466 GO:0019717 synaptosome GABBR1 
ENSG00000206466 GO:0008021 synaptic vesicle GABBR1 
ENSG00000206466 GO:0031966 mitochondrial membrane GABBR1 
ENSG00000206466 GO:0043197 dendritic spine GABBR1 
ENSG00000206466 GO:0005625 soluble fraction GABBR1 
ENSG00000206466 GO:0005792 microsome GABBR1 
ENSG00000206466 GO:0030673 axolemma GABBR1 
ENSG00000206466 GO:0043198 dendritic shaft GABBR1 
ENSG00000206466 GO:0045121 membrane raft GABBR1 
ENSG00000206466 GO:0004872 receptor activity GABBR1 
ENSG00000206466 GO:0004871 signal transducer activity GABBR1 
ENSG00000206466 GO:0004930 G-protein coupled receptor activity GABBR1 
ENSG00000206466 GO:0004965 G-protein coupled GABA receptor activity GABBR1 
ENSG00000206466 GO:0008134 transcription factor binding GABBR1 
ENSG00000206466 GO:0007268 synaptic transmission GABBR1 
ENSG00000206466 GO:0007214 gamma-aminobutyric acid signaling pathway GABBR1 
ENSG00000206466 GO:0005886 plasma membrane GABBR1 
ENSG00000206466 GO:0005576 extracellular region GABBR1 
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ENSG00000206466 GO:0030054 cell junction GABBR1 
ENSG00000206466 GO:0045202 synapse GABBR1 
ENSG00000206466 GO:0045211 postsynaptic membrane GABBR1 
ENSG00000206466 GO:0005887 integral to plasma membrane GABBR1 
ENSG00000206466 GO:0005515 protein binding GABBR1 
ENSG00000237112 GO:0008285 negative regulation of cell proliferation GABBR1 
ENSG00000237112 GO:0007186 G-protein coupled receptor signaling 
pathway 
GABBR1 
ENSG00000237112 GO:0001649 osteoblast differentiation GABBR1 
ENSG00000237112 GO:0007194 negative regulation of adenylate cyclase 
activity 
GABBR1 
ENSG00000237112 GO:0014048 regulation of glutamate secretion GABBR1 
ENSG00000237112 GO:0014053 negative regulation of gamma-aminobutyric 
acid secretion 
GABBR1 
ENSG00000237112 GO:0030817 regulation of cAMP biosynthetic process GABBR1 
ENSG00000237112 GO:0032811 negative regulation of epinephrine secretion GABBR1 
ENSG00000237112 GO:0033602 negative regulation of dopamine secretion GABBR1 
ENSG00000237112 GO:0035094 response to nicotine GABBR1 
ENSG00000237112 GO:0045471 response to ethanol GABBR1 
ENSG00000237112 GO:0050805 negative regulation of synaptic transmission GABBR1 
ENSG00000237112 GO:0060124 positive regulation of growth hormone 
secretion 
GABBR1 
ENSG00000237112 GO:0016020 membrane GABBR1 
ENSG00000237112 GO:0016021 integral to membrane GABBR1 
ENSG00000237112 GO:0005737 cytoplasm GABBR1 
ENSG00000237112 GO:0005789 endoplasmic reticulum membrane GABBR1 
ENSG00000237112 GO:0043025 neuronal cell body GABBR1 
ENSG00000237112 GO:0019717 synaptosome GABBR1 
ENSG00000237112 GO:0008021 synaptic vesicle GABBR1 
ENSG00000237112 GO:0031966 mitochondrial membrane GABBR1 
ENSG00000237112 GO:0043197 dendritic spine GABBR1 
ENSG00000237112 GO:0005625 soluble fraction GABBR1 
ENSG00000237112 GO:0005792 microsome GABBR1 
ENSG00000237112 GO:0030673 axolemma GABBR1 
ENSG00000237112 GO:0043198 dendritic shaft GABBR1 
ENSG00000237112 GO:0045121 membrane raft GABBR1 
ENSG00000237112 GO:0004872 receptor activity GABBR1 
ENSG00000237112 GO:0004871 signal transducer activity GABBR1 
ENSG00000237112 GO:0004930 G-protein coupled receptor activity GABBR1 
ENSG00000237112 GO:0004965 G-protein coupled GABA receptor activity GABBR1 
ENSG00000237112 GO:0008134 transcription factor binding GABBR1 
ENSG00000237112 GO:0007268 synaptic transmission GABBR1 
ENSG00000237112 GO:0007214 gamma-aminobutyric acid signaling pathway GABBR1 
ENSG00000237112 GO:0005886 plasma membrane GABBR1 
ENSG00000237112 GO:0005576 extracellular region GABBR1 
ENSG00000237112 GO:0030054 cell junction GABBR1 
ENSG00000237112 GO:0045202 synapse GABBR1 
ENSG00000237112 GO:0045211 postsynaptic membrane GABBR1 
ENSG00000237112 GO:0005887 integral to plasma membrane GABBR1 
ENSG00000237112 GO:0005515 protein binding GABBR1 
ENSG00000116717 GO:0006915 apoptotic process GADD45A 
ENSG00000116717 GO:0006281 DNA repair GADD45A 
ENSG00000116717 GO:0006950 response to stress GADD45A 
ENSG00000116717 GO:0007050 cell cycle arrest GADD45A 
ENSG00000116717 GO:0000086 G2/M transition of mitotic cell cycle GADD45A 
ENSG00000116717 GO:0000079 regulation of cyclin-dependent protein kinase GADD45A 
  
 224 
activity 
ENSG00000116717 GO:0006469 negative regulation of protein kinase activity GADD45A 
ENSG00000116717 GO:2000379 positive regulation of reactive oxygen 
species metabolic process 
GADD45A 
ENSG00000116717 GO:0042770 signal transduction in response to DNA 
damage 
GADD45A 
ENSG00000116717 GO:0007098 centrosome cycle GADD45A 
ENSG00000116717 GO:0071260 cellular response to mechanical stimulus GADD45A 
ENSG00000116717 GO:0071479 cellular response to ionizing radiation GADD45A 
ENSG00000116717 GO:0051726 regulation of cell cycle GADD45A 
ENSG00000116717 GO:0005634 nucleus GADD45A 
ENSG00000116717 GO:0005515 protein binding GADD45A 
ENSG00000141448 GO:0006357 regulation of transcription from RNA 
polymerase II promoter 
GATA6 
ENSG00000141448 GO:0000122 negative regulation of transcription from RNA 
polymerase II promoter 
GATA6 
ENSG00000141448 GO:0045893 positive regulation of transcription, DNA-
dependent 
GATA6 
ENSG00000141448 GO:0043066 negative regulation of apoptotic process GATA6 
ENSG00000141448 GO:0042475 odontogenesis of dentin-containing tooth GATA6 
ENSG00000141448 GO:0045944 positive regulation of transcription from RNA 
polymerase II promoter 
GATA6 
ENSG00000141448 GO:0048645 organ formation GATA6 
ENSG00000141448 GO:0045892 negative regulation of transcription, DNA-
dependent 
GATA6 
ENSG00000141448 GO:0006355 regulation of transcription, DNA-dependent GATA6 
ENSG00000141448 GO:0055007 cardiac muscle cell differentiation GATA6 
ENSG00000141448 GO:0060045 positive regulation of cardiac muscle cell 
proliferation 
GATA6 
ENSG00000141448 GO:0008584 male gonad development GATA6 
ENSG00000141448 GO:0043627 response to estrogen stimulus GATA6 
ENSG00000141448 GO:0042493 response to drug GATA6 
ENSG00000141448 GO:0001701 in utero embryonic development GATA6 
ENSG00000141448 GO:0043065 positive regulation of apoptotic process GATA6 
ENSG00000141448 GO:0045766 positive regulation of angiogenesis GATA6 
ENSG00000141448 GO:0051145 smooth muscle cell differentiation GATA6 
ENSG00000141448 GO:0009636 response to toxin GATA6 
ENSG00000141448 GO:0051591 response to cAMP GATA6 
ENSG00000141448 GO:0071456 cellular response to hypoxia GATA6 
ENSG00000141448 GO:0060510 Type II pneumocyte differentiation GATA6 
ENSG00000141448 GO:0006644 phospholipid metabolic process GATA6 
ENSG00000141448 GO:0001889 liver development GATA6 
ENSG00000141448 GO:0060575 intestinal epithelial cell differentiation GATA6 
ENSG00000141448 GO:0030513 positive regulation of BMP signaling pathway GATA6 
ENSG00000141448 GO:0035239 tube morphogenesis GATA6 
ENSG00000141448 GO:0007596 blood coagulation GATA6 
ENSG00000141448 GO:0030855 epithelial cell differentiation GATA6 
ENSG00000141448 GO:0031016 pancreas development GATA6 
ENSG00000141448 GO:0006366 transcription from RNA polymerase II 
promoter 
GATA6 
ENSG00000141448 GO:0007492 endoderm development GATA6 
ENSG00000141448 GO:0003148 outflow tract septum morphogenesis GATA6 
ENSG00000141448 GO:0070848 response to growth factor stimulus GATA6 
ENSG00000141448 GO:0060430 lung saccule development GATA6 
ENSG00000141448 GO:0071158 positive regulation of cell cycle arrest GATA6 
ENSG00000141448 GO:0071773 cellular response to BMP stimulus GATA6 
ENSG00000141448 GO:0060947 cardiac vascular smooth muscle cell GATA6 
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differentiation 
ENSG00000141448 GO:0060486 Clara cell differentiation GATA6 
ENSG00000141448 GO:0071371 cellular response to gonadotropin stimulus GATA6 
ENSG00000141448 GO:0032911 negative regulation of transforming growth 
factor beta1 production 
GATA6 
ENSG00000141448 GO:0051891 positive regulation of cardioblast 
differentiation 
GATA6 
ENSG00000141448 GO:0003309 type B pancreatic cell differentiation GATA6 
ENSG00000141448 GO:0003310 pancreatic A cell differentiation GATA6 
ENSG00000141448 GO:0007493 endodermal cell fate determination GATA6 
ENSG00000141448 GO:0032912 negative regulation of transforming growth 
factor beta2 production 
GATA6 
ENSG00000141448 GO:0010468 regulation of gene expression GATA6 
ENSG00000141448 GO:0006915 apoptotic process GATA6 
ENSG00000141448 GO:0005634 nucleus GATA6 
ENSG00000141448 GO:0005667 transcription factor complex GATA6 
ENSG00000141448 GO:0005654 nucleoplasm GATA6 
ENSG00000141448 GO:0003677 DNA binding GATA6 
ENSG00000141448 GO:0003700 sequence-specific DNA binding transcription 
factor activity 
GATA6 
ENSG00000141448 GO:0008270 zinc ion binding GATA6 
ENSG00000141448 GO:0005515 protein binding GATA6 
ENSG00000141448 GO:0046872 metal ion binding GATA6 
ENSG00000141448 GO:0043565 sequence-specific DNA binding GATA6 
ENSG00000141448 GO:0000981 sequence-specific DNA binding RNA 
polymerase II transcription factor activity 
GATA6 
ENSG00000141448 GO:0003690 double-stranded DNA binding GATA6 
ENSG00000141448 GO:0003682 chromatin binding GATA6 
ENSG00000141448 GO:0019901 protein kinase binding GATA6 
ENSG00000141448 GO:0008134 transcription factor binding GATA6 
ENSG00000141448 GO:0044212 transcription regulatory region DNA binding GATA6 
ENSG00000141448 GO:0003705 sequence-specific distal enhancer binding 
RNA polymerase II transcription factor 
activity 
GATA6 
ENSG00000141448 GO:0001103 RNA polymerase II repressing transcription 
factor binding 
GATA6 
ENSG00000092208 GO:0006397 mRNA processing GEMIN2 
ENSG00000092208 GO:0010467 gene expression GEMIN2 
ENSG00000092208 GO:0016070 RNA metabolic process GEMIN2 
ENSG00000092208 GO:0008380 RNA splicing GEMIN2 
ENSG00000092208 GO:0000245 spliceosome assembly GEMIN2 
ENSG00000092208 GO:0000375 RNA splicing, via transesterification reactions GEMIN2 
ENSG00000092208 GO:0000387 spliceosomal snRNP assembly GEMIN2 
ENSG00000092208 GO:0034660 ncRNA metabolic process GEMIN2 
ENSG00000092208 GO:0005634 nucleus GEMIN2 
ENSG00000092208 GO:0005737 cytoplasm GEMIN2 
ENSG00000092208 GO:0005622 intracellular GEMIN2 
ENSG00000092208 GO:0005829 cytosol GEMIN2 
ENSG00000092208 GO:0005654 nucleoplasm GEMIN2 
ENSG00000092208 GO:0005681 spliceosomal complex GEMIN2 
ENSG00000092208 GO:0015030 Cajal body GEMIN2 
ENSG00000092208 GO:0005515 protein binding GEMIN2 
ENSG00000106571 GO:0007411 axon guidance GLI3 
ENSG00000106571 GO:0000122 negative regulation of transcription from RNA 
polymerase II promoter 
GLI3 
ENSG00000106571 GO:0008285 negative regulation of cell proliferation GLI3 
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ENSG00000106571 GO:0045893 positive regulation of transcription, DNA-
dependent 
GLI3 
ENSG00000106571 GO:0043066 negative regulation of apoptotic process GLI3 
ENSG00000106571 GO:0042475 odontogenesis of dentin-containing tooth GLI3 
ENSG00000106571 GO:0045944 positive regulation of transcription from RNA 
polymerase II promoter 
GLI3 
ENSG00000106571 GO:0007507 heart development GLI3 
ENSG00000106571 GO:0048839 inner ear development GLI3 
ENSG00000106571 GO:0045892 negative regulation of transcription, DNA-
dependent 
GLI3 
ENSG00000106571 GO:0009952 anterior/posterior pattern specification GLI3 
ENSG00000106571 GO:0030324 lung development GLI3 
ENSG00000106571 GO:0043586 tongue development GLI3 
ENSG00000106571 GO:0001701 in utero embryonic development GLI3 
ENSG00000106571 GO:0048589 developmental growth GLI3 
ENSG00000106571 GO:0002052 positive regulation of neuroblast proliferation GLI3 
ENSG00000106571 GO:0030318 melanocyte differentiation GLI3 
ENSG00000106571 GO:0048709 oligodendrocyte differentiation GLI3 
ENSG00000106571 GO:0090090 negative regulation of canonical Wnt 
receptor signaling pathway 
GLI3 
ENSG00000106571 GO:0045665 negative regulation of neuron differentiation GLI3 
ENSG00000106571 GO:0007224 smoothened signaling pathway GLI3 
ENSG00000106571 GO:0045669 positive regulation of osteoblast 
differentiation 
GLI3 
ENSG00000106571 GO:0045879 negative regulation of smoothened signaling 
pathway 
GLI3 
ENSG00000106571 GO:0001658 branching involved in ureteric bud 
morphogenesis 
GLI3 
ENSG00000106571 GO:0048704 embryonic skeletal system morphogenesis GLI3 
ENSG00000106571 GO:0021543 pallium development GLI3 
ENSG00000106571 GO:0021798 forebrain dorsal/ventral pattern formation GLI3 
ENSG00000106571 GO:0009954 proximal/distal pattern formation GLI3 
ENSG00000106571 GO:0042733 embryonic digit morphogenesis GLI3 
ENSG00000106571 GO:0021631 optic nerve morphogenesis GLI3 
ENSG00000106571 GO:0048593 camera-type eye morphogenesis GLI3 
ENSG00000106571 GO:0048557 embryonic digestive tract morphogenesis GLI3 
ENSG00000106571 GO:0060021 palate development GLI3 
ENSG00000106571 GO:0045060 negative thymic T cell selection GLI3 
ENSG00000106571 GO:0033077 T cell differentiation in thymus GLI3 
ENSG00000106571 GO:0001656 metanephros development GLI3 
ENSG00000106571 GO:0030879 mammary gland development GLI3 
ENSG00000106571 GO:0016485 protein processing GLI3 
ENSG00000106571 GO:0048663 neuron fate commitment GLI3 
ENSG00000106571 GO:0032332 positive regulation of chondrocyte 
differentiation 
GLI3 
ENSG00000106571 GO:0021915 neural tube development GLI3 
ENSG00000106571 GO:0042307 positive regulation of protein import into 
nucleus 
GLI3 
ENSG00000106571 GO:0021801 cerebral cortex radial glia guided migration GLI3 
ENSG00000106571 GO:0007442 hindgut morphogenesis GLI3 
ENSG00000106571 GO:0021513 spinal cord dorsal/ventral patterning GLI3 
ENSG00000106571 GO:0021544 subpallium development GLI3 
ENSG00000106571 GO:0021775 smoothened signaling pathway involved in 
ventral spinal cord interneuron specification 
GLI3 
ENSG00000106571 GO:0021776 smoothened signaling pathway involved in 
spinal cord motor neuron cell fate 
specification 
GLI3 
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ENSG00000106571 GO:0021861 forebrain radial glial cell differentiation GLI3 
ENSG00000106571 GO:0022018 lateral ganglionic eminence cell proliferation GLI3 
ENSG00000106571 GO:0035295 tube development GLI3 
ENSG00000106571 GO:0046638 positive regulation of alpha-beta T cell 
differentiation 
GLI3 
ENSG00000106571 GO:0046639 negative regulation of alpha-beta T cell 
differentiation 
GLI3 
ENSG00000106571 GO:0048646 anatomical structure formation involved in 
morphogenesis 
GLI3 
ENSG00000106571 GO:0060364 frontal suture morphogenesis GLI3 
ENSG00000106571 GO:0060366 lambdoid suture morphogenesis GLI3 
ENSG00000106571 GO:0060367 sagittal suture morphogenesis GLI3 
ENSG00000106571 GO:0060594 mammary gland specification GLI3 
ENSG00000106571 GO:0060831 smoothened signaling pathway involved in 
dorsal/ventral neural tube patterning 
GLI3 
ENSG00000106571 GO:0060840 artery development GLI3 
ENSG00000106571 GO:0060873 anterior semicircular canal development GLI3 
ENSG00000106571 GO:0060875 lateral semicircular canal development GLI3 
ENSG00000106571 GO:0061005 cell differentiation involved in kidney 
development 
GLI3 
ENSG00000106571 GO:0070242 thymocyte apoptosis GLI3 
ENSG00000106571 GO:0035108 limb morphogenesis GLI3 
ENSG00000106571 GO:0048566 embryonic digestive tract development GLI3 
ENSG00000106571 GO:0043585 nose morphogenesis GLI3 
ENSG00000106571 GO:0060173 limb development GLI3 
ENSG00000106571 GO:0045595 regulation of cell differentiation GLI3 
ENSG00000106571 GO:0048754 branching morphogenesis of a tube GLI3 
ENSG00000106571 GO:0045596 negative regulation of cell differentiation GLI3 
ENSG00000106571 GO:0030326 embryonic limb morphogenesis GLI3 
ENSG00000106571 GO:0048856 anatomical structure development GLI3 
ENSG00000106571 GO:0048598 embryonic morphogenesis GLI3 
ENSG00000106571 GO:0021537 telencephalon development GLI3 
ENSG00000106571 GO:0030900 forebrain development GLI3 
ENSG00000106571 GO:0010468 regulation of gene expression GLI3 
ENSG00000106571 GO:0009953 dorsal/ventral pattern formation GLI3 
ENSG00000106571 GO:0007420 brain development GLI3 
ENSG00000106571 GO:0043010 camera-type eye development GLI3 
ENSG00000106571 GO:0006355 regulation of transcription, DNA-dependent GLI3 
ENSG00000106571 GO:0042981 regulation of apoptotic process GLI3 
ENSG00000106571 GO:0042127 regulation of cell proliferation GLI3 
ENSG00000106571 GO:0007417 central nervous system development GLI3 
ENSG00000106571 GO:0001822 kidney development GLI3 
ENSG00000106571 GO:0005634 nucleus GLI3 
ENSG00000106571 GO:0005737 cytoplasm GLI3 
ENSG00000106571 GO:0016592 mediator complex GLI3 
ENSG00000106571 GO:0005622 intracellular GLI3 
ENSG00000106571 GO:0005829 cytosol GLI3 
ENSG00000106571 GO:0005730 nucleolus GLI3 
ENSG00000106571 GO:0043231 intracellular membrane-bounded organelle GLI3 
ENSG00000106571 GO:0005929 cilium GLI3 
ENSG00000106571 GO:0017053 transcriptional repressor complex GLI3 
ENSG00000106571 GO:0003700 sequence-specific DNA binding transcription 
factor activity 
GLI3 
ENSG00000106571 GO:0008270 zinc ion binding GLI3 
ENSG00000106571 GO:0005515 protein binding GLI3 
ENSG00000106571 GO:0046872 metal ion binding GLI3 
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ENSG00000106571 GO:0043565 sequence-specific DNA binding GLI3 
ENSG00000106571 GO:0042826 histone deacetylase binding GLI3 
ENSG00000106571 GO:0003682 chromatin binding GLI3 
ENSG00000106571 GO:0035035 histone acetyltransferase binding GLI3 
ENSG00000106571 GO:0008013 beta-catenin binding GLI3 
ENSG00000156049 GO:0007165 signal transduction GNA14 
ENSG00000156049 GO:0007186 G-protein coupled receptor signaling 
pathway 
GNA14 
ENSG00000156049 GO:0007188 G-protein signaling, coupled to cAMP 
nucleotide second messenger 
GNA14 
ENSG00000156049 GO:0006184 GTP catabolic process GNA14 
ENSG00000156049 GO:0030168 platelet activation GNA14 
ENSG00000156049 GO:0007596 blood coagulation GNA14 
ENSG00000156049 GO:0006471 protein ADP-ribosylation GNA14 
ENSG00000156049 GO:0060158 activation of phospholipase C activity by 
dopamine receptor signaling pathway 
GNA14 
ENSG00000156049 GO:0005886 plasma membrane GNA14 
ENSG00000156049 GO:0005834 heterotrimeric G-protein complex GNA14 
ENSG00000156049 GO:0031234 extrinsic to internal side of plasma 
membrane 
GNA14 
ENSG00000156049 GO:0000166 nucleotide binding GNA14 
ENSG00000156049 GO:0046872 metal ion binding GNA14 
ENSG00000156049 GO:0005525 GTP binding GNA14 
ENSG00000156049 GO:0005085 guanyl-nucleotide exchange factor activity GNA14 
ENSG00000156049 GO:0004871 signal transducer activity GNA14 
ENSG00000156049 GO:0019001 guanyl nucleotide binding GNA14 
ENSG00000156049 GO:0003924 GTPase activity GNA14 
ENSG00000156049 GO:0001664 G-protein coupled receptor binding GNA14 
ENSG00000156049 GO:0031683 G-protein beta/gamma-subunit complex 
binding 
GNA14 
ENSG00000156049 GO:0004629 phospholipase C activity GNA14 
ENSG00000112293 GO:0008285 negative regulation of cell proliferation GPLD1 
ENSG00000112293 GO:0002062 chondrocyte differentiation GPLD1 
ENSG00000112293 GO:0043065 positive regulation of apoptotic process GPLD1 
ENSG00000112293 GO:0071277 cellular response to calcium ion GPLD1 
ENSG00000112293 GO:0035774 positive regulation of insulin secretion 
involved in cellular response to glucose 
stimulus 
GPLD1 
ENSG00000112293 GO:0032869 cellular response to insulin stimulus GPLD1 
ENSG00000112293 GO:0008286 insulin receptor signaling pathway GPLD1 
ENSG00000112293 GO:0009749 response to glucose stimulus GPLD1 
ENSG00000112293 GO:0001503 ossification GPLD1 
ENSG00000112293 GO:0035690 cellular response to drug GPLD1 
ENSG00000112293 GO:0010867 positive regulation of triglyceride biosynthetic 
process 
GPLD1 
ENSG00000112293 GO:0010694 positive regulation of alkaline phosphatase 
activity 
GPLD1 
ENSG00000112293 GO:0002042 cell migration involved in sprouting 
angiogenesis 
GPLD1 
ENSG00000112293 GO:0071397 cellular response to cholesterol GPLD1 
ENSG00000112293 GO:0045919 positive regulation of cytolysis GPLD1 
ENSG00000112293 GO:0002430 complement receptor mediated signaling 
pathway 
GPLD1 
ENSG00000112293 GO:0046470 phosphatidylcholine metabolic process GPLD1 
ENSG00000112293 GO:0010595 positive regulation of endothelial cell 
migration 
GPLD1 
ENSG00000112293 GO:0051044 positive regulation of membrane protein GPLD1 
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ectodomain proteolysis 
ENSG00000112293 GO:0010897 negative regulation of triglyceride catabolic 
process 
GPLD1 
ENSG00000112293 GO:0010907 positive regulation of glucose metabolic 
process 
GPLD1 
ENSG00000112293 GO:0070633 transepithelial transport GPLD1 
ENSG00000112293 GO:0006507 GPI anchor release GPLD1 
ENSG00000112293 GO:0010983 positive regulation of high-density lipoprotein 
particle clearance 
GPLD1 
ENSG00000112293 GO:0035701 hematopoietic stem cell migration GPLD1 
ENSG00000112293 GO:0051047 positive regulation of secretion GPLD1 
ENSG00000112293 GO:0071401 cellular response to triglyceride GPLD1 
ENSG00000112293 GO:0071467 cellular response to pH GPLD1 
ENSG00000112293 GO:0097241 hematopoietic stem cell migration to bone 
marrow 
GPLD1 
ENSG00000112293 GO:1900076 regulation of cellular response to insulin 
stimulus 
GPLD1 
ENSG00000112293 GO:0005737 cytoplasm GPLD1 
ENSG00000112293 GO:0005576 extracellular region GPLD1 
ENSG00000112293 GO:0005622 intracellular GPLD1 
ENSG00000112293 GO:0005615 extracellular space GPLD1 
ENSG00000112293 GO:0005578 proteinaceous extracellular matrix GPLD1 
ENSG00000112293 GO:0005792 microsome GPLD1 
ENSG00000112293 GO:0044444 cytoplasmic part GPLD1 
ENSG00000112293 GO:0016788 hydrolase activity, acting on ester bonds GPLD1 
ENSG00000112293 GO:0004630 phospholipase D activity GPLD1 
ENSG00000112293 GO:0017080 sodium channel regulator activity GPLD1 
ENSG00000112293 GO:0004621 glycosylphosphatidylinositol phospholipase D 
activity 
GPLD1 
ENSG00000132975 GO:0007186 G-protein coupled receptor signaling 
pathway 
GPR12 
ENSG00000132975 GO:0006874 cellular calcium ion homeostasis GPR12 
ENSG00000132975 GO:0016021 integral to membrane GPR12 
ENSG00000132975 GO:0005886 plasma membrane GPR12 
ENSG00000132975 GO:0005887 integral to plasma membrane GPR12 
ENSG00000132975 GO:0004872 receptor activity GPR12 
ENSG00000132975 GO:0004871 signal transducer activity GPR12 
ENSG00000132975 GO:0004930 G-protein coupled receptor activity GPR12 
ENSG00000132975 GO:0031210 phosphatidylcholine binding GPR12 
ENSG00000151025 GO:0007186 G-protein coupled receptor signaling 
pathway 
GPR158 
ENSG00000151025 GO:0016021 integral to membrane GPR158 
ENSG00000151025 GO:0005886 plasma membrane GPR158 
ENSG00000151025 GO:0004872 receptor activity GPR158 
ENSG00000151025 GO:0004871 signal transducer activity GPR158 
ENSG00000151025 GO:0004930 G-protein coupled receptor activity GPR158 
ENSG00000177885 GO:0007411 axon guidance GRB2 
ENSG00000177885 GO:0030154 cell differentiation GRB2 
ENSG00000177885 GO:0051291 protein heterooligomerization GRB2 
ENSG00000177885 GO:0007568 aging GRB2 
ENSG00000177885 GO:0007265 Ras protein signal transduction GRB2 
ENSG00000177885 GO:0007267 cell-cell signaling GRB2 
ENSG00000177885 GO:0008286 insulin receptor signaling pathway GRB2 
ENSG00000177885 GO:0030168 platelet activation GRB2 
ENSG00000177885 GO:2000379 positive regulation of reactive oxygen 
species metabolic process 
GRB2 
ENSG00000177885 GO:0007596 blood coagulation GRB2 
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ENSG00000177885 GO:0043408 regulation of MAPK cascade GRB2 
ENSG00000177885 GO:0050900 leukocyte migration GRB2 
ENSG00000177885 GO:0031623 receptor internalization GRB2 
ENSG00000177885 GO:0042770 signal transduction in response to DNA 
damage 
GRB2 
ENSG00000177885 GO:0007173 epidermal growth factor receptor signaling 
pathway 
GRB2 
ENSG00000177885 GO:0048646 anatomical structure formation involved in 
morphogenesis 
GRB2 
ENSG00000177885 GO:0071479 cellular response to ionizing radiation GRB2 
ENSG00000177885 GO:0031295 T cell costimulation GRB2 
ENSG00000177885 GO:0008543 fibroblast growth factor receptor signaling 
pathway 
GRB2 
ENSG00000177885 GO:0048011 nerve growth factor receptor signaling 
pathway 
GRB2 
ENSG00000177885 GO:0060670 branching involved in embryonic placenta 
morphogenesis 
GRB2 
ENSG00000177885 GO:0042059 negative regulation of epidermal growth 
factor receptor signaling pathway 
GRB2 
ENSG00000177885 GO:0044419 interspecies interaction between organisms GRB2 
ENSG00000177885 GO:0030838 positive regulation of actin filament 
polymerization 
GRB2 
ENSG00000177885 GO:0016020 membrane GRB2 
ENSG00000177885 GO:0005634 nucleus GRB2 
ENSG00000177885 GO:0005737 cytoplasm GRB2 
ENSG00000177885 GO:0005829 cytosol GRB2 
ENSG00000177885 GO:0005794 Golgi apparatus GRB2 
ENSG00000177885 GO:0005768 endosome GRB2 
ENSG00000177885 GO:0043234 protein complex GRB2 
ENSG00000177885 GO:0012506 vesicle membrane GRB2 
ENSG00000177885 GO:0005886 plasma membrane GRB2 
ENSG00000177885 GO:0005515 protein binding GRB2 
ENSG00000177885 GO:0005154 epidermal growth factor receptor binding GRB2 
ENSG00000177885 GO:0019904 protein domain specific binding GRB2 
ENSG00000177885 GO:0019903 protein phosphatase binding GRB2 
ENSG00000177885 GO:0005070 SH3/SH2 adaptor activity GRB2 
ENSG00000177885 GO:0001784 phosphotyrosine binding GRB2 
ENSG00000177885 GO:0046875 ephrin receptor binding GRB2 
ENSG00000177885 GO:0051219 phosphoprotein binding GRB2 
ENSG00000177885 GO:0043560 insulin receptor substrate binding GRB2 
ENSG00000177885 GO:0005168 neurotrophin TRKA receptor binding GRB2 
ENSG00000163041 GO:0006334 nucleosome assembly H3F3A 
ENSG00000163041 GO:0007596 blood coagulation H3F3A 
ENSG00000163041 GO:0005634 nucleus H3F3A 
ENSG00000163041 GO:0005576 extracellular region H3F3A 
ENSG00000163041 GO:0005694 chromosome H3F3A 
ENSG00000163041 GO:0000786 nucleosome H3F3A 
ENSG00000163041 GO:0005654 nucleoplasm H3F3A 
ENSG00000163041 GO:0003677 DNA binding H3F3A 
ENSG00000132475 GO:0006334 nucleosome assembly H3F3B 
ENSG00000132475 GO:0007596 blood coagulation H3F3B 
ENSG00000132475 GO:0005634 nucleus H3F3B 
ENSG00000132475 GO:0005576 extracellular region H3F3B 
ENSG00000132475 GO:0005694 chromosome H3F3B 
ENSG00000132475 GO:0000786 nucleosome H3F3B 
ENSG00000132475 GO:0005654 nucleoplasm H3F3B 
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ENSG00000132475 GO:0003677 DNA binding H3F3B 
ENSG00000101323 GO:0006979 response to oxidative stress HAO1 
ENSG00000101323 GO:0055114 oxidation-reduction process HAO1 
ENSG00000101323 GO:0044281 small molecule metabolic process HAO1 
ENSG00000101323 GO:0034641 cellular nitrogen compound metabolic 
process 
HAO1 
ENSG00000101323 GO:0006537 glutamate biosynthetic process HAO1 
ENSG00000101323 GO:0001561 fatty acid alpha-oxidation HAO1 
ENSG00000101323 GO:0046487 glyoxylate metabolic process HAO1 
ENSG00000101323 GO:0046296 glycolate catabolic process HAO1 
ENSG00000101323 GO:0005777 peroxisome HAO1 
ENSG00000101323 GO:0005782 peroxisomal matrix HAO1 
ENSG00000101323 GO:0016491 oxidoreductase activity HAO1 
ENSG00000101323 GO:0010181 FMN binding HAO1 
ENSG00000101323 GO:0016638 oxidoreductase activity, acting on the CH-
NH2 group of donors 
HAO1 
ENSG00000101323 GO:0003973 (S)-2-hydroxy-acid oxidase activity HAO1 
ENSG00000101323 GO:0052852 very-long-chain-(S)-2-hydroxy-acid oxidase 
activity 
HAO1 
ENSG00000101323 GO:0052853 long-chain-(S)-2-hydroxy-long-chain-acid 
oxidase activity 
HAO1 
ENSG00000101323 GO:0052854 medium-chain-(S)-2-hydroxy-acid oxidase 
activity 
HAO1 
ENSG00000101323 GO:0008891 glycolate oxidase activity HAO1 
ENSG00000101323 GO:0047969 glyoxylate oxidase activity HAO1 
ENSG00000101323 GO:0015930 glutamate synthase activity HAO1 
ENSG00000119285 GO:0006364 rRNA processing HEATR1 
ENSG00000119285 GO:0005634 nucleus HEATR1 
ENSG00000119285 GO:0005730 nucleolus HEATR1 
ENSG00000119285 GO:0030529 ribonucleoprotein complex HEATR1 
ENSG00000119285 GO:0005488 binding HEATR1 
ENSG00000176387 GO:0008152 metabolic process HSD11B2 
ENSG00000176387 GO:0042493 response to drug HSD11B2 
ENSG00000176387 GO:0032868 response to insulin stimulus HSD11B2 
ENSG00000176387 GO:0007565 female pregnancy HSD11B2 
ENSG00000176387 GO:0001666 response to hypoxia HSD11B2 
ENSG00000176387 GO:0051384 response to glucocorticoid stimulus HSD11B2 
ENSG00000176387 GO:0032094 response to food HSD11B2 
ENSG00000176387 GO:0048545 response to steroid hormone stimulus HSD11B2 
ENSG00000176387 GO:0006704 glucocorticoid biosynthetic process HSD11B2 
ENSG00000176387 GO:0002017 regulation of blood volume by renal 
aldosterone 
HSD11B2 
ENSG00000176387 GO:0055114 oxidation-reduction process HSD11B2 
ENSG00000176387 GO:0006950 response to stress HSD11B2 
ENSG00000176387 GO:0008211 glucocorticoid metabolic process HSD11B2 
ENSG00000176387 GO:0005737 cytoplasm HSD11B2 
ENSG00000176387 GO:0005783 endoplasmic reticulum HSD11B2 
ENSG00000176387 GO:0005792 microsome HSD11B2 
ENSG00000176387 GO:0016491 oxidoreductase activity HSD11B2 
ENSG00000176387 GO:0051287 NAD binding HSD11B2 
ENSG00000176387 GO:0005496 steroid binding HSD11B2 
ENSG00000176387 GO:0003845 11-beta-hydroxysteroid dehydrogenase 
[NAD(P)] activity 
HSD11B2 
ENSG00000134049 GO:0042981 regulation of apoptotic process IER3IP1 
ENSG00000134049 GO:0016020 membrane IER3IP1 
ENSG00000134049 GO:0016021 integral to membrane IER3IP1 
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ENSG00000134049 GO:0005783 endoplasmic reticulum IER3IP1 
ENSG00000134049 GO:0005789 endoplasmic reticulum membrane IER3IP1 
ENSG00000134049 GO:0005794 Golgi apparatus IER3IP1 
ENSG00000027697 GO:0007165 signal transduction IFNGR1 
ENSG00000027697 GO:0009615 response to virus IFNGR1 
ENSG00000027697 GO:0019221 cytokine-mediated signaling pathway IFNGR1 
ENSG00000027697 GO:0060333 interferon-gamma-mediated signaling 
pathway 
IFNGR1 
ENSG00000027697 GO:0060334 regulation of interferon-gamma-mediated 
signaling pathway 
IFNGR1 
ENSG00000027697 GO:0016020 membrane IFNGR1 
ENSG00000027697 GO:0005886 plasma membrane IFNGR1 
ENSG00000027697 GO:0005887 integral to plasma membrane IFNGR1 
ENSG00000027697 GO:0004872 receptor activity IFNGR1 
ENSG00000027697 GO:0019955 cytokine binding IFNGR1 
ENSG00000027697 GO:0004906 interferon-gamma receptor activity IFNGR1 
ENSG00000115590 GO:0006955 immune response IL1R2 
ENSG00000115590 GO:0016021 integral to membrane IL1R2 
ENSG00000115590 GO:0005886 plasma membrane IL1R2 
ENSG00000115590 GO:0005576 extracellular region IL1R2 
ENSG00000115590 GO:0004872 receptor activity IL1R2 
ENSG00000115590 GO:0005515 protein binding IL1R2 
ENSG00000115590 GO:0004908 interleukin-1 receptor activity IL1R2 
ENSG00000115590 GO:0004910 interleukin-1, Type II, blocking receptor 
activity 
IL1R2 
ENSG00000164675 GO:0001669 acrosomal vesicle IQUB 
ENSG00000164675 GO:0009434 microtubule-based flagellum IQUB 
ENSG00000164675 GO:0005515 protein binding IQUB 
ENSG00000140968 GO:0000122 negative regulation of transcription from RNA 
polymerase II promoter 
IRF8 
ENSG00000140968 GO:0045893 positive regulation of transcription, DNA-
dependent 
IRF8 
ENSG00000140968 GO:0006955 immune response IRF8 
ENSG00000140968 GO:0006355 regulation of transcription, DNA-dependent IRF8 
ENSG00000140968 GO:0042742 defense response to bacterium IRF8 
ENSG00000140968 GO:0071222 cellular response to lipopolysaccharide IRF8 
ENSG00000140968 GO:0019221 cytokine-mediated signaling pathway IRF8 
ENSG00000140968 GO:0032729 positive regulation of interferon-gamma 
production 
IRF8 
ENSG00000140968 GO:0044130 negative regulation of growth of symbiont in 
host 
IRF8 
ENSG00000140968 GO:0006909 phagocytosis IRF8 
ENSG00000140968 GO:0042832 defense response to protozoan IRF8 
ENSG00000140968 GO:0032735 positive regulation of interleukin-12 
production 
IRF8 
ENSG00000140968 GO:0030099 myeloid cell differentiation IRF8 
ENSG00000140968 GO:0060333 interferon-gamma-mediated signaling 
pathway 
IRF8 
ENSG00000140968 GO:0060337 type I interferon-mediated signaling pathway IRF8 
ENSG00000140968 GO:0009617 response to bacterium IRF8 
ENSG00000140968 GO:0005634 nucleus IRF8 
ENSG00000140968 GO:0005829 cytosol IRF8 
ENSG00000140968 GO:0003700 sequence-specific DNA binding transcription 
factor activity 
IRF8 
ENSG00000140968 GO:0003705 sequence-specific distal enhancer binding 
RNA polymerase II transcription factor 
activity 
IRF8 
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ENSG00000140968 GO:0000975 regulatory region DNA binding IRF8 
ENSG00000140968 GO:0003677 DNA binding IRF8 
ENSG00000140968 GO:0005515 protein binding IRF8 
ENSG00000175329 GO:0006355 regulation of transcription, DNA-dependent ISX 
ENSG00000175329 GO:0005634 nucleus ISX 
ENSG00000175329 GO:0003700 sequence-specific DNA binding transcription 
factor activity 
ISX 
ENSG00000175329 GO:0043565 sequence-specific DNA binding ISX 
ENSG00000144668 GO:0007155 cell adhesion ITGA9 
ENSG00000144668 GO:0007229 integrin-mediated signaling pathway ITGA9 
ENSG00000144668 GO:0016020 membrane ITGA9 
ENSG00000144668 GO:0016021 integral to membrane ITGA9 
ENSG00000144668 GO:0008305 integrin complex ITGA9 
ENSG00000144668 GO:0004872 receptor activity ITGA9 
ENSG00000144668 GO:0007411 axon guidance ITGA9 
ENSG00000144668 GO:0042060 wound healing ITGA9 
ENSG00000144668 GO:0030593 neutrophil chemotaxis ITGA9 
ENSG00000144668 GO:0005886 plasma membrane ITGA9 
ENSG00000144668 GO:0005624 membrane fraction ITGA9 
ENSG00000144668 GO:0034679 alpha9-beta1 integrin complex ITGA9 
ENSG00000144668 GO:0009925 basal plasma membrane ITGA9 
ENSG00000144668 GO:0043236 laminin binding ITGA9 
ENSG00000144668 GO:0005518 collagen binding ITGA9 
ENSG00000144668 GO:0005515 protein binding ITGA9 
ENSG00000113263 GO:0035556 intracellular signal transduction ITK 
ENSG00000113263 GO:0050852 T cell receptor signaling pathway ITK 
ENSG00000113263 GO:0007202 activation of phospholipase C activity ITK 
ENSG00000113263 GO:0001865 NK T cell differentiation ITK 
ENSG00000113263 GO:0002250 adaptive immune response ITK 
ENSG00000113263 GO:0032609 interferon-gamma production ITK 
ENSG00000113263 GO:0032633 interleukin-4 production ITK 
ENSG00000113263 GO:0005829 cytosol ITK 
ENSG00000113263 GO:0007165 signal transduction ITK 
ENSG00000113263 GO:0001816 cytokine production ITK 
ENSG00000113263 GO:0006468 protein phosphorylation ITK 
ENSG00000113263 GO:0006968 cellular defense response ITK 
ENSG00000113263 GO:0042110 T cell activation ITK 
ENSG00000113263 GO:0005737 cytoplasm ITK 
ENSG00000113263 GO:0000166 nucleotide binding ITK 
ENSG00000113263 GO:0005515 protein binding ITK 
ENSG00000113263 GO:0005524 ATP binding ITK 
ENSG00000113263 GO:0005543 phospholipid binding ITK 
ENSG00000113263 GO:0046872 metal ion binding ITK 
ENSG00000113263 GO:0004672 protein kinase activity ITK 
ENSG00000113263 GO:0004713 protein tyrosine kinase activity ITK 
ENSG00000113263 GO:0004715 non-membrane spanning protein tyrosine 
kinase activity 
ITK 
ENSG00000184408 GO:0006811 ion transport KCND2 
ENSG00000184408 GO:0006813 potassium ion transport KCND2 
ENSG00000184408 GO:0055085 transmembrane transport KCND2 
ENSG00000184408 GO:0051291 protein heterooligomerization KCND2 
ENSG00000184408 GO:0007268 synaptic transmission KCND2 
ENSG00000184408 GO:0001508 regulation of action potential KCND2 
ENSG00000184408 GO:0071805 potassium ion transmembrane transport KCND2 
ENSG00000184408 GO:0016020 membrane KCND2 
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ENSG00000184408 GO:0005886 plasma membrane KCND2 
ENSG00000184408 GO:0042995 cell projection KCND2 
ENSG00000184408 GO:0008076 voltage-gated potassium channel complex KCND2 
ENSG00000184408 GO:0009986 cell surface KCND2 
ENSG00000184408 GO:0043025 neuronal cell body KCND2 
ENSG00000184408 GO:0019717 synaptosome KCND2 
ENSG00000184408 GO:0014069 postsynaptic density KCND2 
ENSG00000184408 GO:0043197 dendritic spine KCND2 
ENSG00000184408 GO:0030425 dendrite KCND2 
ENSG00000184408 GO:0005887 integral to plasma membrane KCND2 
ENSG00000184408 GO:0005216 ion channel activity KCND2 
ENSG00000184408 GO:0005515 protein binding KCND2 
ENSG00000184408 GO:0005249 voltage-gated potassium channel activity KCND2 
ENSG00000184408 GO:0046872 metal ion binding KCND2 
ENSG00000184408 GO:0046982 protein heterodimerization activity KCND2 
ENSG00000184408 GO:0005244 voltage-gated ion channel activity KCND2 
ENSG00000184408 GO:0005250 A-type (transient outward) potassium 
channel activity 
KCND2 
ENSG00000184408 GO:0005267 potassium channel activity KCND2 
ENSG00000135750 GO:0006811 ion transport KCNK1 
ENSG00000135750 GO:0006813 potassium ion transport KCNK1 
ENSG00000135750 GO:0035094 response to nicotine KCNK1 
ENSG00000135750 GO:0007268 synaptic transmission KCNK1 
ENSG00000135750 GO:0071805 potassium ion transmembrane transport KCNK1 
ENSG00000135750 GO:0016020 membrane KCNK1 
ENSG00000135750 GO:0016021 integral to membrane KCNK1 
ENSG00000135750 GO:0005737 cytoplasm KCNK1 
ENSG00000135750 GO:0005886 plasma membrane KCNK1 
ENSG00000135750 GO:0008076 voltage-gated potassium channel complex KCNK1 
ENSG00000135750 GO:0005768 endosome KCNK1 
ENSG00000135750 GO:0031526 brush border membrane KCNK1 
ENSG00000135750 GO:0016324 apical plasma membrane KCNK1 
ENSG00000135750 GO:0005242 inward rectifier potassium channel activity KCNK1 
ENSG00000135750 GO:0005244 voltage-gated ion channel activity KCNK1 
ENSG00000135750 GO:0005267 potassium channel activity KCNK1 
ENSG00000135750 GO:0005216 ion channel activity KCNK1 
ENSG00000156113 GO:0006811 ion transport KCNMA1 
ENSG00000156113 GO:0006813 potassium ion transport KCNMA1 
ENSG00000156113 GO:0055085 transmembrane transport KCNMA1 
ENSG00000156113 GO:0016020 membrane KCNMA1 
ENSG00000156113 GO:0016021 integral to membrane KCNMA1 
ENSG00000156113 GO:0008076 voltage-gated potassium channel complex KCNMA1 
ENSG00000156113 GO:0000166 nucleotide binding KCNMA1 
ENSG00000156113 GO:0005216 ion channel activity KCNMA1 
ENSG00000156113 GO:0005249 voltage-gated potassium channel activity KCNMA1 
ENSG00000156113 GO:0060072 large conductance calcium-activated 
potassium channel activity 
KCNMA1 
ENSG00000156113 GO:0015269 calcium-activated potassium channel activity KCNMA1 
ENSG00000156113 GO:0043065 positive regulation of apoptotic process KCNMA1 
ENSG00000156113 GO:0007268 synaptic transmission KCNMA1 
ENSG00000156113 GO:0006970 response to osmotic stress KCNMA1 
ENSG00000156113 GO:0071805 potassium ion transmembrane transport KCNMA1 
ENSG00000156113 GO:0001666 response to hypoxia KCNMA1 
ENSG00000156113 GO:0007596 blood coagulation KCNMA1 
ENSG00000156113 GO:0042391 regulation of membrane potential KCNMA1 
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ENSG00000156113 GO:0051592 response to calcium ion KCNMA1 
ENSG00000156113 GO:0060083 smooth muscle contraction involved in 
micturition 
KCNMA1 
ENSG00000156113 GO:0045794 negative regulation of cell volume KCNMA1 
ENSG00000156113 GO:0034465 response to carbon monoxide KCNMA1 
ENSG00000156113 GO:0030007 cellular potassium ion homeostasis KCNMA1 
ENSG00000156113 GO:0060073 micturition KCNMA1 
ENSG00000156113 GO:0005886 plasma membrane KCNMA1 
ENSG00000156113 GO:0016324 apical plasma membrane KCNMA1 
ENSG00000156113 GO:0005901 caveola KCNMA1 
ENSG00000156113 GO:0005515 protein binding KCNMA1 
ENSG00000156113 GO:0046872 metal ion binding KCNMA1 
ENSG00000156113 GO:0003779 actin binding KCNMA1 
ENSG00000156113 GO:0005244 voltage-gated ion channel activity KCNMA1 
ENSG00000156113 GO:0005267 potassium channel activity KCNMA1 
ENSG00000156113 GO:0060087 relaxation of vascular smooth muscle KCNMA1 
ENSG00000156113 GO:0060082 eye blink reflex KCNMA1 
ENSG00000156113 GO:0032344 regulation of aldosterone metabolic process KCNMA1 
ENSG00000156113 GO:0042311 vasodilation KCNMA1 
ENSG00000156113 GO:0042491 auditory receptor cell differentiation KCNMA1 
ENSG00000156113 GO:0046541 saliva secretion KCNMA1 
ENSG00000156113 GO:0045475 locomotor rhythm KCNMA1 
ENSG00000156113 GO:0019228 regulation of action potential in neuron KCNMA1 
ENSG00000156113 GO:0048469 cell maturation KCNMA1 
ENSG00000156113 GO:0007623 circadian rhythm KCNMA1 
ENSG00000156113 GO:0050885 neuromuscular process controlling balance KCNMA1 
ENSG00000156113 GO:0007605 sensory perception of sound KCNMA1 
ENSG00000156113 GO:0007628 adult walking behavior KCNMA1 
ENSG00000156113 GO:0051260 protein homooligomerization KCNMA1 
ENSG00000156113 GO:0044444 cytoplasmic part KCNMA1 
ENSG00000156113 GO:0043195 terminal button KCNMA1 
ENSG00000156113 GO:0045211 postsynaptic membrane KCNMA1 
ENSG00000156113 GO:0009897 external side of plasma membrane KCNMA1 
ENSG00000156113 GO:0005783 endoplasmic reticulum KCNMA1 
ENSG00000197993 GO:0006508 proteolysis KEL 
ENSG00000197993 GO:0042310 vasoconstriction KEL 
ENSG00000197993 GO:0016021 integral to membrane KEL 
ENSG00000197993 GO:0005886 plasma membrane KEL 
ENSG00000197993 GO:0004222 metalloendopeptidase activity KEL 
ENSG00000197993 GO:0005515 protein binding KEL 
ENSG00000197993 GO:0046872 metal ion binding KEL 
ENSG00000197993 GO:0008233 peptidase activity KEL 
ENSG00000197993 GO:0008237 metallopeptidase activity KEL 
ENSG00000260040 GO:0006508 proteolysis KEL 
ENSG00000260040 GO:0042310 vasoconstriction KEL 
ENSG00000260040 GO:0016021 integral to membrane KEL 
ENSG00000260040 GO:0005886 plasma membrane KEL 
ENSG00000260040 GO:0004222 metalloendopeptidase activity KEL 
ENSG00000260040 GO:0005515 protein binding KEL 
ENSG00000260040 GO:0046872 metal ion binding KEL 
ENSG00000260040 GO:0008233 peptidase activity KEL 
ENSG00000260040 GO:0008237 metallopeptidase activity KEL 
ENSG00000149571 GO:0030097 hemopoiesis KIRREL3 
ENSG00000149571 GO:0016020 membrane KIRREL3 
ENSG00000149571 GO:0016021 integral to membrane KIRREL3 
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ENSG00000149571 GO:0005886 plasma membrane KIRREL3 
ENSG00000149571 GO:0005576 extracellular region KIRREL3 
ENSG00000149571 GO:0030424 axon KIRREL3 
ENSG00000149571 GO:0043198 dendritic shaft KIRREL3 
ENSG00000149571 GO:0005515 protein binding KIRREL3 
ENSG00000049130 GO:0007155 cell adhesion KITLG 
ENSG00000049130 GO:0016020 membrane KITLG 
ENSG00000049130 GO:0005173 stem cell factor receptor binding KITLG 
ENSG00000049130 GO:0008283 cell proliferation KITLG 
ENSG00000049130 GO:0008284 positive regulation of cell proliferation KITLG 
ENSG00000049130 GO:0007165 signal transduction KITLG 
ENSG00000049130 GO:0043066 negative regulation of apoptotic process KITLG 
ENSG00000049130 GO:0008584 male gonad development KITLG 
ENSG00000049130 GO:0030097 hemopoiesis KITLG 
ENSG00000049130 GO:0001541 ovarian follicle development KITLG 
ENSG00000049130 GO:0001755 neural crest cell migration KITLG 
ENSG00000049130 GO:0050731 positive regulation of peptidyl-tyrosine 
phosphorylation 
KITLG 
ENSG00000049130 GO:0045740 positive regulation of DNA replication KITLG 
ENSG00000049130 GO:0035162 embryonic hemopoiesis KITLG 
ENSG00000049130 GO:0033026 negative regulation of mast cell apoptosis KITLG 
ENSG00000049130 GO:0070668 positive regulation of mast cell proliferation KITLG 
ENSG00000049130 GO:0046579 positive regulation of Ras protein signal 
transduction 
KITLG 
ENSG00000049130 GO:0035234 germ cell programmed cell death KITLG 
ENSG00000049130 GO:0045636 positive regulation of melanocyte 
differentiation 
KITLG 
ENSG00000049130 GO:0002763 positive regulation of myeloid leukocyte 
differentiation 
KITLG 
ENSG00000049130 GO:0016021 integral to membrane KITLG 
ENSG00000049130 GO:0005737 cytoplasm KITLG 
ENSG00000049130 GO:0005886 plasma membrane KITLG 
ENSG00000049130 GO:0005576 extracellular region KITLG 
ENSG00000049130 GO:0005615 extracellular space KITLG 
ENSG00000049130 GO:0005856 cytoskeleton KITLG 
ENSG00000049130 GO:0005515 protein binding KITLG 
ENSG00000049130 GO:0008083 growth factor activity KITLG 
ENSG00000049130 GO:0005125 cytokine activity KITLG 
ENSG00000116977 GO:0005529 sugar binding LGALS8 
ENSG00000116977 GO:0005737 cytoplasm LGALS8 
ENSG00000116977 GO:0005615 extracellular space LGALS8 
ENSG00000072201 GO:0005515 protein binding LNX1 
ENSG00000072201 GO:0051260 protein homooligomerization LNX1 
ENSG00000072201 GO:0042787 protein ubiquitination involved in ubiquitin-
dependent protein catabolic process 
LNX1 
ENSG00000072201 GO:0006511 ubiquitin-dependent protein catabolic 
process 
LNX1 
ENSG00000072201 GO:0005737 cytoplasm LNX1 
ENSG00000072201 GO:0008270 zinc ion binding LNX1 
ENSG00000072201 GO:0016874 ligase activity LNX1 
ENSG00000072201 GO:0046872 metal ion binding LNX1 
ENSG00000072201 GO:0004842 ubiquitin-protein ligase activity LNX1 
ENSG00000072201 GO:0030165 PDZ domain binding LNX1 
ENSG00000081479 GO:0008283 cell proliferation LRP2 
ENSG00000081479 GO:0044281 small molecule metabolic process LRP2 
ENSG00000081479 GO:0031100 organ regeneration LRP2 
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ENSG00000081479 GO:0006629 lipid metabolic process LRP2 
ENSG00000081479 GO:0016197 endosome transport LRP2 
ENSG00000081479 GO:0042493 response to drug LRP2 
ENSG00000081479 GO:0006486 protein glycosylation LRP2 
ENSG00000081479 GO:0007568 aging LRP2 
ENSG00000081479 GO:0006897 endocytosis LRP2 
ENSG00000081479 GO:0032526 response to retinoic acid LRP2 
ENSG00000081479 GO:0006898 receptor-mediated endocytosis LRP2 
ENSG00000081479 GO:0030900 forebrain development LRP2 
ENSG00000081479 GO:0010165 response to X-ray LRP2 
ENSG00000081479 GO:0033280 response to vitamin D LRP2 
ENSG00000081479 GO:0042359 vitamin D metabolic process LRP2 
ENSG00000081479 GO:0045056 transcytosis LRP2 
ENSG00000081479 GO:0046879 hormone secretion LRP2 
ENSG00000081479 GO:0008202 steroid metabolic process LRP2 
ENSG00000081479 GO:0006766 vitamin metabolic process LRP2 
ENSG00000081479 GO:0020028 hemoglobin import LRP2 
ENSG00000081479 GO:0042953 lipoprotein transport LRP2 
ENSG00000081479 GO:0016021 integral to membrane LRP2 
ENSG00000081479 GO:0005737 cytoplasm LRP2 
ENSG00000081479 GO:0005886 plasma membrane LRP2 
ENSG00000081479 GO:0005783 endoplasmic reticulum LRP2 
ENSG00000081479 GO:0005624 membrane fraction LRP2 
ENSG00000081479 GO:0005794 Golgi apparatus LRP2 
ENSG00000081479 GO:0005615 extracellular space LRP2 
ENSG00000081479 GO:0005764 lysosome LRP2 
ENSG00000081479 GO:0005768 endosome LRP2 
ENSG00000081479 GO:0031526 brush border membrane LRP2 
ENSG00000081479 GO:0016324 apical plasma membrane LRP2 
ENSG00000081479 GO:0005905 coated pit LRP2 
ENSG00000081479 GO:0030139 endocytic vesicle LRP2 
ENSG00000081479 GO:0005903 brush border LRP2 
ENSG00000081479 GO:0045177 apical part of cell LRP2 
ENSG00000081479 GO:0004872 receptor activity LRP2 
ENSG00000081479 GO:0005515 protein binding LRP2 
ENSG00000081479 GO:0005509 calcium ion binding LRP2 
ENSG00000081479 GO:0017124 SH3 domain binding LRP2 
ENSG00000081479 GO:0030492 hemoglobin binding LRP2 
ENSG00000081479 GO:0042954 lipoprotein transporter activity LRP2 
ENSG00000081479 GO:0016020 membrane LRP2 
ENSG00000183742 GO:0051781 positive regulation of cell division MACC1 
ENSG00000183742 GO:0006355 regulation of transcription, DNA-dependent MACC1 
ENSG00000183742 GO:0005634 nucleus MACC1 
ENSG00000183742 GO:0005737 cytoplasm MACC1 
ENSG00000183742 GO:0008083 growth factor activity MACC1 
ENSG00000172264 GO:0007420 brain development MACROD2 
ENSG00000172264 GO:0042278 purine nucleoside metabolic process MACROD2 
ENSG00000172264 GO:0005575 cellular_component MACROD2 
ENSG00000172264 GO:0019213 deacetylase activity MACROD2 
ENSG00000155130 GO:0044281 small molecule metabolic process MARCKS 
ENSG00000155130 GO:0050796 regulation of insulin secretion MARCKS 
ENSG00000155130 GO:0006112 energy reserve metabolic process MARCKS 
ENSG00000155130 GO:0005737 cytoplasm MARCKS 
ENSG00000155130 GO:0005886 plasma membrane MARCKS 
ENSG00000155130 GO:0005938 cell cortex MARCKS 
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ENSG00000155130 GO:0005813 centrosome MARCKS 
ENSG00000155130 GO:0015629 actin cytoskeleton MARCKS 
ENSG00000155130 GO:0042585 germinal vesicle MARCKS 
ENSG00000155130 GO:0016020 membrane MARCKS 
ENSG00000155130 GO:0005516 calmodulin binding MARCKS 
ENSG00000155130 GO:0051015 actin filament binding MARCKS 
ENSG00000155130 GO:0005080 protein kinase C binding MARCKS 
ENSG00000155130 GO:0005515 protein binding MARCKS 
ENSG00000171444 GO:0016055 Wnt receptor signaling pathway MCC 
ENSG00000171444 GO:0007165 signal transduction MCC 
ENSG00000171444 GO:0090090 negative regulation of canonical Wnt 
receptor signaling pathway 
MCC 
ENSG00000171444 GO:0050680 negative regulation of epithelial cell 
proliferation 
MCC 
ENSG00000171444 GO:0010633 negative regulation of epithelial cell migration MCC 
ENSG00000171444 GO:0005634 nucleus MCC 
ENSG00000171444 GO:0005737 cytoplasm MCC 
ENSG00000171444 GO:0005886 plasma membrane MCC 
ENSG00000171444 GO:0004872 receptor activity MCC 
ENSG00000171444 GO:0005515 protein binding MCC 
ENSG00000171444 GO:0005509 calcium ion binding MCC 
ENSG00000145794 GO:0007155 cell adhesion MEGF10 
ENSG00000145794 GO:0043654 recognition of apoptotic cell MEGF10 
ENSG00000145794 GO:0006909 phagocytosis MEGF10 
ENSG00000145794 GO:0016021 integral to membrane MEGF10 
ENSG00000145794 GO:0005886 plasma membrane MEGF10 
ENSG00000145794 GO:0042995 cell projection MEGF10 
ENSG00000145794 GO:0001891 phagocytic cup MEGF10 
ENSG00000145794 GO:0016323 basolateral plasma membrane MEGF10 
ENSG00000145794 GO:0005515 protein binding MEGF10 
ENSG00000133808 GO:0005737 cytoplasm MICALCL 
ENSG00000133808 GO:0051019 mitogen-activated protein kinase binding MICALCL 
ENSG00000133808 GO:0008150 biological_process MICALCL 
ENSG00000133808 GO:0007275 multicellular organismal development MICALCL 
ENSG00000133808 GO:0030154 cell differentiation MICALCL 
ENSG00000133808 GO:0007283 spermatogenesis MICALCL 
ENSG00000182208 GO:0005634 nucleus MOB2 
ENSG00000182208 GO:0005737 cytoplasm MOB2 
ENSG00000182208 GO:0048471 perinuclear region of cytoplasm MOB2 
ENSG00000182208 GO:0005730 nucleolus MOB2 
ENSG00000182208 GO:0046872 metal ion binding MOB2 
ENSG00000129422 GO:0005634 nucleus MTUS1 
ENSG00000129422 GO:0005737 cytoplasm MTUS1 
ENSG00000129422 GO:0005886 plasma membrane MTUS1 
ENSG00000129422 GO:0005739 mitochondrion MTUS1 
ENSG00000129422 GO:0005794 Golgi apparatus MTUS1 
ENSG00000129422 GO:0005856 cytoskeleton MTUS1 
ENSG00000129422 GO:0005819 spindle MTUS1 
ENSG00000129422 GO:0005874 microtubule MTUS1 
ENSG00000129422 GO:0005815 microtubule organizing center MTUS1 
ENSG00000172915 GO:0008104 protein localization NBEA 
ENSG00000172915 GO:0005886 plasma membrane NBEA 
ENSG00000172915 GO:0005829 cytosol NBEA 
ENSG00000172915 GO:0005802 trans-Golgi network NBEA 
ENSG00000172915 GO:0012505 endomembrane system NBEA 
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ENSG00000172915 GO:0005488 binding NBEA 
ENSG00000172915 GO:0005515 protein binding NBEA 
ENSG00000172915 GO:0019901 protein kinase binding NBEA 
ENSG00000172915 GO:0005737 cytoplasm NBEA 
ENSG00000162599 GO:0006355 regulation of transcription, DNA-dependent NFIA 
ENSG00000162599 GO:0006260 DNA replication NFIA 
ENSG00000162599 GO:0005634 nucleus NFIA 
ENSG00000162599 GO:0005622 intracellular NFIA 
ENSG00000162599 GO:0030054 cell junction NFIA 
ENSG00000162599 GO:0003677 DNA binding NFIA 
ENSG00000162599 GO:0003700 sequence-specific DNA binding transcription 
factor activity 
NFIA 
ENSG00000162599 GO:0045944 positive regulation of transcription from RNA 
polymerase II promoter 
NFIA 
ENSG00000162599 GO:0014070 response to organic cyclic compound NFIA 
ENSG00000162599 GO:0019079 viral genome replication NFIA 
ENSG00000162599 GO:0008134 transcription factor binding NFIA 
ENSG00000162599 GO:0045893 positive regulation of transcription, DNA-
dependent 
NFIA 
ENSG00000162599 GO:0005515 protein binding NFIA 
ENSG00000187258 GO:0007186 G-protein coupled receptor signaling 
pathway 
NPSR1 
ENSG00000187258 GO:0016021 integral to membrane NPSR1 
ENSG00000187258 GO:0005737 cytoplasm NPSR1 
ENSG00000187258 GO:0005886 plasma membrane NPSR1 
ENSG00000187258 GO:0004872 receptor activity NPSR1 
ENSG00000187258 GO:0004871 signal transducer activity NPSR1 
ENSG00000187258 GO:0004930 G-protein coupled receptor activity NPSR1 
ENSG00000187258 GO:0005000 vasopressin receptor activity NPSR1 
ENSG00000122585 GO:0008283 cell proliferation NPY 
ENSG00000122585 GO:0007218 neuropeptide signaling pathway NPY 
ENSG00000122585 GO:0007586 digestion NPY 
ENSG00000122585 GO:0007631 feeding behavior NPY 
ENSG00000122585 GO:0006816 calcium ion transport NPY 
ENSG00000122585 GO:0021987 cerebral cortex development NPY 
ENSG00000122585 GO:0007610 behavior NPY 
ENSG00000122585 GO:0007268 synaptic transmission NPY 
ENSG00000122585 GO:0045776 negative regulation of blood pressure NPY 
ENSG00000122585 GO:0006928 cellular component movement NPY 
ENSG00000122585 GO:0050909 sensory perception of taste NPY 
ENSG00000122585 GO:0031175 neuron projection development NPY 
ENSG00000122585 GO:0021954 central nervous system neuron development NPY 
ENSG00000122585 GO:0008343 adult feeding behavior NPY 
ENSG00000122585 GO:0032100 positive regulation of appetite NPY 
ENSG00000122585 GO:0008015 blood circulation NPY 
ENSG00000122585 GO:0007187 G-protein signaling, coupled to cyclic 
nucleotide second messenger 
NPY 
ENSG00000122585 GO:0008217 regulation of blood pressure NPY 
ENSG00000122585 GO:0005576 extracellular region NPY 
ENSG00000122585 GO:0005615 extracellular space NPY 
ENSG00000122585 GO:0005623 cell NPY 
ENSG00000122585 GO:0005102 receptor binding NPY 
ENSG00000122585 GO:0004930 G-protein coupled receptor activity NPY 
ENSG00000122585 GO:0005179 hormone activity NPY 
ENSG00000122585 GO:0001664 G-protein coupled receptor binding NPY 
ENSG00000122585 GO:0005246 calcium channel regulator activity NPY 
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ENSG00000122585 GO:0005184 neuropeptide hormone activity NPY 
ENSG00000122585 GO:0031841 neuropeptide Y receptor binding NPY 
ENSG00000197893 GO:0008270 zinc ion binding NRAP 
ENSG00000197893 GO:0008150 biological_process NRAP 
ENSG00000197893 GO:0005916 fascia adherens NRAP 
ENSG00000197893 GO:0005927 muscle tendon junction NRAP 
ENSG00000197893 GO:0030016 myofibril NRAP 
ENSG00000197893 GO:0046872 metal ion binding NRAP 
ENSG00000197893 GO:0003779 actin binding NRAP 
ENSG00000197893 GO:0051371 muscle alpha-actinin binding NRAP 
ENSG00000197893 GO:0017166 vinculin binding NRAP 
ENSG00000197893 GO:0005515 protein binding NRAP 
ENSG00000021645 GO:0005515 protein binding NRXN3 
ENSG00000021645 GO:0007155 cell adhesion NRXN3 
ENSG00000021645 GO:0001525 angiogenesis NRXN3 
ENSG00000021645 GO:0016020 membrane NRXN3 
ENSG00000021645 GO:0016021 integral to membrane NRXN3 
ENSG00000021645 GO:0007411 axon guidance NRXN3 
ENSG00000021645 GO:0005887 integral to plasma membrane NRXN3 
ENSG00000021645 GO:0004872 receptor activity NRXN3 
ENSG00000021645 GO:0046872 metal ion binding NRXN3 
ENSG00000144460 
 
NYAP2 
ENSG00000180988 GO:0007186 G-protein coupled receptor signaling 
pathway 
OR52N2 
ENSG00000180988 GO:0050896 response to stimulus OR52N2 
ENSG00000180988 GO:0016021 integral to membrane OR52N2 
ENSG00000180988 GO:0005886 plasma membrane OR52N2 
ENSG00000180988 GO:0004872 receptor activity OR52N2 
ENSG00000180988 GO:0004871 signal transducer activity OR52N2 
ENSG00000180988 GO:0004930 G-protein coupled receptor activity OR52N2 
ENSG00000180988 GO:0004984 olfactory receptor activity OR52N2 
ENSG00000181074 GO:0007186 G-protein coupled receptor signaling 
pathway 
OR52N4 
ENSG00000181074 GO:0050896 response to stimulus OR52N4 
ENSG00000181074 GO:0016021 integral to membrane OR52N4 
ENSG00000181074 GO:0005886 plasma membrane OR52N4 
ENSG00000181074 GO:0004872 receptor activity OR52N4 
ENSG00000181074 GO:0004871 signal transducer activity OR52N4 
ENSG00000181074 GO:0004930 G-protein coupled receptor activity OR52N4 
ENSG00000181074 GO:0004984 olfactory receptor activity OR52N4 
ENSG00000172457 GO:0007186 G-protein coupled receptor signaling 
pathway 
OR9G4 
ENSG00000172457 GO:0050896 response to stimulus OR9G4 
ENSG00000172457 GO:0016021 integral to membrane OR9G4 
ENSG00000172457 GO:0005886 plasma membrane OR9G4 
ENSG00000172457 GO:0004872 receptor activity OR9G4 
ENSG00000172457 GO:0004871 signal transducer activity OR9G4 
ENSG00000172457 GO:0004930 G-protein coupled receptor activity OR9G4 
ENSG00000172457 GO:0004984 olfactory receptor activity OR9G4 
ENSG00000262647 GO:0007186 G-protein coupled receptor signaling 
pathway 
OR9G4 
ENSG00000262647 GO:0050896 response to stimulus OR9G4 
ENSG00000262647 GO:0016021 integral to membrane OR9G4 
ENSG00000262647 GO:0005886 plasma membrane OR9G4 
ENSG00000262647 GO:0004872 receptor activity OR9G4 
ENSG00000262647 GO:0004871 signal transducer activity OR9G4 
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ENSG00000262647 GO:0004930 G-protein coupled receptor activity OR9G4 
ENSG00000262647 GO:0004984 olfactory receptor activity OR9G4 
ENSG00000169918 GO:0006508 proteolysis OTUD7A 
ENSG00000169918 GO:0005634 nucleus OTUD7A 
ENSG00000169918 GO:0005737 cytoplasm OTUD7A 
ENSG00000169918 GO:0003677 DNA binding OTUD7A 
ENSG00000169918 GO:0008270 zinc ion binding OTUD7A 
ENSG00000169918 GO:0046872 metal ion binding OTUD7A 
ENSG00000169918 GO:0008233 peptidase activity OTUD7A 
ENSG00000169918 GO:0008234 cysteine-type peptidase activity OTUD7A 
ENSG00000134853 GO:0007275 multicellular organismal development PDGFRA 
ENSG00000134853 GO:0008284 positive regulation of cell proliferation PDGFRA 
ENSG00000134853 GO:0042475 odontogenesis of dentin-containing tooth PDGFRA 
ENSG00000134853 GO:0042060 wound healing PDGFRA 
ENSG00000134853 GO:0048839 inner ear development PDGFRA 
ENSG00000134853 GO:0018108 peptidyl-tyrosine phosphorylation PDGFRA 
ENSG00000134853 GO:0006468 protein phosphorylation PDGFRA 
ENSG00000134853 GO:0007169 transmembrane receptor protein tyrosine 
kinase signaling pathway 
PDGFRA 
ENSG00000134853 GO:0032355 response to estradiol stimulus PDGFRA 
ENSG00000134853 GO:0007204 elevation of cytosolic calcium ion 
concentration 
PDGFRA 
ENSG00000134853 GO:0048015 phosphatidylinositol-mediated signaling PDGFRA 
ENSG00000134853 GO:0030324 lung development PDGFRA 
ENSG00000134853 GO:0048146 positive regulation of fibroblast proliferation PDGFRA 
ENSG00000134853 GO:0008585 female gonad development PDGFRA 
ENSG00000134853 GO:0001701 in utero embryonic development PDGFRA 
ENSG00000134853 GO:0048705 skeletal system morphogenesis PDGFRA 
ENSG00000134853 GO:0055003 cardiac myofibril assembly PDGFRA 
ENSG00000134853 GO:0030198 extracellular matrix organization PDGFRA 
ENSG00000134853 GO:0034097 response to cytokine stimulus PDGFRA 
ENSG00000134853 GO:0070374 positive regulation of ERK1 and ERK2 
cascade 
PDGFRA 
ENSG00000134853 GO:0048704 embryonic skeletal system morphogenesis PDGFRA 
ENSG00000134853 GO:0030335 positive regulation of cell migration PDGFRA 
ENSG00000134853 GO:0048008 platelet-derived growth factor receptor 
signaling pathway 
PDGFRA 
ENSG00000134853 GO:0009725 response to hormone stimulus PDGFRA 
ENSG00000134853 GO:0001775 cell activation PDGFRA 
ENSG00000134853 GO:0071230 cellular response to amino acid stimulus PDGFRA 
ENSG00000134853 GO:0030325 adrenal gland development PDGFRA 
ENSG00000134853 GO:0046777 protein autophosphorylation PDGFRA 
ENSG00000134853 GO:0055093 response to hyperoxia PDGFRA 
ENSG00000134853 GO:0023019 signal transduction involved in regulation of 
gene expression 
PDGFRA 
ENSG00000134853 GO:0045740 positive regulation of DNA replication PDGFRA 
ENSG00000134853 GO:0010035 response to inorganic substance PDGFRA 
ENSG00000134853 GO:0060326 cell chemotaxis PDGFRA 
ENSG00000134853 GO:0048557 embryonic digestive tract morphogenesis PDGFRA 
ENSG00000134853 GO:0060021 palate development PDGFRA 
ENSG00000134853 GO:0030539 male genitalia development PDGFRA 
ENSG00000134853 GO:0010544 negative regulation of platelet activation PDGFRA 
ENSG00000134853 GO:0014068 positive regulation of phosphatidylinositol 3-
kinase cascade 
PDGFRA 
ENSG00000134853 GO:0060325 face morphogenesis PDGFRA 
ENSG00000134853 GO:0048701 embryonic cranial skeleton morphogenesis PDGFRA 
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ENSG00000134853 GO:0061298 retina vasculature development in camera-
type eye 
PDGFRA 
ENSG00000134853 GO:0033327 Leydig cell differentiation PDGFRA 
ENSG00000134853 GO:0001553 luteinization PDGFRA 
ENSG00000134853 GO:0008210 estrogen metabolic process PDGFRA 
ENSG00000134853 GO:0042063 gliogenesis PDGFRA 
ENSG00000134853 GO:0072277 metanephric glomerular capillary formation PDGFRA 
ENSG00000134853 GO:0048010 vascular endothelial growth factor receptor 
signaling pathway 
PDGFRA 
ENSG00000134853 GO:2000249 regulation of actin cytoskeleton 
reorganization 
PDGFRA 
ENSG00000134853 GO:0043552 positive regulation of phosphatidylinositol 3-
kinase activity 
PDGFRA 
ENSG00000134853 GO:0070527 platelet aggregation PDGFRA 
ENSG00000134853 GO:0010863 positive regulation of phospholipase C 
activity 
PDGFRA 
ENSG00000134853 GO:0038091 positive regulation of cell proliferation by 
VEGF-activated platelet derived growth 
factor receptor signaling pathway 
PDGFRA 
ENSG00000134853 GO:0035790 platelet-derived growth factor receptor-alpha 
signaling pathway 
PDGFRA 
ENSG00000134853 GO:0050920 regulation of chemotaxis PDGFRA 
ENSG00000134853 GO:2000739 regulation of mesenchymal stem cell 
differentiation 
PDGFRA 
ENSG00000134853 GO:0010033 response to organic substance PDGFRA 
ENSG00000134853 GO:0043627 response to estrogen stimulus PDGFRA 
ENSG00000134853 GO:0009653 anatomical structure morphogenesis PDGFRA 
ENSG00000134853 GO:0009887 organ morphogenesis PDGFRA 
ENSG00000134853 GO:0016477 cell migration PDGFRA 
ENSG00000134853 GO:0016021 integral to membrane PDGFRA 
ENSG00000134853 GO:0005634 nucleus PDGFRA 
ENSG00000134853 GO:0005737 cytoplasm PDGFRA 
ENSG00000134853 GO:0005886 plasma membrane PDGFRA 
ENSG00000134853 GO:0005887 integral to plasma membrane PDGFRA 
ENSG00000134853 GO:0031226 intrinsic to plasma membrane PDGFRA 
ENSG00000134853 GO:0004872 receptor activity PDGFRA 
ENSG00000134853 GO:0000166 nucleotide binding PDGFRA 
ENSG00000134853 GO:0042803 protein homodimerization activity PDGFRA 
ENSG00000134853 GO:0005515 protein binding PDGFRA 
ENSG00000134853 GO:0005524 ATP binding PDGFRA 
ENSG00000134853 GO:0004672 protein kinase activity PDGFRA 
ENSG00000134853 GO:0004714 transmembrane receptor protein tyrosine 
kinase activity 
PDGFRA 
ENSG00000134853 GO:0004713 protein tyrosine kinase activity PDGFRA 
ENSG00000134853 GO:0005161 platelet-derived growth factor receptor 
binding 
PDGFRA 
ENSG00000134853 GO:0043548 phosphatidylinositol 3-kinase binding PDGFRA 
ENSG00000134853 GO:0005018 platelet-derived growth factor alpha-receptor 
activity 
PDGFRA 
ENSG00000134853 GO:0048407 platelet-derived growth factor binding PDGFRA 
ENSG00000134853 GO:0005021 vascular endothelial growth factor-activated 
receptor activity 
PDGFRA 
ENSG00000134853 GO:0038085 vascular endothelial growth factor binding PDGFRA 
ENSG00000182405 
 
PGBD4 
ENSG00000079739 GO:0044281 small molecule metabolic process PGM1 
ENSG00000079739 GO:0005975 carbohydrate metabolic process PGM1 
ENSG00000079739 GO:0006006 glucose metabolic process PGM1 
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ENSG00000079739 GO:0005978 glycogen biosynthetic process PGM1 
ENSG00000079739 GO:0019255 glucose 1-phosphate metabolic process PGM1 
ENSG00000079739 GO:0019388 galactose catabolic process PGM1 
ENSG00000079739 GO:0005980 glycogen catabolic process PGM1 
ENSG00000079739 GO:0005737 cytoplasm PGM1 
ENSG00000079739 GO:0005829 cytosol PGM1 
ENSG00000079739 GO:0015629 actin cytoskeleton PGM1 
ENSG00000079739 GO:0000287 magnesium ion binding PGM1 
ENSG00000079739 GO:0016853 isomerase activity PGM1 
ENSG00000079739 GO:0004614 phosphoglucomutase activity PGM1 
ENSG00000079739 GO:0016868 intramolecular transferase activity, 
phosphotransferases 
PGM1 
ENSG00000122861 GO:0006508 proteolysis PLAU 
ENSG00000122861 GO:0005515 protein binding PLAU 
ENSG00000122861 GO:0004252 serine-type endopeptidase activity PLAU 
ENSG00000122861 GO:0007165 signal transduction PLAU 
ENSG00000122861 GO:0007566 embryo implantation PLAU 
ENSG00000122861 GO:0001525 angiogenesis PLAU 
ENSG00000122861 GO:0042730 fibrinolysis PLAU 
ENSG00000122861 GO:0001666 response to hypoxia PLAU 
ENSG00000122861 GO:0042127 regulation of cell proliferation PLAU 
ENSG00000122861 GO:0006935 chemotaxis PLAU 
ENSG00000122861 GO:0055093 response to hyperoxia PLAU 
ENSG00000122861 GO:0007596 blood coagulation PLAU 
ENSG00000122861 GO:0033628 regulation of cell adhesion mediated by 
integrin 
PLAU 
ENSG00000122861 GO:0061041 regulation of wound healing PLAU 
ENSG00000122861 GO:0043403 skeletal muscle tissue regeneration PLAU 
ENSG00000122861 GO:0010469 regulation of receptor activity PLAU 
ENSG00000122861 GO:0014910 regulation of smooth muscle cell migration PLAU 
ENSG00000122861 GO:2000097 regulation of smooth muscle cell-matrix 
adhesion 
PLAU 
ENSG00000122861 GO:0042060 wound healing PLAU 
ENSG00000122861 GO:0048514 blood vessel morphogenesis PLAU 
ENSG00000122861 GO:0014909 smooth muscle cell migration PLAU 
ENSG00000122861 GO:0005886 plasma membrane PLAU 
ENSG00000122861 GO:0005576 extracellular region PLAU 
ENSG00000122861 GO:0005615 extracellular space PLAU 
ENSG00000122861 GO:0009986 cell surface PLAU 
ENSG00000122861 GO:0008233 peptidase activity PLAU 
ENSG00000122861 GO:0016301 kinase activity PLAU 
ENSG00000100941 GO:0007155 cell adhesion PNN 
ENSG00000100941 GO:0006355 regulation of transcription, DNA-dependent PNN 
ENSG00000100941 GO:0008380 RNA splicing PNN 
ENSG00000100941 GO:0000398 nuclear mRNA splicing, via spliceosome PNN 
ENSG00000100941 GO:0005634 nucleus PNN 
ENSG00000100941 GO:0005737 cytoplasm PNN 
ENSG00000100941 GO:0005886 plasma membrane PNN 
ENSG00000100941 GO:0005882 intermediate filament PNN 
ENSG00000100941 GO:0005911 cell-cell junction PNN 
ENSG00000100941 GO:0016607 nuclear speck PNN 
ENSG00000100941 GO:0030057 desmosome PNN 
ENSG00000100941 GO:0071013 catalytic step 2 spliceosome PNN 
ENSG00000100941 GO:0003677 DNA binding PNN 
ENSG00000100941 GO:0005198 structural molecule activity PNN 
ENSG00000128567 GO:0030335 positive regulation of cell migration PODXL 
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ENSG00000128567 GO:0016477 cell migration PODXL 
ENSG00000128567 GO:0007162 negative regulation of cell adhesion PODXL 
ENSG00000128567 GO:0050900 leukocyte migration PODXL 
ENSG00000128567 GO:0022408 negative regulation of cell-cell adhesion PODXL 
ENSG00000128567 GO:0032534 regulation of microvillus assembly PODXL 
ENSG00000128567 GO:0033634 positive regulation of cell-cell adhesion 
mediated by integrin 
PODXL 
ENSG00000128567 GO:0072015 glomerular visceral epithelial cell 
development 
PODXL 
ENSG00000128567 GO:0072175 epithelial tube formation PODXL 
ENSG00000128567 GO:0005737 cytoplasm PODXL 
ENSG00000128567 GO:0005886 plasma membrane PODXL 
ENSG00000128567 GO:0005730 nucleolus PODXL 
ENSG00000128567 GO:0043231 intracellular membrane-bounded organelle PODXL 
ENSG00000128567 GO:0005813 centrosome PODXL 
ENSG00000128567 GO:0015629 actin cytoskeleton PODXL 
ENSG00000128567 GO:0001726 ruffle PODXL 
ENSG00000128567 GO:0005887 integral to plasma membrane PODXL 
ENSG00000128567 GO:0030027 lamellipodium PODXL 
ENSG00000128567 GO:0016324 apical plasma membrane PODXL 
ENSG00000128567 GO:0045121 membrane raft PODXL 
ENSG00000128567 GO:0030175 filopodium PODXL 
ENSG00000128567 GO:0031528 microvillus membrane PODXL 
ENSG00000128567 GO:0036057 slit diaphragm PODXL 
ENSG00000128567 GO:0005515 protein binding PODXL 
ENSG00000138738 GO:0045892 negative regulation of transcription, DNA-
dependent 
PRDM5 
ENSG00000138738 GO:0000278 mitotic cell cycle PRDM5 
ENSG00000138738 GO:0016568 chromatin modification PRDM5 
ENSG00000138738 GO:0051567 histone H3-K9 methylation PRDM5 
ENSG00000138738 GO:0016575 histone deacetylation PRDM5 
ENSG00000138738 GO:0005634 nucleus PRDM5 
ENSG00000138738 GO:0005622 intracellular PRDM5 
ENSG00000138738 GO:0008270 zinc ion binding PRDM5 
ENSG00000138738 GO:0005515 protein binding PRDM5 
ENSG00000138738 GO:0046872 metal ion binding PRDM5 
ENSG00000138738 GO:0043565 sequence-specific DNA binding PRDM5 
ENSG00000138738 GO:0000976 transcription regulatory region sequence-
specific DNA binding 
PRDM5 
ENSG00000138738 GO:0044212 transcription regulatory region DNA binding PRDM5 
ENSG00000138738 GO:0070491 repressing transcription factor binding PRDM5 
ENSG00000138738 GO:0003676 nucleic acid binding PRDM5 
ENSG00000164244 GO:0005794 Golgi apparatus PRRC1 
ENSG00000078328 GO:0000166 nucleotide binding RBFOX1 
ENSG00000078328 GO:0003676 nucleic acid binding RBFOX1 
ENSG00000078328 GO:0006397 mRNA processing RBFOX1 
ENSG00000078328 GO:0008380 RNA splicing RBFOX1 
ENSG00000078328 GO:0043484 regulation of RNA splicing RBFOX1 
ENSG00000078328 GO:0050658 RNA transport RBFOX1 
ENSG00000078328 GO:0005634 nucleus RBFOX1 
ENSG00000078328 GO:0005737 cytoplasm RBFOX1 
ENSG00000078328 GO:0005802 trans-Golgi network RBFOX1 
ENSG00000078328 GO:0003723 RNA binding RBFOX1 
ENSG00000078328 GO:0005515 protein binding RBFOX1 
ENSG00000078328 GO:0008022 protein C-terminus binding RBFOX1 
ENSG00000143839 GO:0006508 proteolysis REN 
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ENSG00000143839 GO:0006950 response to stress REN 
ENSG00000143839 GO:0008584 male gonad development REN 
ENSG00000143839 GO:0042493 response to drug REN 
ENSG00000143839 GO:0048469 cell maturation REN 
ENSG00000143839 GO:0051591 response to cAMP REN 
ENSG00000143839 GO:0008217 regulation of blood pressure REN 
ENSG00000143839 GO:0001822 kidney development REN 
ENSG00000143839 GO:0043408 regulation of MAPK cascade REN 
ENSG00000143839 GO:0001823 mesonephros development REN 
ENSG00000143839 GO:0009755 hormone-mediated signaling pathway REN 
ENSG00000143839 GO:0002003 angiotensin maturation REN 
ENSG00000143839 GO:0002018 renin-angiotensin regulation of aldosterone 
production 
REN 
ENSG00000143839 GO:0042756 drinking behavior REN 
ENSG00000143839 GO:0070305 response to cGMP REN 
ENSG00000143839 GO:0002016 regulation of blood volume by renin-
angiotensin 
REN 
ENSG00000143839 GO:0010033 response to organic substance REN 
ENSG00000143839 GO:0016020 membrane REN 
ENSG00000143839 GO:0005576 extracellular region REN 
ENSG00000143839 GO:0005622 intracellular REN 
ENSG00000143839 GO:0005615 extracellular space REN 
ENSG00000143839 GO:0044444 cytoplasmic part REN 
ENSG00000143839 GO:0005102 receptor binding REN 
ENSG00000143839 GO:0008233 peptidase activity REN 
ENSG00000143839 GO:0004190 aspartic-type endopeptidase activity REN 
ENSG00000143839 GO:0005159 insulin-like growth factor receptor binding REN 
ENSG00000143839 GO:0004175 endopeptidase activity REN 
ENSG00000152214 GO:0007165 signal transduction RIT2 
ENSG00000152214 GO:0007264 small GTPase mediated signal transduction RIT2 
ENSG00000152214 GO:0006886 intracellular protein transport RIT2 
ENSG00000152214 GO:0015031 protein transport RIT2 
ENSG00000152214 GO:0006913 nucleocytoplasmic transport RIT2 
ENSG00000152214 GO:0007268 synaptic transmission RIT2 
ENSG00000152214 GO:0006184 GTP catabolic process RIT2 
ENSG00000152214 GO:0048011 nerve growth factor receptor signaling 
pathway 
RIT2 
ENSG00000152214 GO:0016020 membrane RIT2 
ENSG00000152214 GO:0005886 plasma membrane RIT2 
ENSG00000152214 GO:0005622 intracellular RIT2 
ENSG00000152214 GO:0000166 nucleotide binding RIT2 
ENSG00000152214 GO:0005516 calmodulin binding RIT2 
ENSG00000152214 GO:0005525 GTP binding RIT2 
ENSG00000152214 GO:0003924 GTPase activity RIT2 
ENSG00000152214 GO:0005515 protein binding RIT2 
ENSG00000185008 GO:0007411 axon guidance ROBO2 
ENSG00000185008 GO:0001656 metanephros development ROBO2 
ENSG00000185008 GO:0030673 axolemma ROBO2 
ENSG00000185008 GO:0005515 protein binding ROBO2 
ENSG00000185008 GO:0046982 protein heterodimerization activity ROBO2 
ENSG00000185008 GO:0007275 multicellular organismal development ROBO2 
ENSG00000185008 GO:0030154 cell differentiation ROBO2 
ENSG00000185008 GO:0007420 brain development ROBO2 
ENSG00000185008 GO:0007417 central nervous system development ROBO2 
ENSG00000185008 GO:0007156 homophilic cell adhesion ROBO2 
ENSG00000185008 GO:0050772 positive regulation of axonogenesis ROBO2 
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ENSG00000185008 GO:0032870 cellular response to hormone stimulus ROBO2 
ENSG00000185008 GO:0001657 ureteric bud development ROBO2 
ENSG00000185008 GO:0031290 retinal ganglion cell axon guidance ROBO2 
ENSG00000185008 GO:0051964 negative regulation of synapse assembly ROBO2 
ENSG00000185008 GO:0021891 olfactory bulb interneuron development ROBO2 
ENSG00000185008 GO:0016199 axon midline choice point recognition ROBO2 
ENSG00000185008 GO:0061364 apoptotic process involved in luteolysis ROBO2 
ENSG00000185008 GO:0050925 negative regulation of negative chemotaxis ROBO2 
ENSG00000185008 GO:0016020 membrane ROBO2 
ENSG00000185008 GO:0016021 integral to membrane ROBO2 
ENSG00000185008 GO:0009986 cell surface ROBO2 
ENSG00000185008 GO:0042802 identical protein binding ROBO2 
ENSG00000185008 GO:0008046 axon guidance receptor activity ROBO2 
ENSG00000185008 GO:0007155 cell adhesion ROBO2 
ENSG00000143365 GO:0006355 regulation of transcription, DNA-dependent RORC 
ENSG00000143365 GO:0043401 steroid hormone mediated signaling pathway RORC 
ENSG00000143365 GO:0005634 nucleus RORC 
ENSG00000143365 GO:0003700 sequence-specific DNA binding transcription 
factor activity 
RORC 
ENSG00000143365 GO:0008270 zinc ion binding RORC 
ENSG00000143365 GO:0043565 sequence-specific DNA binding RORC 
ENSG00000143365 GO:0003707 steroid hormone receptor activity RORC 
ENSG00000143365 GO:0007275 multicellular organismal development RORC 
ENSG00000143365 GO:0030154 cell differentiation RORC 
ENSG00000143365 GO:0006468 protein phosphorylation RORC 
ENSG00000143365 GO:0010467 gene expression RORC 
ENSG00000143365 GO:0033077 T cell differentiation in thymus RORC 
ENSG00000143365 GO:0046632 alpha-beta T cell differentiation RORC 
ENSG00000143365 GO:0048535 lymph node development RORC 
ENSG00000143365 GO:0030522 intracellular receptor mediated signaling 
pathway 
RORC 
ENSG00000143365 GO:0048537 mucosal-associated lymphoid tissue 
development 
RORC 
ENSG00000143365 GO:0072539 T-helper 17 cell differentiation RORC 
ENSG00000143365 GO:0005654 nucleoplasm RORC 
ENSG00000143365 GO:0004872 receptor activity RORC 
ENSG00000143365 GO:0003677 DNA binding RORC 
ENSG00000143365 GO:0046872 metal ion binding RORC 
ENSG00000143365 GO:0004879 ligand-activated sequence-specific DNA 
binding RNA polymerase II transcription 
factor activity 
RORC 
ENSG00000143365 GO:0005515 protein binding RORC 
ENSG00000114993 GO:0007165 signal transduction RTKN 
ENSG00000114993 GO:0005622 intracellular RTKN 
ENSG00000114993 GO:0005515 protein binding RTKN 
ENSG00000114993 GO:0005543 phospholipid binding RTKN 
ENSG00000114993 GO:0006915 apoptotic process RTKN 
ENSG00000114993 GO:0007266 Rho protein signal transduction RTKN 
ENSG00000114993 GO:0045767 regulation of anti-apoptosis RTKN 
ENSG00000114993 GO:0005575 cellular_component RTKN 
ENSG00000114993 GO:0000166 nucleotide binding RTKN 
ENSG00000114993 GO:0005525 GTP binding RTKN 
ENSG00000114993 GO:0005095 GTPase inhibitor activity RTKN 
ENSG00000114993 GO:0017049 GTP-Rho binding RTKN 
ENSG00000114993 GO:0017048 Rho GTPase binding RTKN 
ENSG00000075223 GO:0007411 axon guidance SEMA3C 
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ENSG00000075223 GO:0030154 cell differentiation SEMA3C 
ENSG00000075223 GO:0007507 heart development SEMA3C 
ENSG00000075223 GO:0001974 blood vessel remodeling SEMA3C 
ENSG00000075223 GO:0006955 immune response SEMA3C 
ENSG00000075223 GO:0009791 post-embryonic development SEMA3C 
ENSG00000075223 GO:0042493 response to drug SEMA3C 
ENSG00000075223 GO:0001756 somitogenesis SEMA3C 
ENSG00000075223 GO:0001755 neural crest cell migration SEMA3C 
ENSG00000075223 GO:0003151 outflow tract morphogenesis SEMA3C 
ENSG00000075223 GO:0021915 neural tube development SEMA3C 
ENSG00000075223 GO:0060666 dichotomous subdivision of terminal units 
involved in salivary gland branching 
SEMA3C 
ENSG00000075223 GO:0003215 cardiac right ventricle morphogenesis SEMA3C 
ENSG00000075223 GO:0060174 limb bud formation SEMA3C 
ENSG00000075223 GO:0003350 pulmonary myocardium development SEMA3C 
ENSG00000075223 GO:0016020 membrane SEMA3C 
ENSG00000075223 GO:0005576 extracellular region SEMA3C 
ENSG00000075223 GO:0005615 extracellular space SEMA3C 
ENSG00000075223 GO:0004872 receptor activity SEMA3C 
ENSG00000075223 GO:0005515 protein binding SEMA3C 
ENSG00000075223 GO:0030215 semaphorin receptor binding SEMA3C 
ENSG00000075223 GO:0007275 multicellular organismal development SEMA3C 
ENSG00000155926 GO:0005737 cytoplasm SLA 
ENSG00000155926 GO:0005768 endosome SLA 
ENSG00000155926 GO:0005515 protein binding SLA 
ENSG00000155926 GO:0005070 SH3/SH2 adaptor activity SLA 
ENSG00000109171 GO:0031116 positive regulation of microtubule 
polymerization 
SLAIN2 
ENSG00000109171 GO:0031122 cytoplasmic microtubule organization SLAIN2 
ENSG00000109171 GO:0007020 microtubule nucleation SLAIN2 
ENSG00000109171 GO:0031113 regulation of microtubule polymerization SLAIN2 
ENSG00000109171 GO:0005737 cytoplasm SLAIN2 
ENSG00000109171 GO:0005813 centrosome SLAIN2 
ENSG00000109171 GO:0015630 microtubule cytoskeleton SLAIN2 
ENSG00000109171 GO:0035371 microtubule plus end SLAIN2 
ENSG00000109171 GO:0005515 protein binding SLAIN2 
ENSG00000124140 GO:0006811 ion transport SLC12A5 
ENSG00000124140 GO:0006813 potassium ion transport SLC12A5 
ENSG00000124140 GO:0055085 transmembrane transport SLC12A5 
ENSG00000124140 GO:0035264 multicellular organism growth SLC12A5 
ENSG00000124140 GO:0006810 transport SLC12A5 
ENSG00000124140 GO:0042493 response to drug SLC12A5 
ENSG00000124140 GO:0007268 synaptic transmission SLC12A5 
ENSG00000124140 GO:0006821 chloride transport SLC12A5 
ENSG00000124140 GO:0007612 learning SLC12A5 
ENSG00000124140 GO:0051452 intracellular pH reduction SLC12A5 
ENSG00000124140 GO:0015696 ammonium transport SLC12A5 
ENSG00000124140 GO:0040040 thermosensory behavior SLC12A5 
ENSG00000124140 GO:0016020 membrane SLC12A5 
ENSG00000124140 GO:0016021 integral to membrane SLC12A5 
ENSG00000124140 GO:0005886 plasma membrane SLC12A5 
ENSG00000124140 GO:0043204 perikaryon SLC12A5 
ENSG00000124140 GO:0032590 dendrite membrane SLC12A5 
ENSG00000124140 GO:0015379 potassium:chloride symporter activity SLC12A5 
ENSG00000124140 GO:0051739 ammonia transmembrane transporter activity SLC12A5 
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ENSG00000124140 GO:0015377 cation:chloride symporter activity SLC12A5 
ENSG00000124140 GO:0006873 cellular ion homeostasis SLC12A5 
ENSG00000124140 GO:0015293 symporter activity SLC12A5 
ENSG00000124140 GO:0005515 protein binding SLC12A5 
ENSG00000109762 GO:0007154 cell communication SNX25 
ENSG00000109762 GO:0015031 protein transport SNX25 
ENSG00000109762 GO:0038032 termination of G-protein coupled receptor 
signaling pathway 
SNX25 
ENSG00000109762 GO:0016020 membrane SNX25 
ENSG00000109762 GO:0005768 endosome SNX25 
ENSG00000109762 GO:0010008 endosome membrane SNX25 
ENSG00000109762 GO:0005515 protein binding SNX25 
ENSG00000109762 GO:0035091 phosphatidylinositol binding SNX25 
ENSG00000130340 GO:0006886 intracellular protein transport SNX9 
ENSG00000130340 GO:0007154 cell communication SNX9 
ENSG00000130340 GO:0006898 receptor-mediated endocytosis SNX9 
ENSG00000130340 GO:0043547 positive regulation of GTPase activity SNX9 
ENSG00000130340 GO:0032461 positive regulation of protein oligomerization SNX9 
ENSG00000130340 GO:0060988 lipid tube assembly SNX9 
ENSG00000130340 GO:0005737 cytoplasm SNX9 
ENSG00000130340 GO:0005886 plasma membrane SNX9 
ENSG00000130340 GO:0005622 intracellular SNX9 
ENSG00000130340 GO:0005794 Golgi apparatus SNX9 
ENSG00000130340 GO:0005802 trans-Golgi network SNX9 
ENSG00000130340 GO:0001726 ruffle SNX9 
ENSG00000130340 GO:0030659 cytoplasmic vesicle membrane SNX9 
ENSG00000130340 GO:0005625 soluble fraction SNX9 
ENSG00000130340 GO:0005792 microsome SNX9 
ENSG00000130340 GO:0031234 extrinsic to internal side of plasma 
membrane 
SNX9 
ENSG00000130340 GO:0016023 cytoplasmic membrane-bounded vesicle SNX9 
ENSG00000130340 GO:0030136 clathrin-coated vesicle SNX9 
ENSG00000130340 GO:0042803 protein homodimerization activity SNX9 
ENSG00000130340 GO:0005515 protein binding SNX9 
ENSG00000130340 GO:0008289 lipid binding SNX9 
ENSG00000130340 GO:0031625 ubiquitin protein ligase binding SNX9 
ENSG00000130340 GO:0035091 phosphatidylinositol binding SNX9 
ENSG00000130340 GO:0005545 1-phosphatidylinositol binding SNX9 
ENSG00000124766 GO:0008285 negative regulation of cell proliferation SOX4 
ENSG00000124766 GO:0045893 positive regulation of transcription, DNA-
dependent 
SOX4 
ENSG00000124766 GO:0008284 positive regulation of cell proliferation SOX4 
ENSG00000124766 GO:0043066 negative regulation of apoptotic process SOX4 
ENSG00000124766 GO:0045944 positive regulation of transcription from RNA 
polymerase II promoter 
SOX4 
ENSG00000124766 GO:0001501 skeletal system development SOX4 
ENSG00000124766 GO:0007507 heart development SOX4 
ENSG00000124766 GO:0006355 regulation of transcription, DNA-dependent SOX4 
ENSG00000124766 GO:0048485 sympathetic nervous system development SOX4 
ENSG00000124766 GO:0060070 canonical Wnt receptor signaling pathway SOX4 
ENSG00000124766 GO:0006977 DNA damage response, signal transduction 
by p53 class mediator resulting in cell cycle 
arrest 
SOX4 
ENSG00000124766 GO:0021522 spinal cord motor neuron differentiation SOX4 
ENSG00000124766 GO:0043065 positive regulation of apoptotic process SOX4 
ENSG00000124766 GO:0042593 glucose homeostasis SOX4 
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ENSG00000124766 GO:0035019 somatic stem cell maintenance SOX4 
ENSG00000124766 GO:0031647 regulation of protein stability SOX4 
ENSG00000124766 GO:0032024 positive regulation of insulin secretion SOX4 
ENSG00000124766 GO:0090263 positive regulation of canonical Wnt receptor 
signaling pathway 
SOX4 
ENSG00000124766 GO:0045727 positive regulation of translation SOX4 
ENSG00000124766 GO:0060548 negative regulation of cell death SOX4 
ENSG00000124766 GO:0060412 ventricular septum morphogenesis SOX4 
ENSG00000124766 GO:0001841 neural tube formation SOX4 
ENSG00000124766 GO:0050821 protein stabilization SOX4 
ENSG00000124766 GO:0031018 endocrine pancreas development SOX4 
ENSG00000124766 GO:0071333 cellular response to glucose stimulus SOX4 
ENSG00000124766 GO:0021510 spinal cord development SOX4 
ENSG00000124766 GO:0030217 T cell differentiation SOX4 
ENSG00000124766 GO:0014009 glial cell proliferation SOX4 
ENSG00000124766 GO:0030177 positive regulation of Wnt receptor signaling 
pathway 
SOX4 
ENSG00000124766 GO:0031397 negative regulation of protein ubiquitination SOX4 
ENSG00000124766 GO:0003289 atrial septum primum morphogenesis SOX4 
ENSG00000124766 GO:0003215 cardiac right ventricle morphogenesis SOX4 
ENSG00000124766 GO:0003211 cardiac ventricle formation SOX4 
ENSG00000124766 GO:0060174 limb bud formation SOX4 
ENSG00000124766 GO:0002328 pro-B cell differentiation SOX4 
ENSG00000124766 GO:0003357 noradrenergic neuron differentiation SOX4 
ENSG00000124766 GO:0042769 DNA damage response, detection of DNA 
damage 
SOX4 
ENSG00000124766 GO:0046826 negative regulation of protein export from 
nucleus 
SOX4 
ENSG00000124766 GO:0003183 mitral valve morphogenesis SOX4 
ENSG00000124766 GO:0021782 glial cell development SOX4 
ENSG00000124766 GO:0060563 neuroepithelial cell differentiation SOX4 
ENSG00000124766 GO:0060993 kidney morphogenesis SOX4 
ENSG00000124766 GO:0035910 ascending aorta morphogenesis SOX4 
ENSG00000124766 GO:2000761 positive regulation of N-terminal peptidyl-
lysine acetylation 
SOX4 
ENSG00000124766 GO:0005634 nucleus SOX4 
ENSG00000124766 GO:0005737 cytoplasm SOX4 
ENSG00000124766 GO:0005739 mitochondrion SOX4 
ENSG00000124766 GO:0003677 DNA binding SOX4 
ENSG00000124766 GO:0003700 sequence-specific DNA binding transcription 
factor activity 
SOX4 
ENSG00000124766 GO:0005515 protein binding SOX4 
ENSG00000124766 GO:0000976 transcription regulatory region sequence-
specific DNA binding 
SOX4 
ENSG00000124766 GO:0001077 RNA polymerase II core promoter proximal 
region sequence-specific DNA binding 
transcription factor activity involved in 
positive regulation of transcription 
SOX4 
ENSG00000124766 GO:0001105 RNA polymerase II transcription coactivator 
activity 
SOX4 
ENSG00000124766 GO:0001046 core promoter sequence-specific DNA 
binding 
SOX4 
ENSG00000124766 GO:0001071 nucleic acid binding transcription factor 
activity 
SOX4 
ENSG00000144681 GO:0007165 signal transduction STAC 
ENSG00000144681 GO:0035556 intracellular signal transduction STAC 
ENSG00000144681 GO:0034605 cellular response to heat STAC 
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ENSG00000144681 GO:0005737 cytoplasm STAC 
ENSG00000144681 GO:0005625 soluble fraction STAC 
ENSG00000144681 GO:0005515 protein binding STAC 
ENSG00000144681 GO:0046872 metal ion binding STAC 
ENSG00000198648 GO:0006468 protein phosphorylation STK39 
ENSG00000198648 GO:0006950 response to stress STK39 
ENSG00000198648 GO:0023014 signal transduction by phosphorylation STK39 
ENSG00000198648 GO:0043268 positive regulation of potassium ion transport STK39 
ENSG00000198648 GO:0005634 nucleus STK39 
ENSG00000198648 GO:0005737 cytoplasm STK39 
ENSG00000198648 GO:0005624 membrane fraction STK39 
ENSG00000198648 GO:0005856 cytoskeleton STK39 
ENSG00000198648 GO:0016323 basolateral plasma membrane STK39 
ENSG00000198648 GO:0016324 apical plasma membrane STK39 
ENSG00000198648 GO:0000166 nucleotide binding STK39 
ENSG00000198648 GO:0005524 ATP binding STK39 
ENSG00000198648 GO:0004672 protein kinase activity STK39 
ENSG00000198648 GO:0004713 protein tyrosine kinase activity STK39 
ENSG00000198648 GO:0019901 protein kinase binding STK39 
ENSG00000198648 GO:0004702 receptor signaling protein serine/threonine 
kinase activity 
STK39 
ENSG00000198648 GO:0004674 protein serine/threonine kinase activity STK39 
ENSG00000198648 GO:0005515 protein binding STK39 
ENSG00000104435 GO:0030182 neuron differentiation STMN2 
ENSG00000104435 GO:0031115 negative regulation of microtubule 
polymerization 
STMN2 
ENSG00000104435 GO:0035556 intracellular signal transduction STMN2 
ENSG00000104435 GO:0007026 negative regulation of microtubule 
depolymerization 
STMN2 
ENSG00000104435 GO:0010977 negative regulation of neuron projection 
development 
STMN2 
ENSG00000104435 GO:0010976 positive regulation of neuron projection 
development 
STMN2 
ENSG00000104435 GO:0031117 positive regulation of microtubule 
depolymerization 
STMN2 
ENSG00000104435 GO:0016020 membrane STMN2 
ENSG00000104435 GO:0005737 cytoplasm STMN2 
ENSG00000104435 GO:0030424 axon STMN2 
ENSG00000104435 GO:0042995 cell projection STMN2 
ENSG00000104435 GO:0005624 membrane fraction STMN2 
ENSG00000104435 GO:0048471 perinuclear region of cytoplasm STMN2 
ENSG00000104435 GO:0005794 Golgi apparatus STMN2 
ENSG00000104435 GO:0005768 endosome STMN2 
ENSG00000104435 GO:0030426 growth cone STMN2 
ENSG00000104435 GO:0005625 soluble fraction STMN2 
ENSG00000104435 GO:0031982 vesicle STMN2 
ENSG00000104435 GO:0005515 protein binding STMN2 
ENSG00000164458 GO:0007275 multicellular organismal development T 
ENSG00000164458 GO:0008284 positive regulation of cell proliferation T 
ENSG00000164458 GO:0007165 signal transduction T 
ENSG00000164458 GO:0006355 regulation of transcription, DNA-dependent T 
ENSG00000164458 GO:0048706 embryonic skeletal system development T 
ENSG00000164458 GO:0060070 canonical Wnt receptor signaling pathway T 
ENSG00000164458 GO:0003007 heart morphogenesis T 
ENSG00000164458 GO:0055007 cardiac muscle cell differentiation T 
ENSG00000164458 GO:0001843 neural tube closure T 
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ENSG00000164458 GO:0001756 somitogenesis T 
ENSG00000164458 GO:0030903 notochord development T 
ENSG00000164458 GO:0023019 signal transduction involved in regulation of 
gene expression 
T 
ENSG00000164458 GO:0060395 SMAD protein signal transduction T 
ENSG00000164458 GO:0007341 penetration of zona pellucida T 
ENSG00000164458 GO:0030509 BMP signaling pathway T 
ENSG00000164458 GO:0001570 vasculogenesis T 
ENSG00000164458 GO:0007498 mesoderm development T 
ENSG00000164458 GO:0008595 anterior/posterior axis specification, embryo T 
ENSG00000164458 GO:0060349 bone morphogenesis T 
ENSG00000164458 GO:0035121 tail morphogenesis T 
ENSG00000164458 GO:0090009 primitive streak formation T 
ENSG00000164458 GO:0001839 neural plate morphogenesis T 
ENSG00000164458 GO:0003257 positive regulation of transcription from RNA 
polymerase II promoter involved in 
myocardial precursor cell differentiation 
T 
ENSG00000164458 GO:0007509 mesoderm migration involved in gastrulation T 
ENSG00000164458 GO:0022414 reproductive process T 
ENSG00000164458 GO:0061371 determination of heart left/right asymmetry T 
ENSG00000164458 GO:0009653 anatomical structure morphogenesis T 
ENSG00000164458 GO:0006366 transcription from RNA polymerase II 
promoter 
T 
ENSG00000164458 GO:0009952 anterior/posterior pattern specification T 
ENSG00000164458 GO:0006357 regulation of transcription from RNA 
polymerase II promoter 
T 
ENSG00000164458 GO:0045944 positive regulation of transcription from RNA 
polymerase II promoter 
T 
ENSG00000164458 GO:0005634 nucleus T 
ENSG00000164458 GO:0005737 cytoplasm T 
ENSG00000164458 GO:0000790 nuclear chromatin T 
ENSG00000164458 GO:0000785 chromatin T 
ENSG00000164458 GO:0003677 DNA binding T 
ENSG00000164458 GO:0003700 sequence-specific DNA binding transcription 
factor activity 
T 
ENSG00000164458 GO:0043565 sequence-specific DNA binding T 
ENSG00000164458 GO:0000980 RNA polymerase II distal enhancer 
sequence-specific DNA binding 
T 
ENSG00000164458 GO:0003705 sequence-specific distal enhancer binding 
RNA polymerase II transcription factor 
activity 
T 
ENSG00000164458 GO:0000981 sequence-specific DNA binding RNA 
polymerase II transcription factor activity 
T 
ENSG00000164458 GO:0005515 protein binding T 
ENSG00000135605 GO:0035556 intracellular signal transduction TEC 
ENSG00000135605 GO:0006468 protein phosphorylation TEC 
ENSG00000135605 GO:0007229 integrin-mediated signaling pathway TEC 
ENSG00000135605 GO:0007243 intracellular protein kinase cascade TEC 
ENSG00000135605 GO:0050853 B cell receptor signaling pathway TEC 
ENSG00000135605 GO:0010543 regulation of platelet activation TEC 
ENSG00000135605 GO:0005737 cytoplasm TEC 
ENSG00000135605 GO:0005886 plasma membrane TEC 
ENSG00000135605 GO:0005829 cytosol TEC 
ENSG00000135605 GO:0005856 cytoskeleton TEC 
ENSG00000135605 GO:0000166 nucleotide binding TEC 
ENSG00000135605 GO:0005515 protein binding TEC 
ENSG00000135605 GO:0005524 ATP binding TEC 
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ENSG00000135605 GO:0005543 phospholipid binding TEC 
ENSG00000135605 GO:0046872 metal ion binding TEC 
ENSG00000135605 GO:0004672 protein kinase activity TEC 
ENSG00000135605 GO:0004713 protein tyrosine kinase activity TEC 
ENSG00000135605 GO:0004715 non-membrane spanning protein tyrosine 
kinase activity 
TEC 
ENSG00000159445 GO:0048015 phosphatidylinositol-mediated signaling THEM4 
ENSG00000159445 GO:0008286 insulin receptor signaling pathway THEM4 
ENSG00000159445 GO:0007173 epidermal growth factor receptor signaling 
pathway 
THEM4 
ENSG00000159445 GO:0008543 fibroblast growth factor receptor signaling 
pathway 
THEM4 
ENSG00000159445 GO:0048011 nerve growth factor receptor signaling 
pathway 
THEM4 
ENSG00000159445 GO:0005737 cytoplasm THEM4 
ENSG00000159445 GO:0005886 plasma membrane THEM4 
ENSG00000159445 GO:0042995 cell projection THEM4 
ENSG00000159445 GO:0005739 mitochondrion THEM4 
ENSG00000159445 GO:0005829 cytosol THEM4 
ENSG00000159445 GO:0043231 intracellular membrane-bounded organelle THEM4 
ENSG00000159445 GO:0032587 ruffle membrane THEM4 
ENSG00000139173 GO:0008150 biological_process TMEM117 
ENSG00000139173 GO:0016020 membrane TMEM117 
ENSG00000139173 GO:0016021 integral to membrane TMEM117 
ENSG00000139173 GO:0005783 endoplasmic reticulum TMEM117 
ENSG00000139173 GO:0003674 molecular_function TMEM117 
ENSG00000173452 GO:0016020 membrane TMEM196 
ENSG00000173452 GO:0016021 integral to membrane TMEM196 
ENSG00000106025 GO:0007166 cell surface receptor signaling pathway TSPAN12 
ENSG00000106025 GO:0045765 regulation of angiogenesis TSPAN12 
ENSG00000106025 GO:0010842 retina layer formation TSPAN12 
ENSG00000106025 GO:0016020 membrane TSPAN12 
ENSG00000106025 GO:0016021 integral to membrane TSPAN12 
ENSG00000106025 GO:0005886 plasma membrane TSPAN12 
ENSG00000106025 GO:0005624 membrane fraction TSPAN12 
ENSG00000106025 GO:0005887 integral to plasma membrane TSPAN12 
ENSG00000186153 GO:0055114 oxidation-reduction process WWOX 
ENSG00000186153 GO:0045944 positive regulation of transcription from RNA 
polymerase II promoter 
WWOX 
ENSG00000186153 GO:0008152 metabolic process WWOX 
ENSG00000186153 GO:0006917 induction of apoptosis WWOX 
ENSG00000186153 GO:0071560 cellular response to transforming growth 
factor beta stimulus 
WWOX 
ENSG00000186153 GO:0048705 skeletal system morphogenesis WWOX 
ENSG00000186153 GO:0043065 positive regulation of apoptotic process WWOX 
ENSG00000186153 GO:0030178 negative regulation of Wnt receptor signaling 
pathway 
WWOX 
ENSG00000186153 GO:0008202 steroid metabolic process WWOX 
ENSG00000186153 GO:0001649 osteoblast differentiation WWOX 
ENSG00000186153 GO:0005634 nucleus WWOX 
ENSG00000186153 GO:0005737 cytoplasm WWOX 
ENSG00000186153 GO:0005886 plasma membrane WWOX 
ENSG00000186153 GO:0005739 mitochondrion WWOX 
ENSG00000186153 GO:0005829 cytosol WWOX 
ENSG00000186153 GO:0005794 Golgi apparatus WWOX 
ENSG00000186153 GO:0005902 microvillus WWOX 
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ENSG00000186153 GO:0000166 nucleotide binding WWOX 
ENSG00000186153 GO:0005515 protein binding WWOX 
ENSG00000186153 GO:0016491 oxidoreductase activity WWOX 
ENSG00000186153 GO:0050662 coenzyme binding WWOX 
ENSG00000186153 GO:0019899 enzyme binding WWOX 
ENSG00000186153 GO:0046983 protein dimerization activity WWOX 
ENSG00000186153 GO:0048037 cofactor binding WWOX 
ENSG00000108039 GO:0006508 proteolysis XPNPEP1 
ENSG00000108039 GO:0009987 cellular process XPNPEP1 
ENSG00000108039 GO:0010815 bradykinin catabolic process XPNPEP1 
ENSG00000108039 GO:0005737 cytoplasm XPNPEP1 
ENSG00000108039 GO:0005829 cytosol XPNPEP1 
ENSG00000108039 GO:0042803 protein homodimerization activity XPNPEP1 
ENSG00000108039 GO:0016787 hydrolase activity XPNPEP1 
ENSG00000108039 GO:0046872 metal ion binding XPNPEP1 
ENSG00000108039 GO:0008233 peptidase activity XPNPEP1 
ENSG00000108039 GO:0004177 aminopeptidase activity XPNPEP1 
ENSG00000108039 GO:0008237 metallopeptidase activity XPNPEP1 
ENSG00000108039 GO:0030145 manganese ion binding XPNPEP1 
ENSG00000108039 GO:0070006 metalloaminopeptidase activity XPNPEP1 
ENSG00000170396 GO:0005622 intracellular ZNF804A 
ENSG00000170396 GO:0008270 zinc ion binding ZNF804A 
ENSG00000170396 GO:0046872 metal ion binding ZNF804A 
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Appendix III- WTCCC Phase II Ulcerative Colitis Cases, 
NBS Controls and 1958BC Controls- Quality Control and 
Data manipulation prior to analysis flowchart. 
 
STEP 1- SENDING A REQUEST TO DOWNLOAD THE DATA & A REQUEST FOR ENCRYPTION KEYS TO BE SENT 
VIA POST 
 
 
 
 
STEP 2- DECRYPTION OF DATA 
Download Gpg4Win from http://www.gnupg.org 
 
 
 
 
STEP 3- CONVERT FROM OXSTAT TO PLINK FORMAT 
Download the static executable version of GTOOL from http://www.well.ox.ac.uk/~cfreeman/software/gwas/gtool.html. The 
GTOOL program will be fed the extracted CHIAMO.gen file (genotype calls) for each Chromosome and the sample file. 
 
 
 
 
STEP 4 CONVERTING ‘NN’ FOR ‘00’ FOR MISSING GENOTYPES 
 
 
 
 
STEP 5- DATA FILTERING ACCORDING TO PROVIDED SNP EXCLUSION LISTS 
STEP 5- PERFORMING QUALITY CONTROL USING R SNPRelate AND GDSFMT PACKAGEs 
 
This step was carried out using the instructions  here: http://corearray.sourceforge.net/tutorials/SNPRelate/ 
Analysis carried out: Principal Components Analysis, IBD Method of Moments, and Multi-Dimensional Scaling Analysis 
using IBS distances. QC filtering used for snps: MAF cut-off = 0.05, missing rate cut-off= 0.05 and ld.threshold = 0.2 
 
 
 
 
STEP 6- REMOVING OUTLIERS EMERGING FROM STEP 5 
 
 
 
 
STEP 6- CONVERT PLINK TO LDU MAPPING APPROACH FORMAT 
 
 
 
 
STEP 6- CONCATENATION OF CONTROL AND CASES DATASETS 
 
 
 
 
STEP 7- DATA GENOTYPE ENCODING (AA, AT… 11, 12, …) 
 
Encoding all the genotypes (A A, A C…) into number codes (1 1, 1 2 …). This step also produces details about the MAF  
(details_genotype.txt) and Hardy Weinberg (fulldetails_genotype.txt- also for MAF)- 
 
 
 
 
STEP 8- DATA SNP FILTERING - IN HOUSE QC 
 
Filtering of  the SNPs which fail HWE test, have a low MAF (<0.03), HWE Chi Squared test >10 or have a percentage 
missingness > 20%. this information is provided in a file in the previous step (fulldetails_* file). This is only done on the id 
filtered concatenated controls dataset. 
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Appendix IV- NIDDK Ulcerative Colitis Cases and 
Crohn’s Disease Controls- Quality Control and Data 
manipulation prior to analysis flowchart. 
 
 
STEP 1- DOWNLOAD THE DATA 
 
 
 
STEP 2- DECRYPTION OF DATA 
Using SRA Toolkit http://www.ncbi.nlm.nih.gov/Traces/sra/sra.cgi?view=toolkit_doc&f=std 
 
 
 
 
STEP 3 RECODING PLINK FILES IN PED AND MAP AND  SPLITTING THESE GENOME WIDE FILES BY 
CHROMOSOME 
 
 
 
 
 
STEP 4 CONVERTING ‘NN’ FOR ‘00’ FOR MISSING GENOTYPES AND ASSIGNING AFFECTION STATUS 
 
 
 
 
 
STEP 5- PERFORMING QUALITY CONTROL USING R SNPRelate AND GDSFMT PACKAGEs 
 
This step was carried out using the instructions  here: http://corearray.sourceforge.net/tutorials/SNPRelate/ 
Analysis carried out: Principal Components Analysis, IBD Method of Moments, and Multi-Dimensional Scaling Analysis 
using IBS distances. QC filtering used for snps: MAF cut-off = 0.05, missing rate cut-off= 0.05 and ld.threshold = 0.2 (see 
pages 22-66 of Lab book Volume 3) 
 
 
 
 
 
STEP 6- REMOVING OUTLIERS EMERGING FROM STEP 5 
 
This is done by identifying the individual ID in the previous step and writing a perl program, which identifies the ID in the 
dataset and removes it- still to be optimised! 
 
 
 
 
 
STEP 7- CONVERT PLINK TO LDU MAPPING APPROACH FORMAT 
 
 
 
 
 
STEP 8- GENOTYPE ENCODING 
 
Encoding all the genotypes (A A, A C…) into number codes (1 1, 1 2 …). This step also produces details about the MAF  
(details_genotype.txt) and Hardy Weinberg (fulldetails_genotype.txt- also for MAF)- 
 
 
 
 
 
STEP 9- - DATA SNP FILTERING -IN HOUSE QC 
 
Filtering of  the SNPs which fail HWE test, have a low MAF (<0.03), HWE Chi Squared test >10 or have a percentage 
missingness > 20%. this information is provided in a file in the previous step (fulldetails_* file). This is only done on the id 
filtered concatenated controls dataset.
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Appendix V- BioMart Analysis from the Ulcerative Colitis 
GWAS described in Chapter IV 
Ensembl Gene ID GO Term 
Accession 
GO Term Name Associated 
Gene Name 
ENSG00000006071  GO:0005524 ATP binding ABCC8  
ENSG00000006071  GO:0005886 plasma membrane ABCC8  
ENSG00000006071  GO:0005975 carbohydrate metabolic process ABCC8  
ENSG00000006071  GO:0006112 energy reserve metabolic process ABCC8  
ENSG00000006071  GO:0006200 ATP catabolic process ABCC8  
ENSG00000006071  GO:0006810 transport ABCC8  
ENSG00000006071  GO:0006813 potassium ion transport ABCC8  
ENSG00000006071  GO:0007165 signal transduction ABCC8  
ENSG00000006071  GO:0007268 synaptic transmission ABCC8  
ENSG00000006071  GO:0008076 voltage-gated potassium channel 
complex 
ABCC8  
ENSG00000006071  GO:0008281 sulfonylurea receptor activity ABCC8  
ENSG00000006071  GO:0015079 potassium ion transmembrane 
transporter activity 
ABCC8  
ENSG00000006071  GO:0016021 integral component of membrane ABCC8  
ENSG00000006071  GO:0016887 ATPase activity ABCC8  
ENSG00000006071  GO:0042626 ATPase activity, coupled to 
transmembrane movement of 
substances 
ABCC8  
ENSG00000006071  GO:0044281 small molecule metabolic process ABCC8  
ENSG00000006071  GO:0044325 ion channel binding ABCC8  
ENSG00000006071  GO:0050796 regulation of insulin secretion ABCC8  
ENSG00000006071  GO:0055085 transmembrane transport ABCC8  
ENSG00000006071  GO:0071805 potassium ion transmembrane 
transport 
ABCC8  
ENSG00000138075  GO:0005515 protein binding ABCG5  
ENSG00000138075  GO:0005524 ATP binding ABCG5  
ENSG00000138075  GO:0005886 plasma membrane ABCG5  
ENSG00000138075  GO:0006200 ATP catabolic process ABCG5  
ENSG00000138075  GO:0007584 response to nutrient ABCG5  
ENSG00000138075  GO:0007588 excretion ABCG5  
ENSG00000138075  GO:0010212 response to ionizing radiation ABCG5  
ENSG00000138075  GO:0010949 negative regulation of intestinal 
phytosterol absorption 
ABCG5  
ENSG00000138075  GO:0015918 sterol transport ABCG5  
ENSG00000138075  GO:0016020 membrane ABCG5  
ENSG00000138075  GO:0016021 integral component of membrane ABCG5  
ENSG00000138075  GO:0016324 apical plasma membrane ABCG5  
ENSG00000138075  GO:0016887 ATPase activity ABCG5  
ENSG00000138075  GO:0017127 cholesterol transporter activity ABCG5  
ENSG00000138075  GO:0030299 intestinal cholesterol absorption ABCG5  
ENSG00000138075  GO:0033344 cholesterol efflux ABCG5  
ENSG00000138075  GO:0042493 response to drug ABCG5  
ENSG00000138075  GO:0042632 cholesterol homeostasis ABCG5  
ENSG00000138075  GO:0044281 small molecule metabolic process ABCG5  
ENSG00000138075  GO:0045177 apical part of cell ABCG5  
ENSG00000138075  GO:0045796 negative regulation of intestinal 
cholesterol absorption 
ABCG5  
ENSG00000138075  GO:0046982 protein heterodimerization activity ABCG5  
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ENSG00000138075  GO:0055085 transmembrane transport ABCG5  
ENSG00000107796  GO:0005515 protein binding ACTA2  
ENSG00000107796  GO:0005524 ATP binding ACTA2  
ENSG00000107796  GO:0005615 extracellular space ACTA2  
ENSG00000107796  GO:0005737 cytoplasm ACTA2  
ENSG00000107796  GO:0005829 cytosol ACTA2  
ENSG00000107796  GO:0005856 cytoskeleton ACTA2  
ENSG00000107796  GO:0006936 muscle contraction ACTA2  
ENSG00000107796  GO:0008217 regulation of blood pressure ACTA2  
ENSG00000107796  GO:0009615 response to virus ACTA2  
ENSG00000107796  GO:0014829 vascular smooth muscle contraction ACTA2  
ENSG00000107796  GO:0015629 actin cytoskeleton ACTA2  
ENSG00000107796  GO:0019901 protein kinase binding ACTA2  
ENSG00000107796  GO:0030485 smooth muscle contractile fiber ACTA2  
ENSG00000107796  GO:0043234 protein complex ACTA2  
ENSG00000107796  GO:0072144 glomerular mesangial cell 
development 
ACTA2  
ENSG00000157985  GO:0005515 protein binding AGAP1  
ENSG00000157985  GO:0005525 GTP binding AGAP1  
ENSG00000157985  GO:0005543 phospholipid binding AGAP1  
ENSG00000157985  GO:0005622 intracellular AGAP1  
ENSG00000157985  GO:0005737 cytoplasm AGAP1  
ENSG00000157985  GO:0006184 GTP catabolic process AGAP1  
ENSG00000157985  GO:0007165 signal transduction AGAP1  
ENSG00000157985  GO:0007264 small GTPase mediated signal 
transduction 
AGAP1  
ENSG00000157985  GO:0008060 ARF GTPase activator activity AGAP1  
ENSG00000157985  GO:0008270 zinc ion binding AGAP1  
ENSG00000157985  GO:0015031 protein transport AGAP1  
ENSG00000157985  GO:0016020 membrane AGAP1  
ENSG00000157985  GO:0032312 regulation of ARF GTPase activity AGAP1  
ENSG00000157985  GO:0043547 positive regulation of GTPase activity AGAP1  
ENSG00000171094  GO:0000187 activation of MAPK activity ALK  
ENSG00000171094  GO:0004672 protein kinase activity ALK  
ENSG00000171094  GO:0004704 NF-kappaB-inducing kinase activity ALK  
ENSG00000171094  GO:0004713 protein tyrosine kinase activity ALK  
ENSG00000171094  GO:0004714 transmembrane receptor protein 
tyrosine kinase activity 
ALK  
ENSG00000171094  GO:0005515 protein binding ALK  
ENSG00000171094  GO:0005524 ATP binding ALK  
ENSG00000171094  GO:0005887 integral component of plasma 
membrane 
ALK  
ENSG00000171094  GO:0006468 protein phosphorylation ALK  
ENSG00000171094  GO:0007165 signal transduction ALK  
ENSG00000171094  GO:0007169 transmembrane receptor protein 
tyrosine kinase signaling pathway 
ALK  
ENSG00000171094  GO:0007399 nervous system development ALK  
ENSG00000171094  GO:0008283 cell proliferation ALK  
ENSG00000171094  GO:0016020 membrane ALK  
ENSG00000171094  GO:0016310 phosphorylation ALK  
ENSG00000171094  GO:0016772 transferase activity, transferring 
phosphorus-containing groups 
ALK  
ENSG00000171094  GO:0018108 peptidyl-tyrosine phosphorylation ALK  
ENSG00000171094  GO:0038061 NIK/NF-kappaB signaling ALK  
ENSG00000171094  GO:0042981 regulation of apoptotic process ALK  
ENSG00000171094  GO:0043234 protein complex ALK  
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ENSG00000171094  GO:0046777 protein autophosphorylation ALK  
ENSG00000171094  GO:0048666 neuron development ALK  
ENSG00000171094  GO:0051092 positive regulation of NF-kappaB 
transcription factor activity 
ALK  
ENSG00000171094  GO:0070062 extracellular vesicular exosome ALK  
ENSG00000148513  GO:0003677 DNA binding ANKRD30A  
ENSG00000148513  GO:0003700 sequence-specific DNA binding 
transcription factor activity 
ANKRD30A  
ENSG00000148513  GO:0005515 protein binding ANKRD30A  
ENSG00000148513  GO:0005634 nucleus ANKRD30A  
ENSG00000148513  GO:0006355 regulation of transcription, DNA-
templated 
ANKRD30A  
ENSG00000071205  GO:0005100 Rho GTPase activator activity ARHGAP10  
ENSG00000071205  GO:0005515 protein binding ARHGAP10  
ENSG00000071205  GO:0005622 intracellular ARHGAP10  
ENSG00000071205  GO:0005829 cytosol ARHGAP10  
ENSG00000071205  GO:0005886 plasma membrane ARHGAP10  
ENSG00000071205  GO:0006915 apoptotic process ARHGAP10  
ENSG00000071205  GO:0007010 cytoskeleton organization ARHGAP10  
ENSG00000071205  GO:0007165 signal transduction ARHGAP10  
ENSG00000071205  GO:0007264 small GTPase mediated signal 
transduction 
ARHGAP10  
ENSG00000071205  GO:0032321 positive regulation of Rho GTPase 
activity 
ARHGAP10  
ENSG00000071205  GO:0042981 regulation of apoptotic process ARHGAP10  
ENSG00000071205  GO:0043066 negative regulation of apoptotic 
process 
ARHGAP10  
ENSG00000071205  GO:0048471 perinuclear region of cytoplasm ARHGAP10  
ENSG00000071205  GO:0051056 regulation of small GTPase mediated 
signal transduction 
ARHGAP10  
ENSG00000133794  GO:0000060 protein import into nucleus, 
translocation 
ARNTL  
ENSG00000133794  GO:0000976 transcription regulatory region 
sequence-specific DNA binding 
ARNTL  
ENSG00000133794  GO:0000982 RNA polymerase II core promoter 
proximal region sequence-specific 
DNA binding transcription factor 
activity 
ARNTL  
ENSG00000133794  GO:0001047 core promoter binding ARNTL  
ENSG00000133794  GO:0001190 RNA polymerase II transcription factor 
binding transcription factor activity 
involved in positive regulation of 
transcription 
ARNTL  
ENSG00000133794  GO:0003677 DNA binding ARNTL  
ENSG00000133794  GO:0003700 sequence-specific DNA binding 
transcription factor activity 
ARNTL  
ENSG00000133794  GO:0004871 signal transducer activity ARNTL  
ENSG00000133794  GO:0005515 protein binding ARNTL  
ENSG00000133794  GO:0005634 nucleus ARNTL  
ENSG00000133794  GO:0005667 transcription factor complex ARNTL  
ENSG00000133794  GO:0005737 cytoplasm ARNTL  
ENSG00000133794  GO:0006355 regulation of transcription, DNA-
templated 
ARNTL  
ENSG00000133794  GO:0006366 transcription from RNA polymerase II 
promoter 
ARNTL  
ENSG00000133794  GO:0007165 signal transduction ARNTL  
ENSG00000133794  GO:0007283 spermatogenesis ARNTL  
ENSG00000133794  GO:0007623 circadian rhythm ARNTL  
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ENSG00000133794  GO:0016604 nuclear body ARNTL  
ENSG00000133794  GO:0016605 PML body ARNTL  
ENSG00000133794  GO:0017162 aryl hydrocarbon receptor binding ARNTL  
ENSG00000133794  GO:0032007 negative regulation of TOR signaling ARNTL  
ENSG00000133794  GO:0032922 circadian regulation of gene 
expression 
ARNTL  
ENSG00000133794  GO:0033391 chromatoid body ARNTL  
ENSG00000133794  GO:0042176 regulation of protein catabolic process ARNTL  
ENSG00000133794  GO:0042634 regulation of hair cycle ARNTL  
ENSG00000133794  GO:0042753 positive regulation of circadian rhythm ARNTL  
ENSG00000133794  GO:0043161 proteasome-mediated ubiquitin-
dependent protein catabolic process 
ARNTL  
ENSG00000133794  GO:0043425 bHLH transcription factor binding ARNTL  
ENSG00000133794  GO:0043565 sequence-specific DNA binding ARNTL  
ENSG00000133794  GO:0045599 negative regulation of fat cell 
differentiation 
ARNTL  
ENSG00000133794  GO:0045892 negative regulation of transcription, 
DNA-templated 
ARNTL  
ENSG00000133794  GO:0045893 positive regulation of transcription, 
DNA-templated 
ARNTL  
ENSG00000133794  GO:0045944 positive regulation of transcription 
from RNA polymerase II promoter 
ARNTL  
ENSG00000133794  GO:0046982 protein heterodimerization activity ARNTL  
ENSG00000133794  GO:0046983 protein dimerization activity ARNTL  
ENSG00000133794  GO:0050767 regulation of neurogenesis ARNTL  
ENSG00000133794  GO:0050796 regulation of insulin secretion ARNTL  
ENSG00000133794  GO:0051726 regulation of cell cycle ARNTL  
ENSG00000133794  GO:0051775 response to redox state ARNTL  
ENSG00000133794  GO:0051879 Hsp90 protein binding ARNTL  
ENSG00000133794  GO:0070888 E-box binding ARNTL  
ENSG00000133794  GO:0090263 positive regulation of canonical Wnt 
signaling pathway 
ARNTL  
ENSG00000133794  GO:0090403 oxidative stress-induced premature 
senescence 
ARNTL  
ENSG00000133794  GO:2000074 regulation of type B pancreatic cell 
development 
ARNTL  
ENSG00000133794  GO:2000323 negative regulation of glucocorticoid 
receptor signaling pathway 
ARNTL  
ENSG00000133794  GO:2000772 regulation of cellular senescence ARNTL  
ENSG00000133794  GO:2001016 positive regulation of skeletal muscle 
cell differentiation 
ARNTL  
ENSG00000172318  GO:0000139 Golgi membrane B3GALT1  
ENSG00000172318  GO:0006486 protein glycosylation B3GALT1  
ENSG00000172318  GO:0008378 galactosyltransferase activity B3GALT1  
ENSG00000172318  GO:0008499 UDP-galactose:beta-N-
acetylglucosamine beta-1,3-
galactosyltransferase activity 
B3GALT1  
ENSG00000172318  GO:0009312 oligosaccharide biosynthetic process B3GALT1  
ENSG00000172318  GO:0016020 membrane B3GALT1  
ENSG00000172318  GO:0016021 integral component of membrane B3GALT1  
ENSG00000161267  GO:0001889 liver development BDH1  
ENSG00000275544  GO:0003858 3-hydroxybutyrate dehydrogenase 
activity 
BDH1  
ENSG00000161267  GO:0003858 3-hydroxybutyrate dehydrogenase 
activity 
BDH1  
ENSG00000161267  GO:0005543 phospholipid binding BDH1  
ENSG00000275544  GO:0005634 nucleus BDH1  
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ENSG00000161267  GO:0005634 nucleus BDH1  
ENSG00000275544  GO:0005739 mitochondrion BDH1  
ENSG00000161267  GO:0005739 mitochondrion BDH1  
ENSG00000161267  GO:0005743 mitochondrial inner membrane BDH1  
ENSG00000275544  GO:0005759 mitochondrial matrix BDH1  
ENSG00000161267  GO:0005759 mitochondrial matrix BDH1  
ENSG00000161267  GO:0007420 brain development BDH1  
ENSG00000161267  GO:0007584 response to nutrient BDH1  
ENSG00000275544  GO:0008152 metabolic process BDH1  
ENSG00000161267  GO:0008152 metabolic process BDH1  
ENSG00000161267  GO:0009636 response to toxic substance BDH1  
ENSG00000161267  GO:0009725 response to hormone BDH1  
ENSG00000275544  GO:0016491 oxidoreductase activity BDH1  
ENSG00000161267  GO:0016491 oxidoreductase activity BDH1  
ENSG00000161267  GO:0032355 response to estradiol BDH1  
ENSG00000161267  GO:0032868 response to insulin BDH1  
ENSG00000161267  GO:0042493 response to drug BDH1  
ENSG00000161267  GO:0042594 response to starvation BDH1  
ENSG00000275544  GO:0044255 cellular lipid metabolic process BDH1  
ENSG00000161267  GO:0044255 cellular lipid metabolic process BDH1  
ENSG00000275544  GO:0044281 small molecule metabolic process BDH1  
ENSG00000161267  GO:0044281 small molecule metabolic process BDH1  
ENSG00000161267  GO:0045471 response to ethanol BDH1  
ENSG00000161267  GO:0046686 response to cadmium ion BDH1  
ENSG00000275544  GO:0046950 cellular ketone body metabolic 
process 
BDH1  
ENSG00000161267  GO:0046950 cellular ketone body metabolic 
process 
BDH1  
ENSG00000275544  GO:0046951 ketone body biosynthetic process BDH1  
ENSG00000161267  GO:0046951 ketone body biosynthetic process BDH1  
ENSG00000275544  GO:0046952 ketone body catabolic process BDH1  
ENSG00000161267  GO:0046952 ketone body catabolic process BDH1  
ENSG00000161267  GO:0051412 response to corticosterone BDH1  
ENSG00000275544  GO:0055114 oxidation-reduction process BDH1  
ENSG00000161267  GO:0055114 oxidation-reduction process BDH1  
ENSG00000161267  GO:0060416 response to growth hormone BDH1  
ENSG00000161267  GO:0060612 adipose tissue development BDH1  
ENSG00000186190  GO:0005576 extracellular region BPIFB3  
ENSG00000186190  GO:0005737 cytoplasm BPIFB3  
ENSG00000186190  GO:0008289 lipid binding BPIFB3  
ENSG00000186190  GO:0045087 innate immune response BPIFB3  
ENSG00000186191  GO:0005576 extracellular region BPIFB4  
ENSG00000186191  GO:0005737 cytoplasm BPIFB4  
ENSG00000186191  GO:0008289 lipid binding BPIFB4  
ENSG00000136261  GO:0005488 binding BZW2 
ENSG00000136261  GO:0005515 protein binding BZW2 
ENSG00000136261  GO:0007399 nervous system development BZW2 
ENSG00000136261  GO:0016020 membrane BZW2 
ENSG00000136261  GO:0030154 cell differentiation BZW2 
ENSG00000120055  GO:0005515 protein binding C10orf95  
ENSG00000186493  GO:0005576 extracellular region C5orf38  
ENSG00000205174  GO:0016021 integral component of membrane C7orf66  
ENSG00000188782  GO:0001669 acrosomal vesicle CATSPER4  
ENSG00000188782  GO:0005216 ion channel activity CATSPER4  
ENSG00000188782  GO:0005227 calcium activated cation channel 
activity 
CATSPER4  
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ENSG00000188782  GO:0005245 voltage-gated calcium channel activity CATSPER4  
ENSG00000188782  GO:0005515 protein binding CATSPER4  
ENSG00000188782  GO:0005886 plasma membrane CATSPER4  
ENSG00000188782  GO:0006811 ion transport CATSPER4  
ENSG00000188782  GO:0006812 cation transport CATSPER4  
ENSG00000188782  GO:0006814 sodium ion transport CATSPER4  
ENSG00000188782  GO:0007275 multicellular organismal development CATSPER4  
ENSG00000188782  GO:0007283 spermatogenesis CATSPER4  
ENSG00000188782  GO:0007338 single fertilization CATSPER4  
ENSG00000188782  GO:0016020 membrane CATSPER4  
ENSG00000188782  GO:0030154 cell differentiation CATSPER4  
ENSG00000188782  GO:0030317 sperm motility CATSPER4  
ENSG00000188782  GO:0032504 multicellular organism reproduction CATSPER4  
ENSG00000188782  GO:0034220 ion transmembrane transport CATSPER4  
ENSG00000188782  GO:0034765 regulation of ion transmembrane 
transport 
CATSPER4  
ENSG00000188782  GO:0035036 sperm-egg recognition CATSPER4  
ENSG00000188782  GO:0036128 CatSper complex CATSPER4  
ENSG00000188782  GO:0048240 sperm capacitation CATSPER4  
ENSG00000188782  GO:0055085 transmembrane transport CATSPER4  
ENSG00000188782  GO:0070509 calcium ion import CATSPER4  
ENSG00000188782  GO:0086010 membrane depolarization during 
action potential 
CATSPER4  
ENSG00000188782  GO:0097228 sperm principal piece CATSPER4  
ENSG00000054803  GO:0005515 protein binding CBLN4  
ENSG00000054803  GO:0005615 extracellular space CBLN4  
ENSG00000054803  GO:0009306 protein secretion CBLN4  
ENSG00000054803  GO:0030054 cell junction CBLN4  
ENSG00000054803  GO:0045202 synapse CBLN4  
ENSG00000123106  GO:0005634 nucleus CCDC91  
ENSG00000123106  GO:0005794 Golgi apparatus CCDC91  
ENSG00000123106  GO:0015031 protein transport CCDC91  
ENSG00000123106  GO:0016020 membrane CCDC91  
ENSG00000123106  GO:0042802 identical protein binding CCDC91  
ENSG00000111860  GO:0005737 cytoplasm CEP85L  
ENSG00000111860  GO:0005813 centrosome CEP85L  
ENSG00000174600  GO:0001501 skeletal system development CMKLR1  
ENSG00000174600  GO:0004872 receptor activity CMKLR1  
ENSG00000174600  GO:0004930 G-protein coupled receptor activity CMKLR1  
ENSG00000174600  GO:0004950 chemokine receptor activity CMKLR1  
ENSG00000174600  GO:0005515 protein binding CMKLR1  
ENSG00000174600  GO:0005886 plasma membrane CMKLR1  
ENSG00000174600  GO:0005887 integral component of plasma 
membrane 
CMKLR1  
ENSG00000174600  GO:0006935 chemotaxis CMKLR1  
ENSG00000174600  GO:0006955 immune response CMKLR1  
ENSG00000174600  GO:0007186 G-protein coupled receptor signaling 
pathway 
CMKLR1  
ENSG00000174600  GO:0010759 positive regulation of macrophage 
chemotaxis 
CMKLR1  
ENSG00000174600  GO:0016021 integral component of membrane CMKLR1  
ENSG00000174600  GO:0032088 negative regulation of NF-kappaB 
transcription factor activity 
CMKLR1  
ENSG00000174600  GO:0032695 negative regulation of interleukin-12 
production 
CMKLR1  
ENSG00000174600  GO:0045600 positive regulation of fat cell CMKLR1  
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differentiation 
ENSG00000174600  GO:0050848 regulation of calcium-mediated 
signaling 
CMKLR1  
ENSG00000174600  GO:0070098 chemokine-mediated signaling 
pathway 
CMKLR1  
ENSG00000174469  GO:0005515 protein binding CNTNAP2  
ENSG00000174469  GO:0005769 early endosome CNTNAP2  
ENSG00000174469  GO:0005794 Golgi apparatus CNTNAP2  
ENSG00000174469  GO:0007155 cell adhesion CNTNAP2  
ENSG00000174469  GO:0007420 brain development CNTNAP2  
ENSG00000174469  GO:0007612 learning CNTNAP2  
ENSG00000174469  GO:0008038 neuron recognition CNTNAP2  
ENSG00000174469  GO:0008076 voltage-gated potassium channel 
complex 
CNTNAP2  
ENSG00000174469  GO:0009986 cell surface CNTNAP2  
ENSG00000174469  GO:0016020 membrane CNTNAP2  
ENSG00000174469  GO:0016021 integral component of membrane CNTNAP2  
ENSG00000174469  GO:0019226 transmission of nerve impulse CNTNAP2  
ENSG00000174469  GO:0019899 enzyme binding CNTNAP2  
ENSG00000174469  GO:0021756 striatum development CNTNAP2  
ENSG00000174469  GO:0021761 limbic system development CNTNAP2  
ENSG00000174469  GO:0021794 thalamus development CNTNAP2  
ENSG00000174469  GO:0021987 cerebral cortex development CNTNAP2  
ENSG00000174469  GO:0030424 axon CNTNAP2  
ENSG00000174469  GO:0030425 dendrite CNTNAP2  
ENSG00000174469  GO:0030534 adult behavior CNTNAP2  
ENSG00000174469  GO:0030673 axolemma CNTNAP2  
ENSG00000174469  GO:0031175 neuron projection development CNTNAP2  
ENSG00000174469  GO:0034613 cellular protein localization CNTNAP2  
ENSG00000174469  GO:0035176 social behavior CNTNAP2  
ENSG00000174469  GO:0043025 neuronal cell body CNTNAP2  
ENSG00000174469  GO:0043204 perikaryon CNTNAP2  
ENSG00000174469  GO:0044224 juxtaparanode region of axon CNTNAP2  
ENSG00000174469  GO:0045163 clustering of voltage-gated potassium 
channels 
CNTNAP2  
ENSG00000174469  GO:0071109 superior temporal gyrus development CNTNAP2  
ENSG00000174469  GO:0071205 protein localization to juxtaparanode 
region of axon 
CNTNAP2  
ENSG00000174469  GO:0071625 vocalization behavior CNTNAP2  
ENSG00000133103  GO:0000139 Golgi membrane COG6 
ENSG00000133103  GO:0006891 intra-Golgi vesicle-mediated transport COG6 
ENSG00000133103  GO:0015031 protein transport COG6 
ENSG00000133103  GO:0017119 Golgi transport complex COG6 
ENSG00000133103  GO:0070085 glycosylation COG6 
ENSG00000145781  GO:0005515 protein binding COMMD10  
ENSG00000173085  GO:0002083 4-hydroxybenzoate 
decaprenyltransferase activity 
COQ2 
ENSG00000173085  GO:0004659 prenyltransferase activity COQ2 
ENSG00000173085  GO:0005739 mitochondrion COQ2 
ENSG00000173085  GO:0005743 mitochondrial inner membrane COQ2 
ENSG00000173085  GO:0006071 glycerol metabolic process COQ2 
ENSG00000173085  GO:0006744 ubiquinone biosynthetic process COQ2 
ENSG00000173085  GO:0008152 metabolic process COQ2 
ENSG00000173085  GO:0008219 cell death COQ2 
ENSG00000173085  GO:0008299 isoprenoid biosynthetic process COQ2 
ENSG00000173085  GO:0009058 biosynthetic process COQ2 
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ENSG00000173085  GO:0016021 integral component of membrane COQ2 
ENSG00000173085  GO:0044281 small molecule metabolic process COQ2 
ENSG00000173085  GO:0047293 4-hydroxybenzoate 
nonaprenyltransferase activity 
COQ2 
ENSG00000134030  GO:0000184 nuclear-transcribed mRNA catabolic 
process, nonsense-mediated decay 
CTIF 
ENSG00000134030  GO:0003723 RNA binding CTIF 
ENSG00000134030  GO:0005488 binding CTIF 
ENSG00000134030  GO:0005515 protein binding CTIF 
ENSG00000134030  GO:0005737 cytoplasm CTIF 
ENSG00000134030  GO:0006446 regulation of translational initiation CTIF 
ENSG00000134030  GO:0048471 perinuclear region of cytoplasm CTIF 
ENSG00000066032  GO:0005198 structural molecule activity CTNNA2  
ENSG00000066032  GO:0005200 structural constituent of cytoskeleton CTNNA2  
ENSG00000066032  GO:0005515 protein binding CTNNA2  
ENSG00000066032  GO:0005737 cytoplasm CTNNA2  
ENSG00000066032  GO:0005829 cytosol CTNNA2  
ENSG00000066032  GO:0005912 adherens junction CTNNA2  
ENSG00000066032  GO:0005913 cell-cell adherens junction CTNNA2  
ENSG00000066032  GO:0007155 cell adhesion CTNNA2  
ENSG00000066032  GO:0007409 axonogenesis CTNNA2  
ENSG00000066032  GO:0015629 actin cytoskeleton CTNNA2  
ENSG00000066032  GO:0016323 basolateral plasma membrane CTNNA2  
ENSG00000066032  GO:0016337 single organismal cell-cell adhesion CTNNA2  
ENSG00000066032  GO:0021942 radial glia guided migration of Purkinje 
cell 
CTNNA2  
ENSG00000066032  GO:0030027 lamellipodium CTNNA2  
ENSG00000066032  GO:0030424 axon CTNNA2  
ENSG00000066032  GO:0042692 muscle cell differentiation CTNNA2  
ENSG00000066032  GO:0045296 cadherin binding CTNNA2  
ENSG00000066032  GO:0048813 dendrite morphogenesis CTNNA2  
ENSG00000066032  GO:0048854 brain morphogenesis CTNNA2  
ENSG00000066032  GO:0051015 actin filament binding CTNNA2  
ENSG00000066032  GO:0051149 positive regulation of muscle cell 
differentiation 
CTNNA2  
ENSG00000066032  GO:0051823 regulation of synapse structural 
plasticity 
CTNNA2  
ENSG00000066032  GO:0060134 prepulse inhibition CTNNA2  
ENSG00000121966  GO:0000187 activation of MAPK activity CXCR4  
ENSG00000121966  GO:0001569 patterning of blood vessels CXCR4  
ENSG00000121966  GO:0001618 virus receptor activity CXCR4  
ENSG00000121966  GO:0001666 response to hypoxia CXCR4  
ENSG00000121966  GO:0001667 ameboidal cell migration CXCR4  
ENSG00000121966  GO:0001764 neuron migration CXCR4  
ENSG00000121966  GO:0002407 dendritic cell chemotaxis CXCR4  
ENSG00000121966  GO:0003779 actin binding CXCR4  
ENSG00000121966  GO:0004930 G-protein coupled receptor activity CXCR4  
ENSG00000121966  GO:0005515 protein binding CXCR4  
ENSG00000121966  GO:0005737 cytoplasm CXCR4  
ENSG00000121966  GO:0005764 lysosome CXCR4  
ENSG00000121966  GO:0005769 early endosome CXCR4  
ENSG00000121966  GO:0005770 late endosome CXCR4  
ENSG00000121966  GO:0005886 plasma membrane CXCR4  
ENSG00000121966  GO:0005911 cell-cell junction CXCR4  
ENSG00000121966  GO:0006915 apoptotic process CXCR4  
ENSG00000121966  GO:0006954 inflammatory response CXCR4  
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ENSG00000121966  GO:0007186 G-protein coupled receptor signaling 
pathway 
CXCR4  
ENSG00000121966  GO:0007204 positive regulation of cytosolic calcium 
ion concentration 
CXCR4  
ENSG00000121966  GO:0007281 germ cell development CXCR4  
ENSG00000121966  GO:0007420 brain development CXCR4  
ENSG00000121966  GO:0008045 motor neuron axon guidance CXCR4  
ENSG00000121966  GO:0008354 germ cell migration CXCR4  
ENSG00000121966  GO:0009615 response to virus CXCR4  
ENSG00000121966  GO:0009897 external side of plasma membrane CXCR4  
ENSG00000121966  GO:0009986 cell surface CXCR4  
ENSG00000121966  GO:0015026 coreceptor activity CXCR4  
ENSG00000121966  GO:0016021 integral component of membrane CXCR4  
ENSG00000121966  GO:0016023 cytoplasmic membrane-bounded 
vesicle 
CXCR4  
ENSG00000121966  GO:0016032 viral process CXCR4  
ENSG00000121966  GO:0016494 C-X-C chemokine receptor activity CXCR4  
ENSG00000121966  GO:0019722 calcium-mediated signaling CXCR4  
ENSG00000121966  GO:0019955 cytokine binding CXCR4  
ENSG00000121966  GO:0030054 cell junction CXCR4  
ENSG00000121966  GO:0030260 entry into host cell CXCR4  
ENSG00000121966  GO:0030334 regulation of cell migration CXCR4  
ENSG00000121966  GO:0030426 growth cone CXCR4  
ENSG00000121966  GO:0031252 cell leading edge CXCR4  
ENSG00000121966  GO:0031410 cytoplasmic vesicle CXCR4  
ENSG00000121966  GO:0031625 ubiquitin protein ligase binding CXCR4  
ENSG00000121966  GO:0032027 myosin light chain binding CXCR4  
ENSG00000121966  GO:0042098 T cell proliferation CXCR4  
ENSG00000121966  GO:0042119 neutrophil activation CXCR4  
ENSG00000121966  GO:0043130 ubiquitin binding CXCR4  
ENSG00000121966  GO:0043217 myelin maintenance CXCR4  
ENSG00000121966  GO:0048699 generation of neurons CXCR4  
ENSG00000121966  GO:0048714 positive regulation of oligodendrocyte 
differentiation 
CXCR4  
ENSG00000121966  GO:0050920 regulation of chemotaxis CXCR4  
ENSG00000121966  GO:0061351 neural precursor cell proliferation CXCR4  
ENSG00000121966  GO:0070062 extracellular vesicular exosome CXCR4  
ENSG00000121966  GO:0070098 chemokine-mediated signaling 
pathway 
CXCR4  
ENSG00000121966  GO:0071345 cellular response to cytokine stimulus CXCR4  
ENSG00000164821  GO:0005576 extracellular region DEFA4  
ENSG00000164821  GO:0005615 extracellular space DEFA4  
ENSG00000164821  GO:0005796 Golgi lumen DEFA4  
ENSG00000164821  GO:0006952 defense response DEFA4  
ENSG00000164821  GO:0019731 antibacterial humoral response DEFA4  
ENSG00000164821  GO:0031640 killing of cells of other organism DEFA4  
ENSG00000164821  GO:0045087 innate immune response DEFA4  
ENSG00000164821  GO:0050832 defense response to fungus DEFA4  
ENSG00000164825  GO:0002227 innate immune response in mucosa DEFB1  
ENSG00000164825  GO:0002526 acute inflammatory response DEFB1  
ENSG00000164825  GO:0005576 extracellular region DEFB1  
ENSG00000164825  GO:0005615 extracellular space DEFB1  
ENSG00000164825  GO:0005796 Golgi lumen DEFB1  
ENSG00000164825  GO:0006935 chemotaxis DEFB1  
ENSG00000164825  GO:0006952 defense response DEFB1  
ENSG00000164825  GO:0006955 immune response DEFB1  
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ENSG00000164825  GO:0007186 G-protein coupled receptor signaling 
pathway 
DEFB1  
ENSG00000164825  GO:0009617 response to bacterium DEFB1  
ENSG00000164825  GO:0019731 antibacterial humoral response DEFB1  
ENSG00000164825  GO:0033574 response to testosterone DEFB1  
ENSG00000164825  GO:0045087 innate immune response DEFB1  
ENSG00000164825  GO:0050830 defense response to Gram-positive 
bacterium 
DEFB1  
ENSG00000164825  GO:0070062 extracellular vesicular exosome DEFB1  
ENSG00000173253  GO:0003674 molecular_function DMRT2  
ENSG00000173253  GO:0003700 sequence-specific DNA binding 
transcription factor activity 
DMRT2  
ENSG00000173253  GO:0005575 cellular_component DMRT2  
ENSG00000173253  GO:0005634 nucleus DMRT2  
ENSG00000173253  GO:0006351 transcription, DNA-templated DMRT2  
ENSG00000173253  GO:0006355 regulation of transcription, DNA-
templated 
DMRT2  
ENSG00000173253  GO:0007530 sex determination DMRT2  
ENSG00000173253  GO:0008150 biological_process DMRT2  
ENSG00000173253  GO:0008584 male gonad development DMRT2  
ENSG00000173253  GO:0014807 regulation of somitogenesis DMRT2  
ENSG00000173253  GO:0042803 protein homodimerization activity DMRT2  
ENSG00000173253  GO:0043565 sequence-specific DNA binding DMRT2  
ENSG00000173253  GO:0046872 metal ion binding DMRT2  
ENSG00000173253  GO:0048706 embryonic skeletal system 
development 
DMRT2  
ENSG00000173253  GO:2000287 positive regulation of myotome 
development 
DMRT2  
ENSG00000206052  GO:0005158 insulin receptor binding DOK6  
ENSG00000206052  GO:0005515 protein binding DOK6  
ENSG00000117543  GO:0004164 diphthine synthase activity DPH5  
ENSG00000117543  GO:0005575 cellular_component DPH5  
ENSG00000117543  GO:0008152 metabolic process DPH5  
ENSG00000117543  GO:0008168 methyltransferase activity DPH5  
ENSG00000117543  GO:0017183 peptidyl-diphthamide biosynthetic 
process from peptidyl-histidine 
DPH5  
ENSG00000117543  GO:0032259 methylation DPH5  
ENSG00000138036  GO:0003774 motor activity DYNC2LI1  
ENSG00000138036  GO:0005515 protein binding DYNC2LI1  
ENSG00000138036  GO:0005829 cytosol DYNC2LI1  
ENSG00000138036  GO:0005858 axonemal dynein complex DYNC2LI1  
ENSG00000138036  GO:0005881 cytoplasmic microtubule DYNC2LI1  
ENSG00000138036  GO:0005930 axoneme DYNC2LI1  
ENSG00000138036  GO:0007368 determination of left/right symmetry DYNC2LI1  
ENSG00000138036  GO:0008152 metabolic process DYNC2LI1  
ENSG00000138036  GO:0019886 antigen processing and presentation 
of exogenous peptide antigen via 
MHC class II 
DYNC2LI1  
ENSG00000138036  GO:0030990 intraciliary transport particle DYNC2LI1  
ENSG00000138036  GO:0031512 motile primary cilium DYNC2LI1  
ENSG00000138036  GO:0036064 ciliary basal body DYNC2LI1  
ENSG00000138036  GO:0042384 cilium assembly DYNC2LI1  
ENSG00000138036  GO:0045177 apical part of cell DYNC2LI1  
ENSG00000138036  GO:0072372 primary cilium DYNC2LI1  
ENSG00000186197  GO:0001942 hair follicle development EDARADD  
ENSG00000186197  GO:0005515 protein binding EDARADD  
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ENSG00000186197  GO:0005737 cytoplasm EDARADD  
ENSG00000186197  GO:0007165 signal transduction EDARADD  
ENSG00000186197  GO:0030154 cell differentiation EDARADD  
ENSG00000186197  GO:0042475 odontogenesis of dentin-containing 
tooth 
EDARADD  
ENSG00000186197  GO:0061153 trachea gland development EDARADD  
ENSG00000078401  GO:0000122 negative regulation of transcription 
from RNA polymerase II promoter 
EDN1  
ENSG00000078401  GO:0001501 skeletal system development EDN1  
ENSG00000078401  GO:0001516 prostaglandin biosynthetic process EDN1  
ENSG00000078401  GO:0001569 patterning of blood vessels EDN1  
ENSG00000078401  GO:0001666 response to hypoxia EDN1  
ENSG00000078401  GO:0001701 in utero embryonic development EDN1  
ENSG00000078401  GO:0001821 histamine secretion EDN1  
ENSG00000078401  GO:0003100 regulation of systemic arterial blood 
pressure by endothelin 
EDN1  
ENSG00000078401  GO:0005102 receptor binding EDN1  
ENSG00000078401  GO:0005125 cytokine activity EDN1  
ENSG00000078401  GO:0005179 hormone activity EDN1  
ENSG00000078401  GO:0005515 protein binding EDN1  
ENSG00000078401  GO:0005576 extracellular region EDN1  
ENSG00000078401  GO:0005615 extracellular space EDN1  
ENSG00000078401  GO:0005737 cytoplasm EDN1  
ENSG00000078401  GO:0006885 regulation of pH EDN1  
ENSG00000078401  GO:0007166 cell surface receptor signaling 
pathway 
EDN1  
ENSG00000078401  GO:0007186 G-protein coupled receptor signaling 
pathway 
EDN1  
ENSG00000078401  GO:0007204 positive regulation of cytosolic calcium 
ion concentration 
EDN1  
ENSG00000078401  GO:0007205 protein kinase C-activating G-protein 
coupled receptor signaling pathway 
EDN1  
ENSG00000078401  GO:0007267 cell-cell signaling EDN1  
ENSG00000078401  GO:0007507 heart development EDN1  
ENSG00000078401  GO:0007585 respiratory gaseous exchange EDN1  
ENSG00000078401  GO:0007589 body fluid secretion EDN1  
ENSG00000078401  GO:0008217 regulation of blood pressure EDN1  
ENSG00000078401  GO:0008284 positive regulation of cell proliferation EDN1  
ENSG00000078401  GO:0009953 dorsal/ventral pattern formation EDN1  
ENSG00000078401  GO:0010193 response to ozone EDN1  
ENSG00000078401  GO:0010259 multicellular organismal aging EDN1  
ENSG00000078401  GO:0010460 positive regulation of heart rate EDN1  
ENSG00000078401  GO:0010595 positive regulation of endothelial cell 
migration 
EDN1  
ENSG00000078401  GO:0010613 positive regulation of cardiac muscle 
hypertrophy 
EDN1  
ENSG00000078401  GO:0010870 positive regulation of receptor 
biosynthetic process 
EDN1  
ENSG00000078401  GO:0014032 neural crest cell development EDN1  
ENSG00000078401  GO:0014065 phosphatidylinositol 3-kinase signaling EDN1  
ENSG00000078401  GO:0014823 response to activity EDN1  
ENSG00000078401  GO:0014824 artery smooth muscle contraction EDN1  
ENSG00000078401  GO:0014826 vein smooth muscle contraction EDN1  
ENSG00000078401  GO:0015758 glucose transport EDN1  
ENSG00000078401  GO:0016049 cell growth EDN1  
ENSG00000078401  GO:0019229 regulation of vasoconstriction EDN1  
ENSG00000078401  GO:0019233 sensory perception of pain EDN1  
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ENSG00000078401  GO:0019722 calcium-mediated signaling EDN1  
ENSG00000078401  GO:0030072 peptide hormone secretion EDN1  
ENSG00000078401  GO:0030185 nitric oxide transport EDN1  
ENSG00000078401  GO:0030195 negative regulation of blood 
coagulation 
EDN1  
ENSG00000078401  GO:0030335 positive regulation of cell migration EDN1  
ENSG00000078401  GO:0030818 negative regulation of cAMP 
biosynthetic process 
EDN1  
ENSG00000078401  GO:0031583 phospholipase D-activating G-protein 
coupled receptor signaling pathway 
EDN1  
ENSG00000078401  GO:0031707 endothelin A receptor binding EDN1  
ENSG00000078401  GO:0031708 endothelin B receptor binding EDN1  
ENSG00000078401  GO:0032269 negative regulation of cellular protein 
metabolic process 
EDN1  
ENSG00000078401  GO:0032308 positive regulation of prostaglandin 
secretion 
EDN1  
ENSG00000078401  GO:0032496 response to lipopolysaccharide EDN1  
ENSG00000078401  GO:0033093 Weibel-Palade body EDN1  
ENSG00000078401  GO:0033574 response to testosterone EDN1  
ENSG00000078401  GO:0034392 negative regulation of smooth muscle 
cell apoptotic process 
EDN1  
ENSG00000078401  GO:0034696 response to prostaglandin F EDN1  
ENSG00000078401  GO:0035094 response to nicotine EDN1  
ENSG00000078401  GO:0035556 intracellular signal transduction EDN1  
ENSG00000078401  GO:0035690 cellular response to drug EDN1  
ENSG00000078401  GO:0035810 positive regulation of urine volume EDN1  
ENSG00000078401  GO:0035815 positive regulation of renal sodium 
excretion 
EDN1  
ENSG00000078401  GO:0035994 response to muscle stretch EDN1  
ENSG00000078401  GO:0042045 epithelial fluid transport EDN1  
ENSG00000078401  GO:0042310 vasoconstriction EDN1  
ENSG00000078401  GO:0042313 protein kinase C deactivation EDN1  
ENSG00000078401  GO:0042474 middle ear morphogenesis EDN1  
ENSG00000078401  GO:0042482 positive regulation of odontogenesis EDN1  
ENSG00000078401  GO:0042493 response to drug EDN1  
ENSG00000078401  GO:0042554 superoxide anion generation EDN1  
ENSG00000078401  GO:0043179 rhythmic excitation EDN1  
ENSG00000078401  GO:0043200 response to amino acid EDN1  
ENSG00000078401  GO:0043406 positive regulation of MAP kinase 
activity 
EDN1  
ENSG00000078401  GO:0043507 positive regulation of JUN kinase 
activity 
EDN1  
ENSG00000078401  GO:0044321 response to leptin EDN1  
ENSG00000078401  GO:0045178 basal part of cell EDN1  
ENSG00000078401  GO:0045321 leukocyte activation EDN1  
ENSG00000078401  GO:0045429 positive regulation of nitric oxide 
biosynthetic process 
EDN1  
ENSG00000078401  GO:0045793 positive regulation of cell size EDN1  
ENSG00000078401  GO:0045840 positive regulation of mitosis EDN1  
ENSG00000078401  GO:0045944 positive regulation of transcription 
from RNA polymerase II promoter 
EDN1  
ENSG00000078401  GO:0045987 positive regulation of smooth muscle 
contraction 
EDN1  
ENSG00000078401  GO:0046887 positive regulation of hormone 
secretion 
EDN1  
ENSG00000078401  GO:0046888 negative regulation of hormone 
secretion 
EDN1  
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ENSG00000078401  GO:0048016 inositol phosphate-mediated signaling EDN1  
ENSG00000078401  GO:0048237 rough endoplasmic reticulum lumen EDN1  
ENSG00000078401  GO:0048514 blood vessel morphogenesis EDN1  
ENSG00000078401  GO:0048661 positive regulation of smooth muscle 
cell proliferation 
EDN1  
ENSG00000078401  GO:0051216 cartilage development EDN1  
ENSG00000078401  GO:0051482 positive regulation of cytosolic calcium 
ion concentration involved in 
phospholipase C-activating G-protein 
coupled signaling pathway 
EDN1  
ENSG00000078401  GO:0051771 negative regulation of nitric-oxide 
synthase biosynthetic process 
EDN1  
ENSG00000078401  GO:0051899 membrane depolarization EDN1  
ENSG00000078401  GO:0051930 regulation of sensory perception of 
pain 
EDN1  
ENSG00000078401  GO:0060137 maternal process involved in 
parturition 
EDN1  
ENSG00000078401  GO:0060298 positive regulation of sarcomere 
organization 
EDN1  
ENSG00000078401  GO:0060585 positive regulation of prostaglandin-
endoperoxide synthase activity 
EDN1  
ENSG00000078401  GO:0070101 positive regulation of chemokine-
mediated signaling pathway 
EDN1  
ENSG00000078401  GO:0071277 cellular response to calcium ion EDN1  
ENSG00000078401  GO:0071346 cellular response to interferon-gamma EDN1  
ENSG00000078401  GO:0071347 cellular response to interleukin-1 EDN1  
ENSG00000078401  GO:0071356 cellular response to tumor necrosis 
factor 
EDN1  
ENSG00000078401  GO:0071375 cellular response to peptide hormone 
stimulus 
EDN1  
ENSG00000078401  GO:0071385 cellular response to glucocorticoid 
stimulus 
EDN1  
ENSG00000078401  GO:0071389 cellular response to mineralocorticoid 
stimulus 
EDN1  
ENSG00000078401  GO:0071398 cellular response to fatty acid EDN1  
ENSG00000078401  GO:0071456 cellular response to hypoxia EDN1  
ENSG00000078401  GO:0071548 response to dexamethasone EDN1  
ENSG00000078401  GO:0071559 response to transforming growth 
factor beta 
EDN1  
ENSG00000078401  GO:0071560 cellular response to transforming 
growth factor beta stimulus 
EDN1  
ENSG00000078401  GO:0090023 positive regulation of neutrophil 
chemotaxis 
EDN1  
ENSG00000078401  GO:1902074 response to salt EDN1  
ENSG00000164307  GO:0001525 angiogenesis ERAP1  
ENSG00000164307  GO:0002474 antigen processing and presentation 
of peptide antigen via MHC class I 
ERAP1  
ENSG00000164307  GO:0004177 aminopeptidase activity ERAP1  
ENSG00000164307  GO:0005138 interleukin-6 receptor binding ERAP1  
ENSG00000164307  GO:0005151 interleukin-1, Type II receptor binding ERAP1  
ENSG00000164307  GO:0005515 protein binding ERAP1  
ENSG00000164307  GO:0005576 extracellular region ERAP1  
ENSG00000164307  GO:0005615 extracellular space ERAP1  
ENSG00000164307  GO:0005737 cytoplasm ERAP1  
ENSG00000164307  GO:0005783 endoplasmic reticulum ERAP1  
ENSG00000164307  GO:0005788 endoplasmic reticulum lumen ERAP1  
ENSG00000164307  GO:0005789 endoplasmic reticulum membrane ERAP1  
ENSG00000164307  GO:0005829 cytosol ERAP1  
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ENSG00000164307  GO:0006508 proteolysis ERAP1  
ENSG00000164307  GO:0006509 membrane protein ectodomain 
proteolysis 
ERAP1  
ENSG00000164307  GO:0008217 regulation of blood pressure ERAP1  
ENSG00000164307  GO:0008235 metalloexopeptidase activity ERAP1  
ENSG00000164307  GO:0008237 metallopeptidase activity ERAP1  
ENSG00000164307  GO:0008270 zinc ion binding ERAP1  
ENSG00000164307  GO:0009617 response to bacterium ERAP1  
ENSG00000164307  GO:0016020 membrane ERAP1  
ENSG00000164307  GO:0016021 integral component of membrane ERAP1  
ENSG00000164307  GO:0019885 antigen processing and presentation 
of endogenous peptide antigen via 
MHC class I 
ERAP1  
ENSG00000164307  GO:0045088 regulation of innate immune response ERAP1  
ENSG00000164307  GO:0045444 fat cell differentiation ERAP1  
ENSG00000164307  GO:0045766 positive regulation of angiogenesis ERAP1  
ENSG00000164307  GO:0070062 extracellular vesicular exosome ERAP1  
ENSG00000082805  GO:0000139 Golgi membrane ERC1  
ENSG00000082805  GO:0005515 protein binding ERC1  
ENSG00000082805  GO:0005737 cytoplasm ERC1  
ENSG00000082805  GO:0006355 regulation of transcription, DNA-
templated 
ERC1  
ENSG00000082805  GO:0007252 I-kappaB phosphorylation ERC1  
ENSG00000082805  GO:0007275 multicellular organismal development ERC1  
ENSG00000082805  GO:0008385 IkappaB kinase complex ERC1  
ENSG00000082805  GO:0015031 protein transport ERC1  
ENSG00000082805  GO:0017137 Rab GTPase binding ERC1  
ENSG00000082805  GO:0042147 retrograde transport, endosome to 
Golgi 
ERC1  
ENSG00000082805  GO:0042734 presynaptic membrane ERC1  
ENSG00000082805  GO:0043522 leucine zipper domain binding ERC1  
ENSG00000082805  GO:0045202 synapse ERC1  
ENSG00000082805  GO:0051092 positive regulation of NF-kappaB 
transcription factor activity 
ERC1  
ENSG00000064655  GO:0000287 magnesium ion binding EYA2  
ENSG00000064655  GO:0004725 protein tyrosine phosphatase activity EYA2  
ENSG00000064655  GO:0005515 protein binding EYA2  
ENSG00000064655  GO:0005634 nucleus EYA2  
ENSG00000064655  GO:0005737 cytoplasm EYA2  
ENSG00000064655  GO:0005813 centrosome EYA2  
ENSG00000064655  GO:0006281 DNA repair EYA2  
ENSG00000064655  GO:0006351 transcription, DNA-templated EYA2  
ENSG00000064655  GO:0006355 regulation of transcription, DNA-
templated 
EYA2  
ENSG00000064655  GO:0006470 protein dephosphorylation EYA2  
ENSG00000064655  GO:0007275 multicellular organismal development EYA2  
ENSG00000064655  GO:0007501 mesodermal cell fate specification EYA2  
ENSG00000064655  GO:0014706 striated muscle tissue development EYA2  
ENSG00000064655  GO:0016576 histone dephosphorylation EYA2  
ENSG00000064655  GO:0035335 peptidyl-tyrosine dephosphorylation EYA2  
ENSG00000064655  GO:0097192 extrinsic apoptotic signaling pathway 
in absence of ligand 
EYA2  
ENSG00000064655  GO:0097345 mitochondrial outer membrane 
permeabilization 
EYA2  
ENSG00000026103  GO:0002377 immunoglobulin production FAS  
ENSG00000026103  GO:0003014 renal system process FAS  
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ENSG00000026103  GO:0004871 signal transducer activity FAS  
ENSG00000026103  GO:0004872 receptor activity FAS  
ENSG00000026103  GO:0004888 transmembrane signaling receptor 
activity 
FAS  
ENSG00000026103  GO:0005515 protein binding FAS  
ENSG00000026103  GO:0005576 extracellular region FAS  
ENSG00000026103  GO:0005634 nucleus FAS  
ENSG00000026103  GO:0005737 cytoplasm FAS  
ENSG00000026103  GO:0005829 cytosol FAS  
ENSG00000026103  GO:0005886 plasma membrane FAS  
ENSG00000026103  GO:0006461 protein complex assembly FAS  
ENSG00000026103  GO:0006915 apoptotic process FAS  
ENSG00000026103  GO:0006919 activation of cysteine-type 
endopeptidase activity involved in 
apoptotic process 
FAS  
ENSG00000026103  GO:0006924 activation-induced cell death of T cells FAS  
ENSG00000026103  GO:0006925 inflammatory cell apoptotic process FAS  
ENSG00000026103  GO:0006927 transformed cell apoptotic process FAS  
ENSG00000026103  GO:0006955 immune response FAS  
ENSG00000026103  GO:0007165 signal transduction FAS  
ENSG00000026103  GO:0007623 circadian rhythm FAS  
ENSG00000026103  GO:0008625 extrinsic apoptotic signaling pathway 
via death domain receptors 
FAS  
ENSG00000026103  GO:0009636 response to toxic substance FAS  
ENSG00000026103  GO:0009897 external side of plasma membrane FAS  
ENSG00000026103  GO:0009986 cell surface FAS  
ENSG00000026103  GO:0010467 gene expression FAS  
ENSG00000026103  GO:0016021 integral component of membrane FAS  
ENSG00000026103  GO:0019724 B cell mediated immunity FAS  
ENSG00000026103  GO:0019900 kinase binding FAS  
ENSG00000026103  GO:0031264 death-inducing signaling complex FAS  
ENSG00000026103  GO:0031265 CD95 death-inducing signaling 
complex 
FAS  
ENSG00000026103  GO:0032464 positive regulation of protein 
homooligomerization 
FAS  
ENSG00000026103  GO:0042802 identical protein binding FAS  
ENSG00000026103  GO:0042981 regulation of apoptotic process FAS  
ENSG00000026103  GO:0043029 T cell homeostasis FAS  
ENSG00000026103  GO:0043065 positive regulation of apoptotic 
process 
FAS  
ENSG00000026103  GO:0043066 negative regulation of apoptotic 
process 
FAS  
ENSG00000026103  GO:0045060 negative thymic T cell selection FAS  
ENSG00000026103  GO:0045121 membrane raft FAS  
ENSG00000026103  GO:0045619 regulation of lymphocyte 
differentiation 
FAS  
ENSG00000026103  GO:0045637 regulation of myeloid cell 
differentiation 
FAS  
ENSG00000026103  GO:0048536 spleen development FAS  
ENSG00000026103  GO:0050869 negative regulation of B cell activation FAS  
ENSG00000026103  GO:0051260 protein homooligomerization FAS  
ENSG00000026103  GO:0051384 response to glucocorticoid FAS  
ENSG00000026103  GO:0051402 neuron apoptotic process FAS  
ENSG00000026103  GO:0070062 extracellular vesicular exosome FAS  
ENSG00000026103  GO:0071260 cellular response to mechanical 
stimulus 
FAS  
ENSG00000026103  GO:0071285 cellular response to lithium ion FAS  
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ENSG00000026103  GO:0071455 cellular response to hyperoxia FAS  
ENSG00000026103  GO:0097049 motor neuron apoptotic process FAS  
ENSG00000026103  GO:0097190 apoptotic signaling pathway FAS  
ENSG00000026103  GO:0097191 extrinsic apoptotic signaling pathway FAS  
ENSG00000026103  GO:0097192 extrinsic apoptotic signaling pathway 
in absence of ligand 
FAS  
ENSG00000026103  GO:0097527 necroptotic signaling pathway FAS  
ENSG00000026103  GO:2001239 regulation of extrinsic apoptotic 
signaling pathway in absence of 
ligand 
FAS  
ENSG00000026103  GO:2001241 positive regulation of extrinsic 
apoptotic signaling pathway in 
absence of ligand 
FAS  
ENSG00000183580  GO:0000086 G2/M transition of mitotic cell cycle FBXL7  
ENSG00000183580  GO:0000151 ubiquitin ligase complex FBXL7  
ENSG00000183580  GO:0004842 ubiquitin-protein transferase activity FBXL7  
ENSG00000183580  GO:0005515 protein binding FBXL7  
ENSG00000183580  GO:0005737 cytoplasm FBXL7  
ENSG00000183580  GO:0005813 centrosome FBXL7  
ENSG00000183580  GO:0006511 ubiquitin-dependent protein catabolic 
process 
FBXL7  
ENSG00000183580  GO:0007067 mitotic nuclear division FBXL7  
ENSG00000183580  GO:0008283 cell proliferation FBXL7  
ENSG00000183580  GO:0016567 protein ubiquitination FBXL7  
ENSG00000183580  GO:0019005 SCF ubiquitin ligase complex FBXL7  
ENSG00000183580  GO:0031146 SCF-dependent proteasomal 
ubiquitin-dependent protein catabolic 
process 
FBXL7  
ENSG00000189283  GO:0000166 nucleotide binding FHIT  
ENSG00000189283  GO:0003824 catalytic activity FHIT  
ENSG00000189283  GO:0005515 protein binding FHIT  
ENSG00000189283  GO:0005634 nucleus FHIT  
ENSG00000189283  GO:0005737 cytoplasm FHIT  
ENSG00000189283  GO:0005739 mitochondrion FHIT  
ENSG00000189283  GO:0005829 cytosol FHIT  
ENSG00000189283  GO:0006163 purine nucleotide metabolic process FHIT  
ENSG00000189283  GO:0006260 DNA replication FHIT  
ENSG00000189283  GO:0006351 transcription, DNA-templated FHIT  
ENSG00000189283  GO:0006355 regulation of transcription, DNA-
templated 
FHIT  
ENSG00000189283  GO:0009117 nucleotide metabolic process FHIT  
ENSG00000189283  GO:0016787 hydrolase activity FHIT  
ENSG00000189283  GO:0031625 ubiquitin protein ligase binding FHIT  
ENSG00000189283  GO:0032435 negative regulation of proteasomal 
ubiquitin-dependent protein catabolic 
process 
FHIT  
ENSG00000189283  GO:0042802 identical protein binding FHIT  
ENSG00000189283  GO:0047710 bis(5'-adenosyl)-triphosphatase 
activity 
FHIT  
ENSG00000189283  GO:0070062 extracellular vesicular exosome FHIT  
ENSG00000189283  GO:0072332 intrinsic apoptotic signaling pathway 
by p53 class mediator 
FHIT  
ENSG00000185070  GO:0005057 receptor signaling protein activity FLRT2  
ENSG00000185070  GO:0005515 protein binding FLRT2  
ENSG00000185070  GO:0005578 proteinaceous extracellular matrix FLRT2  
ENSG00000185070  GO:0005615 extracellular space FLRT2  
ENSG00000185070  GO:0005887 integral component of plasma FLRT2  
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membrane 
ENSG00000185070  GO:0007155 cell adhesion FLRT2  
ENSG00000185070  GO:0007411 axon guidance FLRT2  
ENSG00000185070  GO:0008150 biological_process FLRT2  
ENSG00000185070  GO:0030674 protein binding, bridging FLRT2  
ENSG00000185070  GO:0035556 intracellular signal transduction FLRT2  
ENSG00000185070  GO:0045499 chemorepellent activity FLRT2  
ENSG00000185070  GO:0050919 negative chemotaxis FLRT2  
ENSG00000185070  GO:0070062 extracellular vesicular exosome FLRT2  
ENSG00000185070  GO:2001222 regulation of neuron migration FLRT2  
ENSG00000125848  GO:0005057 receptor signaling protein activity FLRT3  
ENSG00000125848  GO:0005515 protein binding FLRT3  
ENSG00000125848  GO:0005578 proteinaceous extracellular matrix FLRT3  
ENSG00000125848  GO:0005615 extracellular space FLRT3  
ENSG00000125848  GO:0005887 integral component of plasma 
membrane 
FLRT3  
ENSG00000125848  GO:0007155 cell adhesion FLRT3  
ENSG00000125848  GO:0007411 axon guidance FLRT3  
ENSG00000125848  GO:0008150 biological_process FLRT3  
ENSG00000125848  GO:0030674 protein binding, bridging FLRT3  
ENSG00000125848  GO:0035556 intracellular signal transduction FLRT3  
ENSG00000125848  GO:0045499 chemorepellent activity FLRT3  
ENSG00000125848  GO:0050919 negative chemotaxis FLRT3  
ENSG00000151474  GO:0005737 cytoplasm FRMD4A  
ENSG00000151474  GO:0005856 cytoskeleton FRMD4A  
ENSG00000151474  GO:0005923 tight junction FRMD4A  
ENSG00000151474  GO:0030674 protein binding, bridging FRMD4A  
ENSG00000151474  GO:0090162 establishment of epithelial cell polarity FRMD4A  
ENSG00000053108  GO:0005509 calcium ion binding FSTL4  
ENSG00000053108  GO:0005515 protein binding FSTL4  
ENSG00000053108  GO:0005576 extracellular region FSTL4  
ENSG00000168843  GO:0005509 calcium ion binding FSTL5  
ENSG00000168843  GO:0005515 protein binding FSTL5  
ENSG00000168843  GO:0005576 extracellular region FSTL5  
ENSG00000082074  GO:0005102 receptor binding FYB  
ENSG00000082074  GO:0005515 protein binding FYB  
ENSG00000082074  GO:0005634 nucleus FYB  
ENSG00000082074  GO:0005829 cytosol FYB  
ENSG00000082074  GO:0006468 protein phosphorylation FYB  
ENSG00000082074  GO:0006607 NLS-bearing protein import into 
nucleus 
FYB  
ENSG00000082074  GO:0006955 immune response FYB  
ENSG00000082074  GO:0007165 signal transduction FYB  
ENSG00000082074  GO:0008150 biological_process FYB  
ENSG00000082074  GO:0015629 actin cytoskeleton FYB  
ENSG00000082074  GO:0032403 protein complex binding FYB  
ENSG00000082074  GO:0035556 intracellular signal transduction FYB  
ENSG00000082074  GO:0050852 T cell receptor signaling pathway FYB  
ENSG00000094755  GO:0004890 GABA-A receptor activity GABRP  
ENSG00000094755  GO:0005230 extracellular ligand-gated ion channel 
activity 
GABRP  
ENSG00000094755  GO:0005254 chloride channel activity GABRP  
ENSG00000094755  GO:0005886 plasma membrane GABRP  
ENSG00000094755  GO:0006810 transport GABRP  
ENSG00000094755  GO:0006811 ion transport GABRP  
ENSG00000094755  GO:0007165 signal transduction GABRP  
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ENSG00000094755  GO:0016020 membrane GABRP  
ENSG00000094755  GO:0016021 integral component of membrane GABRP  
ENSG00000094755  GO:0030054 cell junction GABRP  
ENSG00000094755  GO:0034220 ion transmembrane transport GABRP  
ENSG00000094755  GO:0034707 chloride channel complex GABRP  
ENSG00000094755  GO:0045202 synapse GABRP  
ENSG00000094755  GO:0045211 postsynaptic membrane GABRP  
ENSG00000094755  GO:1902476 chloride transmembrane transport GABRP  
ENSG00000168505  GO:0001569 patterning of blood vessels GBX2  
ENSG00000168505  GO:0001755 neural crest cell migration GBX2  
ENSG00000168505  GO:0003677 DNA binding GBX2  
ENSG00000168505  GO:0003700 sequence-specific DNA binding 
transcription factor activity 
GBX2  
ENSG00000168505  GO:0005634 nucleus GBX2  
ENSG00000168505  GO:0006351 transcription, DNA-templated GBX2  
ENSG00000168505  GO:0006355 regulation of transcription, DNA-
templated 
GBX2  
ENSG00000168505  GO:0007399 nervous system development GBX2  
ENSG00000168505  GO:0007411 axon guidance GBX2  
ENSG00000168505  GO:0008283 cell proliferation GBX2  
ENSG00000168505  GO:0021549 cerebellum development GBX2  
ENSG00000168505  GO:0021555 midbrain-hindbrain boundary 
morphogenesis 
GBX2  
ENSG00000168505  GO:0021568 rhombomere 2 development GBX2  
ENSG00000168505  GO:0021794 thalamus development GBX2  
ENSG00000168505  GO:0021884 forebrain neuron development GBX2  
ENSG00000168505  GO:0021930 cerebellar granule cell precursor 
proliferation 
GBX2  
ENSG00000168505  GO:0030902 hindbrain development GBX2  
ENSG00000168505  GO:0030917 midbrain-hindbrain boundary 
development 
GBX2  
ENSG00000168505  GO:0035239 tube morphogenesis GBX2  
ENSG00000168505  GO:0042472 inner ear morphogenesis GBX2  
ENSG00000168505  GO:0043565 sequence-specific DNA binding GBX2  
ENSG00000168505  GO:0048483 autonomic nervous system 
development 
GBX2  
ENSG00000131459  GO:0004360 glutamine-fructose-6-phosphate 
transaminase (isomerizing) activity 
GFPT2  
ENSG00000131459  GO:0005829 cytosol GFPT2  
ENSG00000131459  GO:0005975 carbohydrate metabolic process GFPT2  
ENSG00000131459  GO:0006002 fructose 6-phosphate metabolic 
process 
GFPT2  
ENSG00000131459  GO:0006048 UDP-N-acetylglucosamine 
biosynthetic process 
GFPT2  
ENSG00000131459  GO:0006112 energy reserve metabolic process GFPT2  
ENSG00000131459  GO:0006488 dolichol-linked oligosaccharide 
biosynthetic process 
GFPT2  
ENSG00000131459  GO:0006541 glutamine metabolic process GFPT2  
ENSG00000131459  GO:0008152 metabolic process GFPT2  
ENSG00000131459  GO:0016051 carbohydrate biosynthetic process GFPT2  
ENSG00000131459  GO:0018279 protein N-linked glycosylation via 
asparagine 
GFPT2  
ENSG00000131459  GO:0030246 carbohydrate binding GFPT2  
ENSG00000131459  GO:0043687 post-translational protein modification GFPT2  
ENSG00000131459  GO:0044267 cellular protein metabolic process GFPT2  
ENSG00000106571  GO:0000122 negative regulation of transcription 
from RNA polymerase II promoter 
GLI3  
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ENSG00000106571  GO:0000978 RNA polymerase II core promoter 
proximal region sequence-specific 
DNA binding 
GLI3  
ENSG00000106571  GO:0001656 metanephros development GLI3  
ENSG00000106571  GO:0001658 branching involved in ureteric bud 
morphogenesis 
GLI3  
ENSG00000106571  GO:0001701 in utero embryonic development GLI3  
ENSG00000106571  GO:0001822 kidney development GLI3  
ENSG00000106571  GO:0002052 positive regulation of neuroblast 
proliferation 
GLI3  
ENSG00000106571  GO:0003682 chromatin binding GLI3  
ENSG00000106571  GO:0003700 sequence-specific DNA binding 
transcription factor activity 
GLI3  
ENSG00000106571  GO:0005515 protein binding GLI3  
ENSG00000106571  GO:0005634 nucleus GLI3  
ENSG00000106571  GO:0005737 cytoplasm GLI3  
ENSG00000106571  GO:0005829 cytosol GLI3  
ENSG00000106571  GO:0005929 cilium GLI3  
ENSG00000106571  GO:0006351 transcription, DNA-templated GLI3  
ENSG00000106571  GO:0006355 regulation of transcription, DNA-
templated 
GLI3  
ENSG00000106571  GO:0007224 smoothened signaling pathway GLI3  
ENSG00000106571  GO:0007389 pattern specification process GLI3  
ENSG00000106571  GO:0007411 axon guidance GLI3  
ENSG00000106571  GO:0007417 central nervous system development GLI3  
ENSG00000106571  GO:0007420 brain development GLI3  
ENSG00000106571  GO:0007442 hindgut morphogenesis GLI3  
ENSG00000106571  GO:0007507 heart development GLI3  
ENSG00000106571  GO:0008013 beta-catenin binding GLI3  
ENSG00000106571  GO:0008285 negative regulation of cell proliferation GLI3  
ENSG00000106571  GO:0009952 anterior/posterior pattern specification GLI3  
ENSG00000106571  GO:0009953 dorsal/ventral pattern formation GLI3  
ENSG00000106571  GO:0009954 proximal/distal pattern formation GLI3  
ENSG00000106571  GO:0010468 regulation of gene expression GLI3  
ENSG00000106571  GO:0016485 protein processing GLI3  
ENSG00000106571  GO:0016592 mediator complex GLI3  
ENSG00000106571  GO:0016607 nuclear speck GLI3  
ENSG00000106571  GO:0017053 transcriptional repressor complex GLI3  
ENSG00000106571  GO:0021513 spinal cord dorsal/ventral patterning GLI3  
ENSG00000106571  GO:0021522 spinal cord motor neuron 
differentiation 
GLI3  
ENSG00000106571  GO:0021537 telencephalon development GLI3  
ENSG00000106571  GO:0021543 pallium development GLI3  
ENSG00000106571  GO:0021544 subpallium development GLI3  
ENSG00000106571  GO:0021631 optic nerve morphogenesis GLI3  
ENSG00000106571  GO:0021766 hippocampus development GLI3  
ENSG00000106571  GO:0021775 smoothened signaling pathway 
involved in ventral spinal cord 
interneuron specification 
GLI3  
ENSG00000106571  GO:0021776 smoothened signaling pathway 
involved in spinal cord motor neuron 
cell fate specification 
GLI3  
ENSG00000106571  GO:0021798 forebrain dorsal/ventral pattern 
formation 
GLI3  
ENSG00000106571  GO:0021801 cerebral cortex radial glia guided 
migration 
GLI3  
ENSG00000106571  GO:0021861 forebrain radial glial cell differentiation GLI3  
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ENSG00000106571  GO:0021915 neural tube development GLI3  
ENSG00000106571  GO:0022018 lateral ganglionic eminence cell 
proliferation 
GLI3  
ENSG00000106571  GO:0030318 melanocyte differentiation GLI3  
ENSG00000106571  GO:0030324 lung development GLI3  
ENSG00000106571  GO:0030326 embryonic limb morphogenesis GLI3  
ENSG00000106571  GO:0030879 mammary gland development GLI3  
ENSG00000106571  GO:0030900 forebrain development GLI3  
ENSG00000106571  GO:0032332 positive regulation of chondrocyte 
differentiation 
GLI3  
ENSG00000106571  GO:0033077 T cell differentiation in thymus GLI3  
ENSG00000106571  GO:0035035 histone acetyltransferase binding GLI3  
ENSG00000106571  GO:0035108 limb morphogenesis GLI3  
ENSG00000106571  GO:0035295 tube development GLI3  
ENSG00000106571  GO:0042060 wound healing GLI3  
ENSG00000106571  GO:0042127 regulation of cell proliferation GLI3  
ENSG00000106571  GO:0042307 positive regulation of protein import 
into nucleus 
GLI3  
ENSG00000106571  GO:0042475 odontogenesis of dentin-containing 
tooth 
GLI3  
ENSG00000106571  GO:0042733 embryonic digit morphogenesis GLI3  
ENSG00000106571  GO:0042826 histone deacetylase binding GLI3  
ENSG00000106571  GO:0042981 regulation of apoptotic process GLI3  
ENSG00000106571  GO:0043010 camera-type eye development GLI3  
ENSG00000106571  GO:0043066 negative regulation of apoptotic 
process 
GLI3  
ENSG00000106571  GO:0043565 sequence-specific DNA binding GLI3  
ENSG00000106571  GO:0043585 nose morphogenesis GLI3  
ENSG00000106571  GO:0043586 tongue development GLI3  
ENSG00000106571  GO:0043627 response to estrogen GLI3  
ENSG00000106571  GO:0045060 negative thymic T cell selection GLI3  
ENSG00000106571  GO:0045595 regulation of cell differentiation GLI3  
ENSG00000106571  GO:0045596 negative regulation of cell 
differentiation 
GLI3  
ENSG00000106571  GO:0045665 negative regulation of neuron 
differentiation 
GLI3  
ENSG00000106571  GO:0045669 positive regulation of osteoblast 
differentiation 
GLI3  
ENSG00000106571  GO:0045879 negative regulation of smoothened 
signaling pathway 
GLI3  
ENSG00000106571  GO:0045892 negative regulation of transcription, 
DNA-templated 
GLI3  
ENSG00000106571  GO:0045893 positive regulation of transcription, 
DNA-templated 
GLI3  
ENSG00000106571  GO:0045944 positive regulation of transcription 
from RNA polymerase II promoter 
GLI3  
ENSG00000106571  GO:0046638 positive regulation of alpha-beta T cell 
differentiation 
GLI3  
ENSG00000106571  GO:0046639 negative regulation of alpha-beta T 
cell differentiation 
GLI3  
ENSG00000106571  GO:0046872 metal ion binding GLI3  
ENSG00000106571  GO:0048557 embryonic digestive tract 
morphogenesis 
GLI3  
ENSG00000106571  GO:0048566 embryonic digestive tract 
development 
GLI3  
ENSG00000106571  GO:0048589 developmental growth GLI3  
ENSG00000106571  GO:0048593 camera-type eye morphogenesis GLI3  
ENSG00000106571  GO:0048598 embryonic morphogenesis GLI3  
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ENSG00000106571  GO:0048646 anatomical structure formation 
involved in morphogenesis 
GLI3  
ENSG00000106571  GO:0048663 neuron fate commitment GLI3  
ENSG00000106571  GO:0048704 embryonic skeletal system 
morphogenesis 
GLI3  
ENSG00000106571  GO:0048709 oligodendrocyte differentiation GLI3  
ENSG00000106571  GO:0048754 branching morphogenesis of an 
epithelial tube 
GLI3  
ENSG00000106571  GO:0048839 inner ear development GLI3  
ENSG00000106571  GO:0048856 anatomical structure development GLI3  
ENSG00000106571  GO:0060021 palate development GLI3  
ENSG00000106571  GO:0060173 limb development GLI3  
ENSG00000106571  GO:0060364 frontal suture morphogenesis GLI3  
ENSG00000106571  GO:0060366 lambdoid suture morphogenesis GLI3  
ENSG00000106571  GO:0060367 sagittal suture morphogenesis GLI3  
ENSG00000106571  GO:0060594 mammary gland specification GLI3  
ENSG00000106571  GO:0060831 smoothened signaling pathway 
involved in dorsal/ventral neural tube 
patterning 
GLI3  
ENSG00000106571  GO:0060840 artery development GLI3  
ENSG00000106571  GO:0060873 anterior semicircular canal 
development 
GLI3  
ENSG00000106571  GO:0060875 lateral semicircular canal development GLI3  
ENSG00000106571  GO:0061005 cell differentiation involved in kidney 
development 
GLI3  
ENSG00000106571  GO:0070242 thymocyte apoptotic process GLI3  
ENSG00000106571  GO:0072372 primary cilium GLI3  
ENSG00000106571  GO:0090090 negative regulation of canonical Wnt 
signaling pathway 
GLI3  
ENSG00000182512  GO:0005634 nucleus GLRX5  
ENSG00000182512  GO:0005739 mitochondrion GLRX5  
ENSG00000182512  GO:0009055 electron carrier activity GLRX5  
ENSG00000182512  GO:0015035 protein disulfide oxidoreductase 
activity 
GLRX5  
ENSG00000182512  GO:0030097 hemopoiesis GLRX5  
ENSG00000182512  GO:0045454 cell redox homeostasis GLRX5  
ENSG00000182512  GO:0046872 metal ion binding GLRX5  
ENSG00000182512  GO:0051537 2 iron, 2 sulfur cluster binding GLRX5  
ENSG00000182512  GO:0055114 oxidation-reduction process GLRX5  
ENSG00000214415  GO:0001580 detection of chemical stimulus 
involved in sensory perception of 
bitter taste 
GNAT3  
ENSG00000214415  GO:0001664 G-protein coupled receptor binding GNAT3  
ENSG00000214415  GO:0001669 acrosomal vesicle GNAT3  
ENSG00000214415  GO:0001750 photoreceptor outer segment GNAT3  
ENSG00000214415  GO:0001917 photoreceptor inner segment GNAT3  
ENSG00000214415  GO:0003924 GTPase activity GNAT3  
ENSG00000214415  GO:0004871 signal transducer activity GNAT3  
ENSG00000214415  GO:0005525 GTP binding GNAT3  
ENSG00000214415  GO:0005737 cytoplasm GNAT3  
ENSG00000214415  GO:0005834 heterotrimeric G-protein complex GNAT3  
ENSG00000214415  GO:0005886 plasma membrane GNAT3  
ENSG00000214415  GO:0005930 axoneme GNAT3  
ENSG00000214415  GO:0006184 GTP catabolic process GNAT3  
ENSG00000214415  GO:0007165 signal transduction GNAT3  
ENSG00000214415  GO:0007186 G-protein coupled receptor signaling 
pathway 
GNAT3  
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ENSG00000214415  GO:0007188 adenylate cyclase-modulating G-
protein coupled receptor signaling 
pathway 
GNAT3  
ENSG00000214415  GO:0007193 adenylate cyclase-inhibiting G-protein 
coupled receptor signaling pathway 
GNAT3  
ENSG00000214415  GO:0007268 synaptic transmission GNAT3  
ENSG00000214415  GO:0007596 blood coagulation GNAT3  
ENSG00000214415  GO:0008020 G-protein coupled photoreceptor 
activity 
GNAT3  
ENSG00000214415  GO:0009584 detection of visible light GNAT3  
ENSG00000214415  GO:0016324 apical plasma membrane GNAT3  
ENSG00000214415  GO:0019001 guanyl nucleotide binding GNAT3  
ENSG00000214415  GO:0030168 platelet activation GNAT3  
ENSG00000214415  GO:0031683 G-protein beta/gamma-subunit 
complex binding 
GNAT3  
ENSG00000214415  GO:0035094 response to nicotine GNAT3  
ENSG00000214415  GO:0043234 protein complex GNAT3  
ENSG00000214415  GO:0046872 metal ion binding GNAT3  
ENSG00000214415  GO:0050909 sensory perception of taste GNAT3  
ENSG00000214415  GO:0050913 sensory perception of bitter taste GNAT3  
ENSG00000214415  GO:0050916 sensory perception of sweet taste GNAT3  
ENSG00000214415  GO:0050917 sensory perception of umami taste GNAT3  
ENSG00000180269  GO:0004930 G-protein coupled receptor activity GPR139  
ENSG00000180269  GO:0005886 plasma membrane GPR139  
ENSG00000180269  GO:0007186 G-protein coupled receptor signaling 
pathway 
GPR139  
ENSG00000180269  GO:0007200 phospholipase C-activating G-protein 
coupled receptor signaling pathway 
GPR139  
ENSG00000180269  GO:0007218 neuropeptide signaling pathway GPR139  
ENSG00000180269  GO:0008188 neuropeptide receptor activity GPR139  
ENSG00000180269  GO:0016021 integral component of membrane GPR139  
ENSG00000180269  GO:0046983 protein dimerization activity GPR139  
ENSG00000085382  GO:0000139 Golgi membrane HACE1  
ENSG00000085382  GO:0004842 ubiquitin-protein transferase activity HACE1  
ENSG00000085382  GO:0005515 protein binding HACE1  
ENSG00000085382  GO:0005634 nucleus HACE1  
ENSG00000085382  GO:0005783 endoplasmic reticulum HACE1  
ENSG00000085382  GO:0006351 transcription, DNA-templated HACE1  
ENSG00000085382  GO:0006355 regulation of transcription, DNA-
templated 
HACE1  
ENSG00000085382  GO:0007030 Golgi organization HACE1  
ENSG00000085382  GO:0007049 cell cycle HACE1  
ENSG00000085382  GO:0016567 protein ubiquitination HACE1  
ENSG00000085382  GO:0016601 Rac protein signal transduction HACE1  
ENSG00000085382  GO:0016874 ligase activity HACE1  
ENSG00000085382  GO:0017137 Rab GTPase binding HACE1  
ENSG00000085382  GO:0030334 regulation of cell migration HACE1  
ENSG00000085382  GO:0032580 Golgi cisterna membrane HACE1  
ENSG00000085382  GO:0042787 protein ubiquitination involved in 
ubiquitin-dependent protein catabolic 
process 
HACE1  
ENSG00000085382  GO:0048365 Rac GTPase binding HACE1  
ENSG00000085382  GO:0061025 membrane fusion HACE1  
ENSG00000085382  GO:0070936 protein K48-linked ubiquitination HACE1  
ENSG00000232962  GO:0002587 negative regulation of antigen 
processing and presentation of 
peptide antigen via MHC class II 
HLA-DOA  
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ENSG00000232962  GO:0005515 protein binding HLA-DOA  
ENSG00000232962  GO:0005765 lysosomal membrane HLA-DOA  
ENSG00000232962  GO:0005886 plasma membrane HLA-DOA  
ENSG00000232962  GO:0006955 immune response HLA-DOA  
ENSG00000232962  GO:0007165 signal transduction HLA-DOA  
ENSG00000232962  GO:0010008 endosome membrane HLA-DOA  
ENSG00000232962  GO:0016020 membrane HLA-DOA  
ENSG00000232962  GO:0016021 integral component of membrane HLA-DOA  
ENSG00000232962  GO:0019882 antigen processing and presentation HLA-DOA  
ENSG00000232962  GO:0019886 antigen processing and presentation 
of exogenous peptide antigen via 
MHC class II 
HLA-DOA  
ENSG00000232962  GO:0023026 MHC class II protein complex binding HLA-DOA  
ENSG00000232962  GO:0032395 MHC class II receptor activity HLA-DOA  
ENSG00000232962  GO:0042613 MHC class II protein complex HLA-DOA  
ENSG00000232962  GO:0045580 regulation of T cell differentiation HLA-DOA  
ENSG00000230763  GO:0000139 Golgi membrane HLA-DPB1  
ENSG00000237710  GO:0000139 Golgi membrane HLA-DPB1  
ENSG00000226826  GO:0000139 Golgi membrane HLA-DPB1  
ENSG00000223865  GO:0000139 Golgi membrane HLA-DPB1  
ENSG00000215048  GO:0000139 Golgi membrane HLA-DPB1  
ENSG00000236693  GO:0000139 Golgi membrane HLA-DPB1  
ENSG00000237710  GO:0002504 antigen processing and presentation 
of peptide or polysaccharide antigen 
via MHC class II 
HLA-DPB1  
ENSG00000230763  GO:0005515 protein binding HLA-DPB1  
ENSG00000230763  GO:0005765 lysosomal membrane HLA-DPB1  
ENSG00000230763  GO:0005886 plasma membrane HLA-DPB1  
ENSG00000230763  GO:0006955 immune response HLA-DPB1  
ENSG00000230763  GO:0009986 cell surface HLA-DPB1  
ENSG00000230763  GO:0010008 endosome membrane HLA-DPB1  
ENSG00000230763  GO:0012507 ER to Golgi transport vesicle 
membrane 
HLA-DPB1  
ENSG00000230763  GO:0016020 membrane HLA-DPB1  
ENSG00000237710  GO:0016021 integral component of membrane HLA-DPB1  
ENSG00000230763  GO:0019221 cytokine-mediated signaling pathway HLA-DPB1  
ENSG00000230763  GO:0019882 antigen processing and presentation HLA-DPB1  
ENSG00000230763  GO:0019886 antigen processing and presentation 
of exogenous peptide antigen via 
MHC class II 
HLA-DPB1  
ENSG00000230763  GO:0030658 transport vesicle membrane HLA-DPB1  
ENSG00000230763  GO:0030666 endocytic vesicle membrane HLA-DPB1  
ENSG00000230763  GO:0030669 clathrin-coated endocytic vesicle 
membrane 
HLA-DPB1  
ENSG00000230763  GO:0031295 T cell costimulation HLA-DPB1  
ENSG00000230763  GO:0032588 trans-Golgi network membrane HLA-DPB1  
ENSG00000230763  GO:0032729 positive regulation of interferon-
gamma production 
HLA-DPB1  
ENSG00000230763  GO:0042102 positive regulation of T cell 
proliferation 
HLA-DPB1  
ENSG00000230763  GO:0042605 peptide antigen binding HLA-DPB1  
ENSG00000230763  GO:0042613 MHC class II protein complex HLA-DPB1  
ENSG00000230763  GO:0050852 T cell receptor signaling pathway HLA-DPB1  
ENSG00000230763  GO:0050870 positive regulation of T cell activation HLA-DPB1  
ENSG00000230763  GO:0060333 interferon-gamma-mediated signaling 
pathway 
HLA-DPB1  
ENSG00000230763  GO:0071556 integral component of lumenal side of HLA-DPB1  
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endoplasmic reticulum membrane 
ENSG00000173083  GO:0004566 beta-glucuronidase activity HPSE  
ENSG00000173083  GO:0005515 protein binding HPSE  
ENSG00000173083  GO:0005576 extracellular region HPSE  
ENSG00000173083  GO:0005634 nucleus HPSE  
ENSG00000173083  GO:0005764 lysosome HPSE  
ENSG00000173083  GO:0005765 lysosomal membrane HPSE  
ENSG00000173083  GO:0005975 carbohydrate metabolic process HPSE  
ENSG00000173083  GO:0006027 glycosaminoglycan catabolic process HPSE  
ENSG00000173083  GO:0006029 proteoglycan metabolic process HPSE  
ENSG00000173083  GO:0007160 cell-matrix adhesion HPSE  
ENSG00000173083  GO:0008152 metabolic process HPSE  
ENSG00000173083  GO:0010575 positive regulation vascular 
endothelial growth factor production 
HPSE  
ENSG00000173083  GO:0016020 membrane HPSE  
ENSG00000173083  GO:0016798 hydrolase activity, acting on glycosyl 
bonds 
HPSE  
ENSG00000173083  GO:0030194 positive regulation of blood 
coagulation 
HPSE  
ENSG00000173083  GO:0030200 heparan sulfate proteoglycan 
catabolic process 
HPSE  
ENSG00000173083  GO:0030203 glycosaminoglycan metabolic process HPSE  
ENSG00000173083  GO:0030305 heparanase activity HPSE  
ENSG00000173083  GO:0033690 positive regulation of osteoblast 
proliferation 
HPSE  
ENSG00000173083  GO:0042060 wound healing HPSE  
ENSG00000173083  GO:0043202 lysosomal lumen HPSE  
ENSG00000173083  GO:0043231 intracellular membrane-bounded 
organelle 
HPSE  
ENSG00000173083  GO:0044281 small molecule metabolic process HPSE  
ENSG00000173083  GO:0045121 membrane raft HPSE  
ENSG00000173083  GO:0045545 syndecan binding HPSE  
ENSG00000173083  GO:0046983 protein dimerization activity HPSE  
ENSG00000173083  GO:0051797 regulation of hair follicle development HPSE  
ENSG00000173083  GO:0051798 positive regulation of hair follicle 
development 
HPSE  
ENSG00000173083  GO:0051897 positive regulation of protein kinase B 
signaling 
HPSE  
ENSG00000173083  GO:0060055 angiogenesis involved in wound 
healing 
HPSE  
ENSG00000173083  GO:0061042 vascular wound healing HPSE  
ENSG00000170606  GO:0000902 cell morphogenesis HSPA4  
ENSG00000170606  GO:0005515 protein binding HSPA4  
ENSG00000170606  GO:0005524 ATP binding HSPA4  
ENSG00000170606  GO:0005739 mitochondrion HSPA4  
ENSG00000170606  GO:0005829 cytosol HSPA4  
ENSG00000170606  GO:0006986 response to unfolded protein HSPA4  
ENSG00000170606  GO:0045040 protein import into mitochondrial outer 
membrane 
HSPA4  
ENSG00000170606  GO:0051131 chaperone-mediated protein complex 
assembly 
HSPA4  
ENSG00000170606  GO:0070062 extracellular vesicular exosome HSPA4  
ENSG00000137959  GO:0005737 cytoplasm IFI44L  
ENSG00000137959  GO:0006955 immune response IFI44L  
ENSG00000137959  GO:0051607 defense response to virus IFI44L  
ENSG00000188487  GO:0000132 establishment of mitotic spindle 
orientation 
INSC  
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ENSG00000188487  GO:0005488 binding INSC  
ENSG00000188487  GO:0005515 protein binding INSC  
ENSG00000188487  GO:0005737 cytoplasm INSC  
ENSG00000188487  GO:0007399 nervous system development INSC  
ENSG00000188487  GO:0045177 apical part of cell INSC  
ENSG00000188487  GO:0060487 lung epithelial cell differentiation INSC  
ENSG00000170561  GO:0001656 metanephros development IRX2  
ENSG00000170561  GO:0003677 DNA binding IRX2  
ENSG00000170561  GO:0003700 sequence-specific DNA binding 
transcription factor activity 
IRX2  
ENSG00000170561  GO:0005634 nucleus IRX2  
ENSG00000170561  GO:0006355 regulation of transcription, DNA-
templated 
IRX2  
ENSG00000170561  GO:0043565 sequence-specific DNA binding IRX2  
ENSG00000170561  GO:0072086 specification of loop of Henle identity IRX2  
ENSG00000170561  GO:0072272 proximal/distal pattern formation 
involved in metanephric nephron 
development 
IRX2  
ENSG00000140015  GO:0000155 phosphorelay sensor kinase activity KCNH5  
ENSG00000140015  GO:0000160 phosphorelay signal transduction 
system 
KCNH5  
ENSG00000140015  GO:0004871 signal transducer activity KCNH5  
ENSG00000140015  GO:0005216 ion channel activity KCNH5  
ENSG00000140015  GO:0005249 voltage-gated potassium channel 
activity 
KCNH5  
ENSG00000140015  GO:0005516 calmodulin binding KCNH5  
ENSG00000140015  GO:0005622 intracellular KCNH5  
ENSG00000140015  GO:0005886 plasma membrane KCNH5  
ENSG00000140015  GO:0005887 integral component of plasma 
membrane 
KCNH5  
ENSG00000140015  GO:0006355 regulation of transcription, DNA-
templated 
KCNH5  
ENSG00000140015  GO:0006811 ion transport KCNH5  
ENSG00000140015  GO:0007165 signal transduction KCNH5  
ENSG00000140015  GO:0007268 synaptic transmission KCNH5  
ENSG00000140015  GO:0009986 cell surface KCNH5  
ENSG00000140015  GO:0010389 regulation of G2/M transition of mitotic 
cell cycle 
KCNH5  
ENSG00000140015  GO:0016020 membrane KCNH5  
ENSG00000140015  GO:0023014 signal transduction by phosphorylation KCNH5  
ENSG00000140015  GO:0034765 regulation of ion transmembrane 
transport 
KCNH5  
ENSG00000140015  GO:0042391 regulation of membrane potential KCNH5  
ENSG00000140015  GO:0055085 transmembrane transport KCNH5  
ENSG00000140015  GO:0071805 potassium ion transmembrane 
transport 
KCNH5  
ENSG00000182132  GO:0005244 voltage-gated ion channel activity KCNIP1  
ENSG00000182132  GO:0005267 potassium channel activity KCNIP1  
ENSG00000182132  GO:0005509 calcium ion binding KCNIP1  
ENSG00000182132  GO:0005513 detection of calcium ion KCNIP1  
ENSG00000182132  GO:0005515 protein binding KCNIP1  
ENSG00000182132  GO:0005578 proteinaceous extracellular matrix KCNIP1  
ENSG00000182132  GO:0005886 plasma membrane KCNIP1  
ENSG00000182132  GO:0007165 signal transduction KCNIP1  
ENSG00000182132  GO:0007268 synaptic transmission KCNIP1  
ENSG00000182132  GO:0015459 potassium channel regulator activity KCNIP1  
ENSG00000182132  GO:0030425 dendrite KCNIP1  
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ENSG00000182132  GO:0034705 potassium channel complex KCNIP1  
ENSG00000182132  GO:0034765 regulation of ion transmembrane 
transport 
KCNIP1  
ENSG00000182132  GO:0043025 neuronal cell body KCNIP1  
ENSG00000182132  GO:0044325 ion channel binding KCNIP1  
ENSG00000182132  GO:0045760 positive regulation of action potential KCNIP1  
ENSG00000182132  GO:0046982 protein heterodimerization activity KCNIP1  
ENSG00000182132  GO:0047485 protein N-terminus binding KCNIP1  
ENSG00000182132  GO:0071805 potassium ion transmembrane 
transport 
KCNIP1  
ENSG00000109787  GO:0003677 DNA binding KLF3  
ENSG00000109787  GO:0003700 sequence-specific DNA binding 
transcription factor activity 
KLF3  
ENSG00000109787  GO:0005634 nucleus KLF3  
ENSG00000109787  GO:0006351 transcription, DNA-templated KLF3  
ENSG00000109787  GO:0006355 regulation of transcription, DNA-
templated 
KLF3  
ENSG00000109787  GO:0007275 multicellular organismal development KLF3  
ENSG00000109787  GO:0046872 metal ion binding KLF3  
ENSG00000109787  GO:1901653 cellular response to peptide KLF3  
ENSG00000168216  GO:0005158 insulin receptor binding LMBRD1  
ENSG00000168216  GO:0005764 lysosome LMBRD1  
ENSG00000168216  GO:0005765 lysosomal membrane LMBRD1  
ENSG00000168216  GO:0005886 plasma membrane LMBRD1  
ENSG00000168216  GO:0006766 vitamin metabolic process LMBRD1  
ENSG00000168216  GO:0006767 water-soluble vitamin metabolic 
process 
LMBRD1  
ENSG00000168216  GO:0006810 transport LMBRD1  
ENSG00000168216  GO:0009235 cobalamin metabolic process LMBRD1  
ENSG00000168216  GO:0016020 membrane LMBRD1  
ENSG00000168216  GO:0016021 integral component of membrane LMBRD1  
ENSG00000168216  GO:0016032 viral process LMBRD1  
ENSG00000168216  GO:0031419 cobalamin binding LMBRD1  
ENSG00000168216  GO:0038016 insulin receptor internalization LMBRD1  
ENSG00000168216  GO:0044281 small molecule metabolic process LMBRD1  
ENSG00000168216  GO:0045334 clathrin-coated endocytic vesicle LMBRD1  
ENSG00000168216  GO:0046325 negative regulation of glucose import LMBRD1  
ENSG00000168216  GO:0046627 negative regulation of insulin receptor 
signaling pathway 
LMBRD1  
ENSG00000168216  GO:0051898 negative regulation of protein kinase B 
signaling 
LMBRD1  
ENSG00000081479  GO:0001523 retinoid metabolic process LRP2  
ENSG00000081479  GO:0005509 calcium ion binding LRP2  
ENSG00000081479  GO:0005515 protein binding LRP2  
ENSG00000081479  GO:0005764 lysosome LRP2  
ENSG00000081479  GO:0005765 lysosomal membrane LRP2  
ENSG00000081479  GO:0005768 endosome LRP2  
ENSG00000081479  GO:0005783 endoplasmic reticulum LRP2  
ENSG00000081479  GO:0005794 Golgi apparatus LRP2  
ENSG00000081479  GO:0005886 plasma membrane LRP2  
ENSG00000081479  GO:0005903 brush border LRP2  
ENSG00000081479  GO:0005905 coated pit LRP2  
ENSG00000081479  GO:0006486 protein glycosylation LRP2  
ENSG00000081479  GO:0006629 lipid metabolic process LRP2  
ENSG00000081479  GO:0006766 vitamin metabolic process LRP2  
ENSG00000081479  GO:0006897 endocytosis LRP2  
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ENSG00000081479  GO:0006898 receptor-mediated endocytosis LRP2  
ENSG00000081479  GO:0007603 phototransduction, visible light LRP2  
ENSG00000081479  GO:0008202 steroid metabolic process LRP2  
ENSG00000081479  GO:0008283 cell proliferation LRP2  
ENSG00000081479  GO:0016020 membrane LRP2  
ENSG00000081479  GO:0016021 integral component of membrane LRP2  
ENSG00000081479  GO:0016324 apical plasma membrane LRP2  
ENSG00000081479  GO:0017124 SH3 domain binding LRP2  
ENSG00000081479  GO:0030139 endocytic vesicle LRP2  
ENSG00000081479  GO:0030900 forebrain development LRP2  
ENSG00000081479  GO:0031526 brush border membrane LRP2  
ENSG00000081479  GO:0042359 vitamin D metabolic process LRP2  
ENSG00000081479  GO:0043235 receptor complex LRP2  
ENSG00000081479  GO:0044281 small molecule metabolic process LRP2  
ENSG00000081479  GO:0045177 apical part of cell LRP2  
ENSG00000081479  GO:0070062 extracellular vesicular exosome LRP2  
ENSG00000172264  GO:0005634 nucleus MACROD2  
ENSG00000172264  GO:0006974 cellular response to DNA damage 
stimulus 
MACROD2  
ENSG00000172264  GO:0007420 brain development MACROD2  
ENSG00000172264  GO:0016798 hydrolase activity, acting on glycosyl 
bonds 
MACROD2  
ENSG00000172264  GO:0019213 deacetylase activity MACROD2  
ENSG00000172264  GO:0042278 purine nucleoside metabolic process MACROD2  
ENSG00000172264  GO:0051725 protein de-ADP-ribosylation MACROD2  
ENSG00000152127  GO:0000139 Golgi membrane MGAT5  
ENSG00000152127  GO:0005794 Golgi apparatus MGAT5  
ENSG00000152127  GO:0006487 protein N-linked glycosylation MGAT5  
ENSG00000152127  GO:0008375 acetylglucosaminyltransferase activity MGAT5  
ENSG00000152127  GO:0016021 integral component of membrane MGAT5  
ENSG00000152127  GO:0018279 protein N-linked glycosylation via 
asparagine 
MGAT5  
ENSG00000152127  GO:0030144 alpha-1,6-mannosylglycoprotein 6-
beta-N-acetylglucosaminyltransferase 
activity 
MGAT5  
ENSG00000152127  GO:0043687 post-translational protein modification MGAT5  
ENSG00000152127  GO:0044267 cellular protein metabolic process MGAT5  
ENSG00000152127  GO:0070062 extracellular vesicular exosome MGAT5  
ENSG00000137675  GO:0004222 metalloendopeptidase activity MMP27  
ENSG00000137675  GO:0005509 calcium ion binding MMP27  
ENSG00000137675  GO:0005578 proteinaceous extracellular matrix MMP27  
ENSG00000137675  GO:0006508 proteolysis MMP27  
ENSG00000137675  GO:0008237 metallopeptidase activity MMP27  
ENSG00000137675  GO:0008270 zinc ion binding MMP27  
ENSG00000137675  GO:0030574 collagen catabolic process MMP27  
ENSG00000137675  GO:0031012 extracellular matrix MMP27  
ENSG00000135698  GO:0000087 mitotic M phase MPHOSPH6  
ENSG00000135698  GO:0000176 nuclear exosome (RNase complex) MPHOSPH6  
ENSG00000135698  GO:0000178 exosome (RNase complex) MPHOSPH6  
ENSG00000135698  GO:0000460 maturation of 5.8S rRNA MPHOSPH6  
ENSG00000135698  GO:0003723 RNA binding MPHOSPH6  
ENSG00000135698  GO:0005515 protein binding MPHOSPH6  
ENSG00000135698  GO:0005634 nucleus MPHOSPH6  
ENSG00000135698  GO:0005730 nucleolus MPHOSPH6  
ENSG00000135698  GO:0005737 cytoplasm MPHOSPH6  
ENSG00000170681  GO:0005737 cytoplasm MURC  
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ENSG00000170681  GO:0006351 transcription, DNA-templated MURC  
ENSG00000170681  GO:0007517 muscle organ development MURC  
ENSG00000170681  GO:0030018 Z disc MURC  
ENSG00000170681  GO:0030154 cell differentiation MURC  
ENSG00000170681  GO:0045944 positive regulation of transcription 
from RNA polymerase II promoter 
MURC  
ENSG00000034971  GO:0001649 osteoblast differentiation MYOC  
ENSG00000034971  GO:0001953 negative regulation of cell-matrix 
adhesion 
MYOC  
ENSG00000034971  GO:0001968 fibronectin binding MYOC  
ENSG00000034971  GO:0005109 frizzled binding MYOC  
ENSG00000034971  GO:0005515 protein binding MYOC  
ENSG00000034971  GO:0005578 proteinaceous extracellular matrix MYOC  
ENSG00000034971  GO:0005615 extracellular space MYOC  
ENSG00000034971  GO:0005741 mitochondrial outer membrane MYOC  
ENSG00000034971  GO:0005743 mitochondrial inner membrane MYOC  
ENSG00000034971  GO:0005758 mitochondrial intermembrane space MYOC  
ENSG00000034971  GO:0005783 endoplasmic reticulum MYOC  
ENSG00000034971  GO:0005791 rough endoplasmic reticulum MYOC  
ENSG00000034971  GO:0005794 Golgi apparatus MYOC  
ENSG00000034971  GO:0005929 cilium MYOC  
ENSG00000034971  GO:0014068 positive regulation of 
phosphatidylinositol 3-kinase signaling 
MYOC  
ENSG00000034971  GO:0014734 skeletal muscle hypertrophy MYOC  
ENSG00000034971  GO:0016023 cytoplasmic membrane-bounded 
vesicle 
MYOC  
ENSG00000034971  GO:0022011 myelination in peripheral nervous 
system 
MYOC  
ENSG00000034971  GO:0030335 positive regulation of cell migration MYOC  
ENSG00000034971  GO:0030971 receptor tyrosine kinase binding MYOC  
ENSG00000034971  GO:0031012 extracellular matrix MYOC  
ENSG00000034971  GO:0031175 neuron projection development MYOC  
ENSG00000034971  GO:0031410 cytoplasmic vesicle MYOC  
ENSG00000034971  GO:0032027 myosin light chain binding MYOC  
ENSG00000034971  GO:0033268 node of Ranvier MYOC  
ENSG00000034971  GO:0035024 negative regulation of Rho protein 
signal transduction 
MYOC  
ENSG00000034971  GO:0038031 non-canonical Wnt signaling pathway 
via JNK cascade 
MYOC  
ENSG00000034971  GO:0038133 ERBB2-ERBB3 signaling pathway MYOC  
ENSG00000034971  GO:0043408 regulation of MAPK cascade MYOC  
ENSG00000034971  GO:0045162 clustering of voltage-gated sodium 
channels 
MYOC  
ENSG00000034971  GO:0051496 positive regulation of stress fiber 
assembly 
MYOC  
ENSG00000034971  GO:0051497 negative regulation of stress fiber 
assembly 
MYOC  
ENSG00000034971  GO:0051894 positive regulation of focal adhesion 
assembly 
MYOC  
ENSG00000034971  GO:0051897 positive regulation of protein kinase B 
signaling 
MYOC  
ENSG00000034971  GO:0051901 positive regulation of mitochondrial 
depolarization 
MYOC  
ENSG00000034971  GO:0060348 bone development MYOC  
ENSG00000034971  GO:0070062 extracellular vesicular exosome MYOC  
ENSG00000034971  GO:1900026 positive regulation of substrate 
adhesion-dependent cell spreading 
MYOC  
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ENSG00000161048  GO:0004620 phospholipase activity NAPEPLD  
ENSG00000275723  GO:0008152 metabolic process NAPEPLD  
ENSG00000161048  GO:0008152 metabolic process NAPEPLD  
ENSG00000275723  GO:0008270 zinc ion binding NAPEPLD  
ENSG00000161048  GO:0008270 zinc ion binding NAPEPLD  
ENSG00000275723  GO:0009395 phospholipid catabolic process NAPEPLD  
ENSG00000161048  GO:0009395 phospholipid catabolic process NAPEPLD  
ENSG00000275723  GO:0042622 photoreceptor outer segment 
membrane 
NAPEPLD  
ENSG00000161048  GO:0042622 photoreceptor outer segment 
membrane 
NAPEPLD  
ENSG00000275723  GO:0070062 extracellular vesicular exosome NAPEPLD  
ENSG00000161048  GO:0070062 extracellular vesicular exosome NAPEPLD  
ENSG00000275723  GO:0070290 N-acylphosphatidylethanolamine-
specific phospholipase D activity 
NAPEPLD  
ENSG00000161048  GO:0070290 N-acylphosphatidylethanolamine-
specific phospholipase D activity 
NAPEPLD  
ENSG00000166833  GO:0003025 regulation of systemic arterial blood 
pressure by baroreceptor feedback 
NAV2  
ENSG00000166833  GO:0004386 helicase activity NAV2  
ENSG00000166833  GO:0005515 protein binding NAV2  
ENSG00000166833  GO:0005524 ATP binding NAV2  
ENSG00000166833  GO:0005614 interstitial matrix NAV2  
ENSG00000166833  GO:0005634 nucleus NAV2  
ENSG00000166833  GO:0007399 nervous system development NAV2  
ENSG00000166833  GO:0007605 sensory perception of sound NAV2  
ENSG00000166833  GO:0007608 sensory perception of smell NAV2  
ENSG00000166833  GO:0007626 locomotory behavior NAV2  
ENSG00000166833  GO:0008152 metabolic process NAV2  
ENSG00000166833  GO:0008201 heparin binding NAV2  
ENSG00000166833  GO:0021554 optic nerve development NAV2  
ENSG00000166833  GO:0021563 glossopharyngeal nerve development NAV2  
ENSG00000166833  GO:0021564 vagus nerve development NAV2  
ENSG00000166833  GO:0031012 extracellular matrix NAV2  
ENSG00000151779  GO:0000956 nuclear-transcribed mRNA catabolic 
process 
NBAS  
ENSG00000151779  GO:0005515 protein binding NBAS  
ENSG00000151779  GO:0005737 cytoplasm NBAS  
ENSG00000151779  GO:0016020 membrane NBAS  
ENSG00000151779  GO:2000623 negative regulation of nuclear-
transcribed mRNA catabolic process, 
nonsense-mediated decay 
NBAS  
ENSG00000277586  GO:0000226 microtubule cytoskeleton organization NEFL  
ENSG00000277586  GO:0005198 structural molecule activity NEFL  
ENSG00000277586  GO:0005200 structural constituent of cytoskeleton NEFL  
ENSG00000277586  GO:0005515 protein binding NEFL  
ENSG00000277586  GO:0005737 cytoplasm NEFL  
ENSG00000277586  GO:0005829 cytosol NEFL  
ENSG00000277586  GO:0005882 intermediate filament NEFL  
ENSG00000277586  GO:0005883 neurofilament NEFL  
ENSG00000277586  GO:0007268 synaptic transmission NEFL  
ENSG00000277586  GO:0008022 protein C-terminus binding NEFL  
ENSG00000277586  GO:0008089 anterograde axon cargo transport NEFL  
ENSG00000277586  GO:0008090 retrograde axon cargo transport NEFL  
ENSG00000277586  GO:0008219 cell death NEFL  
ENSG00000277586  GO:0009636 response to toxic substance NEFL  
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ENSG00000277586  GO:0010033 response to organic substance NEFL  
ENSG00000277586  GO:0010243 response to organonitrogen 
compound 
NEFL  
ENSG00000277586  GO:0014012 peripheral nervous system axon 
regeneration 
NEFL  
ENSG00000277586  GO:0019896 axon transport of mitochondrion NEFL  
ENSG00000277586  GO:0019904 protein domain specific binding NEFL  
ENSG00000277586  GO:0030424 axon NEFL  
ENSG00000277586  GO:0030426 growth cone NEFL  
ENSG00000277586  GO:0030674 protein binding, bridging NEFL  
ENSG00000277586  GO:0031133 regulation of axon diameter NEFL  
ENSG00000277586  GO:0033596 TSC1-TSC2 complex NEFL  
ENSG00000277586  GO:0033693 neurofilament bundle assembly NEFL  
ENSG00000277586  GO:0040011 locomotion NEFL  
ENSG00000277586  GO:0042802 identical protein binding NEFL  
ENSG00000277586  GO:0043005 neuron projection NEFL  
ENSG00000277586  GO:0043274 phospholipase binding NEFL  
ENSG00000277586  GO:0043434 response to peptide hormone NEFL  
ENSG00000277586  GO:0043524 negative regulation of neuron 
apoptotic process 
NEFL  
ENSG00000277586  GO:0045109 intermediate filament organization NEFL  
ENSG00000277586  GO:0045110 intermediate filament bundle 
assembly 
NEFL  
ENSG00000277586  GO:0048812 neuron projection morphogenesis NEFL  
ENSG00000277586  GO:0050772 positive regulation of axonogenesis NEFL  
ENSG00000277586  GO:0050885 neuromuscular process controlling 
balance 
NEFL  
ENSG00000277586  GO:0051258 protein polymerization NEFL  
ENSG00000277586  GO:0051412 response to corticosterone NEFL  
ENSG00000277586  GO:0060052 neurofilament cytoskeleton 
organization 
NEFL  
ENSG00000147862  GO:0000122 negative regulation of transcription 
from RNA polymerase II promoter 
NFIB  
ENSG00000147862  GO:0000978 RNA polymerase II core promoter 
proximal region sequence-specific 
DNA binding 
NFIB  
ENSG00000147862  GO:0000981 sequence-specific DNA binding RNA 
polymerase II transcription factor 
activity 
NFIB  
ENSG00000147862  GO:0001077 RNA polymerase II core promoter 
proximal region sequence-specific 
DNA binding transcription factor 
activity involved in positive regulation 
of transcription 
NFIB  
ENSG00000147862  GO:0001106 RNA polymerase II transcription 
corepressor activity 
NFIB  
ENSG00000147862  GO:0002062 chondrocyte differentiation NFIB  
ENSG00000147862  GO:0003677 DNA binding NFIB  
ENSG00000147862  GO:0003690 double-stranded DNA binding NFIB  
ENSG00000147862  GO:0003700 sequence-specific DNA binding 
transcription factor activity 
NFIB  
ENSG00000147862  GO:0005622 intracellular NFIB  
ENSG00000147862  GO:0005634 nucleus NFIB  
ENSG00000147862  GO:0005730 nucleolus NFIB  
ENSG00000147862  GO:0006260 DNA replication NFIB  
ENSG00000147862  GO:0006351 transcription, DNA-templated NFIB  
ENSG00000147862  GO:0006355 regulation of transcription, DNA-
templated 
NFIB  
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ENSG00000147862  GO:0006366 transcription from RNA polymerase II 
promoter 
NFIB  
ENSG00000147862  GO:0008285 negative regulation of cell proliferation NFIB  
ENSG00000147862  GO:0010001 glial cell differentiation NFIB  
ENSG00000147862  GO:0021740 principal sensory nucleus of trigeminal 
nerve development 
NFIB  
ENSG00000147862  GO:0021960 anterior commissure morphogenesis NFIB  
ENSG00000147862  GO:0030324 lung development NFIB  
ENSG00000147862  GO:0030900 forebrain development NFIB  
ENSG00000147862  GO:0030902 hindbrain development NFIB  
ENSG00000147862  GO:0043392 negative regulation of DNA binding NFIB  
ENSG00000147862  GO:0044300 cerebellar mossy fiber NFIB  
ENSG00000147862  GO:0045944 positive regulation of transcription 
from RNA polymerase II promoter 
NFIB  
ENSG00000147862  GO:0060486 Clara cell differentiation NFIB  
ENSG00000147862  GO:0060509 Type I pneumocyte differentiation NFIB  
ENSG00000147862  GO:0060510 Type II pneumocyte differentiation NFIB  
ENSG00000147862  GO:0061141 lung ciliated cell differentiation NFIB  
ENSG00000147862  GO:0071679 commissural neuron axon guidance NFIB  
ENSG00000147862  GO:2000791 negative regulation of mesenchymal 
cell proliferation involved in lung 
development 
NFIB  
ENSG00000147862  GO:2000795 negative regulation of epithelial cell 
proliferation involved in lung 
morphogenesis 
NFIB  
ENSG00000139910  GO:0000398 mRNA splicing, via spliceosome NOVA1  
ENSG00000139910  GO:0003723 RNA binding NOVA1  
ENSG00000139910  GO:0003729 mRNA binding NOVA1  
ENSG00000139910  GO:0005634 nucleus NOVA1  
ENSG00000139910  GO:0005730 nucleolus NOVA1  
ENSG00000139910  GO:0006396 RNA processing NOVA1  
ENSG00000139910  GO:0007268 synaptic transmission NOVA1  
ENSG00000139910  GO:0007626 locomotory behavior NOVA1  
ENSG00000139910  GO:0008380 RNA splicing NOVA1  
ENSG00000139910  GO:0043231 intracellular membrane-bounded 
organelle 
NOVA1  
ENSG00000139910  GO:0044822 poly(A) RNA binding NOVA1  
ENSG00000139910  GO:0051252 regulation of RNA metabolic process NOVA1  
ENSG00000158458  GO:0005102 receptor binding NRG2  
ENSG00000158458  GO:0005515 protein binding NRG2  
ENSG00000158458  GO:0005576 extracellular region NRG2  
ENSG00000158458  GO:0005886 plasma membrane NRG2  
ENSG00000158458  GO:0007165 signal transduction NRG2  
ENSG00000158458  GO:0007173 epidermal growth factor receptor 
signaling pathway 
NRG2  
ENSG00000158458  GO:0008083 growth factor activity NRG2  
ENSG00000158458  GO:0008543 fibroblast growth factor receptor 
signaling pathway 
NRG2  
ENSG00000158458  GO:0009790 embryo development NRG2  
ENSG00000158458  GO:0016021 integral component of membrane NRG2  
ENSG00000158458  GO:0038095 Fc-epsilon receptor signaling pathway NRG2  
ENSG00000158458  GO:0045087 innate immune response NRG2  
ENSG00000158458  GO:0048011 neurotrophin TRK receptor signaling 
pathway 
NRG2  
ENSG00000158458  GO:0048015 phosphatidylinositol-mediated 
signaling 
NRG2  
ENSG00000144460  GO:0005515 protein binding NYAP2  
  
 287 
ENSG00000144460  GO:0014065 phosphatidylinositol 3-kinase signaling NYAP2  
ENSG00000144460  GO:0048812 neuron projection morphogenesis NYAP2  
ENSG00000168092  GO:0003847 1-alkyl-2-acetylglycerophosphocholine 
esterase activity 
PAFAH1B2  
ENSG00000168092  GO:0005515 protein binding PAFAH1B2  
ENSG00000168092  GO:0005730 nucleolus PAFAH1B2  
ENSG00000168092  GO:0005737 cytoplasm PAFAH1B2  
ENSG00000168092  GO:0005829 cytosol PAFAH1B2  
ENSG00000168092  GO:0005886 plasma membrane PAFAH1B2  
ENSG00000168092  GO:0006629 lipid metabolic process PAFAH1B2  
ENSG00000168092  GO:0007283 spermatogenesis PAFAH1B2  
ENSG00000168092  GO:0007420 brain development PAFAH1B2  
ENSG00000168092  GO:0008152 metabolic process PAFAH1B2  
ENSG00000168092  GO:0016042 lipid catabolic process PAFAH1B2  
ENSG00000168092  GO:0016239 positive regulation of macroautophagy PAFAH1B2  
ENSG00000168092  GO:0016787 hydrolase activity PAFAH1B2  
ENSG00000168092  GO:0016788 hydrolase activity, acting on ester 
bonds 
PAFAH1B2  
ENSG00000168092  GO:0042803 protein homodimerization activity PAFAH1B2  
ENSG00000168092  GO:0046982 protein heterodimerization activity PAFAH1B2  
ENSG00000168092  GO:0070062 extracellular vesicular exosome PAFAH1B2  
ENSG00000139946  GO:0001934 positive regulation of protein 
phosphorylation 
PELI2  
ENSG00000139946  GO:0002224 toll-like receptor signaling pathway PELI2  
ENSG00000139946  GO:0002755 MyD88-dependent toll-like receptor 
signaling pathway 
PELI2  
ENSG00000139946  GO:0005515 protein binding PELI2  
ENSG00000139946  GO:0005829 cytosol PELI2  
ENSG00000139946  GO:0008063 Toll signaling pathway PELI2  
ENSG00000139946  GO:0016567 protein ubiquitination PELI2  
ENSG00000139946  GO:0016874 ligase activity PELI2  
ENSG00000139946  GO:0034134 toll-like receptor 2 signaling pathway PELI2  
ENSG00000139946  GO:0034142 toll-like receptor 4 signaling pathway PELI2  
ENSG00000139946  GO:0034146 toll-like receptor 5 signaling pathway PELI2  
ENSG00000139946  GO:0034162 toll-like receptor 9 signaling pathway PELI2  
ENSG00000139946  GO:0034166 toll-like receptor 10 signaling pathway PELI2  
ENSG00000139946  GO:0038123 toll-like receptor TLR1:TLR2 signaling 
pathway 
PELI2  
ENSG00000139946  GO:0038124 toll-like receptor TLR6:TLR2 signaling 
pathway 
PELI2  
ENSG00000139946  GO:0043123 positive regulation of I-kappaB 
kinase/NF-kappaB signaling 
PELI2  
ENSG00000139946  GO:0043410 positive regulation of MAPK cascade PELI2  
ENSG00000139946  GO:0045087 innate immune response PELI2  
ENSG00000196570  GO:0003779 actin binding PFN3  
ENSG00000196570  GO:0005515 protein binding PFN3  
ENSG00000196570  GO:0005634 nucleus PFN3  
ENSG00000196570  GO:0005737 cytoplasm PFN3  
ENSG00000196570  GO:0005856 cytoskeleton PFN3  
ENSG00000196570  GO:0008289 lipid binding PFN3  
ENSG00000196570  GO:0030036 actin cytoskeleton organization PFN3  
ENSG00000112137  GO:0003779 actin binding PHACTR1  
ENSG00000112137  GO:0004864 protein phosphatase inhibitor activity PHACTR1  
ENSG00000112137  GO:0005634 nucleus PHACTR1  
ENSG00000112137  GO:0005829 cytosol PHACTR1  
ENSG00000112137  GO:0030054 cell junction PHACTR1  
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ENSG00000112137  GO:0031032 actomyosin structure organization PHACTR1  
ENSG00000112137  GO:0031532 actin cytoskeleton reorganization PHACTR1  
ENSG00000112137  GO:0043086 negative regulation of catalytic activity PHACTR1  
ENSG00000112137  GO:0043149 stress fiber assembly PHACTR1  
ENSG00000112137  GO:0045202 synapse PHACTR1  
ENSG00000112137  GO:0048870 cell motility PHACTR1  
ENSG00000057294  GO:0002159 desmosome assembly PKP2  
ENSG00000057294  GO:0003674 molecular_function PKP2  
ENSG00000057294  GO:0005080 protein kinase C binding PKP2  
ENSG00000057294  GO:0005488 binding PKP2  
ENSG00000057294  GO:0005515 protein binding PKP2  
ENSG00000057294  GO:0005634 nucleus PKP2  
ENSG00000057294  GO:0005882 intermediate filament PKP2  
ENSG00000057294  GO:0005886 plasma membrane PKP2  
ENSG00000057294  GO:0005911 cell-cell junction PKP2  
ENSG00000057294  GO:0005912 adherens junction PKP2  
ENSG00000057294  GO:0007507 heart development PKP2  
ENSG00000057294  GO:0008285 negative regulation of cell proliferation PKP2  
ENSG00000057294  GO:0010765 positive regulation of sodium ion 
transport 
PKP2  
ENSG00000057294  GO:0014704 intercalated disc PKP2  
ENSG00000057294  GO:0016021 integral component of membrane PKP2  
ENSG00000057294  GO:0016264 gap junction assembly PKP2  
ENSG00000057294  GO:0016337 single organismal cell-cell adhesion PKP2  
ENSG00000057294  GO:0017080 sodium channel regulator activity PKP2  
ENSG00000057294  GO:0019215 intermediate filament binding PKP2  
ENSG00000057294  GO:0030054 cell junction PKP2  
ENSG00000057294  GO:0030057 desmosome PKP2  
ENSG00000057294  GO:0030336 negative regulation of cell migration PKP2  
ENSG00000057294  GO:0032947 protein complex scaffold PKP2  
ENSG00000057294  GO:0034334 adherens junction maintenance PKP2  
ENSG00000057294  GO:0044325 ion channel binding PKP2  
ENSG00000057294  GO:0045110 intermediate filament bundle 
assembly 
PKP2  
ENSG00000057294  GO:0048496 maintenance of organ identity PKP2  
ENSG00000057294  GO:0055010 ventricular cardiac muscle tissue 
morphogenesis 
PKP2  
ENSG00000057294  GO:0055088 lipid homeostasis PKP2  
ENSG00000057294  GO:0086001 cardiac muscle cell action potential PKP2  
ENSG00000057294  GO:0086002 cardiac muscle cell action potential 
involved in contraction 
PKP2  
ENSG00000057294  GO:0086005 ventricular cardiac muscle cell action 
potential 
PKP2  
ENSG00000057294  GO:0086019 cell-cell signaling involved in cardiac 
conduction 
PKP2  
ENSG00000057294  GO:0086064 cell communication by electrical 
coupling involved in cardiac 
conduction 
PKP2  
ENSG00000057294  GO:0086069 bundle of His cell to Purkinje myocyte 
communication 
PKP2  
ENSG00000057294  GO:0086091 regulation of heart rate by cardiac 
conduction 
PKP2  
ENSG00000057294  GO:2000810 regulation of tight junction assembly PKP2  
ENSG00000153246  GO:0001816 cytokine production PLA2R1  
ENSG00000153246  GO:0004872 receptor activity PLA2R1  
ENSG00000153246  GO:0005576 extracellular region PLA2R1  
ENSG00000153246  GO:0005886 plasma membrane PLA2R1  
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ENSG00000153246  GO:0005887 integral component of plasma 
membrane 
PLA2R1  
ENSG00000153246  GO:0006898 receptor-mediated endocytosis PLA2R1  
ENSG00000153246  GO:0009986 cell surface PLA2R1  
ENSG00000153246  GO:0016021 integral component of membrane PLA2R1  
ENSG00000153246  GO:0030246 carbohydrate binding PLA2R1  
ENSG00000153246  GO:0043235 receptor complex PLA2R1  
ENSG00000153246  GO:0043274 phospholipase binding PLA2R1  
ENSG00000153246  GO:0043517 positive regulation of DNA damage 
response, signal transduction by p53 
class mediator 
PLA2R1  
ENSG00000153246  GO:0070062 extracellular vesicular exosome PLA2R1  
ENSG00000153246  GO:0072593 reactive oxygen species metabolic 
process 
PLA2R1  
ENSG00000153246  GO:0090238 positive regulation of arachidonic acid 
secretion 
PLA2R1  
ENSG00000153246  GO:0090399 replicative senescence PLA2R1  
ENSG00000153246  GO:0090403 oxidative stress-induced premature 
senescence 
PLA2R1  
ENSG00000153246  GO:1900138 negative regulation of phospholipase 
A2 activity 
PLA2R1  
ENSG00000153246  GO:1900139 negative regulation of arachidonic 
acid secretion 
PLA2R1  
ENSG00000138814  GO:0000082 G1/S transition of mitotic cell cycle PPP3CA  
ENSG00000138814  GO:0001975 response to amphetamine PPP3CA  
ENSG00000138814  GO:0004721 phosphoprotein phosphatase activity PPP3CA  
ENSG00000138814  GO:0004722 protein serine/threonine phosphatase 
activity 
PPP3CA  
ENSG00000138814  GO:0004723 calcium-dependent protein 
serine/threonine phosphatase activity 
PPP3CA  
ENSG00000138814  GO:0005509 calcium ion binding PPP3CA  
ENSG00000138814  GO:0005515 protein binding PPP3CA  
ENSG00000138814  GO:0005516 calmodulin binding PPP3CA  
ENSG00000138814  GO:0005634 nucleus PPP3CA  
ENSG00000138814  GO:0005654 nucleoplasm PPP3CA  
ENSG00000138814  GO:0005737 cytoplasm PPP3CA  
ENSG00000138814  GO:0005739 mitochondrion PPP3CA  
ENSG00000138814  GO:0005829 cytosol PPP3CA  
ENSG00000138814  GO:0005955 calcineurin complex PPP3CA  
ENSG00000138814  GO:0006470 protein dephosphorylation PPP3CA  
ENSG00000138814  GO:0006606 protein import into nucleus PPP3CA  
ENSG00000138814  GO:0006816 calcium ion transport PPP3CA  
ENSG00000138814  GO:0008144 drug binding PPP3CA  
ENSG00000138814  GO:0014883 transition between fast and slow fiber PPP3CA  
ENSG00000138814  GO:0016020 membrane PPP3CA  
ENSG00000138814  GO:0016311 dephosphorylation PPP3CA  
ENSG00000138814  GO:0016787 hydrolase activity PPP3CA  
ENSG00000138814  GO:0019722 calcium-mediated signaling PPP3CA  
ENSG00000138814  GO:0019899 enzyme binding PPP3CA  
ENSG00000138814  GO:0030018 Z disc PPP3CA  
ENSG00000138814  GO:0033173 calcineurin-NFAT signaling cascade PPP3CA  
ENSG00000138814  GO:0033192 calmodulin-dependent protein 
phosphatase activity 
PPP3CA  
ENSG00000138814  GO:0033555 multicellular organismal response to 
stress 
PPP3CA  
ENSG00000138814  GO:0035690 cellular response to drug PPP3CA  
ENSG00000138814  GO:0038095 Fc-epsilon receptor signaling pathway PPP3CA  
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ENSG00000138814  GO:0042110 T cell activation PPP3CA  
ENSG00000138814  GO:0042383 sarcolemma PPP3CA  
ENSG00000138814  GO:0045087 innate immune response PPP3CA  
ENSG00000138814  GO:0045944 positive regulation of transcription 
from RNA polymerase II promoter 
PPP3CA  
ENSG00000138814  GO:0046676 negative regulation of insulin secretion PPP3CA  
ENSG00000138814  GO:0046982 protein heterodimerization activity PPP3CA  
ENSG00000138814  GO:0046983 protein dimerization activity PPP3CA  
ENSG00000138814  GO:0048741 skeletal muscle fiber development PPP3CA  
ENSG00000138814  GO:0050804 regulation of synaptic transmission PPP3CA  
ENSG00000138814  GO:0051592 response to calcium ion PPP3CA  
ENSG00000138814  GO:0060079 regulation of excitatory postsynaptic 
membrane potential 
PPP3CA  
ENSG00000138814  GO:0071333 cellular response to glucose stimulus PPP3CA  
ENSG00000122420  GO:0004930 G-protein coupled receptor activity PTGFR  
ENSG00000122420  GO:0004958 prostaglandin F receptor activity PTGFR  
ENSG00000122420  GO:0005576 extracellular region PTGFR  
ENSG00000122420  GO:0005737 cytoplasm PTGFR  
ENSG00000122420  GO:0005886 plasma membrane PTGFR  
ENSG00000122420  GO:0005887 integral component of plasma 
membrane 
PTGFR  
ENSG00000122420  GO:0007186 G-protein coupled receptor signaling 
pathway 
PTGFR  
ENSG00000122420  GO:0007567 parturition PTGFR  
ENSG00000122420  GO:0016021 integral component of membrane PTGFR  
ENSG00000122420  GO:0032496 response to lipopolysaccharide PTGFR  
ENSG00000122420  GO:0035584 calcium-mediated signaling using 
intracellular calcium source 
PTGFR  
ENSG00000122420  GO:0043066 negative regulation of apoptotic 
process 
PTGFR  
ENSG00000144642  GO:0000166 nucleotide binding RBMS3  
ENSG00000144642  GO:0003676 nucleic acid binding RBMS3  
ENSG00000144642  GO:0003723 RNA binding RBMS3  
ENSG00000144642  GO:0003730 mRNA 3'-UTR binding RBMS3  
ENSG00000144642  GO:0005737 cytoplasm RBMS3  
ENSG00000144642  GO:0045727 positive regulation of translation RBMS3  
ENSG00000148908  GO:0005096 GTPase activator activity RGS10  
ENSG00000148908  GO:0005515 protein binding RGS10  
ENSG00000148908  GO:0005634 nucleus RGS10  
ENSG00000148908  GO:0005737 cytoplasm RGS10  
ENSG00000148908  GO:0005886 plasma membrane RGS10  
ENSG00000148908  GO:0008277 regulation of G-protein coupled 
receptor protein signaling pathway 
RGS10  
ENSG00000148908  GO:0038032 termination of G-protein coupled 
receptor signaling pathway 
RGS10  
ENSG00000148908  GO:0043025 neuronal cell body RGS10  
ENSG00000148908  GO:0043197 dendritic spine RGS10  
ENSG00000148908  GO:0043547 positive regulation of GTPase activity RGS10  
ENSG00000148908  GO:0043679 axon terminus RGS10  
ENSG00000169220  GO:0000922 spindle pole RGS14  
ENSG00000169220  GO:0001965 G-protein alpha-subunit binding RGS14  
ENSG00000169220  GO:0005057 receptor signaling protein activity RGS14  
ENSG00000169220  GO:0005092 GDP-dissociation inhibitor activity RGS14  
ENSG00000169220  GO:0005096 GTPase activator activity RGS14  
ENSG00000169220  GO:0005515 protein binding RGS14  
ENSG00000169220  GO:0005634 nucleus RGS14  
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ENSG00000169220  GO:0005737 cytoplasm RGS14  
ENSG00000169220  GO:0005813 centrosome RGS14  
ENSG00000169220  GO:0005819 spindle RGS14  
ENSG00000169220  GO:0005874 microtubule RGS14  
ENSG00000169220  GO:0005886 plasma membrane RGS14  
ENSG00000169220  GO:0006913 nucleocytoplasmic transport RGS14  
ENSG00000169220  GO:0006979 response to oxidative stress RGS14  
ENSG00000169220  GO:0007051 spindle organization RGS14  
ENSG00000169220  GO:0007059 chromosome segregation RGS14  
ENSG00000169220  GO:0007067 mitotic nuclear division RGS14  
ENSG00000169220  GO:0007165 signal transduction RGS14  
ENSG00000169220  GO:0007612 learning RGS14  
ENSG00000169220  GO:0007616 long-term memory RGS14  
ENSG00000169220  GO:0008017 microtubule binding RGS14  
ENSG00000169220  GO:0008277 regulation of G-protein coupled 
receptor protein signaling pathway 
RGS14  
ENSG00000169220  GO:0008542 visual learning RGS14  
ENSG00000169220  GO:0010070 zygote asymmetric cell division RGS14  
ENSG00000169220  GO:0014069 postsynaptic density RGS14  
ENSG00000169220  GO:0016604 nuclear body RGS14  
ENSG00000169220  GO:0016605 PML body RGS14  
ENSG00000169220  GO:0019901 protein kinase binding RGS14  
ENSG00000169220  GO:0030054 cell junction RGS14  
ENSG00000169220  GO:0030159 receptor signaling complex scaffold 
activity 
RGS14  
ENSG00000169220  GO:0030425 dendrite RGS14  
ENSG00000169220  GO:0030695 GTPase regulator activity RGS14  
ENSG00000169220  GO:0031914 negative regulation of synaptic 
plasticity 
RGS14  
ENSG00000169220  GO:0032794 GTPase activating protein binding RGS14  
ENSG00000169220  GO:0035556 intracellular signal transduction RGS14  
ENSG00000169220  GO:0038032 termination of G-protein coupled 
receptor signaling pathway 
RGS14  
ENSG00000169220  GO:0043197 dendritic spine RGS14  
ENSG00000169220  GO:0043407 negative regulation of MAP kinase 
activity 
RGS14  
ENSG00000169220  GO:0043547 positive regulation of GTPase activity RGS14  
ENSG00000169220  GO:0043620 regulation of DNA-templated 
transcription in response to stress 
RGS14  
ENSG00000169220  GO:0045211 postsynaptic membrane RGS14  
ENSG00000169220  GO:0048008 platelet-derived growth factor receptor 
signaling pathway 
RGS14  
ENSG00000169220  GO:0050769 positive regulation of neurogenesis RGS14  
ENSG00000169220  GO:0051301 cell division RGS14  
ENSG00000169220  GO:0060291 long-term synaptic potentiation RGS14  
ENSG00000169220  GO:0070373 negative regulation of ERK1 and 
ERK2 cascade 
RGS14  
ENSG00000069667  GO:0001222 transcription corepressor binding RORA  
ENSG00000069667  GO:0001223 transcription coactivator binding RORA  
ENSG00000069667  GO:0001525 angiogenesis RORA  
ENSG00000069667  GO:0003677 DNA binding RORA  
ENSG00000069667  GO:0003700 sequence-specific DNA binding 
transcription factor activity 
RORA  
ENSG00000069667  GO:0003707 steroid hormone receptor activity RORA  
ENSG00000069667  GO:0004879 ligand-activated sequence-specific 
DNA binding RNA polymerase II 
transcription factor activity 
RORA  
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ENSG00000069667  GO:0005515 protein binding RORA  
ENSG00000069667  GO:0005634 nucleus RORA  
ENSG00000069667  GO:0005654 nucleoplasm RORA  
ENSG00000069667  GO:0006351 transcription, DNA-templated RORA  
ENSG00000069667  GO:0006355 regulation of transcription, DNA-
templated 
RORA  
ENSG00000069667  GO:0006367 transcription initiation from RNA 
polymerase II promoter 
RORA  
ENSG00000069667  GO:0006805 xenobiotic metabolic process RORA  
ENSG00000069667  GO:0006809 nitric oxide biosynthetic process RORA  
ENSG00000069667  GO:0007623 circadian rhythm RORA  
ENSG00000069667  GO:0008013 beta-catenin binding RORA  
ENSG00000069667  GO:0008134 transcription factor binding RORA  
ENSG00000069667  GO:0008142 oxysterol binding RORA  
ENSG00000069667  GO:0008270 zinc ion binding RORA  
ENSG00000069667  GO:0008589 regulation of smoothened signaling 
pathway 
RORA  
ENSG00000069667  GO:0010467 gene expression RORA  
ENSG00000069667  GO:0010575 positive regulation vascular 
endothelial growth factor production 
RORA  
ENSG00000069667  GO:0010906 regulation of glucose metabolic 
process 
RORA  
ENSG00000069667  GO:0019218 regulation of steroid metabolic 
process 
RORA  
ENSG00000069667  GO:0021702 cerebellar Purkinje cell differentiation RORA  
ENSG00000069667  GO:0021930 cerebellar granule cell precursor 
proliferation 
RORA  
ENSG00000069667  GO:0030522 intracellular receptor signaling 
pathway 
RORA  
ENSG00000069667  GO:0032922 circadian regulation of gene 
expression 
RORA  
ENSG00000069667  GO:0036315 cellular response to sterol RORA  
ENSG00000069667  GO:0042692 muscle cell differentiation RORA  
ENSG00000069667  GO:0042752 regulation of circadian rhythm RORA  
ENSG00000069667  GO:0042753 positive regulation of circadian rhythm RORA  
ENSG00000069667  GO:0043030 regulation of macrophage activation RORA  
ENSG00000069667  GO:0043124 negative regulation of I-kappaB 
kinase/NF-kappaB signaling 
RORA  
ENSG00000069667  GO:0043401 steroid hormone mediated signaling 
pathway 
RORA  
ENSG00000069667  GO:0043565 sequence-specific DNA binding RORA  
ENSG00000069667  GO:0045599 negative regulation of fat cell 
differentiation 
RORA  
ENSG00000069667  GO:0045893 positive regulation of transcription, 
DNA-templated 
RORA  
ENSG00000069667  GO:0045944 positive regulation of transcription 
from RNA polymerase II promoter 
RORA  
ENSG00000069667  GO:0046068 cGMP metabolic process RORA  
ENSG00000069667  GO:0050728 negative regulation of inflammatory 
response 
RORA  
ENSG00000069667  GO:0060850 regulation of transcription involved in 
cell fate commitment 
RORA  
ENSG00000069667  GO:0070328 triglyceride homeostasis RORA  
ENSG00000069667  GO:0071456 cellular response to hypoxia RORA  
ENSG00000069667  GO:0072539 T-helper 17 cell differentiation RORA  
ENSG00000069667  GO:0098531 direct ligand regulated sequence-
specific DNA binding transcription 
factor activity 
RORA  
  
 293 
ENSG00000069667  GO:2000188 regulation of cholesterol homeostasis RORA  
ENSG00000137872  GO:0004872 receptor activity SEMA6D  
ENSG00000137872  GO:0005515 protein binding SEMA6D  
ENSG00000137872  GO:0005737 cytoplasm SEMA6D  
ENSG00000137872  GO:0005886 plasma membrane SEMA6D  
ENSG00000137872  GO:0007275 multicellular organismal development SEMA6D  
ENSG00000137872  GO:0007411 axon guidance SEMA6D  
ENSG00000137872  GO:0014911 positive regulation of smooth muscle 
cell migration 
SEMA6D  
ENSG00000137872  GO:0014912 negative regulation of smooth muscle 
cell migration 
SEMA6D  
ENSG00000137872  GO:0016020 membrane SEMA6D  
ENSG00000137872  GO:0016021 integral component of membrane SEMA6D  
ENSG00000137872  GO:0021591 ventricular system development SEMA6D  
ENSG00000137872  GO:0030215 semaphorin receptor binding SEMA6D  
ENSG00000198964  GO:0000138 Golgi trans cisterna SGMS1  
ENSG00000198964  GO:0000139 Golgi membrane SGMS1  
ENSG00000198964  GO:0003824 catalytic activity SGMS1  
ENSG00000198964  GO:0005515 protein binding SGMS1  
ENSG00000198964  GO:0005634 nucleus SGMS1  
ENSG00000198964  GO:0005783 endoplasmic reticulum SGMS1  
ENSG00000198964  GO:0005886 plasma membrane SGMS1  
ENSG00000198964  GO:0006665 sphingolipid metabolic process SGMS1  
ENSG00000198964  GO:0006686 sphingomyelin biosynthetic process SGMS1  
ENSG00000198964  GO:0006915 apoptotic process SGMS1  
ENSG00000198964  GO:0006954 inflammatory response SGMS1  
ENSG00000198964  GO:0010628 positive regulation of gene expression SGMS1  
ENSG00000198964  GO:0016020 membrane SGMS1  
ENSG00000198964  GO:0016021 integral component of membrane SGMS1  
ENSG00000198964  GO:0016049 cell growth SGMS1  
ENSG00000198964  GO:0016301 kinase activity SGMS1  
ENSG00000198964  GO:0016310 phosphorylation SGMS1  
ENSG00000198964  GO:0030148 sphingolipid biosynthetic process SGMS1  
ENSG00000198964  GO:0030173 integral component of Golgi 
membrane 
SGMS1  
ENSG00000198964  GO:0033188 sphingomyelin synthase activity SGMS1  
ENSG00000198964  GO:0044281 small molecule metabolic process SGMS1  
ENSG00000198964  GO:0047493 ceramide cholinephosphotransferase 
activity 
SGMS1  
ENSG00000198964  GO:0071222 cellular response to 
lipopolysaccharide 
SGMS1  
ENSG00000198964  GO:0071356 cellular response to tumor necrosis 
factor 
SGMS1  
ENSG00000198964  GO:2001237 negative regulation of extrinsic 
apoptotic signaling pathway 
SGMS1  
ENSG00000116991  GO:0005096 GTPase activator activity SIPA1L2  
ENSG00000116991  GO:0005515 protein binding SIPA1L2  
ENSG00000116991  GO:0043547 positive regulation of GTPase activity SIPA1L2  
ENSG00000116991  GO:0051056 regulation of small GTPase mediated 
signal transduction 
SIPA1L2  
ENSG00000180251  GO:0001696 gastric acid secretion SLC9A4  
ENSG00000180251  GO:0002064 epithelial cell development SLC9A4  
ENSG00000180251  GO:0005886 plasma membrane SLC9A4  
ENSG00000180251  GO:0006811 ion transport SLC9A4  
ENSG00000180251  GO:0006812 cation transport SLC9A4  
ENSG00000180251  GO:0006814 sodium ion transport SLC9A4  
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ENSG00000180251  GO:0006885 regulation of pH SLC9A4  
ENSG00000180251  GO:0015299 solute:proton antiporter activity SLC9A4  
ENSG00000180251  GO:0015385 sodium:proton antiporter activity SLC9A4  
ENSG00000180251  GO:0016021 integral component of membrane SLC9A4  
ENSG00000180251  GO:0016323 basolateral plasma membrane SLC9A4  
ENSG00000180251  GO:0016324 apical plasma membrane SLC9A4  
ENSG00000180251  GO:0035725 sodium ion transmembrane transport SLC9A4  
ENSG00000180251  GO:0055085 transmembrane transport SLC9A4  
ENSG00000180251  GO:1902600 hydrogen ion transmembrane 
transport 
SLC9A4  
ENSG00000125398  GO:0000976 transcription regulatory region 
sequence-specific DNA binding 
SOX9  
ENSG00000125398  GO:0000981 sequence-specific DNA binding RNA 
polymerase II transcription factor 
activity 
SOX9  
ENSG00000125398  GO:0001046 core promoter sequence-specific DNA 
binding 
SOX9  
ENSG00000125398  GO:0001077 RNA polymerase II core promoter 
proximal region sequence-specific 
DNA binding transcription factor 
activity involved in positive regulation 
of transcription 
SOX9  
ENSG00000125398  GO:0001158 enhancer sequence-specific DNA 
binding 
SOX9  
ENSG00000125398  GO:0001501 skeletal system development SOX9  
ENSG00000125398  GO:0001502 cartilage condensation SOX9  
ENSG00000125398  GO:0001503 ossification SOX9  
ENSG00000125398  GO:0001658 branching involved in ureteric bud 
morphogenesis 
SOX9  
ENSG00000125398  GO:0001708 cell fate specification SOX9  
ENSG00000125398  GO:0001837 epithelial to mesenchymal transition SOX9  
ENSG00000125398  GO:0001894 tissue homeostasis SOX9  
ENSG00000125398  GO:0001934 positive regulation of protein 
phosphorylation 
SOX9  
ENSG00000125398  GO:0001942 hair follicle development SOX9  
ENSG00000125398  GO:0002053 positive regulation of mesenchymal 
cell proliferation 
SOX9  
ENSG00000125398  GO:0002062 chondrocyte differentiation SOX9  
ENSG00000125398  GO:0002063 chondrocyte development SOX9  
ENSG00000125398  GO:0002683 negative regulation of immune system 
process 
SOX9  
ENSG00000125398  GO:0003170 heart valve development SOX9  
ENSG00000125398  GO:0003179 heart valve morphogenesis SOX9  
ENSG00000125398  GO:0003188 heart valve formation SOX9  
ENSG00000125398  GO:0003203 endocardial cushion morphogenesis SOX9  
ENSG00000125398  GO:0003413 chondrocyte differentiation involved in 
endochondral bone morphogenesis 
SOX9  
ENSG00000125398  GO:0003415 chondrocyte hypertrophy SOX9  
ENSG00000125398  GO:0003677 DNA binding SOX9  
ENSG00000125398  GO:0003682 chromatin binding SOX9  
ENSG00000125398  GO:0003700 sequence-specific DNA binding 
transcription factor activity 
SOX9  
ENSG00000125398  GO:0003705 RNA polymerase II distal enhancer 
sequence-specific DNA binding 
transcription factor activity 
SOX9  
ENSG00000125398  GO:0004672 protein kinase activity SOX9  
ENSG00000125398  GO:0005515 protein binding SOX9  
ENSG00000125398  GO:0005634 nucleus SOX9  
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ENSG00000125398  GO:0005667 transcription factor complex SOX9  
ENSG00000125398  GO:0006334 nucleosome assembly SOX9  
ENSG00000125398  GO:0006338 chromatin remodeling SOX9  
ENSG00000125398  GO:0006357 regulation of transcription from RNA 
polymerase II promoter 
SOX9  
ENSG00000125398  GO:0006366 transcription from RNA polymerase II 
promoter 
SOX9  
ENSG00000125398  GO:0006461 protein complex assembly SOX9  
ENSG00000125398  GO:0006468 protein phosphorylation SOX9  
ENSG00000125398  GO:0007010 cytoskeleton organization SOX9  
ENSG00000125398  GO:0007165 signal transduction SOX9  
ENSG00000125398  GO:0007173 epidermal growth factor receptor 
signaling pathway 
SOX9  
ENSG00000125398  GO:0007283 spermatogenesis SOX9  
ENSG00000125398  GO:0007417 central nervous system development SOX9  
ENSG00000125398  GO:0007507 heart development SOX9  
ENSG00000125398  GO:0008013 beta-catenin binding SOX9  
ENSG00000125398  GO:0008284 positive regulation of cell proliferation SOX9  
ENSG00000125398  GO:0008285 negative regulation of cell proliferation SOX9  
ENSG00000125398  GO:0008584 male gonad development SOX9  
ENSG00000125398  GO:0010564 regulation of cell cycle process SOX9  
ENSG00000125398  GO:0010628 positive regulation of gene expression SOX9  
ENSG00000125398  GO:0010634 positive regulation of epithelial cell 
migration 
SOX9  
ENSG00000125398  GO:0014032 neural crest cell development SOX9  
ENSG00000125398  GO:0014068 positive regulation of 
phosphatidylinositol 3-kinase signaling 
SOX9  
ENSG00000125398  GO:0016337 single organismal cell-cell adhesion SOX9  
ENSG00000125398  GO:0019100 male germ-line sex determination SOX9  
ENSG00000125398  GO:0019933 cAMP-mediated signaling SOX9  
ENSG00000125398  GO:0030154 cell differentiation SOX9  
ENSG00000125398  GO:0030155 regulation of cell adhesion SOX9  
ENSG00000125398  GO:0030198 extracellular matrix organization SOX9  
ENSG00000125398  GO:0030238 male sex determination SOX9  
ENSG00000125398  GO:0030279 negative regulation of ossification SOX9  
ENSG00000125398  GO:0030502 negative regulation of bone 
mineralization 
SOX9  
ENSG00000125398  GO:0030850 prostate gland development SOX9  
ENSG00000125398  GO:0030857 negative regulation of epithelial cell 
differentiation 
SOX9  
ENSG00000125398  GO:0030858 positive regulation of epithelial cell 
differentiation 
SOX9  
ENSG00000125398  GO:0030879 mammary gland development SOX9  
ENSG00000125398  GO:0030903 notochord development SOX9  
ENSG00000125398  GO:0030916 otic vesicle formation SOX9  
ENSG00000125398  GO:0031018 endocrine pancreas development SOX9  
ENSG00000125398  GO:0032331 negative regulation of chondrocyte 
differentiation 
SOX9  
ENSG00000125398  GO:0032332 positive regulation of chondrocyte 
differentiation 
SOX9  
ENSG00000125398  GO:0034236 protein kinase A catalytic subunit 
binding 
SOX9  
ENSG00000125398  GO:0035019 somatic stem cell maintenance SOX9  
ENSG00000125398  GO:0035326 enhancer binding SOX9  
ENSG00000125398  GO:0035622 intrahepatic bile duct development SOX9  
ENSG00000125398  GO:0042127 regulation of cell proliferation SOX9  
ENSG00000125398  GO:0042981 regulation of apoptotic process SOX9  
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ENSG00000125398  GO:0043066 negative regulation of apoptotic 
process 
SOX9  
ENSG00000125398  GO:0043234 protein complex SOX9  
ENSG00000125398  GO:0043425 bHLH transcription factor binding SOX9  
ENSG00000125398  GO:0043491 protein kinase B signaling SOX9  
ENSG00000125398  GO:0043565 sequence-specific DNA binding SOX9  
ENSG00000125398  GO:0044212 transcription regulatory region DNA 
binding 
SOX9  
ENSG00000125398  GO:0044798 nuclear transcription factor complex SOX9  
ENSG00000125398  GO:0045165 cell fate commitment SOX9  
ENSG00000125398  GO:0045595 regulation of cell differentiation SOX9  
ENSG00000125398  GO:0045662 negative regulation of myoblast 
differentiation 
SOX9  
ENSG00000125398  GO:0045732 positive regulation of protein catabolic 
process 
SOX9  
ENSG00000125398  GO:0045892 negative regulation of transcription, 
DNA-templated 
SOX9  
ENSG00000125398  GO:0045893 positive regulation of transcription, 
DNA-templated 
SOX9  
ENSG00000125398  GO:0045944 positive regulation of transcription 
from RNA polymerase II promoter 
SOX9  
ENSG00000125398  GO:0046533 negative regulation of photoreceptor 
cell differentiation 
SOX9  
ENSG00000125398  GO:0046982 protein heterodimerization activity SOX9  
ENSG00000125398  GO:0048709 oligodendrocyte differentiation SOX9  
ENSG00000125398  GO:0050679 positive regulation of epithelial cell 
proliferation 
SOX9  
ENSG00000125398  GO:0050680 negative regulation of epithelial cell 
proliferation 
SOX9  
ENSG00000125398  GO:0051216 cartilage development SOX9  
ENSG00000125398  GO:0060008 Sertoli cell differentiation SOX9  
ENSG00000125398  GO:0060009 Sertoli cell development SOX9  
ENSG00000125398  GO:0060018 astrocyte fate commitment SOX9  
ENSG00000125398  GO:0060041 retina development in camera-type 
eye 
SOX9  
ENSG00000125398  GO:0060174 limb bud formation SOX9  
ENSG00000125398  GO:0060221 retinal rod cell differentiation SOX9  
ENSG00000125398  GO:0060350 endochondral bone morphogenesis SOX9  
ENSG00000125398  GO:0060441 epithelial tube branching involved in 
lung morphogenesis 
SOX9  
ENSG00000125398  GO:0060487 lung epithelial cell differentiation SOX9  
ENSG00000125398  GO:0060512 prostate gland morphogenesis SOX9  
ENSG00000125398  GO:0060517 epithelial cell proliferation involved in 
prostatic bud elongation 
SOX9  
ENSG00000125398  GO:0060729 intestinal epithelial structure 
maintenance 
SOX9  
ENSG00000125398  GO:0060784 regulation of cell proliferation involved 
in tissue homeostasis 
SOX9  
ENSG00000125398  GO:0061036 positive regulation of cartilage 
development 
SOX9  
ENSG00000125398  GO:0061046 regulation of branching involved in 
lung morphogenesis 
SOX9  
ENSG00000125398  GO:0061138 morphogenesis of a branching 
epithelium 
SOX9  
ENSG00000125398  GO:0070168 negative regulation of biomineral 
tissue development 
SOX9  
ENSG00000125398  GO:0070371 ERK1 and ERK2 cascade SOX9  
ENSG00000125398  GO:0071260 cellular response to mechanical SOX9  
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stimulus 
ENSG00000125398  GO:0071300 cellular response to retinoic acid SOX9  
ENSG00000125398  GO:0071347 cellular response to interleukin-1 SOX9  
ENSG00000125398  GO:0071364 cellular response to epidermal growth 
factor stimulus 
SOX9  
ENSG00000125398  GO:0071504 cellular response to heparin SOX9  
ENSG00000125398  GO:0071560 cellular response to transforming 
growth factor beta stimulus 
SOX9  
ENSG00000125398  GO:0071599 otic vesicle development SOX9  
ENSG00000125398  GO:0072034 renal vesicle induction SOX9  
ENSG00000125398  GO:0072170 metanephric tubule development SOX9  
ENSG00000125398  GO:0072189 ureter development SOX9  
ENSG00000125398  GO:0072190 ureter urothelium development SOX9  
ENSG00000125398  GO:0072193 ureter smooth muscle cell 
differentiation 
SOX9  
ENSG00000125398  GO:0072197 ureter morphogenesis SOX9  
ENSG00000125398  GO:0072289 metanephric nephron tubule formation SOX9  
ENSG00000125398  GO:0090090 negative regulation of canonical Wnt 
signaling pathway 
SOX9  
ENSG00000125398  GO:0090103 cochlea morphogenesis SOX9  
ENSG00000125398  GO:0090184 positive regulation of kidney 
development 
SOX9  
ENSG00000125398  GO:0090190 positive regulation of branching 
involved in ureteric bud 
morphogenesis 
SOX9  
ENSG00000125398  GO:0097157 pre-mRNA intronic binding SOX9  
ENSG00000125398  GO:1901203 positive regulation of extracellular 
matrix assembly 
SOX9  
ENSG00000125398  GO:2000020 positive regulation of male gonad 
development 
SOX9  
ENSG00000125398  GO:2000138 positive regulation of cell proliferation 
involved in heart morphogenesis 
SOX9  
ENSG00000125398  GO:2000741 positive regulation of mesenchymal 
stem cell differentiation 
SOX9  
ENSG00000125398  GO:2000794 regulation of epithelial cell proliferation 
involved in lung morphogenesis 
SOX9  
ENSG00000125398  GO:2001054 negative regulation of mesenchymal 
cell apoptotic process 
SOX9  
ENSG00000164056  GO:0000132 establishment of mitotic spindle 
orientation 
SPRY1  
ENSG00000164056  GO:0001656 metanephros development SPRY1  
ENSG00000164056  GO:0001657 ureteric bud development SPRY1  
ENSG00000164056  GO:0001759 organ induction SPRY1  
ENSG00000164056  GO:0005515 protein binding SPRY1  
ENSG00000164056  GO:0005829 cytosol SPRY1  
ENSG00000164056  GO:0005886 plasma membrane SPRY1  
ENSG00000164056  GO:0007173 epidermal growth factor receptor 
signaling pathway 
SPRY1  
ENSG00000164056  GO:0007275 multicellular organismal development SPRY1  
ENSG00000164056  GO:0008285 negative regulation of cell proliferation SPRY1  
ENSG00000164056  GO:0009966 regulation of signal transduction SPRY1  
ENSG00000164056  GO:0016020 membrane SPRY1  
ENSG00000164056  GO:0034261 negative regulation of Ras GTPase 
activity 
SPRY1  
ENSG00000164056  GO:0040037 negative regulation of fibroblast 
growth factor receptor signaling 
pathway 
SPRY1  
ENSG00000164056  GO:0042059 negative regulation of epidermal SPRY1  
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growth factor receptor signaling 
pathway 
ENSG00000164056  GO:0043407 negative regulation of MAP kinase 
activity 
SPRY1  
ENSG00000164056  GO:0046580 negative regulation of Ras protein 
signal transduction 
SPRY1  
ENSG00000164056  GO:0051387 negative regulation of neurotrophin 
TRK receptor signaling pathway 
SPRY1  
ENSG00000164056  GO:0060449 bud elongation involved in lung 
branching 
SPRY1  
ENSG00000164056  GO:0070373 negative regulation of ERK1 and 
ERK2 cascade 
SPRY1  
ENSG00000114850  GO:0005784 Sec61 translocon complex SSR3  
ENSG00000114850  GO:0006412 translation SSR3  
ENSG00000114850  GO:0006613 cotranslational protein targeting to 
membrane 
SSR3  
ENSG00000114850  GO:0006614 SRP-dependent cotranslational 
protein targeting to membrane 
SSR3  
ENSG00000114850  GO:0010467 gene expression SSR3  
ENSG00000114850  GO:0030176 integral component of endoplasmic 
reticulum membrane 
SSR3  
ENSG00000114850  GO:0044267 cellular protein metabolic process SSR3  
ENSG00000068781  GO:0005515 protein binding STON1-
GTF2A1L  
ENSG00000068781  GO:0005672 transcription factor TFIIA complex STON1-
GTF2A1L  
ENSG00000068781  GO:0006367 transcription initiation from RNA 
polymerase II promoter 
STON1-
GTF2A1L  
ENSG00000068781  GO:0006886 intracellular protein transport STON1-
GTF2A1L  
ENSG00000068781  GO:0006897 endocytosis STON1-
GTF2A1L  
ENSG00000068781  GO:0016192 vesicle-mediated transport STON1-
GTF2A1L  
ENSG00000068781  GO:0030131 clathrin adaptor complex STON1-
GTF2A1L  
ENSG00000163513  GO:0001568 blood vessel development TGFBR2  
ENSG00000163513  GO:0001569 patterning of blood vessels TGFBR2  
ENSG00000163513  GO:0001570 vasculogenesis TGFBR2  
ENSG00000163513  GO:0001701 in utero embryonic development TGFBR2  
ENSG00000163513  GO:0002053 positive regulation of mesenchymal 
cell proliferation 
TGFBR2  
ENSG00000163513  GO:0002088 lens development in camera-type eye TGFBR2  
ENSG00000163513  GO:0002651 positive regulation of tolerance 
induction to self antigen 
TGFBR2  
ENSG00000163513  GO:0002663 positive regulation of B cell tolerance 
induction 
TGFBR2  
ENSG00000163513  GO:0002666 positive regulation of T cell tolerance 
induction 
TGFBR2  
ENSG00000163513  GO:0004672 protein kinase activity TGFBR2  
ENSG00000163513  GO:0004674 protein serine/threonine kinase activity TGFBR2  
ENSG00000163513  GO:0004675 transmembrane receptor protein 
serine/threonine kinase activity 
TGFBR2  
ENSG00000163513  GO:0004702 receptor signaling protein 
serine/threonine kinase activity 
TGFBR2  
ENSG00000163513  GO:0004713 protein tyrosine kinase activity TGFBR2  
ENSG00000163513  GO:0004872 receptor activity TGFBR2  
ENSG00000163513  GO:0005024 transforming growth factor beta- TGFBR2  
  
 299 
activated receptor activity 
ENSG00000163513  GO:0005026 transforming growth factor beta 
receptor activity, type II 
TGFBR2  
ENSG00000163513  GO:0005515 protein binding TGFBR2  
ENSG00000163513  GO:0005524 ATP binding TGFBR2  
ENSG00000163513  GO:0005539 glycosaminoglycan binding TGFBR2  
ENSG00000163513  GO:0005737 cytoplasm TGFBR2  
ENSG00000163513  GO:0005829 cytosol TGFBR2  
ENSG00000163513  GO:0005886 plasma membrane TGFBR2  
ENSG00000163513  GO:0005887 integral component of plasma 
membrane 
TGFBR2  
ENSG00000163513  GO:0005901 caveola TGFBR2  
ENSG00000163513  GO:0006468 protein phosphorylation TGFBR2  
ENSG00000163513  GO:0006898 receptor-mediated endocytosis TGFBR2  
ENSG00000163513  GO:0006915 apoptotic process TGFBR2  
ENSG00000163513  GO:0007179 transforming growth factor beta 
receptor signaling pathway 
TGFBR2  
ENSG00000163513  GO:0007182 common-partner SMAD protein 
phosphorylation 
TGFBR2  
ENSG00000163513  GO:0007224 smoothened signaling pathway TGFBR2  
ENSG00000163513  GO:0007369 gastrulation TGFBR2  
ENSG00000163513  GO:0007420 brain development TGFBR2  
ENSG00000163513  GO:0007507 heart development TGFBR2  
ENSG00000163513  GO:0007566 embryo implantation TGFBR2  
ENSG00000163513  GO:0007568 aging TGFBR2  
ENSG00000163513  GO:0007584 response to nutrient TGFBR2  
ENSG00000163513  GO:0008284 positive regulation of cell proliferation TGFBR2  
ENSG00000163513  GO:0008285 negative regulation of cell proliferation TGFBR2  
ENSG00000163513  GO:0009612 response to mechanical stimulus TGFBR2  
ENSG00000163513  GO:0009749 response to glucose TGFBR2  
ENSG00000163513  GO:0009887 organ morphogenesis TGFBR2  
ENSG00000163513  GO:0009897 external side of plasma membrane TGFBR2  
ENSG00000163513  GO:0009986 cell surface TGFBR2  
ENSG00000163513  GO:0010033 response to organic substance TGFBR2  
ENSG00000163513  GO:0010634 positive regulation of epithelial cell 
migration 
TGFBR2  
ENSG00000163513  GO:0014070 response to organic cyclic compound TGFBR2  
ENSG00000163513  GO:0016020 membrane TGFBR2  
ENSG00000163513  GO:0016021 integral component of membrane TGFBR2  
ENSG00000163513  GO:0016772 transferase activity, transferring 
phosphorus-containing groups 
TGFBR2  
ENSG00000163513  GO:0018105 peptidyl-serine phosphorylation TGFBR2  
ENSG00000163513  GO:0018107 peptidyl-threonine phosphorylation TGFBR2  
ENSG00000163513  GO:0023014 signal transduction by phosphorylation TGFBR2  
ENSG00000163513  GO:0030324 lung development TGFBR2  
ENSG00000163513  GO:0030512 negative regulation of transforming 
growth factor beta receptor signaling 
pathway 
TGFBR2  
ENSG00000163513  GO:0031100 organ regeneration TGFBR2  
ENSG00000163513  GO:0031435 mitogen-activated protein kinase 
kinase kinase binding 
TGFBR2  
ENSG00000163513  GO:0032147 activation of protein kinase activity TGFBR2  
ENSG00000163513  GO:0034713 type I transforming growth factor beta 
receptor binding 
TGFBR2  
ENSG00000163513  GO:0034714 type III transforming growth factor 
beta receptor binding 
TGFBR2  
ENSG00000163513  GO:0035162 embryonic hemopoiesis TGFBR2  
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ENSG00000163513  GO:0042060 wound healing TGFBR2  
ENSG00000163513  GO:0042127 regulation of cell proliferation TGFBR2  
ENSG00000163513  GO:0042493 response to drug TGFBR2  
ENSG00000163513  GO:0043011 myeloid dendritic cell differentiation TGFBR2  
ENSG00000163513  GO:0043235 receptor complex TGFBR2  
ENSG00000163513  GO:0043415 positive regulation of skeletal muscle 
tissue regeneration 
TGFBR2  
ENSG00000163513  GO:0043627 response to estrogen TGFBR2  
ENSG00000163513  GO:0045121 membrane raft TGFBR2  
ENSG00000163513  GO:0045766 positive regulation of angiogenesis TGFBR2  
ENSG00000163513  GO:0046332 SMAD binding TGFBR2  
ENSG00000163513  GO:0046872 metal ion binding TGFBR2  
ENSG00000163513  GO:0048545 response to steroid hormone TGFBR2  
ENSG00000163513  GO:0048565 digestive tract development TGFBR2  
ENSG00000163513  GO:0048661 positive regulation of smooth muscle 
cell proliferation 
TGFBR2  
ENSG00000163513  GO:0048701 embryonic cranial skeleton 
morphogenesis 
TGFBR2  
ENSG00000163513  GO:0050431 transforming growth factor beta 
binding 
TGFBR2  
ENSG00000163513  GO:0051138 positive regulation of NK T cell 
differentiation 
TGFBR2  
ENSG00000163513  GO:0051216 cartilage development TGFBR2  
ENSG00000163513  GO:0060021 palate development TGFBR2  
ENSG00000163513  GO:0060044 negative regulation of cardiac muscle 
cell proliferation 
TGFBR2  
ENSG00000163513  GO:0060389 pathway-restricted SMAD protein 
phosphorylation 
TGFBR2  
ENSG00000163513  GO:0060425 lung morphogenesis TGFBR2  
ENSG00000163513  GO:0060433 bronchus development TGFBR2  
ENSG00000163513  GO:0060434 bronchus morphogenesis TGFBR2  
ENSG00000163513  GO:0060439 trachea morphogenesis TGFBR2  
ENSG00000163513  GO:0060440 trachea formation TGFBR2  
ENSG00000163513  GO:0060443 mammary gland morphogenesis TGFBR2  
ENSG00000163513  GO:0060463 lung lobe morphogenesis TGFBR2  
ENSG00000163513  GO:0070022 transforming growth factor beta 
receptor homodimeric complex 
TGFBR2  
ENSG00000163513  GO:0070723 response to cholesterol TGFBR2  
ENSG00000163513  GO:1990086 lens fiber cell apoptotic process TGFBR2  
ENSG00000163513  GO:2000379 positive regulation of reactive oxygen 
species metabolic process 
TGFBR2  
ENSG00000069702  GO:0001568 blood vessel development TGFBR3  
ENSG00000069702  GO:0001666 response to hypoxia TGFBR3  
ENSG00000069702  GO:0001701 in utero embryonic development TGFBR3  
ENSG00000069702  GO:0001824 blastocyst development TGFBR3  
ENSG00000069702  GO:0001837 epithelial to mesenchymal transition TGFBR3  
ENSG00000069702  GO:0001889 liver development TGFBR3  
ENSG00000069702  GO:0003007 heart morphogenesis TGFBR3  
ENSG00000069702  GO:0005024 transforming growth factor beta-
activated receptor activity 
TGFBR3  
ENSG00000069702  GO:0005114 type II transforming growth factor beta 
receptor binding 
TGFBR3  
ENSG00000069702  GO:0005160 transforming growth factor beta 
receptor binding 
TGFBR3  
ENSG00000069702  GO:0005515 protein binding TGFBR3  
ENSG00000069702  GO:0005539 glycosaminoglycan binding TGFBR3  
ENSG00000069702  GO:0005578 proteinaceous extracellular matrix TGFBR3  
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ENSG00000069702  GO:0005615 extracellular space TGFBR3  
ENSG00000069702  GO:0005737 cytoplasm TGFBR3  
ENSG00000069702  GO:0005783 endoplasmic reticulum TGFBR3  
ENSG00000069702  GO:0005887 integral component of plasma 
membrane 
TGFBR3  
ENSG00000069702  GO:0006461 protein complex assembly TGFBR3  
ENSG00000069702  GO:0006955 immune response TGFBR3  
ENSG00000069702  GO:0007179 transforming growth factor beta 
receptor signaling pathway 
TGFBR3  
ENSG00000069702  GO:0007181 transforming growth factor beta 
receptor complex assembly 
TGFBR3  
ENSG00000069702  GO:0008201 heparin binding TGFBR3  
ENSG00000069702  GO:0009897 external side of plasma membrane TGFBR3  
ENSG00000069702  GO:0009986 cell surface TGFBR3  
ENSG00000069702  GO:0010633 negative regulation of epithelial cell 
migration 
TGFBR3  
ENSG00000069702  GO:0010719 negative regulation of epithelial to 
mesenchymal transition 
TGFBR3  
ENSG00000069702  GO:0015026 coreceptor activity TGFBR3  
ENSG00000069702  GO:0016049 cell growth TGFBR3  
ENSG00000069702  GO:0016477 cell migration TGFBR3  
ENSG00000069702  GO:0017134 fibroblast growth factor binding TGFBR3  
ENSG00000069702  GO:0030165 PDZ domain binding TGFBR3  
ENSG00000069702  GO:0030509 BMP signaling pathway TGFBR3  
ENSG00000069702  GO:0030511 positive regulation of transforming 
growth factor beta receptor signaling 
pathway 
TGFBR3  
ENSG00000069702  GO:0030512 negative regulation of transforming 
growth factor beta receptor signaling 
pathway 
TGFBR3  
ENSG00000069702  GO:0031100 organ regeneration TGFBR3  
ENSG00000069702  GO:0032354 response to follicle-stimulating 
hormone 
TGFBR3  
ENSG00000069702  GO:0034673 inhibin-betaglycan-ActRII complex TGFBR3  
ENSG00000069702  GO:0034695 response to prostaglandin E TGFBR3  
ENSG00000069702  GO:0034699 response to luteinizing hormone TGFBR3  
ENSG00000069702  GO:0035556 intracellular signal transduction TGFBR3  
ENSG00000069702  GO:0043393 regulation of protein binding TGFBR3  
ENSG00000069702  GO:0046332 SMAD binding TGFBR3  
ENSG00000069702  GO:0048185 activin binding TGFBR3  
ENSG00000069702  GO:0050431 transforming growth factor beta 
binding 
TGFBR3  
ENSG00000069702  GO:0050680 negative regulation of epithelial cell 
proliferation 
TGFBR3  
ENSG00000069702  GO:0051092 positive regulation of NF-kappaB 
transcription factor activity 
TGFBR3  
ENSG00000069702  GO:0051271 negative regulation of cellular 
component movement 
TGFBR3  
ENSG00000069702  GO:0055010 ventricular cardiac muscle tissue 
morphogenesis 
TGFBR3  
ENSG00000069702  GO:0060021 palate development TGFBR3  
ENSG00000069702  GO:0060038 cardiac muscle cell proliferation TGFBR3  
ENSG00000069702  GO:0060216 definitive hemopoiesis TGFBR3  
ENSG00000069702  GO:0060317 cardiac epithelial to mesenchymal 
transition 
TGFBR3  
ENSG00000069702  GO:0060318 definitive erythrocyte differentiation TGFBR3  
ENSG00000069702  GO:0060347 heart trabecula formation TGFBR3  
ENSG00000069702  GO:0060389 pathway-restricted SMAD protein TGFBR3  
  
 302 
phosphorylation 
ENSG00000069702  GO:0070062 extracellular vesicular exosome TGFBR3  
ENSG00000069702  GO:0070123 transforming growth factor beta 
receptor activity, type III 
TGFBR3  
ENSG00000159445  GO:0005739 mitochondrion THEM4  
ENSG00000159445  GO:0005743 mitochondrial inner membrane THEM4  
ENSG00000159445  GO:0005758 mitochondrial intermembrane space THEM4  
ENSG00000159445  GO:0005829 cytosol THEM4  
ENSG00000159445  GO:0005886 plasma membrane THEM4  
ENSG00000159445  GO:0006631 fatty acid metabolic process THEM4  
ENSG00000159445  GO:0007173 epidermal growth factor receptor 
signaling pathway 
THEM4  
ENSG00000159445  GO:0008286 insulin receptor signaling pathway THEM4  
ENSG00000159445  GO:0008543 fibroblast growth factor receptor 
signaling pathway 
THEM4  
ENSG00000159445  GO:0016290 palmitoyl-CoA hydrolase activity THEM4  
ENSG00000159445  GO:0032587 ruffle membrane THEM4  
ENSG00000159445  GO:0038095 Fc-epsilon receptor signaling pathway THEM4  
ENSG00000159445  GO:0043491 protein kinase B signaling THEM4  
ENSG00000159445  GO:0045087 innate immune response THEM4  
ENSG00000159445  GO:0048011 neurotrophin TRK receptor signaling 
pathway 
THEM4  
ENSG00000159445  GO:0048015 phosphatidylinositol-mediated 
signaling 
THEM4  
ENSG00000159445  GO:1902108 regulation of mitochondrial membrane 
permeability involved in apoptotic 
process 
THEM4  
ENSG00000171914  GO:0001726 ruffle TLN2  
ENSG00000171914  GO:0003779 actin binding TLN2  
ENSG00000171914  GO:0005158 insulin receptor binding TLN2  
ENSG00000171914  GO:0005198 structural molecule activity TLN2  
ENSG00000171914  GO:0005200 structural constituent of cytoskeleton TLN2  
ENSG00000171914  GO:0005515 protein binding TLN2  
ENSG00000171914  GO:0005737 cytoplasm TLN2  
ENSG00000171914  GO:0005856 cytoskeleton TLN2  
ENSG00000171914  GO:0005886 plasma membrane TLN2  
ENSG00000171914  GO:0005911 cell-cell junction TLN2  
ENSG00000171914  GO:0005916 fascia adherens TLN2  
ENSG00000171914  GO:0005925 focal adhesion TLN2  
ENSG00000171914  GO:0007016 cytoskeletal anchoring at plasma 
membrane 
TLN2  
ENSG00000171914  GO:0007043 cell-cell junction assembly TLN2  
ENSG00000171914  GO:0007155 cell adhesion TLN2  
ENSG00000171914  GO:0015629 actin cytoskeleton TLN2  
ENSG00000171914  GO:0045202 synapse TLN2  
ENSG00000171914  GO:0051015 actin filament binding TLN2  
ENSG00000138111  GO:0016021 integral component of membrane TMEM180  
ENSG00000187806  GO:0016021 integral component of membrane TMEM202  
ENSG00000141655  GO:0001503 ossification TNFRSF11A  
ENSG00000141655  GO:0002250 adaptive immune response TNFRSF11A  
ENSG00000141655  GO:0002548 monocyte chemotaxis TNFRSF11A  
ENSG00000141655  GO:0004872 receptor activity TNFRSF11A  
ENSG00000141655  GO:0004888 transmembrane signaling receptor 
activity 
TNFRSF11A  
ENSG00000141655  GO:0005031 tumor necrosis factor-activated 
receptor activity 
TNFRSF11A  
ENSG00000141655  GO:0005515 protein binding TNFRSF11A  
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ENSG00000141655  GO:0007165 signal transduction TNFRSF11A  
ENSG00000141655  GO:0007267 cell-cell signaling TNFRSF11A  
ENSG00000141655  GO:0007275 multicellular organismal development TNFRSF11A  
ENSG00000141655  GO:0008284 positive regulation of cell proliferation TNFRSF11A  
ENSG00000141655  GO:0009314 response to radiation TNFRSF11A  
ENSG00000141655  GO:0009897 external side of plasma membrane TNFRSF11A  
ENSG00000141655  GO:0009986 cell surface TNFRSF11A  
ENSG00000141655  GO:0016021 integral component of membrane TNFRSF11A  
ENSG00000141655  GO:0019955 cytokine binding TNFRSF11A  
ENSG00000141655  GO:0030316 osteoclast differentiation TNFRSF11A  
ENSG00000141655  GO:0032496 response to lipopolysaccharide TNFRSF11A  
ENSG00000141655  GO:0033209 tumor necrosis factor-mediated 
signaling pathway 
TNFRSF11A  
ENSG00000141655  GO:0034097 response to cytokine TNFRSF11A  
ENSG00000141655  GO:0034612 response to tumor necrosis factor TNFRSF11A  
ENSG00000141655  GO:0043123 positive regulation of I-kappaB 
kinase/NF-kappaB signaling 
TNFRSF11A  
ENSG00000141655  GO:0043507 positive regulation of JUN kinase 
activity 
TNFRSF11A  
ENSG00000141655  GO:0046872 metal ion binding TNFRSF11A  
ENSG00000141655  GO:0048535 lymph node development TNFRSF11A  
ENSG00000141655  GO:0051091 positive regulation of sequence-
specific DNA binding transcription 
factor activity 
TNFRSF11A  
ENSG00000141655  GO:0051092 positive regulation of NF-kappaB 
transcription factor activity 
TNFRSF11A  
ENSG00000141655  GO:0060086 circadian temperature homeostasis TNFRSF11A  
ENSG00000141655  GO:0060749 mammary gland alveolus 
development 
TNFRSF11A  
ENSG00000141655  GO:0070555 response to interleukin-1 TNFRSF11A  
ENSG00000141655  GO:0071812 positive regulation of fever generation 
by positive regulation of prostaglandin 
secretion 
TNFRSF11A  
ENSG00000141655  GO:0071847 TNFSF11-mediated signaling pathway TNFRSF11A  
ENSG00000141655  GO:0071848 positive regulation of ERK1 and ERK2 
cascade via TNFSF11-mediated 
signaling 
TNFRSF11A  
ENSG00000198846  GO:0003677 DNA binding TOX 
ENSG00000198846  GO:0005634 nucleus TOX 
ENSG00000196511  GO:0004788 thiamine diphosphokinase activity TPK1  
ENSG00000196511  GO:0005524 ATP binding TPK1  
ENSG00000196511  GO:0005829 cytosol TPK1  
ENSG00000196511  GO:0006766 vitamin metabolic process TPK1  
ENSG00000196511  GO:0006767 water-soluble vitamin metabolic 
process 
TPK1  
ENSG00000196511  GO:0006772 thiamine metabolic process TPK1  
ENSG00000196511  GO:0009229 thiamine diphosphate biosynthetic 
process 
TPK1  
ENSG00000196511  GO:0016301 kinase activity TPK1  
ENSG00000196511  GO:0016310 phosphorylation TPK1  
ENSG00000196511  GO:0030975 thiamine binding TPK1  
ENSG00000196511  GO:0042723 thiamine-containing compound 
metabolic process 
TPK1  
ENSG00000196511  GO:0044281 small molecule metabolic process TPK1  
ENSG00000072657  GO:0004177 aminopeptidase activity TRHDE  
ENSG00000072657  GO:0005887 integral component of plasma 
membrane 
TRHDE  
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ENSG00000072657  GO:0006508 proteolysis TRHDE  
ENSG00000072657  GO:0007165 signal transduction TRHDE  
ENSG00000072657  GO:0007267 cell-cell signaling TRHDE  
ENSG00000072657  GO:0008237 metallopeptidase activity TRHDE  
ENSG00000072657  GO:0008270 zinc ion binding TRHDE  
ENSG00000072657  GO:0070062 extracellular vesicular exosome TRHDE  
ENSG00000032389  GO:0005515 protein binding TSSC1  
ENSG00000170035  GO:0004842 ubiquitin-protein transferase activity UBE2E3  
ENSG00000170035  GO:0005524 ATP binding UBE2E3  
ENSG00000170035  GO:0005634 nucleus UBE2E3  
ENSG00000170035  GO:0005737 cytoplasm UBE2E3  
ENSG00000170035  GO:0008152 metabolic process UBE2E3  
ENSG00000170035  GO:0016881 acid-amino acid ligase activity UBE2E3  
ENSG00000170035  GO:0040008 regulation of growth UBE2E3  
ENSG00000170035  GO:0070534 protein K63-linked ubiquitination UBE2E3  
ENSG00000170035  GO:0070936 protein K48-linked ubiquitination UBE2E3  
ENSG00000170035  GO:0070979 protein K11-linked ubiquitination UBE2E3  
ENSG00000140455  GO:0000122 negative regulation of transcription 
from RNA polymerase II promoter 
USP3  
ENSG00000140455  GO:0000278 mitotic cell cycle USP3  
ENSG00000140455  GO:0000790 nuclear chromatin USP3  
ENSG00000140455  GO:0001046 core promoter sequence-specific DNA 
binding 
USP3  
ENSG00000140455  GO:0003682 chromatin binding USP3  
ENSG00000140455  GO:0004221 ubiquitin thiolesterase activity USP3  
ENSG00000140455  GO:0004843 ubiquitin-specific protease activity USP3  
ENSG00000140455  GO:0005634 nucleus USP3  
ENSG00000140455  GO:0006281 DNA repair USP3  
ENSG00000140455  GO:0006511 ubiquitin-dependent protein catabolic 
process 
USP3  
ENSG00000140455  GO:0008234 cysteine-type peptidase activity USP3  
ENSG00000140455  GO:0008270 zinc ion binding USP3  
ENSG00000140455  GO:0016578 histone deubiquitination USP3  
ENSG00000140455  GO:0031647 regulation of protein stability USP3  
ENSG00000140455  GO:0036459 ubiquitinyl hydrolase activity USP3  
ENSG00000140455  GO:0042393 histone binding USP3  
ENSG00000118369  GO:0004843 ubiquitin-specific protease activity USP35  
ENSG00000118369  GO:0005488 binding USP35  
ENSG00000118369  GO:0006511 ubiquitin-dependent protein catabolic 
process 
USP35  
ENSG00000118369  GO:0008234 cysteine-type peptidase activity USP35  
ENSG00000118369  GO:0016579 protein deubiquitination USP35  
ENSG00000118369  GO:0036459 ubiquitinyl hydrolase activity USP35  
ENSG00000117533  GO:0000139 Golgi membrane VAMP4  
ENSG00000117533  GO:0005764 lysosome VAMP4  
ENSG00000117533  GO:0005768 endosome VAMP4  
ENSG00000117533  GO:0005794 Golgi apparatus VAMP4  
ENSG00000117533  GO:0005802 trans-Golgi network VAMP4  
ENSG00000117533  GO:0009986 cell surface VAMP4  
ENSG00000117533  GO:0016021 integral component of membrane VAMP4  
ENSG00000117533  GO:0016192 vesicle-mediated transport VAMP4  
ENSG00000117533  GO:0031201 SNARE complex VAMP4  
ENSG00000117533  GO:0035493 SNARE complex assembly VAMP4  
ENSG00000117533  GO:0042996 regulation of Golgi to plasma 
membrane protein transport 
VAMP4  
ENSG00000117533  GO:0043001 Golgi to plasma membrane protein VAMP4  
  
 305 
 
transport 
ENSG00000075035  GO:0016021 integral component of membrane WSCD2 
ENSG00000206579  GO:0016021 integral component of membrane XKR4  
ENSG00000145817  GO:0005789 endoplasmic reticulum membrane YIPF5  
ENSG00000145817  GO:0015031 protein transport YIPF5  
ENSG00000145817  GO:0016020 membrane YIPF5  
ENSG00000145817  GO:0016021 integral component of membrane YIPF5  
ENSG00000145817  GO:0016192 vesicle-mediated transport YIPF5  
ENSG00000145817  GO:0030134 ER to Golgi transport vesicle YIPF5  
ENSG00000145817  GO:0032580 Golgi cisterna membrane YIPF5  
ENSG00000145817  GO:0042175 nuclear outer membrane-endoplasmic 
reticulum membrane network 
YIPF5  
ENSG00000145817  GO:0060628 regulation of ER to Golgi vesicle-
mediated transport 
YIPF5  
ENSG00000145817  GO:0070971 endoplasmic reticulum exit site YIPF5  
ENSG00000181722  GO:0000122 negative regulation of transcription 
from RNA polymerase II promoter 
ZBTB20  
ENSG00000181722  GO:0001078 RNA polymerase II core promoter 
proximal region sequence-specific 
DNA binding transcription factor 
activity involved in negative regulation 
of transcription 
ZBTB20  
ENSG00000181722  GO:0003677 DNA binding ZBTB20  
ENSG00000181722  GO:0005515 protein binding ZBTB20  
ENSG00000181722  GO:0005634 nucleus ZBTB20  
ENSG00000181722  GO:0006351 transcription, DNA-templated ZBTB20  
ENSG00000181722  GO:0046872 metal ion binding ZBTB20  
